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ABSTRACT 
This thesis reports on an investigation of the relationship 
between administration of the amino acid, 1-tryptophan and 
measures of psychological state in normal and depressed 
individuals. L-Tryptophan was administered in doses from 2 to 6 
grams/day to twelve normal and eight depressed subjects for one 
to four weeks. This condition was compared with placebo and 
baseline phases within individuals. Mood state was monitored 
twice daily across all experimental phases by a series of 16 
Visual Analogue Mood Scales (Norris, 
three principal factors, labelled: 
1971) which condensed to 
alertness, contentedness and 
calmness. Side effects were also checked on a daily basis. 
Weekly ratings for the Zung depression Scale (Zung, 1965), State 
Anxiety Scale CSpielberger, 1970) and the Hopkin's Symptom Check 
List (Derogatis, 1974) were obtained throughout the trial for all 
subjects. Consideration of antidepressant effects was limited to 
depressed subjects. There was a lack of dramatic or consistent 
psychological effects for tryptophan relative to placebo or 
baseline phases within all subjects. Slight effects were limited 
to a reduction in alertness for four subjects and an increase in 
contentedness for two further individuals, one of whom was 
depressed. However, in no case were effects considered to be of 
general psychological or specific therapeutic 
notable increase in the severity and variety of 
apparent for nine out of twenty subjects. 
considered to have potential therapeutic 
biochmemically and/or psychologically select 
function for 1-tryptophan as an agent in the 
brain serotonergic function is also proposed. 
significance. A 







L-Tryptophan may be classed as a nutritionally essential 
amino acid in humans. The relevance of this compound to 
psychological state stems from its physiological role as a 
precursor to the brain amine, serotonin. Alterations in brain 
serotonin activity have been associated with a wide range of 
psychological states including depression (Coppen & Wood, 1983; 
Asberg & Traskman, 1981; van Praag & Korf, 1970; McGeer et al., 
1978; Banki et al, 1981(a>; (b)). The theoretical and empirical 
evidence relating serotonin metabolism to states of depression is 
evaluated in Chapter II. Motivation for psychological 
investigations of tryptophan administration relate to its assumed 
ability to increase the functional turnover of brain serotonin. 
Evidence bearing on this assumption is also presented in Chapter 
II. The desirability of establishing a therapeutic role for a 
physiologically natural substance represents another motivation 
for psychological investigation of 1-tryptophan. 
Lehman (1978) has proposed a set of criteria for the type of 
drugs psychiatrists might hope for in the future as well as those 








Greater therapeutic efficacy than existing drugs for the 
same indication 
Lower t0>dci ty 
Fewer or less disturbing side effects 
More desirable pharmacokinetic features 
Different action mechanisms 
A basically different chemical structure 
~ jtV(1I·;; ,<1 1.''1, /i° {iv\1 I°'/{/),., 
c/ . V' • 
psychopathological. aspects of the condition that is being 
treated" 
With respect to the above points, the therapeutic efficacy 
and pharmacokinetic desirability of tryptophan, relative to 
existing drugs, remains to be determined. However, it seems 
1 
reasonable to expect that a normal physiological compound will be 
characterized by lower toxicity and fewer side effects than nan 
physiological drugs. L-Tryptaphan also appears to have a more 
specific brain action that of increasing serotonin synthesis 
than other antidepressant drugs. This last factor indicates a 
value far tryptaphan in investigating the 'serotonin depletion' 
hypotheses of depression (Carroll, 1971), and is further 
discussed in Chapters II and IV. 
L-Tryptophan is presently available in New Zealand through 
Health Food Distributer's and has received compelling 
advertisements from such sources. For example, comments 
appearing in the Christchurch Shopping Guide (1983, 1984) read as 
follows. 
"L-Tryptophan can virtually wipe out depression, anxiety and 
sleep problems for millions .•• it can calm you down when your'e 
nervous or suffering stress, perk you up when you're blue and 
help you sleep like a baby" 
In contrast, evidence considered in the present thesis for 
1-tryptaphan·s mood altering potential is injected with 
controversy. Reports of antidepressant efficacy range from no 
better than placebo CBunney et al., 1971; Murphy et al., 1974; 
Mendels et al., 1975; Farkas et al., 1976; Cooper & Datta, 1980) 
to effects comparable with ECT (Coppen et al., 1967). 
The mood altering effects of tryptophan in normal (non 
depressed) subjects has received little investigation to date. 
The present study addresses relationships between 1-tryptophan 
administration and psychological state in normal as well as 
depressed individuals. Most past investigations of 1-
tryptophan·s antidepressant effects have been based on the 
criterion of significant group differences between tryptophan and 
alternative treatments ranging from placebo to tricyclics or ECT. 
Such approaches have overlooked the possibility that tryptophan·s 
therapeutic potential is limited to psychologically and/or 
biochemically select individuals. The present thesis is 
concerned with the need for evaluating 1-tryptophan's efficacy 
within individuals. This approach characterizes the present 
2 
e>:periment (Chapters III and IV) and recommendations for future 
research (Chapter V>. 




relationships between administration of 
and self assessments of select aspects 
1-
of 
state in both normal and depressed individuals. 
By extending consideration to past investigations, attempts are 
made to evaluate tryptophan·s psychological effects 
particularly its therapeutic potential. Finally, tryptophan's 
value as as an agent in the investigation of serotonergic 
functioning is considered. Clearly, motivation for all aspects of 
the above inquiry rest on certain assumptions relating to the 
biological basis of behaviour. 
The most pertinent assumption underlying the present 
experiment is that certain changes in psychological state, 
with including antidepressant effects, may be correlated 
administration of the serotonin precursor tryptophan. 
Justification for this assumption is presented in the form of an 
evaluation of the psychological investigations of tryptophan 
administration in Chapter II. Much of the evidence in this area 
is focused on tryptophan's antidepressant potential. However, 
consideration is also given to tryptophan's hypnotic action and 
effects related to administration in normal 
individuals. 
(non psychiatric) 
Subsequently, if specific and consistent effects such as 
an antidepressant response (in depressed subjects) can be 
demonstrated, then it is assumed that the most suitable theory of 
action mechanisms relates to the ability of 1-tryptophan to 
effect an elevation in the functional turnover of brain 
serotonin. The biochemical pathway relevant to cerebral 
serotonin synthesis is presented in Chapter II. The assumed 
preferential relevance of this pathway over alternative catabolic 
courses, i.e. the psychological significance of serotonin 
metabolism is also discussed. The proposed mechanism of action 
(Figure 2-2) requires that certain metabolic conditions within 
and between plasma and brain environments are established. The 
relevance of such conditions to psychological state (i.e. 1. 
-:r 
·-' 
plasma - psychological 2. brain - psychological) and to each 
other (i.e. plasma brain) are presented and evaluated in 
Chapter II. As indicated from this evaluation, such information 
X\ is of value in reducing the conflict em,in~ting from purely 
psychological investigations and argues in favour of biochemical 
screening and monitoring of subjects particularly in the 
therapeutic context. 
Assumptions regarding the psychological status of 
participants in the present study require justification. As 
already mentioned part of the present thesis is concerned with 
the evaluation of tryptophan's antidepressant potential. As 
indicated from Chapter IV, only eight of the twenty participants 
could be considered depressed on the basis of ·motivation for 
participation' and only five of these eight on the basis of 
initial SDS (Zung Depression) scores. Consequently, evaluation 
of 1-tryptophan's antidepressant effects was limited to these 
individuals. It was not assumed that non depressed participants-
would act as models for the antidepressant action of tryptophan. 
However, the use of scales (particularly the VAMS) which had 
demonstrated sensitivity within both normal and depressed/anxious 
subjects allowed exploration of a response continuum between 
these two groups. 




all of the tasks required of subjects. The 
conditions were the same as those described for 
(Chapter IV>. This procedure involved the maximum 
dose of tryptophan as well as the maximum length of 
participation. Analysis of the author's trial was not included in 
this thesis. However, the experience proved useful in that it 
led to certain design modifications prior to the start of the 
main experiment. 
All references to 'tryptophan' in the present thesis are 
synonomous with '1-tryptophan' unless otherwise stated. The 
significance of 1 and d isomers is discussed in Chapter II. 
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CHAPTER II 
PSYCHOBIOLOGY OF TRYPTOPHAN 
2.1 INTRODUCTION 
This chapter provides a description and evaluation of the 
psychobiological relationships of tryptophan in humans. The 
evidence considered provides background information relevant to 
the design and outcome of the present experiment. Consideration 
is also given to areas beyond the boundaries of the present 
investigation, in order that a broader based evaluation of 
tryptophan's therapeutic and general mood altering potential may 
be formulated. 
Initial consideration is given to evidence emerging from 
purely psychological investigations of tryptophan administration 
in depressed and normal individuals. Studies in this context 
ignore the pharmacological sequences hypothesized to intervene 
between tryptophan ingestion and altered psychological state 
(Figure 2-2). Thus, such investigations are considered to 
contribute a low level of information towards understanding of 
the psychobiological relationships of tryptophan administration. 
Outcome from studies in this context is typified by conflict with 
respect to both general mood altering properties and therapeutic 
efficacy. 
While some of the conflict from psychological investigations 
of tryptophan administration is considered attributable to 
various design differences and inadequacies, it is proposed that 
additional areas of controversy may be reduced through knowledge 
of basic biochemical and metabolic processes of the amino acid 
and the relationships of these processes to tryptophan intake and 
psychological state. Consequently consideration is given to the 
basic structural, biochemical and metabolic features of 
tryptophan and subsequently the psychophysiological and 
psychopharmacological relationships relevant to depression and 
normal psychological functioning. 
5 
2.2 PSYCHOLOGICAL STUDIES 
The majority of information in this context relates to the 
antidepressant effects of tryptophan administration. 
Consideration is also given to the general mood altering effects 
associated with tryptophan intake in normal subjects. 
2.2.1 Antidepressant trials 
The motivation for antidepressant applications of tryptophan 
stems from information relating to two major areas of research to 
be described in following sections of this chapter. Firstly 
comparative biochemical investigations of depressed and normal 
subjects have indicated differences relating to tryptophan and 
serotonin metabolism. The implication from such findings is that 
certain types of depression may be characterized by functional 
abnormalities in these systems. The second line of evidence 
relates to the demonstration that administration of tryptophan to 
certain depressives correlates with antidepressant response and 
certain specific changes in metabolic parameters of tryptophan. 
2.2.1.1 Tryptophan versus standard tricyclics 
Nine 
tryptophan's 
studies were considered in the 
therapeutic efficacy relative 
evaluation of 
to standard 
tricyclics. The description and basic outcome emerging from such 
studies is presented in Table 2-1. The six studies in this 
context comparing tryptophan with imipramine and the two with 
amitriptyline resulted in positive outcomes. That is, in all the 
above eight cases tryptophan was considered as efficacious as the 
tricyclics in the treatment of depression. The investigation 
indicating superiority of tricyclics over tryptophan varied in 
two important respects from the remaining studies. Firstly, 
trytophan was compared with clomipramine and doxepin and 
secondly, the tryptophan dose employed was half that of the 
lowest dose used in the positive studies. 
These studies indicate tryptophan may be as efficacious in 
the treatment of depression as imipramine and amitriptyline. 
This indication is further endorsed by the fact that most of the 
6 
"' 
Table 2-1 Studies comparino the antidepressant efficacy of tryptoohan 
with tricvclics: imipramine, amitriptyline, clomipramine and doxepin 
Authors 
Chouinard et al 
(1979) 
Copper. et al 
(1972) 
Herrington et al 
(1976) 
.Jensen et al 
(1975) 
Kline t, Shah 
<1974) 
Lindberg et al 
(1979) 
Linnoila et al 
(1980) 
Rao & Broadhurst 
(1976) 
Thomson et al 
<l 982) 





initial mean HDS scores: 
tryptophan= ~ 41 
imipramine= ~ 38 
"primary depression 11 
(Kline, 1961) 




(MRC criteria, 19651 
initial mean HOS scores: 
tryptophan= ~ 24 
amitrie.!::Yline= ~ 22 
"endogenous depression" 
(unspecified criteria) 






"38 endogenous inpatients 





initial mean HDS scores: 
tryptophan= ~ 26 
clomipramine= ~ 27 
do>:epi n= ~ 25. 5 
11 depressive illness 11 
(Clinical Psychiatric: 
Committee, 1965) 




depression at least 2 
weeks" 
initial mean HDS scores: 
tryptophan= 18.21 
amitriptyline= 17 .. 35 
HDS Hami !ton depression seal e tot al seer!.' ( Hi!mi !ton, 1965) 
approximate score ie: interpreted from gr~phic displays 











































































above studies involved randomized, double blind experimental 
procedures. All the studies were considered to have run for 
sufficient duration. Although 28 days is generally regarded as a 
minimum fair test of an antidepressant (Cooper & Sudhir, 1980), 
Wittenborn (1978) suggests three weeks should generally be 
sufficient for tests of antidepressant efficacy. Most studies, 
with the possible exception of Chouinard et al. (1979) and Rao & 
Broadhurst (1976), could be considered to have involved 
comparison of sufficiently large groups in either condition. 
However, there do remain some methodological and design 
procedures which could be considered to detract from the validity 
of indivivdual studies. Firstly, all the studies cited in Table 
2-1 were based on group comparative approaches. Discussion 
relating to the inadequacy of this design is presented in Chapter 
III. In general, the problem here is considered to relate to the 
potential inaccuracy of evaluations based on a group response. 
In the case of the above investigations it may only take a few 
dramatic/extreme individual reactions to shift a 'group response' 
away from an outcome which is representative of most of the 
individuals. There was little evidence in the above 
investigations that attention had been paid to individual 
effects. In this respect, Kellner et al. (1978) note that, "a 
drug trial with a group ••• is more likely to yeild statistically 
significant drug/placebo differences than an intensive design 
with a single case". 
A second methodological aspect of the above investigations 
which demands consideration concerns the psychological status of 
the groups and individuals studied. As is evident from Table 2-
1, classification was often limited to global statements such as 
'primary affective disorder', 'primary depressive disorder' and 
'endogenous depression'. In some cases criteria for such 
judgements conformed to standard nosological systems and in other 
cases they were unspecified. Such variation hinders comparison of 
the above investigations and in some cases leads to uncertainty 
over the type of depressions being considered. 
As indicated in Table 2-1, seven of the nine studies 
considered supplied information on the severity of depression in 
B 
the form of mean Hamilton Depression Scale <HDS) scores. On 
this basis most investigations could be considered to have 
involved subjects with moderate levels of depression. Finally, 
it should be noted that three of the studies considered here 
employed concurrent administration of pyridoxine (vitamin B6) 
with tryptophan. However, the procedure did not appear to be 
significantly associated with therapeutic outcome. 
Studies comparing tryptophan with the tricyclics seem 
pertinent in establishing tryptophan·s antidepressant utility at 
a fairly rigorous level. That is, James et al. (1976) consider 
tricyclics to be the drugs of choice in depressive illness, 
presumably because of their relatively frequent utilization and 
wide ranging efficacy. Thus, demonstration of a drug's 
antidepressant efficacy equal to that of the tricyclics should 
endorse its potential therapeutic value. However, studies 
comparing tryptophan with ECT and placebo are less positive. 
2.2.1.2 Tryptophan versus ECT 
Experimental details for the three studies considered in 
this section are documented in Table Clearly, such 
investigations are precluded from conformation to double blind 
standards. That is, the disparities in administrative procedures 
between tryptophan and ECT are unlikely to keep either the 
dispenser of therapies or the recipient in ignorance of treatment 
differences. 
As is evident from Table 2-2, two of the three studies 
(Carroll et al., 1970 & Herrington et al., 1974) found tryptophan 
to be significantly less effective than ECT in treatment of 
severe depression, while Coppen et al. ·s (1967) results suggest 
that tryptophan was as effective as ECT. All studies involved 
severely depressed inpatients, although the criteria for 
classification were not clearly specified in any case. 
Coppen et al. 's (1967) study was the only one not to employ 
random assignment procedures. However this feature alone seems 
insufficient to account for the difference in outcome relative to 
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initial mean HDS total: 
tryptophan = 26.3 
ECT = 26.6 
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to require ECT 
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severe depression,initial 
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Criteria for antidepressant 
e-fficacy required reduction 
of 8 pts on HDS. Final HDS 
mean total: tryptophan = 21.0 
ECT = 11-6 
Thus, tryptophan considered 
ineffective. All ECT patients 
improved rapidly in 3 weeks, 1 
tryptophan patient was symptom 
free, 2 improved 8? 3 worse .. 
no sig. difference in depression 
self ratings at completion, 22% 
EC~~zoup t« 16:~ tryptophan group 
rel:'9_ed further treatment prior 
to discharge. 
Authors conclude ECT superior to 
tryptophan & consider it unlikely 
that tryptophan has a -function in 
the treatment o-f patients 
considered to require ECT. Final 
HDS totals: no sig di-ff at 2 weeks 
but at 4 weeks tryptophan = ~15 
ECT = ~5 
i.e. ECT mean HDS sig lower. 
~ 
r 
administration of 100mg of pyridoxine with tryptophan and in all 
cases the duration of application was considered sufficient, in 
the light of Wittenborn's (1978) recommendations. The lower 
dose in Coppen et al. 's (1967) does not provide an adequate 
explanation of outcome difference. While it is possible that the 
ability to accomplish accurate self ratings (the method of 
assessment used in Coppen et al. 's (1967) study) may be impaired 
in severely depressed patients, claims far tryptaphan's 
effectiveness were not entirely dependent on such criteria9 The 
outcome from this study was also supported by the finding that 
only 16% of the tryptophan group (compared to 22% of the ECT 
group) required further treatment prior to discharge. 
Finally, an important factor emerging from Herrington et 
al. 's (1974) trial relates ta the elevation in tryptophan dose at 
the second week of administration. This intervention coincided 
with a seperatian in therapeutic effect between the ECT and 
tryptophan groups. That is, up to the end of the second week 
there was no significant difference between the groups on HDS. 
Following this point the ECT group continued to improve while 
mean ratings from the tryptophan group stabilized, such that by 
completion of the fourth week the difference was signifcant, in 
favour of ECT. Evidence emerging from Chouinard et al. ·s (1978) 
investigation of. appropriate dose ranges would suggest that 
Bgms/day (the dose for the last two weeks of Herrington et al. 's 
(1974) trial) is in excess of optimum levels and could be 
expected to relate to therapeutic decline. 
Although two of the above studies indicated tryptophan was 
inferior ta ECT, such information does not in itself justify 
supposition that tryptophan is inadequate as an antidepressant. 
Both studies indicated notable declines in mean HDS scares for 
the tryptophan condition. In addition, the coincidence of change 
in dosage with reduction in the rate of therapeutic 
for Herrington et al. ·s (1974) tryptophan group 




insufficient to allow definitive judgement of tryptophan's 
potential rating against ECT a therapeutically potent 
aprroach to treatment of severe depression. However, the 
demonstration of some antidepressant effect for tryptophan, in 
11 
all of the above studies is supportive of the need for further 
investigation of its efficacy. 
2.2.1.3 Tryptophan versus placebo 
2-3. 
The studies considered in this section are outlined in Table 
An inherent assumption of most investigations comparing the 
antidepressant efficacy of tryptophan with the tricyciics seems 
to be that administration of the latter compounds are exerting 
effects superior to placebo. However, trials indicating 
tryptophan·s equality or superiority relative to the tricyclics 
are not necessarily sufficient to determine whether tryptophan·s 
psychological effects have a true pharmacological base. There is 
a need to demonstrate tryptophan's efficacy relative to placebo 
before significant pharmacological effects can be assumed. 
Unfortunately there is an absence of studies involving concurrent 
comparison of tryptophan, placebo and antidepressants such as the 
tricyclics and ECT. However, studies comparing tryptophan with 
placebo are considered in this section. 
Although the severity of depressions considered in these 
trials is not always stated, there were general indications from 
some that only subjects with mild to moderate depression were 
accepted, e.g. minimum HDS inclusion scores of 12 and 16 were 
set by Thomson et al. ( 1982) and Farkas et al. ( 1976) 
respectively. The ethical problems associated with administering 
placebo to depressed patients is also likely to have resulted in 
inclusion of less severely depressed patients than for studies 
comparing tryptophan with the tricyclics. As evident from Table 
2-3, all studies employed double blind procedures. Three of the 
six investigations involved cross over of conditions within 
subjects, considered by the present author to represent a more 
valid comparison of effects than between group evaluations. At 
least four of the studies were considered to involve adequate 
trial lengths for detection of antidepressant effects. However, 
in four of the studies dose levels could be considered ta exceed 
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Studies c:omparino the antidepressant e·Ffic:ac:y of 
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double blind, non 
random c:rossover. 
Unipolar & bipolar dep, double blind 
min HDS of 16 required tryptophan n=6 
for inclusion, there- placebo n=3 
fore, not severe dep 
primary affective dis, 
(c:riteria of Feighner, 
1972). 10=unipolar, 
6=bipolar. 
mild to mod depress, 
(criteria unspec:ified) 
mean age approx BOyrs 
general practise 
patients c:omplaining 
of depression for at 
least two weeks. Most 
met the c:riteria for 
primary affective 
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no sig diff for tryptophan 
relative to placebo & no sig 
antidep. resp from tryptophan 
no sig diff for tryptophan 
relative to placebo, 1/16 
unipolars - sig improv & 5/8 
bipolars - sig reduction of manic: 
symptoms with tryptophan 
no sig diff for tryptophan 
relative to placebo. No sig 
improvemnent with tryptophan 
or placebo but antidep trends 
for both 
no sig diff for tryptophan 
relative to placebo. Sig 
antidep resp 1/10 unipolar 
& 3/6 bipolar on tryptophan 
no sig diff for tryptophan 
relative to plac:ebo. Trends 
apparent for antidepressant 
resp on both tryp and placebo 
tryptophan sig greater r·esponse 
than placebo. Plac:ebo also 
assoc:iated with notable 
improvement 
Given the above limitations, there is still concensus 
between studies that the antidepressant effects of tryptophan are 
not significantly different from placebo. Five out of six 
studies were in agreement in this respect. In the study 
indicating tryptaphan·s superiority ta placebo the difference was 
only significant at the 0.05 level. The above outcome indicates 
the need far a re-examination of the meaning of results 
demonstrating comparable efficacy of tryptophan relative to the 
tricyclics. It should be noted that although there was a general 
lack of antidepressant difference for tryptophan versus placebo, 
that placebo administration was clearly related to 
antidepressant effects (Cooper & Datta, 1980; Thomson et al., 
1982; Mendels et al., 1975), as evidenced by marked declines in 
HDS scores in this condition. Unfortunately, the authors did not 
comment on the significance of such effects. 
Thus, while tryptophan appears to be comparable in efficacy 
to standard tricyclics, the present results indicate the need for 
demonstration of tryptophan's effects relative to placebo and 
tricyclics within the same study and preferably within 
individuals before it can be assumed the psychology of tryptophan 
administration involves more than placebo effects. 
2.2.1.4 Tryptophan's potentiating power 
{a) With tricyclics 
As indicated in Table 2-4, three studies are considered 
which involve comparison of tryptophan administered concurrently 
with amitriptyline and clomipramine versus the latter compounds 
alone. All studies were considered to run for a reasonable trial 
period. Each study employed an effective dose of approximately 
3gms/day tryptophan in conjunction with therapeutic tricyclic 
doses. That is, the dose levels of tricyclics alone, led to 
significant antidepressant respones in all cases. As evident 
from Table 2-4, the addition of tryptophan to an amitriptyline 
regime in the first study (Lopez-Ibor Alina et al., 1973), was 
not considered to potentiate the antidepressant response. 
Although not significant, there was a noticeable decline in 
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week placebo foll 
by compar of: 
1. n=28 placebo 
2. n=31 amitryp 
3. n=29 tryp 
4. n=27 amit+tryp 
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effcv (l > 
dose ~3gms 
Outcome 
no overall sig diff betw 
tryp & ami tryp + tr·yp, 
although tryp comb showed 
slightly greater reduc in 
symps relative to amitryp 
while all three trts sig 
greater placebo. Comb sig 
superior in relieving depr 
mood than either alone 
significantly greater antidp 
effect apparent for clom+tryp 
group at 12 days relative to 
clom+placebo 
alone. The same study also demonstrated a significant increase 






in the HDS total 
although there was no 
score for the combined 
administration relative to amitriptyline alone, a significant 
reduction was noted for symptoms relevant to depressed mood. 
Thus, there is evidence that addition of 3gms/day tryptophan to 
150mg/day amitriptyline may result in slight increases in 
therapeutic response relative to tryptophan alone. In the case 
of clomipramine, the authors (Walinder et al., 1976) claimed that 
addition of tryptophan led to a significantly greater and more 
rapid antidepressant response relative to clomipramine alone. 
The finding of slight to significant improvement for 
tryptophan + the tricylclics relative to the tricyclics alone, 
indicates a potential role for tryptophan in this therapeutic 
context. However, investigaton within individuals and exploration 
of dose variations as well as side effect incidence is required 
before its value is established. 
(b) With ECT 
Studies considered in this context are described in Table 2-
5. Clearly, all subjects in such studies could be considered 
severely depressed. The two most comparable investigations 
indicated no potentiation of ECT by the addition of tryptophan, 
relative to the addition of saline or placebo (Kirkegaard et 
al., 1978) and (d'Elia et al., 1977) respectively. A major 
drawback to investigation in both these cases was the lack of 
within subject monitoring. Also, the commencement of tryptophan 
administration occurred just prior to the first ECT, thus, in 
some cases tryptophan may have been consumed for an insufficient 
period to prior to therapeutic remission. In the case of 
Kirkegaard et al. 's (1978) investigation, a dose of 10mg/kg would 
seem therapeutically inadequate in the light of Chouinard et 
al 's (1978) recommendations. 
The final study considered in this section concerns a single 
case. The positive response claimed for tryptophan + ECT + 
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no sig diff betw groups in 
level/rate of improvement 
no diff in recov betw 
ECT+tryp & ECT+plac 
marked improvement noted 
after addition 7gms/day 
tryp to ECT+amitrip. 




lable 2-6 Studies comparing tryptophan·s potentiating influence 
with MAOI"s 
Author Psychological status 
of subjects 
Coppen et al, severe depression 
1963 
Coppen et al, severe depression 
1967 
Glassman & severe depression 
Platman,1969 
Gutierrez & severe endog dep 
Lopez-lbor 
Alino, 1971 
Pare, 1963 depressed patients 
who prev responded 
to various MADI's 









































6gms dl tryp 
3 (1) 
7 .. 5-15 
Outcome 
tryp+MAOI gave 
sig greater improvement 
than MADI alone 
some incr in response 
for tryp+MAOI compared tryp 
alone but tryp alone also 
gave a sig antidep response 
sig greater improvement from 
MAOI+tryp than MADI alone 
sig greater improvement for tryp 
+MADI relative to MADI+placebo, 
onset of effect much more rapid 
for tryp+MADI than MADI+placebo 
6/14 sig improvement after 
3-4 days of tryp addition to 
MADI, and all relapsed when tryp 
replaced by placebo 
need for further within subject comparisons before tryptophan·s 
value as a potentiat• r of ECT is dismissed. 
Cc) With MADI's 
The information considered here offers greater consistency 
with respect to the potentiating role of tryptophan. As 
indicated in Table 2-6, four of the five studies considered 
indicated significant improvement for an MADI+tryptophan relative 
to an MADI alone. 
by MADI's alone, 
In all cases significant response was obtained 
indicating that dose levels of these compounds 
were therapeutically adequate without addition of tryptophan. 
The remaining study considered in this section actually involved 
comparison of an MADI+tryptophan with tryptophan alone. In this 
case the combination was noted to be more effective than 
tryptophan alone but not significantly so. 
While variability in factors such as dose level and 
administration length was apparent across the above studies, 




in antidepressant effect from concomitant 
of an MADI and tryptophan, than either compound 
is, the main focus of MADI action is to impede 
deamination of 5HT. While tryptophan administration alone, may 
be expected to increase serotonin synthesis, it can not be 
assumed that this action equates with increased functional /-'f serotonin activity. The.,,,::_'l;f,lefincrease in 5HT synthesis following 
tryptophan administration may also lead to rapid breakdown of the 
amine to 5HIAA. The potentially synergistic psychological action 
of these componds, then, has biochemical support in that MADI 
action may be expected to prolong the functional action of 
elevated 5HT levels induced through tryptaphan administration. 
2-7. 
2.2.2 Tryptophan·s effects in normal subjects 
The studies considered in this section are detailed in Table 
It should be stated that 'normal' in this context refers to 
non psychiatric subjects - specifically free from depression. In 
addition, none of the studies considered in this context have 




Table 2-7 Studies i nvesti • ati no the rel ati onshi p bet•1een 
trvptophan administration and psycholooical state 
in normal subjects 
Author 
Charney et al, 
1982. 






Greenwood et al, n=6 males 
1974. 
Greenwood et al, n=6 male 
1975. n=4 female 
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and 6 hr foll up 
Ui l 14 days 
single dose 
mood ratings at 
one hour 
single dose, 
mood ratings at 
hourly intervals 
over 3 hours 
single doses, 






sig incr for tryptophan on: 
drowsiness by 757. for 9/10 
lasting 2 hrs; mellow & 
hi oh by 757. for 6/ 10. All 
sensations peaking at 30-50mins. 
Most subjects reported infusion to 
be pleasant experience. 4/10 mild 
to transient nausea during 
infusion, passed at 60mins. 
5/10 lightheadedness 
oral Ci)drowsiness: 20-30 min -foll 
(il50 & 100mg/kg admin, lasting 2-4 hours; 
nausea: 30min after admin, 
<ii)50mg/kg lasting up 3 hours. 
intravenous 






(iilsimilar effects with lethargy 
often persisting into evening. 
sig increase for tryp vs saline 
(both doses)on VAMS dimensions:~ 
clumsy, bored, incompetent 
dreamy, mentally slow and 
letharoic and for 100mg/kg only: 
increase: relaxed and calm 
VAMS factors 'alertnes~howed sig 
decrease, 'calmness' sig increase and 
no change in 'contentedness'. 
sig increase for tryp vs placebo 
on:drowsiness, clumsiness, 
muzziness and mentally slow 
as measured by VAMS - used in present 
study. Freq reports nausea for 
at least half subjects 10-30mins 
foll admin and incr headache 
during 2nd hour. 
5/7 complained drowsiness 1-2 
hours foll 30 & 70mg/kg. All subjects 
became listless & yawned freq foll 90 
Rather, the focus of such investigations has been the detection 
of general mood altering effects and side effects associated with 
tryptophan ingestion. 
As is apparent from Table 2-7, most studies involved 
investigation of acute tryptophan doses and monitoring of 
psychological states from one to three hours following 
administration. In this respect such studies deviate 
considerably from the focus of trials investigating 
antidepressant effects and also from the longitudinal approach to 
the investigation of general mood altering effects employed in 
the present thesis. Most studies employed relatively high dose 
levels, in keeping with quantities employed by therapeutic 
investigations. 
The main significant effect reported by all the 
investigations in Table 2-7, was 'drowsiness·. Other effects 
common to most studies concerned similar reactions described as 
'lethergy·, 'lightheadedness' or 'mentally slow'. The only other 
common effect within and across studies concerned reports of 
nausea which generally only lasted from 1/2 to 1 hour. Finally 
two of th~ five studies noted significant increases in euphoric 
effects. 
Thus, it is difficult to establish whether limitation of 
reports to a few negative side effects is characteristic of 
tryptophan relationships in normal subjects as opposed to 
depressives, or rather a consequence of the focus of measuring 
reactions for only a short period following a single tryptophan 
administration. The possibility exists that normal subjects may 
be more oriented to the expectation of negative side effects as 
opposed to depressed individuals who may be more oriented towards 
expectations of therapeutic effects. This speculation is 
supported by findings that placebo administration resulted in 
significant increases in the incidence and severity of side 
effects in normal as opposed to depressed patients (Green, 1964). 
There remains insufficient evidence to speculate on the dynamics 
of longterm tryptophan administration in normal subjects. 
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2.2.3 Effects on sleep 
It is not intended to review the literature concerning 
tryptophan relationships to sleep in the present thesis. Various 
controversial claims relating to tryptophan's hypnotic properties 
have been made. Results for significant reductions in sleep 
latency i.e. the time taken to fall asleep have been repeatedly 
forwarded by Hartman et al. (1976, 1977 ,1981) and Hartman & 
Spinweber (1979). However, other studies have failed to support 
such claims (Adam & Oswald, 1979) and still others report an 
increase in the time to fall asleep (Gnirss et al., 1978). 
While some investigators have reported significant increases in 
total sleep time (Wyatt et al., 1970; Hartman et al., 1976), 
this parameter does not seem as pertinent as relationships to 
sleep latency and quotas of REM or slow wave sleep. 
2.2.4 Value of psychological investigations of 
tryptophan administration 











tryptophan. Results from studies considered in this section, 
investigating antidepressant efficacy, range from effects no 
better than placebo to levels of response exceeding ECT. While 
there are suggestions from most therapeutic applications that 
tryptophan has antidepressant properties, the lack of unanimity 
regarding the magnitude and specificity of effects indicates the 
need for more refined psychological investigation. Overall, the 
methodology employed by the majority of the above studies is 
considered inappropriate as a strategy for evaluation of 
tryptophan·s therapeutic potential and, as indicated above, may 
be responsible for much of the conflict in outcome between 
investigations. 
One of the main propositions to be developed within this 
thesis is that tryptophan's therapeutic value appears to be of 
relevance to biochemically and possibly psychologically select 
groups of depressives. Thus, even in studies where biochemical 
information is unavailable a more refined approach to the 
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evaluation of tryptophan's efficacy is indicated. Instead of the 
persistent investigation of group differences as a basis for 
setting tryptophan's value, a more selective focus on individual 
response is required. In addition, the need for a more specific 
qualification of the type of depressions and relationship to 
outcome is suggested. 
The casual application of terms such as 'endogenous 
depression' by many of the above studies do not facilitate 
comparison, particularly when 
classifications are unspecified. 
the criteria for such ~('' 
This particular label appears 1 
to have evolved through a wide variety of semantic definitions. 
The original application of the term to psychology by Gillepsie 
(1929) referred to an emotional response to environmental changes 
which did not demand the presence of a precipitating event. 
Then, according to Katz & Hirchfeld (1978) endogenous depression 
became poised in contrast to neurotic/reactive depression. The 
more recent concept of endogeneity refers to the following 
behaviour/symptom oriented complex: "early morning waking, 
an ore>~ i a and weight 1 oss, psychomotor disturbance, diurnal mood 
variation, severe depressed mood and lack of reactivity to 
environmental stimuli" (Katz & Hirchfeld, 1978). The foregoing 
variation in the meaning of this term raises uncertainty as ta 
the present consistency of its semantic application, 
hindering comparison of investigations. 
thus 
Two studies considered above (Murphy et al., 1974; Farkas et 
al., 1976) indicated significantly different therapeutic response 
between bipolar and unipolar classifications of depression. 
Thus, polarity of depression may provide a useful predictor far 
therapeutic response to tryptophan. 
Overall the findings from psychological investigations are 
considered insufficient to match Wittenborn's (1978) 
far the utility of new drugs. There it is stated, 
guidelines 
"In general 
the case for a new psychotropic agent is strengthened if it 
exceeds placebo and also equals or exceeds a standard medication 
in two out of three studies". While the latter criterion has 
been met there is still insufficient evidence to establish 
tryptophan's value relative to placebo. 
2.2 BIOCHEMISTRY AND METABOLISM OF TRYPTOPHAN 
This section is devoted to an outline of tryptophan's 
structure, composition and biochemical properties along with a 
discussion of the catabolic pathways considered relevant to the 
present inquiry e.g. mood alteration and negative side effect 
e>~peri ence. 
For the purposes of the present thesis, classification of 1-
tryptophan as one of the eight to ten 1 nutritionally essential 
amino acids in man seems most pertinent. That is, 1-tryptophan 
cannot be synthesized from the necessary precursor components 
within the human system and must be supplied through the diet. 
Proposed daily requirements range from 0.5 g/day (Rose et al. , 
1954) to more recent recommendations of 0.2 - 0.24 g/day (Lloyd 
et al., 1978 and Harper et al., 1977 respectively). 
2.2.1 The molecular structure of tryptophan 
coo 
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1 Arginine & histidine are sometimes classed as semi-essential as they may 
be synthesized within human tissue but not in sufficient quantity to support 
growth in younger individuals (Harper et al., 1977), 
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The structure is characterized by attachment of an indole 
ring to the basic amino acid complex. The single assymetric 
carbon atom determines the existence of two optically isomeric 
forms, i.e. (1) levorotary (1) rotates the polarized light plane 
to the left and (2) dextrorotary (d) to the right. D-amino acids 
do occur in cells and in polypeptides <Harper, 1977), however, 
the d seris are not incorporated into proteins and in the case of 
tryptophan the 1 and d isomers are metabolized by the human 
system to kynurenine but further catabolism only occurs with the 
1 form. For the purposes of the present study, metabolism of d-
tryptophan is considered to be psychologically irrelevant. With 
respect to the present thesis, administered tryptophan consisted 
only of the 1 isomer, similarly most references to past research 
are focused on the 1 form. Thus, reference to tryptophan from 
this point, unless otherwise stated, is synonymous with 1-
tryptophan. 
2.2.2 Tryptophan metabolism 
Illustration and description of the biosynthesis of 
tryptophan was ommited from this investigation, as the processes 
involved b~ar no direct relevance to the inquiry. Meister (1967) 
has traced the biosynthetic processes for tryptophan in detail. 
Catabolism follows several courses on entry to the human 
system (see Figure 2-1). A large proportion of ingested 
tryptophan is utilized in the synthesis of tissue proteins 
(Harper et al., 1977; Lloyd et al., 1978) - the processes of 
which are ommitted from this discussion. The biological half-
life of tryptophan has been determined at 15.84 hours in man 
(Ritschel, 1970). This index refers to the time required for 
half the amount of the drug absorbed to be eliminated, whether by 
excretion or catabolism, following establishment of equilibrium. 
This parameter is of relevance to therapeutic dose levels. As 
Ritschel (1970} notes, drugs with long half lives need to be 
administered at longer intervals relative to drugs with shorter 
biological half-lives in order to maintain therapeutic 
concentrations. Exact relationships between biological half 
life, required dose levels and frequency of admi~istration are 




Figur-e 2-1 BIOCHEMICAL PATHWAYS OF TRYPTOPHAN RELEVANT TO THE 
PRESENT THESIS 
TRYPTAMINE-----INDOLEACETIC ACID CIAA) 
monoamine 
oxidase 






















5-HYDROXYTRYPTAMINE C5HT>----• 5-HYDROXYINDOLEACETIC ACID (5HIAA) 
(ser-otonin) monoamine 
oxidase 
the present study can be more easily justified on the basis of a 
long biological half life relative to other common antidepressant 
drugs, e.g. imipramine = 3.5 hours. 
2.2.2.1 The serotonin pathway 
The pathway of direct relevance to the present study 
concerns the cerebral synthesis of serotonin (5HT). 
Approximately 1% of ingested tryptophan follows this course 
(Figure 2-1). The process involves oxidation of tryptophan to 5-
hydroxytryptophan and decarboxylation of this amino acid to 5-
hydroxytryptamine (serotonin). Serotonin is also synthesized in 
relatively high 
approximately 907. 
concentrations peripherally, that 
of the body's total concentration 
is, 
is 
detectable in the thrombocytes and argentaffine cells of the the 
intestinal wall. Its function here is uncertain but it may be 
( implicated in the processes of perfstal sis (Graham, 1979). Most 
of the remaining 5HT is distributed in the platelets (8%) and 
central nervous system (CNS) (2%). Within the CNS, 5HT cell 
bodies 
nuclei 
are almost exclusively located in the brainstem 
(Aghajanian & Wang, 1978). Serotonin does not pass 




1977; Goodman et al., 1980) thus, for the purposes of the 
present investigation peripheral synthesis is considered to bear 
no significant relationship to brain synthesis or concentration. 
Within the brain, tryptophan hydroxylase - the rate limiting 
step for 5HT synthesis - is generally agreed to be unsaturated 
with its substrate under normal physiological conditions 
Hamon i,. (Eccleston et al., 1965; Friedman et al., 1972; 
Glowinski 1974; Neckers et al., 1977), thus, the rate of brain 
5HT synthesis should be effected by tryptophan supply among other 
variables. The importance of elevation in central serotonin 
synthesis (or rather functional turnover of this indoleamine) to 
psychological state will be explicated later in this chapter. 
2 Goodman et al. ( 1980) note it is unusual to encounter central effects upon 
parenteral administration of 5HT, 
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2.2.2.2 The kynurenine - anthranilate pathway 
The second relevant and quantitatively major degradative 
course, accounting for 98% (Hagen & Cohen, 1966) of tryptophan 
catabolism, is known as the 'kynnurenine-anthranilate· pathway. 
Here tryptophan is oxidized to kynurenine, which is converted to 
3-hydroxyanthranilic acid, nicotinic acid (niacin) and other 
components in the liver. In man 60mg of tryptophan will lead to 
the production of approximately 1mg nicotinic acid <Harper et 
al., 1977). This pathway is of relevance in the therapeutic 
context to the extent that it may detract from central serotonin 
synthesis under elevated tryptophan conditions. That is, 
tryptophan pyrrolase (the rate limiting enzyme in this pathway) 
is inducible by its substrate i.e. tryptophan <Knox & Auerbach, 
1955, Harper et al., 1977). This reasoning has led to 
investigation of the effects of concomitant administration of 
tryptophan pyrrolase inhibitors with therapeutic tryptophan doses 
(Green et al., 1980 (b)). The efficacy of this approach is 
considered in Chapter III, in relation to discussion of dose 
levels for the present experiment. The finding by Green & Curzon 
(1969) that hydrocortisone administration in rats led to an 
elevation of tryptophan pyrrolase activity as well as a reduction 
in brain 5HTP further suggests the significance of competition 
for tryptophan between the kynurenine anthranilate pathway and 
the central serotonin course. 
The 'kynurenine-anthranilate· pathway is of relevance to the 
present investigation for two other reasons. This pathway is 
responsible for the production of niacin (vitamin B3). Niacin is 
conveniently used 
nicotinic acid and 
to cover the description of two 
nicotinamide. Nicotinic acid 
compounds 
is easily 
converted to the physiologically active nicotinamide which 
functions metabolically as a component of two co-enzymes (NAO & 
NADP), (Pike & Brown, 1975). The widespread function of these 
co-enzymes in cellular metabolism (i.e. participation in over 40 
different metabolic reactions involving electron transfer (Lloyd 
et al., 1978)) indicate a deficiency of the vitamin would have 
dramatic effects on cellular respiration. The well documented 
symptom profile resulting from niacin deficiency is termed 
pellagra. The condition includes skin lesions, diarrhea and 
28 
neurologic symptoms e.g. dementia (Goth, 1978). Tryptophan will 
normally contribute to the body's niacin supply given conditions 
such as an adequate supply of pyridoxine (vitamin B6) (Harper et 
al, 1977). A pellagrin state may, then, be a consequence of both 
tryptophan and niacin dietary deficiencies. 
With respect to the present investigation and past trials 
involving the administration of therapeutic doses of tryptophan, 
it is probable that niacin levels will be significantly elevated. 
It is the potential consequence of this metabolic disturbance 
that is of relevance to the present inquiry. Niacin is able to 
pass the blood-brain barrier and may be subsequently effective in 
cerebral metabolism. 
Application of niacin in the psychotherapeutic context 
marked the inception of the orthomolecular psychiatric movement. 
Hoffer g< Osmond ( 1966) claim that a large proportion of 
individuals diagnosed as schizophrenic are likely to be vitamin 
dependent and consider such a biochemical imbalance to be 
causative of the schizophrenic syndrome. The deficiency states 
of which Hoffer speaks will not necessarily be characterized by 
physical pellagrin type symptoms although similarities have been 
drawn between the psychological manifestations of schizophrenia 
and pellagrin psychosis. Thus, Hoffer (1974) postulates that 
schizophrenia and certain depressions are consequences of 
psychological niacin deficiencies. Unfortunately, 
sucesses reported by the same author, following 
therapeutic 
megadose 
administration of vitamin B3 to schizophrenics and depressives, 
are confounded by the concomitant application of alternative 
thet-api es. That is, in addition to vitamin B3 application, the 
sucessful cases were subjected to therapies including drastic 
dietary alteration, administration of conventional tranquilizers, 
antidepressants and ECT. Confcurrent administration of several;c 
treatments, inhibits attribution or proportioning of efficacy to 
singular components such as vitamins. 
A comprehensive study by Wittenborn ( 1975), comparing 
administration of 3000mg/day of nicotinic acid with a control 
regime of 6 mg/day to groups of 60 and 40 schizophrenics 
respectively for two years, has since failed to support 
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Hoffer's (1974) claims. In addition, the American Psychiatric 
Association, based on a contracted report on the assessment of 
megavitamin therapy (Lipton et al., 1974), have effectively 
dismissed claims such as Hoffer's, as being empirically and 
theoretically unfounded. 
Dakshinamurti (1977) has noted the demonstration of abnormal 
EEG waking state patterns, i.e. total absence of alpha rhythms, 
in 10 out of 29 patients with pellagra which were normalized 
following 10 - 42 days treatment with niacin. Also, Goldsmith 
( 1956, 1958) reported the appearance of mental depression in 
human adults after 6-8 weeks of dietary induced niacin 
deficiencies. Finally Kety (1975) maintains that early in this 
century, as many as 10% of patients in mental hospitals were 
there owing to mental disturbances relating to pellagra. 







with the pellagrin electrophysiological 
syndrome indicate that niacin levels may have psychoactive 
relevance. Consequently, the influences of this vitamin must be 
considered in the psychophysiological analysis of tryptophan 
administration. 
The second relevant aspect of niacin to the present inquiry 
relates to the side effects associated with megadose 
administration of tryptophan. A specific reaction has been 
ascribed to elevated niacin levels. The reaction is held to be 
associated with nicotinic acid not nicotinamide. Symptoms have 
been described as follows: flushing of the head and neck and 
sometimes the shoulders and arms (Finkel, 1975); warm, itchy 
flush an hour after ingestion (Atkins & Linde, 1977); skin turns 
pink, flushing itchiness and prickliness (Cheraskin et al., 
1974). Cheraskin et al. (1974) maintains that neither the 
flushing or other side effects are dangerous. The effects are 
simply held to be the result of vasodilation (Finkel, 1975; Goth, 
1978). This reaction was of relevance to the experimental 
outcome for subjects 01 and 02 (Chapter IV). 
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2.2.2.3 Tryptamine synthesis 
As evident from Figure 2-1, tryptophan also acts as a 
precursor in the synthesis of brain tryptamine. The physiology 
of this process has been well established by Young & Gauthier 
(1981). In humans CSF indoleaectic acid CIAA> concentration is 
positively correlated with CSF tryptophan concentration. The 
implication from Young & Gauthier's (1981) research is that 
physiological variations in brain tryptophan appear significantly 
and positively related to tryptamine as well as serotonin 
turnover. 
Young & Gauthier (1981) have also established the magnitude 
of relationship between an oral load of 3 & 6 gms of tryptophan 
and assumed 5HT and tryptamine synthesis measured via cisternal 
5HIAA and IAA levels respectively, eight hours after 
administration. Both trytophan loads produced an approximate 507. 
increase in cisternal 5HIAA while IAA levels were doubled and 
quadruppled by 3 and 6gms respectively. Thus, CNS tryptamine 
appears more sensitive than 5HT metabolism to oral tryptophan 
loads. It seems that past claims of tryptamine's insignificance 
relative to serotonin metabolism in the manifestation of mood 
changes (Curzon, 1969), may be due for reconsideration in the 
light of Young & Gauthier's (1981) findings. The psychological 
significance of tryptamine elevation in relation to trytophan 
administration has not, as yet, been documented. 
Further investigation is required in order to establish the 
psychobiological relevance of both nicotinic acid and tryptamine 
relationships to altered tryptophan metabolism. No further 
consideration is given to the significance of these relationships 
in the present thesis. Although subsequent consideration of 
action mechanisms is devoted to serotonin synthesis, the 
potential importance of alternative pathways is not dismissed. 
31 
2.3 PSYCHOPHYSIOL• GICAL AND PSYCHDPHARMACOLDGICAL RELATIONSHIPS 
OF TRYPTOPHAN 
This section is concerned with the relationships between 
indices of tryptophan and serotonin metabolism and their 
relevance to psychological state. Such information is seen as 
reducing the conflict associated with relationships between 
tryptophan administration and mood alteration - particulalry in 
the therapeutic context. In addition, consideration of such 
relationships is considered as a necessary prerequisite to the 
evaluation of tryptophan·s role in investigations of serotonergic 
functioning. Finally such information provides a background to 
the motivation for and evaluation of the present experiment. 
2.3.1 Plasma dynamics of tryptophan 
Most investigations of the psychophysiological and 
psychopharmacological relationships of tryptophan in humans are 
limited by the inaccessibility of relevant brain metabolites. 
Consequently there is a need to determine whether peripheral 
metabolic indices can provide valid correlates of cerberal 
tryptophan and serotonin metabolism and of psychological state. 
As well as contributing to determination of action mechanisms, 
such parameters may provide useful predictors of psychological 
(particularly therapeutic) response to tryptophan administration. 
Two such parameters within the peripheral plasma environment, 
have emerged as useful indicators in the above respects. 
2.3.1.1 Free and total plasma levels 
McMenamy et al. (1958) demonstrated tryptophan's uniqueness 
amoung amino acids in its high affinity for binding to human 
serum albumin, predominantly at a single site, in a highly 
stereospecific manner. In humans, an estimated 80-90% of 
tryptophan is albumin bound (Pardridge, 1979). The consequence 
of this high ·state bound' level on availabiltiy and transport of 
tryptophan to the brain is uncertain. However, is commonly held 
that the unbound or free component is the fraction of relevance 
in this respect. 
Figure 2-2 Summary of relationships relevant to 
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The above diagram represents a summarized overview of various 
psychobiological correlates of tryptophan administration in 
humans. The scheme represents an integration of emprically based 
information from past studies on tryptophan and serotonergic 
activity. The insertion of double arrows between processes is 
meant to indicate the generally accepted sequence of events for 
the mechanism of action appropriate to tryptophan ingestion. 
This hypothesis is considered the most relevant to the present 
thesis - particularly with respect to antidepressant action. 
No one study incorporates all of the above information and the 
majority have been limited to investigation between the proposed 
extremes of this chain, i.e. adminitration of trytophan and ~5 
alteration in psychological state.~ The accompanying text 
contained in this chapter, considers the evidence relevant to 
relationships between the processes stated in this diagram, 
Ca) Diurnal variations 
Tagliamonte et al. (1974) demonstrated concentrations of 
free serum tryptophan to be 45% higher at midnight than at noon 
in normal subjects. Conversely, total plasma concentrations 
(i.e. free + bound components) did not demonstrate significant 
alterations. The above findings have subsequently led to 
proposals of optimal times for the therapeutic administration of 
tryptophan. On the assumption that the free plasma tr~ophan /-p 
fraction is of relevance to both brain concentrations of 
trytophan and serotonin turnover, it has been postulated that 
tryptophan doses will be maximally utilized to therapeutic 
advantage if administered at night. This was one reason for night 
time administration of tryptophan in the present study. 
More recent investigation by Niskanen et al. ( 1976) has, 
however, failed to support the existence of marked diurnal 
fluctuations in free plasma tryptophan concentrations in normal 
subjects. These authors compared free and total plasma 
concentrations between healthy controls and depressed patients 
(both before and after antidepressant treatment). Seven 
measurements were made over a 24 hour cycle at 4 hourly 
intervals. 
establish 
Cleat-I y, further investigation is required to 
the e;,;istence within and between different 
psychological groups with respect to circadian cycles of plasma 
tryptophan .. 
Evidence also indicates the need for consideration of 
dietary parameters. Young et al. ( 1969) demonstrated that 
changes in meal spacing significantly altered the diurnal pattern 
of plasma tryptophan concentrations. Similarly, as evident from 
diet composition may also Wurtman's 
account 
(1983) demonstrations, 
for variation in diurnal patterns and consequent 
relations proposed between such patterns and psychological state. 
Thus, there is a need to clarify the contributions of factors 
such as psychological status (especially depressed versus 
normal), dietary influences and the differences between total and 
free concentrations with respect to diurnal patterns of 
tryptophan metabolism. 
34 
(b) Seasonal variations 
Coppen & Wood (1983) have considered plasma tryptophan data 
from drug free depressives and normal healthy controls in 
relation to the month of blood collection. Results indicated 
controls to exhibit significantly higher levels of free 
tryptophan than depressives in the Spring, Autumn and early 
Winter, while there was very little difference in the late Winter 
and Summer. 
(c) Relationships to age, height and weight and sex 
The influence of age, height and body weight on total 
plasma tryptophan has been investigated in normals and 
depressives (Banki & Molnar, 1981 Ca) & (b)). No significant 
correlations emerged between such parameters for the combined 
groups. However, it was only after eliminating the effects for 
age, height and weight that significant differences in total 
plasma concentrations between depressives and normals emerged. 
Rose (1967) found sex differences in tryptophan metabolism which 
may be attributable to the changes in tryptophan metabolism 
associated with the menstrual cycle. 
(d) Relationships to diet 
A lack of dietary tryptophan has been demonstrated to cause 
a marked reduction in free serum tryptophan (Biggio et al., 
1974), while protein malnourishment in rats leads to an increase 
in plasma free tryptophan (Miller et al., 1977). Coppen & Wood 
(1978) have demonstrated increased free plasma tryptophan values 
in depressed patients an high protein diet compared to those on 
an ordinary hospital diet. 
(e) Relationships to psychological state 
Total plasma differences between normals and depressives 
Total plasma concentration does not generally support 
biochemical differentiation between groups of normals and 
depressives. Several studies investigating baseline differences 
have indicated no difference between depressives and controls in 
total plasma concentration (Niskanen et al., 1976; Garfinkel et 
al, 1976; Riley & Shaw, 1981; Sepping et al., 1977; Coppen et 
al., 1973; Moller et al., 1976,1979; Whalley et al., 1980; Hoes 
et al., 1981). In addition, no significant differences were 
discernable between depressives and controls up to 6 hours 
following a therapeutic dose ( Hoes et al., 1981; Moller et 
al., 1982). However, three investigations have indicated 
significant elevation of total plasma levels in depressives 
relative to controls (Garfinkel et al., 1976; Coppen, et al. 
1974; Banki & Molnar, 1981 Cb)). In the first case, the 
difference was not detected until administration of a peripheral 
decarboxylase inhibitor. Such evidence tentatively suggests the 
presence of a reduced flux of tryptophan from albumin in 
depression, which 
synthesis is able 
is masked while peripheral indoleamine 
to proceed. Finally, one investigation 
indicated significantly lower concentrations in 
compared to normals (DeMyer et al., 1981). 
depressives 
Total plasma differences between depressives before and after 
recovery 
Evidence emerging from comparison of total tryptophan levels 
in depressives before and after recovery (following a variety of 
antidepressant therapies), also indicates a lack of 
diff~rentiation by this index (Peet et al., 1976; Coppen et al., 
1973; Moller et al., 1979; Niskanen et al., 1976; Hoes et al., 
1981). Although, Whalley et al. (1980) demonstrated a 
significant reduction following a course of ECT in severe 
depressives. 
The value of such studies is impaired by the fact that most 
involved comparison of a pre recovery group with a different post 
recovery group. This approach overlooks the possibility that 
individual differences in pre recovery concentrations may relate 
significantly to post recovery levels. One investigation (Banki 
et al., 1981 Cb)), indicated no difference (on mean HDS scores) 
between low and high total plasma tryptophan subgroups of 
depressives but significantly increased levels of suicidal 
behaviour were associated with the low plasma group. Although 
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high individual variability within the depressive group has been 
observed in more of the above studies (e.g. Whalley et al., 
1980>, no attempts have been made to investigate the relationship 
of such variability to therapeutic response - either to 
conventional therapies or to tryptophan. 
Relevance of total plasma levels to trvptophan adminitration 
The one investigation comparing therapeutic response to 
tryptophan, with total plasma levels in depressives, indicated no 
significant relationships for the group (Hoes et al., 1981). 
However, demand for significant group differences may have led to 
neglect of significant effects for select biochemical or 
psychological types. Until such individual evaluations are 
conducted relevance of this index remains uncertain. 
Free plasma differences between normals and depressives 
A full spectrum of conflicting relationships emerges for 
free plasma levels. Results range from no baseline difference 
between depressives and controls (Garfinkel et al., 1976; Sepping 
et al., 1977; Moller et al., 1976; Riley & Shaw, 1981; Whalley et 
al., 1980; Menna-Perper et al., 1983), to significantly lower 
levels in depressives (Coppen et al., 1973; Coppen & Wood, 1983) 
and finally to significantly higher levels in depressives 
(Niskanen et al., 1976). As with total levels, Garfinkel et al. 
(1976) demonstrated a normal-depressive differentiation following 
administration of carbidopa (peripheral decarboxylase inhibitor), 
that is, a significant increase was observed in depressives and a 
decrease in controls. Similarly, although no baseline 
differences were apparent between normals and depressives, 
insulin administration led to a significant decline in depresives 
but not controls (Menna-Perper et al., 1983). 
Free plasma differences between depressives before and after 
recovery 
Studies comparing depressives before and after recovery 
similarly range from no difference (Moller et al., 1979; Peet et 





at post recovery versus pre recovery (Coppen et 
Finally, Niskanen et al. (1976) demonstrated higher 
concentrations for poorly improved versus well 
improved depressives. Clearly such investigations are limited, 
as are the total plasma investigations, by the failure to take 
account of pre and post recovery levels at an individual level. 
Total and free plasma relationships to psychological state in 
normal subjects 
Most investigations of the relationships between 
psychological state and plasma tryptophan in normal individuals, 
have been related to single doses. In such studies monitoring of 
psychological state is typically limited to anywhere from two to 
four hours. The most frequent reports in this context are for 
significant concurrent elevations in total and free plasma levels 
and subjective ratings of drowsiness (Charney et al., 1982; 
Greenwood et al., 1974; 1975; Yuwiler et al., 1981). Although 
there are indications of similar relationships fallowing chronic 
administration for two weeks (Yuwiler et al., 1981), there has 
been a lack of investigation of general mood altering effects 
following longterm tryptophan administration in normal subjects. 
Value of total and free plasma concentrations as correlates of 
psychological state 
The conflict in outcome between the above investigations 
contributes to the uncertainty of free or total plasma indices as 
reliable and valid correlates of psychological state in depressed 
or normal individuals. The emerging opinion that disorders of 
tryptophan metabolism are only of relevance in select groups of 
depressives (van Praag, 1981; Cappen & Wood, 1983; Faire et al., 
1979; Moller et al., 1980), needs to be acknowledged. Rather 
than comparing large heterogeneous (psychological and 
biochemical) 
individuals 
groups of depressives, 
with abnormal plasma 
focus on relationships in 
tryptophan concentrations 
relative to those with normal levels may be mare fruitful. 
diet, 
The variation in plasma tryptaphan levels with respect to 
time of day, season, sex and weight need ta be considered 
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before relationships to psychological state can be confidently 
determined. It is probable that much of the conflict between the 
studies considered so far may relate to such differences. For 
example, while most investigations employed 12 hour fasting 
periods prior to sampling plasma, the dietary controls before 
this time were highly variable with respect to quantity and 
composition. As previously considered, dietary composition may 
significantly effect plasma tryptophan dynamics <Wurtman, 1982). 
Similarly, the failure ta report tryptaphan sampling times and 
the limitation of several studies to investigation of female 
subjects suggests further potential sources of conflict. 





assay methods - according to Denckla & 
one (Knott & Curzon, 1972) reported data on 
Dewey 
the 
reliability of the procedure within their investigation. Thus, 
potential differences in the accuracy of measurement between 
studies may also contribute to conflicting outcome. 
Approaches to investigation of plasma tryptophan, which take 
concurrent account of the above confounding influences, are 
demanded before the physiological and pharmacological utility of 
such indices can be appropriately assessed. 
(g) Relationships of free and total plasma tryptophan 
to brain trvptophan and serotonin 
If plasma tryptaphan concentrations are to be considered as 
reliable correlates of the psychopharmacological action of the 
amino acid, then it is necessary ta establish something of their 
relationship to brain tryptophan and serotonin metabolism within 






















over which is the superior index simply reflects a 
of viewpoints. However, the same authors 
the superiority of free plasma as opposed to total 
levels, 
Other 
in paralleling CSF tryptophan concentrations in humans. 
studies support existence of significant positive 
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correlations between free but not total plasma tryptophan and 
lumbar and ventricular tryptophan as well as 5HIAA levels 
(Curzon, 1981; Young et al., 1976). In addition, Perez-Cruet et 
al. (1974) demonstrated positive but non-significant correlations 
between free plasma tryptophan and the above CSF indices. In 
contrast, 
higher 
investigation of total plasma revealed significantly 
levels in depressed versus normal controls without 
concomitant changes in CSF tryptophan. 
Information from rat studies also supports significant 
increases in free plasma tryptophan, brain tryptophan and brain 
5HIAA but not total plasma tryptophan (Knott & Curzon, 1972). 
Similarly, concomitant decreases in the above indices (excluding 
total plasma tryptophan and including brain 5HT> have been 
demonstrated following a tryptophan free diet (Biggio et al., 
1974). 
The the above studies indicating a positive correlation 
between free plasma tryptophan and CSF tryptophan and 5HIAA do 
I 
not of course prove that brain tryptophan levels and functional 
5HT synthesis, in humans, is increased by tryptophan 
administration. However, preliminary results from psychiatric 
patients undergoing stereotactic surgery indicated concentrations 
of frontal cortex 5HT were significantly elevated following 
tryptophan infusion (comparable to an oral dose of 3gms) (Curzon, 




not reported. While evidence 





and 5HIAA have been demonstrated in both depressed and normal 
controls, it can not be assumed the relationship is generalizable 
to all types of depression. That is, it is conceivable that 
certain types of depression may be associated with disorders in 
plasma to brain tryptophan transport, in which case such a 
relationship would be expected to break down. 
(h) Value of plasma tryptophan concentrations 
Moller et al. (1980) have reported the inability of plasma 
tryptophan levels to predict antidepressant response to 
tryptophan administration. This conclusion was however only 
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based on the relationship between a single plasma analysis prior 
to tryptophan therapy and following response to two weeks of 
tryptophan ingestion. 
Overall, the 
means of selecting 
value of plasma tryptophan levels as a valid 
positive responders to tryptophan therapy 
remains to be determined. However, there is sufficient evidence 
to indicate that free plasma levels may be of relevance as 
indicators of brain tryptophan and serotonin metabolism and 
associated changes in psychological state. Evaluation of the 
utility of such indices still demands investigation within 
individuals, in order to determine the existence of relationships 
between psychological types and biochemical profiles. The 
validity of such investigations will also demand that account is 
taken of potentially confounding variables such as diet, time of 
day, season, age, sex and weight - demonstrated to relate 
signifcantly to plasma tryptophan concentrations. 
2.3.1.2 Ratio of tryptophan to other 5 other amino acids 
Several authors have argued that the plasma ratio of 
tryptophan ·to five other neutral amino acids (trp/5aa ratio) may 
be a more pertinent indicator than free plasma levels of changes 
relevant to psyhological state (Moller et al., 1976, 1980) as 
well as providing a more valid index of associated changes in 
brain tryptophan and serotonin metabolism (Fernstrom et al., 
1973; Fernstrom & Wurtman, 1974; Wurtman, 1982). The blood to 
brain transport of tryptophan and five other neutral amino acids: 
tyrosine, phenylalanine, leucine, isoleucine and valine appear 
dependent on the same carrier molecule in humans (Pardridge, 
1979; Yuwiler et al., 1977; Wurtman, 1982). Thus, it follows 
that access of tryptophan to the brain will depend to some extent 
on the balance of competition between the above amino acids. 
(a) Dietary influences 
Evidence from rat studies indicates the trp/5aa ratio 
increases following carbohydrate ingestion (Fernstrom & Wurtman, 
1974). This phenomenon appears attributable to the selective 
action of insulin in supressing plasma concentrations of neutral 
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amino acids, excluding tryptophan. As Wurtman & Fernstrom (1974) 
have demonstrated, the action of insulin releases plasma albumin 
from free fatty acid bonds. Consequently, tryptophan's high 
albumin binding affinity results in a maintenance of plasma 
tryptophan levels relative to the the other neutral amino acids 
with low binding affinities. In contrast, protein consumption 
is likely to reduce the ratio, owing to the under representation 
of tryptophan in most protein foods relative to the other neutral 
amino acids. 
Cb) Relationship to age 
Moller et al. (1980) reported a significant 
correlation between age and the trp/5aa ratio (r=-0.53 7 
in a normal sample <n=60). 
(c) Relationship to psychological state 
Differences between normals and depressives 
negative 
p<0.001) 
Lower trp/5aa ratios have been demonstrated in depressives 
relative td normals (DeMeyer et al., 1981). However, the groups 
compared were small, n=18 and n=10 respectively and intergroup 
variability was high. For this reason, more confidence is 
attributed to Moller et al. ·s (1980) finding of no overall 
differentiation between depressives (n=87) and normals 
There 
with 
are some indications of an increase in the trp/5aa 




However, more pertinent findings have emerged from investigation 
of select depressed individuals with plasma ratios (tryptophan 
relative to 3 and 5 competitiors) well below the normal range. 
Significantly positive antidepressant response to tryptophan 
therapy was associated with low trp/5aa ratios, relative to 
depressed individuals with normal ratios where therapeutic 
effect was negligible (Moller et al., 1976; 1980). 
(d) Relevance to tryptophan adminstration 
Firstly, findings that brain tryptophan concentration and 
serotonin synthesis might be dependent on the trp/5aa ratio in 
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humans (Fernstrom & Wurtman, 1974; James et al., 1976; Curzon, 
1981) indicate that administration of tryptophan in such a way as 





in the psychotherapeutic context, investigations 
al. (1980) have indicated the potential value of 
the trp/5aa ratio as a predictor of therapeutic 
tryptophan in both unipolar and bipolar depression. 
response to 
That is, if 
their total depressive sample (n=87), heterogeneous with respect 
the above index, was considered, then a satisfactory therapeutic 
response would have been of the order of 28¼ (comparable to the 
placebo effect - Wechsler et al., 1965). However, selection of 
patients with plasma ratios below the 30th (n=18) or 15th (n=10) 
percentiles demonstrated a remission frequency following 
tryptophan therapy of 60¼ and 80¼ respectively (i.e. of an order 
comparable to that following tricyclic therapy and ECT 
respectively Wechsler et al., 1965). Thus, it appears the 
plasma trp/5aa ratio may be indicative of tryptophan metabolism 
disorders in some depressions, which are responsive to tryptophan 
therapy. 
(e) Relationship of trp/5aa ratio to brain tryptophan and 
serotonin 
A clear positive correlation has been established between 
brain tryptophan concentration and the trp/5aa ratio (Fernstrom & 
Wurtman, 1974; James et al., 1976; Wurtman, 1982) in rats. 
Fernstrom & Wurtman (1972, 1974) also demonstrated a positive 
correlation between the synthesis of serotonin and the above 
parameters in rats. 
It was found that large increases in plasma tryptophan 
concentrations did not correlate with increases in brain 
tryptophan and serotonin (in rats) unless the trp/5aa ratio was 
elevated (Fernstrom & Wurtman, 1972). Similarly, Yuwiler et al. 
(1977) found the amino acid competition for carrier sites was 
quantitatively the most important factor, relative to the 
concentration of free and bound plasma tryptophan, in regulating 
tryptophan uptake to the brain. 
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The above findings in rats do not necessarily suggest that 
the tryp/5aa ratio is a more reliable indicator of brain 
tryptophan and serotonin metabolism in humans. However, the 
trp/5aa ratio has been demonstrated to more reliably reflect CSF 
tryptophan and 5HIAA concentrations than free or total plasma 
concentrations in humans <Perez-Cruet et al., 1974). 
(f) Value of the trp/5aa ratio relative to plasma free 
tryptophan concentrations 
Several comparative investigations of the two indices in 
both rats and humans have consistently reported the tryp/5aa 
ratio to be superior to free plasma concentrations as a correlate 
of central serotonin metabolism. (Yuwiler et al., 1977; Perez-
Cruet et al., 1974; Ferstrom & Wurtman, 1972). Curzon (1981) has 
suggested that the variability attributed to either index may be 
a consequence of the plasma sampling procedures. As indicated 
above both indices may provide reliable correlates of brain and 
CSF metabolism under certain circumstances. Evidence also 
indicates that certain factors such as diet composition may lead 
to predictable changes in the accuracy of either index as a 
correlate of central metabolism or psychological state. 
Consequently, the most productive future strategies would seem 
best aimed at obtaining information on both parameters across a 
variety of psychophysiological and psychopharmacological 
contexts. In this way, the comparitive value of either index as 
a screening variable for therapeutic applications of tryptophan 
may be established. 
Both indicies demonstrate dramatic physiological 
fluctuations in relation to circadian periods and dietary 
factors. Although, some evidence exists to support significant 
correlations of physiological changes in the plasma indices with 
brain tryptophan concentration and serotonin synthesis (Fernstrom 
& Wurtman, 1971; Wurtman, 1982 - in rats>, it is difficult to 
accept that central serotonin metabolism is totally dependent on 
peripheral indices exhibiting almost constant and dramatic flux. 
Although absence of dietary tryptophan for 24 hours was 
demonstrated to reduce brain tryptophan by 90%, serotonin by 58% 
and 5HIAA by 76% (Biggio et al., 1974) in rats, the sensitivity 
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of the human brain in this respect remains undetermined. 
Neckers et al. (1977) have indicated, that while the above 
plasma indices relate to brain tryptophan concentration, other 
central mechanisms such as changes in tryptophan hydroxylase 
activity in relation to brain tryptophan concentration are 
implicated in the regulation of brain serotonin synthesis in the 
rat. The potential for such regulation in human systems must be 
considered as a possible limitation ta reliance on peripheral 
indicators of central effects. 
2.3.20 __ t_h_e_r __ p.__o_t_e_n_t_i_a_l _ i_n_d_i_c_a_t_o_r_s _ o_f ___ b_r_a_i_n ___ t_r~y~p_t_o~p_h_a_n_ 
concentration 
Other biochemical variables which may be of relevance to 
brain concentrations of tryptophan and associated changes in 
psychological state include the degree to which tryptophan is 
freed from albumin as the blood passes through the brain 
(Pardridge, 1979; and kinetic characteristics of the blood to 
brain transport system (James et al., 1976). Curzon (1969) has 
also proposed associations between disorders of tryptophan 
pyrrolase and depression. That is, it has been suggested that the 
activity of this enzyme is abnormally elevated in certain 
depressions and, thus, may reduce the amount of tryptophan 
normally avialable for transport to the brain. Such parameters 
are of relevance to the present investigation ta the extent that 
disorders in such processes may account for psychological 
resistance to trytophan administration in some individuals. That 
is, unlike plasma tryptophan concentrations and the tryp/5aa 
ratio, where disorders (i.e. deficiencies) may be remediated by 
tryptophan loading, such therapeutic procedures would not 
necessarily be relevant to disorders of the transport system. 
The potential for such disorders in depression has been 
indicated by Garkinkel (1976), where differences in tryptophan 
metabolism between normals and unipolar depressives were not 
revealed until the administration of a peripheral decarboxylase 
inhibitor. The increase in plasma tryptophan concentrations for 
depressives following this intervention, could be indicative of 
reduced CNS uptake of tryptophan. Similary, the findings of 
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Menna-Perper et al. (1983), that depressive-normal differences in 
free tryptophan levels were only revealed following insulin 
administration is indicative of potential tryptophan disorders in 
some depressions, 
the trp/5aa ratio. 
other than plasma tryptophan concentration or 
Obviously further investigation is required to test such 
hypotheses. Meanwhile, the possibility of such disorders must be 
considered as additional sources of potential conflict in the 
outcome between investigations into relationships of plasma 
tryptophan indices, brain metabolism and psychological state. 
2.3.3 Urinary indices of tryptophan metabolism 
A limited number of studies have investigated the 
correlation of urinary catabolites, assumed to reflect tryptophan 
and serotonin metabolism, with psychological state. The 
motivation for investigation being that such products may 
reflect aspects of central nervous system metabolism. Other less 
aspiring studies are based on assumptions that such measurements 
may be indicative of peripheral tryptophan metabolism. 
Frazer et al. (1973) demonstrated no difference in baseline 
urinary excretion of nine such metabolites (including kynurenine, 
5HIAA and IAA) in a small group of depressed and non depressed 
psychiatric patients. Similarly, no changes were determined 
following a 2 gm oral tryptophan load. In addition, Coppen et 
al. (1974) found no difference in 5HIAA and IAA between severe 
depressives and normals or depressives before and after recovery. 
On the basis, of such evidence the authors claim there is no 
support for disorders of peripheral and central tryptophan 
metabolism in depression. In contrast, Garfinkel et al (1979) 
demonstrated significantly higher concentrations of urinary 5HIAA 
in depressives versus controls and 





administration. Such findings contributed to the conclusion of 
reduced CNS uptake of tryptophan in depression. 
It is not considered that a great deal of importance should 
be placed on urinary catabolites as indicators of tryptophan 
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metabolism for as Klerman (1966) commented ''trying to understand 
brain chemistry through the study of urine is like trying to find 
out the secret plans of the Supreme Soviet by analyzing the 
sewage from the Kremlin". The above investigations of urinary 
catabolites are also considered to suffer from many of the 
methodogical inadequacies directed at psychophysiological and 
psychopharmacological investigations of plasma tryptophan such as 
between group comparisons. Despite the appeal of urinary 
monitoring, as a less invasive biochemical procedure, relative to 
plasma or CSF sampling, its value as a reflector of CNS 
metabolism must be considered inferior. For this reason, more in 
depth analysis of the research on 
omitted from the present thesis. 
urinary catabolites was 
2.3c4 Relevance of serotonin to the psychophysioloqical and 
psychopharmacoloqical relationships of tryptophan 
t{ 
Sepf-ate demonstrati ans of significant rel ati onshi ps between 
plasma tryptophan dynamics and psychological state on the one 
hand and between the plasma dynamics and brain tryptophan + 
serotonin metabolites (CSF tryptophan and 5HIAA concentrations 
respectively) on the other indirectly endorse the psychological 
relevance of serotonin with respect to tryptophan metabolism. In 
addition, significant positive correlations are indicated between 
brain tryptophan and serotonin synthesis in rats (Fernstrom & 
Wurtman, 1974) and in humans on the basis of CSF measurements 
(Young & Gauthier, 1981). Tagl i amonte et al. ( 1971), have al so 
indicated in studies with rats that drugs which alter serotonin 
synthesis (e.g. reserpine, lithium, d-amphetamine, p-
chlorophenyalanine) tend to effect parallel changes in brain 
tryptaphan concentration. Whether such drugs effect serotonin 
synthesis via alteration of tryptophan concentration or whether 
al tet-ati ons in serotonin synthesis feed back to control 
tryptophan concentration is uncertain. However, such studies 
indicate close association between tryptophan concentration and 
br~ain serotonin synthesis across a wide variety of 
pharmacological and physiological situations. 
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2.3.4.1 Psychophysioloqical relevance of serotonin 
The psychological significance of serotonin in states of 
depression has been indicated in physiological contexts 
independent of tryptophan administration. The two main sources 
of information in this respect come from correlations between 
psychological state and CSF serotonin metabolites and secondly, 
between postmortem brain 5HIAA concentrations and knowledge of 
affective state prior ta death. 
Measurements of CSF serotonin metabolites such as 5HIAA have 
been made in relation to psychological state on the assumption 
that such concentrations reflect brain serotonin metabolism. 
Several investigations have demonstrated significantly reduced 
CSF 5HIAA concentrations in depressed versus normal individuals 
(Coppen et al., 1972; Asberg & Traskman, 1981; Bridges et al., 
1976; Garelis, 1981; van Praag & Korf, 1970). 
Despite the apparent unanimity of results in this area, 
caution is required in assuming that CSF 5HIAA concentrations are 
reflective of brain serotonin metabolism. Young & Gauthier (1981) 
have demonstrated the potential distortions of measurment arising 
from lumbar punctures which have not been preceeded by cisternal 
displacement (i.e. 0~ displacement of CSF from the lateral 
.L. 
ventricles ta the lumbar sac where it is sampled). Lumbar, as 
opposed to cisternal fluids, appear ta reflect certain biases due 
to the dynamics of the transport systems between the two 
locations. Far example, 5HIAA and IAA are transported out of the 
spinal 
from 
subarachnaid space by the same system, thus competition 
the more abundant 5HIAA is likely to obscure brain 
relationships when the lumbar sample is not preceeded by 
cisternal displacement. 
Other methodological problems such as the failure to match 
controls and depressives far age, sex a?.('body weight - all of /_4 
which may significantly effect CSF measurements <Asberg & 








In addition, such 
psychologically 
heterogeneous samples. Finally numerous criticisms have been 
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leveled at the inaccuracy and unreliability of fluorometric assay 
methods and probenecid techniques (Gabay, 1981). Garelis (1981) 
showed that probenecid administration may result in altered 
serotonin metabolism and psychological state. In addition, its 
application may lead to the unusual event of serotonin exchange 
between the blood and the CSF. 
While the value of CSF 5HIAA as an indicator of tryptophan 
metabolism remains uncertain, the fact that plasma free 
tryptophan levels (Young & Gauthier, 1981; Curzon, 1981; Young et 
al, 1976) and the tryp/5aa ratio {Fernstrom & Wurtman, 1972; 
1974; James et al., 1976; Wurtman, 1982) correlate positively 
with CSF 5HIAA, indicate that such parameters may be of more 
practical value as predictors of therapeutic response to 
tryptophan. Plasma is more acessible to biochemical analysis 
than CSF. In addition, the tryp/5aa ratio has been shown to be a 
useful predictor of therapeutic response to tryptophan (Moller et 
al., 1976; 1980). Finally, there is no compelling evidence to 
indicate the superiority of CSF 5HIAA over the plasma tryptophan 
dynamics as indicators of central serotonin metabolism. 
In th~ context of postmortem investigations, Coppen (1969) 
reported significantly reduced hindbrain serotonin 
concentrations in the autopsied brains of depressed suicide 
victims compared to controls who died of other causes. The same 
author also reported significantly reduced 5HIAA in suicides 
versus non-suicides, with a 25% lower level in depressed versus 
non-depressed subjects. Such findings indicate that serotonin 
synthesis in the brain stem of depressives may be decreased. 
general agreement were the findings of Banki et al. (1981 
In 
( b) ) ' 
where symptoms relating to suicidal behaviour (as well as anxiety 
and insomnia) were significantly more severe in the lower third 
of a depressive inpatient group with respect to CSF-5HIAA 
concentration, relative to the highest third. 
2.3.4.2 Pharmacological relevance of serotonin 
Pharmacologically based inferences concerning the 
psychological importance of serotonin metabolism have largely 
been drawn from the action of certain antidepressant drugs on 
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this neurotransmitter·s activity. Actions of certain tricyclic 
antidepressants in blocking serotonin reuptake, e.g. imipramine 
CCorrodi ~( Fu>:e, 1968), clomipramine (Meek & Werdinius, 1970) 
and nortryptiline CMcGeer et al., 1978) have been demonstrated. 
Similarly, various MADI antidepressants have been shown to 
potentiate serotonergic action (Asberg & Traskman, 1981). As is 
evident from Figure 2-2, inhibition of MADI will inhibit the 
degradation of serotonin to 5HIAA, thus effectively leading to an 
elevation in brain serotonin concentration. The the MADI's and 
tricyclic uptake blockers can both be assumed, on the basis of 
indirect evidence, to increase the concentration of brain 
serotonin. 
depressants 
In addition, administration of psychological 
such as reserpine have been demonstrated to deplete 
both central and peripheral serotonin concentrations (Goth, 1978; 
Goodman ~< Gil man, 1980). Chronic admi 7~trati on of this drug has / (. 
i \,._ ' ' 
been associated with depression and suicide in humans (Goth, 
1978). 
Determination of serotonergic function through investigation 
of drug effects such as the above is hindered by their lack of 
specificity for serotonin. For example reserpine also leads to 
depletion of the catecholamines (Goth, 1978; Mendels & Frazer, 
1974). Similarly, administration of many of the tricyclics 
mentioned above appears to be associated with a blockage of 
catecholamine reuptake (Duquesne & Reeves, 1982). Thus, 
alteration of serotonin metabolism is not the exclusive effect 
of the above agentsa Consequently, the utility of such 
pharmacological evidence is limited to suggestions of the general 
psychological relevance of serotonin to depression. That is, 
there is a general indication that the both tricyclic and MADI's 
act, via different mechanisms, towards a common effect of 
enhancing the availability of brain serotonin (Aghajanian & Wang, 
1978). The above pharmacological findings are insufficient to 
definitively implicate altered serotonin metabolism in the 
pathogenesis of depression. However, in combination with the 
psychophysiological evidence considered previously, there is 
general support for theories of central serotonin depletion in 
some depressions. Further investigation is required to determine 
if serotonin depletion is par~:~:)ed by reductions in free plasma X 
tryptophan concentrations and/or trp/5aa ratios. 
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The difficulties in elucidating relationships between 
serotonergic function and psychological state from investigation 
of drugs such as those mentioned in this section, with non 
specific/exclusive serotonergic effects, indicates a potential 
investigatory role for tryptophan. This proposal is forwarded 
and justified in the final chapter of this thesis. 
2.3.5 Value of psychophysiological and psychopharmacological 
investigations of tryptophan 
Overall, it is considered that the majority of evidence 
lends support to the proposed action mechanism (Figure 2-2). 
Most of the relevant links in the chain have been considered 
separately in the above discussion. Clearly, the inaccessibility 
of brain metabolites in humans has hindered concurrent 
investigation of the total action mechanism. Thus, verfication 
of the sequences between plasma indices and brain relationships 
such as tryptophan and serotonin concentrations has largely been 
limited to rats. That is, the sequential process of: tryptophan 
administration -> increase in plasma tryptophan or competing 
amino acids -> increase in brain tryptophan -> increase in 
serotonin concentration has been clearly established within rats 
(Fernstrom & Wurtman, 1974). 
One aspect of the proposed action mechanism in Figure 2-2 
which has not been sufficiently verified is whether tryptaphan 
administration leads to a functional turnover of brain serotonin 
- a logical requirement if tryptophan administration is to effect 
an alteration in psychological state. The findings that brain 
tryptophan concentration correlates with serotonin synthesis does 
not imply a functional metabolic connection such as alteration in 
transmission of nerve impluses across the synapse. Similarly, 
correlations between plasma parameters (exhibiting correlations 
with brain tryptophan concentration and serotonin synthesis) and 
psychological state do not implicate altered serotonergic 
activity as mediating the relationship. 
In humans the situation is further confounded by uncertainty 
over the relationship of CSF components such as 5HIAA to 
functional brain serotonin metabolism. As Grah/~-Smith (1973) 
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has demonstrated with rats, the assumption of CSF reflection in 
this respect may be unfounded in the context of tryptophan 
administration. That is, administration of tryptophan alone, was 
shown to effect only slight increases in brain 5HT, more dramatic 
5HIAA production and little behavioural change. In contrast, 
administration of tryptaphan following pretreatment with an MADI 
was associated with similar 5HT elevation, reduced 5HIAA relative 
to the former situation, and marked elevation in hyperactive 
behavior. The potential implication of such demonstrations is 
that 5HIAA monitoring, particularly following tryptophan loading, 
may in part be reflective of intraneuronal 5HT metabolism - that 
is serotonin which never becomes functionally active. Thus, it 
must be considered that brain 5HT turnover to 5HIAA (as measured 
in the CSF) in humans may not be exclusively reflective of 
functional serotonergic neuronal activity. 
Finally, while most links in the mechanism proposed in 
Figure 2-2 correlate closely in time, the final aspect of altered 
psychological state is considerably delayed in certain contexts. 
That is, although some psychological correlates have been 
reported between 1/2 and hour to two hours following tryptophan 
administration in normal subjects (Yuwiler et al., 1981; 
Greenwood et al., 1974; 1975; Charney et al., 1982), 
significant antidepressant effects are generally not apparent 
until two weeks of administration. Thus, the rapid increase in 
serotonin turnover following tryptophan administration does not 
correlate immediately with antidepressant effects. However, such 
delays in psychological effect are also typical of most 
antidepressant drugs, including those assumed to primarily alter 
serotonin metabolism. For example, despite the extremely rapid 
pharmacological effect of such drugs e.g. MAO inhibitors can 
double the concentration of brain serotonin in less than an hour 
(Gath, 1978), antidepressant effects are generally not exerted 
for two weeks (Duquesne & Reeves, 1982). Thus, while elevation 
of brain serotonin appears requisite ta the psychological 
correlates of tryptophan and the MAOI's it seems that more long 
term consequences of this process are of specific significance to 
antidepressant effects in both cases. 
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CHAPTER III 
DESIGN AND ANALYSIS 
3.1 INTRODUCTION 
The distinguishing features of the present design include 
its longitudinal time base and a focus on within subject 
assessment and analysis. The design included extended non-
treatment (baseline), placebo and active treatment phases as 
conditions for comparison within subjects. The single case 
approach led to a flexibility in design which would not have been 
possible in a conventional group comparative experiment. That 
is, experimental variables such as phase order, phase length, and 
dose level could be tailored to individual requirements without 
(_ jeopEdizing analytical and evaluative procedures. Similarly, 
the purpose of inquiry i.e. to investigate the mood altering 
properties of tryptophan, was sufficiently flexible to avoid the 
requirement for a homogeneous psychological sample. While 
tryptophan seems to have most relevance as an antidepressant 
there are valid reasons, to be considered in this Chapter, for 
investigating relationships in non depressed individuals. 
Section 3.2 of this chapter provides the background and 
justification for the general design features of the present 
experiment. The following section (3.3) presents a more detailed 
description of experimental procedures and discusses reasons 
behind decisions relating to dose level, phase length and other 
dependent variables. Section 3.4 involves discussion of the 
principles guiding selection of psychological scales. A detailed 
description of each scale is provided along with information on 
the validity and reliability of the instruments. Methods used in 
application and processing of scales are also discussed. 
final section (3.5) data analytic proc~dures are presented. 
In the 
3.2 GENERAL DESIGN FEATURES 
3.2.1 Lonqitudinal time base 
A decision on the longitudinal time profile was necessitated 
by the inclusion of comparative conditions within subjects. 
Recommendations relating to the required length fa~ a fair 
evaluation of active treatment effects were also influential in 
this decision. 
If tryptophan is to be classed as an antidepressant then 28 
days is usually required as the minimum fair test of such 
qualities (Cooper,1979). Wittenborn (1978) advocates two to four 
weeks as sufficient for detection of anxiolytic effects and three 
to four weeks for the discernment of antidepressant drug effects. 
In a review of the therapeutic applications of 
le Praag (1981) reports that ben}(ficial effects, 
tryptophan, van 
if any, appear 
after two to three weeks with gradually increasing prominence in 
the next three to five weeks. The above evidence indicates a 
requirement for a minimum of two weeks to detect therapeutic 
effects. Although only some subjects were classed as depressed 
in the present study, 18 out of a total of 20 participants 
consumed tryptophan for at least two weeks. 
The longitudinal time base, 
to provide a more 




psychological functioning than evaluations based on single pre 
and post intervention measurements. That is, the former 
approach views psychological functioning as a dynamic process 
whereby meaningful changes can be assessed against the background 
noise e.g. circadian fluctuations. In contrast, evaluation based 
on single assessments or short time bases may result in 
unrepresentative impressions of psychological state. 
3.2.2 Sinqle case research 
The decision to focus inquiry and evaluation within subjects 
was based on empirical demonstration of significant inter-
individual differences in variables affecting the psychodynamics 
of trypt • phan ingestion and psychotropic drugs in general. In 
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the context of antidepressant applications of tryptophan certain 
aspects of psychological and biochemical individuality have 
emerged as significant correlates with efficacy. As mentioned in 
Chapter II, factors such as the plasma trp/5aa ratio <Moller et 
al, 1980) and the polarity of depression <Murphy et al, 1974; 
Farkas et al, 1976) correlate significantly with therapeutic 
outcome. Chouinard et al ( 1978) , also demonstrated the 
requirement for higher therapeutic dose levels in bipolar 
depressives compared to unipolars. Thus, · it is apparent that 
certain individual variations mark a source for the reduction of 
conflict surrounding mood altering properties of tryptophan 
administration and indicate the probable limitation of 
tryptophan's effectiveness to select psychological or biochemical 
typesa Consequently, within subject evaluation was considered 
more appropriate to the detection of discriminating factors than 
intergroup comparisons. 
Evidence emerging from orthomolecular approaches to 
psychiatry <Hoffer, 1974) has indicated 1000 fold differences 
between individuals in nutrient doses required to obtain and 
maintain optimal biochemical and psychological states. The 
magnitude of interindividual variation in human pharmacokinetics 
is also supported by evidence from m• ~e conventional therapeutic 
contexts. Duquesne & Reeves (1982) report that dose requirements 
for the tricyclics range from 20 to 300 mg/day between 
individuals. High interindividual differences in drug metabolism 
(e.g. plasma half life and steady state plasma levels) for 
antidepressants: desmethylimipramine and nortripyline have also 
been documented Sjoqvist (1973). Such findings indicate a need to 
analyse individuals separately in order to remain alert to 
further discriminating factors. 
Kratochwil! (1978) notes that acknowledQement of individual 
differences in experimental and physiological psychology 
motivated the development of methodology characterizing group 
approaches to e>:peri mentati on. The group comparative 
methodology, however, appears to have been motivated by the 
search for universal laws which could not be Justifiably drawn 
from single cases. That is, the 'acknowledgement' here seemed 
not concerned with the detection and focus on individual 
differences but with striving to smooth over such variability by 
attending to group averages. Dunlap's ( 1932) comment that 
"thet-e is no average rat" reflects apt criticism of such early 
approaches to group experimentation. Similarly, in the present 
study, group averages were not considered relevant to 
acknowledgement of tryptophan's efficacy within individuals. 
Although the present design structure employed single case 
methodology various experimental decisions were still dependent 
on group derived principles e.g. dose levels, administration time 
and the chosen composition of psychological scales. 
considered that a more ideal methodology would have 
exploration of these variables together with biochemical 





of the transport system within individuals. Time limits precluded 
execution of such ideals in the present study. However, the 
overall ideal of investigating and evaluating relationships 
within individuals was maintained. The philosophy of the present 
design can be considered in keeping with Allport's (1962) claim 
that the science of psychology should attend to the uniqueness of 
the individual. 
3.3 EXPERIMENTAL PROCEDURE 
3.3.1 Subject selection 
Subjects were selected through notices posted at several 
locations throughout Christchurch: Canterbury University, city 
and surburban Health Food Stores and 
School. 
Christchurch Clinical 
The employment of single case methodology allowed greater 
inter subject variability than would have been the case with more 
conventional group designs. This led to exploration of a wider 
range of subject and treatment variables. In contrast, group 
comparative approaches demand randomized subject selection and 
homogeneity for some experimental variables across subjects. 
Exclusion criteria in the present experiment were limited to the 
medical and psychological conditions listed on the demographic 
questionnaire (Appendix A). 
,:::-, 
...ib 
Recipients of antidepressants, tranquilizers and analgesics 
were not excluded, except on grounds of medical advice. 
Consequently, one participant continued to ·consume his usual 
prescribed antidepressants and tranquilizers throughout the 
experimental period. Other subjects periodically consumed 
various non-prescribed painkillers over the trial period. 
Medical advice would have been sought regarding inclusion of 
'severely depressed' <Zung, 1972) subjects. However, this 
situation did not arise. 
All respondents met with the author for a detailed outline 
of the practical experimental requirements and were presented 
with a written outline of the general aims of the research, 
without compromising single blind conditions. After completing 
the demographic questionaire (Appendix A) subjects were given a 
few days to decide on participation. Subjects were in no way 
pressured or coerced into participation. In addition to the 
general undesirability of this recruitment procedure, it was 
considered more likely to obtain motivated and conscientious 
subjects under conditions of voluntary and informed consent. A 
profile of the final sample (n=20) appears in Chapter IV. 
3.3.2 Experimental Design 
At the point of entry to the program subjects were presented 
with the following design options: 
:baseline 11 tablets lwashoutl tablets :baseline 21 
14 days 14-28 days 7 days 7-28 days 7 days 
Subjects were not informed of the differentiation between 
or within a tablet taking phase. For 19 subjects the first 
tablet phase consisted of tryptophan and the second placebo, 
while the order was reversed for the 20th subject. The final 
individual designs indicate slight departures from the above 
pattern for 11 out of 20 subjects. This variability was due to 
preference on the subject's part far an alteration in design 
prior to or during participation, which was acceptable with 
respect to the design limits. In other cases subjects dropped 
out unexpectedly or were advised by the author to reduce the 
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length of participation. The design relevant to each participant 
is presented in Chapter IV. 
It is acknowledged that it would have been desirable to 
place half 
schedule. 
the subjects on a placebo followed by tryptophan 
That is, certain significant effects have been 
reported in relation to the order of active treatment and placebo 
phases (l<och et al., 1983). The reasons against this 
optimization in the present investigation were as follows. For 
subjects seeking primarily therapeutic benefit it seemed more 
desirable to start them on tryptophan as soon as possible in 
order to determine its effectiveness. If the compound proved 
ineffective and/or psychological state deteriorated, subjects 
could be more rapidly referred to alternative therapy sources. 
Secondly, for al 1 subjects, it was considered desirable to 
detect unfavourable reactions to tryptophan early in the program 
so that subjects could drop out near the start. This happened for 
one subject who experienced nausea on two separate occasions 
after consuming 6gms and 3gms respectively for three days. This 
individual was not included in the final analysis due to 
insufficiency of data. Placebo data collected prior to 
tryptophan intake, in this subject, would have been wasted. 
Finally, attempts to evaluate phase order would have required 
between group comparison of small numbers of unmatched subjects. 
With the present design, subjects who left the trial earlier than 
planned had completed at least part tryptophan cnndition. 
3.3.3 Experimental tasks 
During the initial meeting with the author, subjects 
completed the demographic questionaire, Trait and State Anxiety 
Zung Depression scale and the HSCL. Samples of all scales, 
scales appear in Appendix " H7 while descriptions and details on 
application and processing are presented in section 3.5 of this 
chapter. Subjects committed to proceed were given sufficient 
scales to cover the 2 week baseline phase. M~etings between 
subjects and the author were arranged at weekly/fortnightly 
intervals thr• uf'f1t the e,:per-iment to return and replenish 
scales, discuss/"progress and implement design modifications if 
required. Subjects were also urged to make contact with the 
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author more frequently, if necessary, 
queft~ies with the procedure. 
regarding problems or 
All 
visual 
subjects were instructed to complete a series of 16 
analogue moodscales each morning on rising and each 
evening (see Appendix for samples of the scales) for the duration 
of their experimental program. These scales are discussed in 
section 3.5. Subjects were given an option regarding completion 
time for the evening scale but were engendered to keep as close 
as possible to the chosen time from day to day. Consistency was 
checked in this respect for each subject. Most subjects (n=18) 
completed the evening scale just prior to retiring while the 
remaining two chose an earlier period i.e. an return home from 
work. In addition, subjects were instructed to complete the 
State Anxiety, Zung and HSCL scales every seven days throughout 
the program, after the morning moodscale. 
Instructions for scale completion were given 
the duration of time to be covered by each scale) 
(particularly 
and correct 
responding in this respect checked with each subject at the 
initiation of the program. Further details relating to the 
administration of each scale are presented in section 3.5. The 
above format for scale completion was uniform across the baseline 
and washout phases for each subject. During tryptophan and 
placebo phases, the only alteration to the above format was 
ingestion of tablets prior to completion of the evening scale. 
Thus, the first moodscale record for tryptophan and placebo 
phases represents a morning rating approximately 8-12 hours 
following the first ingested dose. 
3.3.4 Dose levels and administration 
Most recommendations for dose level are oriented towards 
depressed individuals. The single case approach allowed for 
flexibility in this parameter, in that dose levels could be 
adjusted on the basis of motivation for entering the study and 
factors such as 'haw many tablets subjects considered they could 
comfortably swallow·. Thus, if a subject was prepared to 
participate on the basis of a lower than recommended dose, they 
could still be usefully included in the study. Before any 
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decisions were made regarding maximum dose levels the literature 
was examined for guidelines and relationships between dose level 
and negative/harmful side effects. 
3.3.4.1 Side effects and toxicity of tryptophan 
Tryptophan was considered a 'drug· within the present study 
due to the fact that it was administered at up to twelve times 
the normal daily dietary requirement. Some investigators avoid 
this classification of tryptophan on the basis of its status as a 
naturally • curring, essential dietary component. This may 
account for the paucity of investigations relevant to toxicity or 
side effects. Comment on the inadequacy of information in this 
regard appears in The Side Effects of Drugs Annual: "Despite the 
plausibility and appeal of tryptophan to treat depression, the 
scientific evidence is currently inadequate to endorse either its 
safety or efficacy" (Blackwel 1, 1980). 
The literature on side effects was considered in conjunction 
with reports on optimal dose levels before upper levels were 
established. Attention was given to studies investigating 
effects in normal (non-psychiatric) as well as depressed 
individuals. A limitation of most studies investigating toxicity 
is their short term duration, i.e. generally such studies have 
depended on monitoring of a single oral 
administration. 
load or seven days 
Young & Sourkes (1977) have presented a list of potentially 
adverse reactions which relate to the increase of peripheral 
catabolites following tryptophan ingestion, e.g., inhibition of 
glucogenesis. However, there is no evidence to indicate the 
degree of severity of such states or of the doses and length of 
administration required to ac¥t}e them. With respect to the 
inhibition of glucogenesis, Milne (1968) has reported evidence 
of hyperglycemia followed by hypoglycemia after lethal doses in 
rats, although this was not considered a significant determinant 
in the causes of mortality. Other studies have reported 
depressed blood sugar levels in response to tryptophan 
administration. Domin• & Krause (1974) reported that several 
subjects exhibited symptoms resembling hypoglycemia following a 
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single 3 gm dose. 
Extrapolating from rats, lethal dose levels (LD50) in humans 
estimated at aprroximately 6.5 mmoles/kg body weight 
(Gullino, 1956) or 93 gms for a 70 kg body weight. The same 
author also reports that acute intravenous doses of 7.5 9ms have 
('.lj{ 
been administered to adults with no evidence of perm~Mept harmful 
r\ , 
effects. Empirically based reports of side effect~ which appear 
with most frequency in the literature, 
depressed samples, include: 
across normal and 
(1) Drowsiness (Charney et al., 1982; 
Shopsin, 
Greenwood et al., 1974; 
1975; 
1962; 
Hat-tmann, 1977, 1981; 
Yuwiler et al., 1981). 
1978; Smith ~< Prockop 7 
The doses for these reports range 
from 1-6 gms/day and length of administration from 1-49 days. 
In general r~ports were noted to occur 1/2 - 1 hour following 
administration and to last one to four hours. 




Car~ral 1 et al • , 1970; Charney et al., 1982; Chouinard et 
1978; Shopsin, 1978; Wyatt et al. 1970; Brezinova et al., 
The nausea was typically characterized as mild and 
transient i.e~ not resulting in vomitting and receeding 30 - 60 
minutes following onset for dose ranges of 3.5 -7.5 gms/day and 
trial times of 14-49 days. 
A limited number of investigations have been conducted into 
the physiological side effects of large tryptophan loads. 
Broadhurst (1970) following 36 laboratory investigations (n=115, 
dose = 6gms/day, time = 28 days), reported no evidence of 
toxicity in this respect. Within the same dose and time 
parameters, Herrington et al. ( 1974, 1976) reported that 
haematological analyses: serum electrolytes, plasma protein and 
liver function tests, were all within the normal range. 
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3.3.4.2 Side effect monitoring in the present study 
It was considered necessary to include some monitoring of 
the commonly reported side effects from the tryptophan literature 
and the more common symptoms (Green, 1964) that would normally be 
reviewed for all psychoactive drugs. Such states were monitered 
throughout all experimental phases. 
information was achf}/ved with a 
(Appendix A). Formulation of this 
Collection of side effect 
daily (evening) checklist 
list is described in section 
Its value as a reliable and valid indicator of the side 
effects associated with chronic tryptophan administration is 
uncertain but it seemed necessary to incorporate some check on 
side the effects reported in the literature which were not 
specifcally 
I\ 
covered in the standard daily scales. Measures of 
potentially harmful physiological/biochemical processes, were not 
feasible within the present study. 
3.3.4.3 Optimum therapeutic dose levels 
Chouinard et al. (1978) indicated the probable existence of 
a "therapeutic window effect" with respect to plasma tryptophan 
concentration. These authors demonstrated that the efficacy of a 
tryptophan+nicotinamide combination in treatment of severe 
depression diminished following a dose increase from 4gms+1gm/day 
to 6gms+1.5g/day, respectively. Other studies have supported the 
therapeutic window proposition. Herrington et al ( 1974, 1976) 
demonstrated an increase of tryptophan dose from 6 to 8 gms/day 
was associated with declines in efficacy. Thus, Chouinard et al. 
(1979) proposed an optimal dose of 6gms/day or below for unipolar 
depression (and above 6gms/day for bipolar depression). Other 
investigations, e.g., Coppen et al. (1972) did not support the 
above findings. A dose of 9gms/day was of significant benefit in 
unipolar depressives. However, the dose was split into three 
daily administrations compared to a single dose in the previous 
Finally, Young & Sourkes (1977) investigated the mean studies. 
daily doses involved in trials reporting antidepressant 
tryptophan action versus those studies reporting no therapeutic 
efficacy. 
(p<. 05) 
The sucessful trials were found to use a significantly 
lower dose i.e., 6.1 +/- 0.6g (6 studies) compared to 
ineffective trials with doses of 8.7 +/- 0.9g (7 studies). 
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Time constraints limited the investigation of optimal dose 
levels within individuals in the present study. Thus, the above 
recommendations were considered in setting the upper dose limit 
for all subjects at 6gms/day. This level could also be 
considered well within limits established to be free of permenant 
harmful/toxic effects (Milne, 1968). 
3.3.4.4 Peripheral pathway inhibitors 
Due to the potential for kynurenine pathway induction to 
detract from brain tryptophan availability (following tryptophan 
loads), investigations have centred on the physiological effects 
of concomitant administration of tryptophan pyrrolase inhibitors 
i.e. nicotinic derivatives (Chouinard et al., 1978, 1979) and 
allopurinol (Shopsin, 1978). Both compounds, via different 
methods, can inhibit tryptophan pyrrolase - an essential enzyme 
for catabolism via the kynurenine course. It is assumed that 
inhibiting the activity of tryptophan's major catabolic pathway 
may increase the quota of tryptophan available to the brain. 
Many studies employing this strategy have failed to make 
comparisons with tryptophan administration alone. Green et al. 
(1980,(b)) noted absence of significant alteration in total/free 
plasma tryptophan following a single 50mg/kg tryptophan load in 
subjects pretreated for 7 days with allupurinol/nicotinamide 
compared with subjects with no pretreatment. There is no evidence 
to support psychological benefits from such procedures or effects 
on brain 5HT turnover in humans. Thus, there is a need to 
establish whether (when tryptophan is administered with pyrrolase 
inhibitors) reduced dose recommendations (Young et al., 1981) are 
effective. Peripheral pathway inhibitors were not available in 
the present investigation. 
3.3.4.5 Pyridoxine supplements 
Pyridoxine (vitamin 
administrered with tryptophan. 
supplements have also 
The rationale here is 
been 
that 
increased kynurenine catabolism may overload enzymes dependent on 
the co-enzyme pyridoxal phosphate, unless pyridoxine is given to 
increase its availability. It is assumed that this procedure may 
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help prevent over-accumulation of tryptophan metabolites such as 
kynurenine (Young et al., 1981). 
Green & Aronson (1980) demonstrated that pretreatment with 
pyridoxine+tryptophan was associated with a plasma kynurenine 
concentration (following a single load) half that of subjects 
where pretreatment consisted of tryptophan alone. Thus, if 
increased plasma kynurenine concentrations following chronic 
tryptophan 
transport 
admi ni stt-ati on are responsible 





administration of a pyridoxine supplement may be instrumental in 
promoting CNS concentrations of tryptophan. Coppen ( 1976) did 
not, however, find any difference in antidepressant efficacy when 
tryptophan was given with or without pyridoxine. It was not 
feesible to include pyridoxine suppliments in the present thesis. 
3.3.4.6 Administration 
In all cases tryptophan and placebo were administered as a 
single oral, daily dose. Both subtances were in the form of 500 
mg tablets and of identical shape and weight. There was a slight 
coat colour difference between tryptophan and placebo which was 
not noticed by subjects. Description of tryptophan and placebo 
composition appears Appendix C. Daily doses were packaged and 
dated in opaque brown envelopes and subjects were instructed to 
open each days packet immediately prior to ingestion so that 
comparison between different days tablets was avoided. 
Findings that plasma free tryptophan levels were 45% higher 
at midnight than at noon (Tagliamonte et al., 1974), and that 
brain serotonin turnover reflects changes associated with this 
tryptophan quota (Bartlett et al., 1981; Curzon, 1981; Fernstrom 
~< Wurtman, 1972; Gessa et al., 1972; Tagliamonte et al., 
1971,1974), suggests tryptophan may have maximal psychological 
effect if ingested at night. Kynurenine pathway activity has 
also been demonstrated to be relatively inactive at this time 
(Curzon, 1969), thus, tryptophan may be less uJiized by this r 
competing (non therapeutic) pathway if taken at night. 
The decision to have subjects consume tryptophan in the 
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evening was in part motivated by the above findings. Evening 
tryptophan consumption also served as a precaution in cases of 
subjects experiencing drowsiness following ingestion. It was 
assumed that such an effect could be turned to advantage if 
tryptophan was consumed prior to retiring. Related support for a 
single nightly dose comes from investigations of the therapeutic 
effects of antidepressants. Recent psychiatric findings support 
the preference for a single nightly dose regime due to improved 
compliance and the benefit of hypnotic effects <Lehman, 1978). 
3.3.5 Placebo administration 
The incorporation of a placebo phase in addition to active 
treatment and non treatment periods (baseline) was seen as a 
desirable control for the components of drug administration which 
are independent of the drug composition. Past studies have 
indicated dramatic effects following placebo administration which 
the effects of active drugs in many 







placebo /-where the "patient tool< 25 pills a day and required 
(1964) reported the systematic withdrawl 11 • Similarly., Green 
manifestation of such adverse conditions as vomiting, sweating, 
diarrhoea, constipation and skin rashes following placebo 
administration. Positive correlations between increased placebo 
dose and the above effects were also demonstrated. Frank (1961) 
reported significant improvement in conditions such as ulcers, 
headaches, warts and numerous psychiatric conditions following 
administration of pharmacologically inert substances. 
These kind of demonstrations indicate the need for 
comparison of tryptophan consumption with a placebo in order that 
relationships of psychological state ta the biochemical activity 
of tryptophan may be separated from other administrative 
processes. While many past investigations have endorsed 
tryptophan's antidepressant value at a level comparable with the 
tricyclics, such trials do not establish tryptophan's superiority 
over placebo. In respect to the latter, the literature is 
controversial. 
One of the main ethical objections to placebo administration 
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in clinical trials relates to the withholding of more 
efficacious treatment. In some cases this has led to comparison 
of the experimental drug with therapeutically established 
compounds. For one subject (16) in the present study, 
experiencing moderate to severe levels of depression 
who was 
(Zung, 
1972), it was considered preferable to avoid exposure to placebo. 
This subject was referred to the study by Student Health 
(Canterbury University) and was consuming the tetracyclic 
antidepressant mianserin on entry to the program. Thus, it was 
considered more desirable to compare ratings on mianserin with 
tryptophan, having incorporated a suitable washout period between 
the two phases. This subject was still informed that he might 
receive placebo on any night of pill consumption. Another 
formerly 
trial. 
depressed subject (02) continued to consume his 
prescribed antidepressant medication throughout the total 
In the case of the remaining three depressed 
administration of placebo, as opposed to referral 
subjects, 
to more 
efficacious therapies, can only be justified on the basis that 
all these subjects gave informed consent with respect to the 
possibility of receiving placebos and were not experiencing 
severe depression according to Zung's ( 1972) classification. 
3.3.6 Dietary/nutritional considerations 
The validity of the present investigation is limited due the 
1 ack of 
which 
information on dietary patterns over the trial period 
may have effected plasma tryptophan levels and 
psychological state. As Wurtman (1982) has indicated, adequate 
detailed assessment of dietary influence would require 
information on diet composition, meal spacing and investigation 
of associated biochemical changes. It was considered that such 
procedures would have increased the burden of e>: per i mental 
subjects. requirements to an unreasonable level for most 
Consi det-ati on of dietary influence in the present experiment was 
limited to information on whether or not participants were 
vegetarians. On the assumption that vegetarian diets may 
represent significant di ffet-ences from omnivorous diets in 
protein-carbohydrate balance, it was considered this division may 
contribute to differences in biochemical and psychological 
states. Wurtman (1982), has demonstrated significant effects of 
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protein - carbohydrate balance on availability 
tryptophan for brain transport. 
3.3.7 Information supplied to participants 
of plasma 
Subjects were supplied with full information on the 
requirements of the experiment while at the same time protecting 
the methodological validity of the investigation. A brief outline 
of the general constitution, occurrance and utilization of 
tryptophan was provided. Subjects were given a restricted 
outline of the design which omitted to differentiate between 
tryptophan and placebo conditions. Subjects were then informed 
that they could receive tryptophan or placebo on any night of 
both phases. By keeping subjects blind to the presence of 
tryptophan and placebo phases it was hoped to deter focus from on 
the expectation of a substance crossover between tablet periods. 
Participants were supplied with assurances regarding the 
safety of tryptophan. This required the provision of limited 
information on side effects. Subjects were not given any 
specific information by the author regarding the reported 
antidepressant and hypnotic effects of tryptophan, although some 
were aware of the reported effects used for advertising the 
product. Subjects were not blind to the general purpose of the 
experiment and are likely to have become more oriented to the 
relevance of specific states such as anxiety, depression and 
alertness throughout the course of the program. Subject 
awareness in this respect was not considered to threaten 
experimental validity provided subjects remained blind to the 
tryptophan and placebo phases. It was hoped the above 
presentation would aid subjects in making more responsible and 
informed decisions over participation. For example, it may have 
been unacceptable, to those seeking therapeutic effects, to be 
subjected to placebo administration. At the conclusion of the 
experiment, subjects were informed of the blind conditions. 
Finally, all subjects were assured of confidentiality and 
anonymity regarding the display of results. 
Problems relating to the validity of the present design are 
discussed in Chapter IV. 
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3.4 PSYCHOLOGICAL SCALES 
3.4.1 Principles quidinq selection 
The focus of inquiry in the present study depended to some 
extent on the psychological profiles of participants and their 
motivations for entering the experiment. For example, it was 
considered appropriate to investigate antidepressant effects only 
in depressed individuals. However, the selection of scales was 
necessarily made prior to establishment of the above information. 
The primary guiding considerations for instrument selection 
combined information from past studies on the psychological 
effects of trypt • phan administration along with the aim to 
incorporate instruments sufficiently flexible and senitive to 
/\, 
detect change in a potentially wide range of psychological types. 
With this background, preference was given to the most reliable 
and valid available scales as well as those that had demonstrated 
sensitivity to psychotropic drug effects. 
The most frequent psychological and somatic states to emerge 
from the literature in relation to tryptophan administration can 
be classified as foJlows: 
( 1) Significant antidepressant effects. The following authors 
report antidepressant effects equivalent to commonly prescribed 
tricyclics such as imipramine and amitriptyline: Coppen et al., 
1972; Jensen et al., 1975; Lindberg et al., 1979; Rao i-< 
Bt-• adhurst, 1976; Herrington et al., 1974, 1976; 
al. , 1979; Broadhurst, 1970; Kline & Shah, 1974. 
Chouinard et 
The above 
studies were based on significant group responses as criteria of 
Numerous additional investigations report effectiveness. 
significant antidepressant responses for some participants 
(Farkas et al., 1976; Carroll et al., 1970; Dunner & Fieve, 1975; 
Moller- et al., 1976; Moller et al., 1979; Moller et al., 1980; 
Murphy et al., 1974). 
(2) States relevant to sleep parameters. Various investigators 
have reported reduction in sleep latency (i.e. time taken to fall 
asleep) (Hartman, 1976; Hartman & Spinweber, 1979; Brown et al., 
1979). Hypnotic effects of tryptophan were demonstrated to be 
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significantly greater than placebo but inferior to conventional 
tranquillizers (Brezinova et al., 1972). 
(3) States outside the therapeutic area which may be classed as 
undesirable side effects, e.g. drowsiness (Yuwiler et al., 1981; 




Shopsin, 1978; Hartman et al., 1981), nausea (Carroll et 
1970; 
1978; 
Broadhurst, 1970; Charney et al., 1982; Chouinard et 
Shopsin, 1978) and euphoria (Charney et al., 1982; 
Smith & Prockop, 1962). Other more somatic or physical states 
include lethargy (Yuwiler et al., 1981), blurred vision (Carroll 
et al. , 1970), dizziness (Thomson et al., 1982) and insomnia 
(Prange et al., 1974). 
Attention was given to scales demonstrating sensitivity to 
as many as possible of the above areas of psychological and 
physical states (excepting those relating to sleep parameters). 
The chosen scales had to be appropriate to a wide range of 
psychological profiles. One extreme of the subject range could 
be considered to comprise normal (non depressed) or adaptive 
functional states and the other extreme disturbed states relating 
to moderate levels of depression (Zung, 1972) or am-;iety. 
Another consideration guiding selection of psychological 
scales was the requirement for self rating instruments. Design 
demands such as daily mood rating (for up to 84 days>, frequent 
measurement of anxiety and depression states combined with a 
mobile population (compared with hospital situations) clearly 
established the logistic need for self-assessment. Additonal Ii 
IA /\ 
factors such as the need for trained or experienced 
administrators in the case of ·other· rater instruments promoted 
selection of the self-rating approach. A final positive 
justification for employment of self rating instruments comes 
from a comment by Raskin et al. ( 1967): "L1ltimately it seems it 
is the patient's interpretation of the altered physiology of the 
drug state that wi 11 determine thet-apeuti c sucess 11 • Although it 
can not be assumed that self rating scales are the best means of 
obtaining such information, it would seem they are logically more 
closely connected to the process than ·other' rater instruments. 
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3.4.2 The chosen scales 
The remainder of this section contains a sequential 
description, evaluation and justification for the scales 
employed. The details relating to administration and processing 
are included with each scale assessment. 
3.4.2.1 Visual Analoque Mood Scale <VAMS) 
(a) Description 
This rating scale was first developed and cpplied by Norris 
(1971) in an assessment and comparison of the subjective effects 
of Nitrazepam (benzodiazepine) and sodium phenobarbitone 
(barbiturate). As evident from Appendix A, the instrument 
comprises a series 
being marked at 
of 16 (100mm) analogue 





descriptive of a particular mood state. Subjects are required to 
rate their feelings at a given moment by marking positions 
relative to the extreme adjectives for each scale. For the 
purposes of the present discussion the instrument is referred to 
as the VAMS. 
Visual Analogue scales have become increasingly popular in 
recent years (Hamilton, 1978). Such scales have been considered 
to overcome the difficulty of establishing the most desirable 
number of response grades. Visual Analogue scales allow the rater 
freedom from forced choice response categories. Such scales have 
been demonstrated to be particularly sensitive and valid 
indicators of drug effects in normal and psychiatric subjects 
(Kellner, 1971,1972; Brand, 1969; Aitken, 1969). 
The motivation for construction of the VAMS related to the 
detection of sedative effects of drugs such as the above. Having 
established the scales they were grouped by Norris (1971) into 
four categories relevant to clinical aspects of sedation: 
(1) Mental sedation or intellectual impairment (items: 1,4,11 7 13) 
(2) Physical sedation or bodily impairments (items: 3,5,6,16) 
(3) Tranquilization or calming effects (items: 2,7,B,12) 
(4) Other types of feelings or attitudes (items: 9 7 10,14 7 15) 
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The items comprising the mental and physical sedation 
categories were combined to produce single composite change 
scares which indicated significant overall drug effects as well 
as discrminating between drugs (nitrazepam and phenobarbit• ne) 
and dose levels (Norris, 1971). 
It was not until the work of Bond & Lader ( 1974) that a 
scale structure based on a large sample of normal subjects was 
established through factor analysis. These authors administered 
the scales to 500 normal, drug free subjects. Following 
principal component factor analysis, three factors with 
eigenvalues exceeding 1 were selected which accounted for more 
than 61'l. of the variance. As indicated from Table 3-1 the 
resultant item custers show some overlap with Narris's 
more intuitive grJ~pings. 
(1971) 
Herbert et al. (1976) have also conducted extensive factor 
analytic procedures with the above scales to determine factors in 
normal volunteers. In this study two principal factors emerged to 
account for 627. and 101/. of the variance respectively. These 
authors claimed to have based such analyses on 735 cases, 
however, this number turns out to be composed of 32-45 repeated 
ratings for only 38 subjects. In this respect it was considered 
preferable to utilize Bond & Lader's factor loadings for data 
reduction purposes in the present investigation. 
(b) Validity 
The factor structure developed by Bond & Lader (1974), based 
on normal subjects, was considered to provide a valid means of 
data reduction for the VAMS in the present study. That is, most 
participants in the present investigation could be considered 
free of psychological disturbance. The alternative of 
establishing an independent strucure on the basis of the present 
sample could not be justified given that the final sample was 








VAMS scale groupings with associated factor loadings 
based on administration to 500 drug free normals 
Scales 





4. clear headed - muzzy 
5. well co-ordinated - clumsy 
9. quick witted - mentally slow 
3. strong - feeble 
interested - bored 
12. proficient incompetent 
13. happy sad 
14. amicable antagonistic 
8. tranquil troubled 
7. contented - discontented 
16. gregarious - withdrawn 
2. calm - excited 


















(from Bond~ Lader, 1974) 
Despite the lack of information regarding the construction 










particularly for their contendedness and calmness 
factors, in a study comparing single doses of butobarbitone and 
sodium flurazepam versus placebo in normal subjects. Lader & 
Tyrer ( 1972) 
propt-anol ol 
also demonstrated significant drug effects for 
and sotatol versus placebo on scales incorporated 
under the alertness and contentedness dimensions. Finally, 
Greenwood et al. (1975) applied the scales to the detection of 
subjective effects following acute oral tryptophan administration 
(5gm dose) in normal subjects. In this investigation four scales 





The characterisitcs of the VAMS, so far described, present 
difficulties in the establishment of reliability. The assumed 
transitory nature of the dimensions under study makes the 
calculation of test-retest measures of reliablity inappropriate. 
Investigations based on alternate forms or split half comparisons 
have not, to date, been conducted. However, Bond & Lader (1974) 
have reported relatively high correlations between similar 
scales, i.e. 
(1) alert-drowsy and attentive-dreamy, r=0.66 (factor 1) 
(2) contented-discontented and happy-sad, r=0.65 (factor 2) 
(3) muzzy-clear headed and lethargic-energetic, r=0.56 (factor 1) 
Such correlations were based on scales with face value 
similarity. The scales used for each correlation also belong to 
the same factor grouping according to Bond & Lader's (1974) 
structure. 
(d) Justification for inclusion 
The VAMS represents, in the author's opinion, the best 
compromise between the features described previously as guiding 
scale choice. The principal reasons for the relevance of this 
scale to the present inquiry are as follows: 
(1) The scale comprised a concise and rapidly executed means of 
assessment for subjective feeling relevant to the moment of 
completion, making it a suitable instrument for twice daily 
administration to subjects. 
(2) The original formulation of the scale was oriented towards 
the detection of psychotropic drug effects and subsequent 
applications have demonstrated its sensitivity in this respect. 
(3) The scale has shown sensitivity to drug effects in normal 
subjects. 
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(4) At face value, many of the adjectives comprising the scales 
bear relevance to frequently reported effects associated with 
past investigations of tryptophan administration. This is 
particularly apparent in the case of scales comprising the 
dimension of alertness (Bond i, Lader, 1974) , such as 
'drowsiness· and to a lesser extent the items relating to the 
contentedness dimension which could be considered relevant to 
'antidepressant· effects or states of 'euphoria". 
(5) The VAMS has demonstrated sensitivity to effects associated 
with tryptophan administration in normal subjects (Greenwood et 
al., 1974; 1975) - particularly the dimension of alertness. 
(6) Finally, the factor structure (based on normal subjects) 
determined by Bond & Lader (1974) could be considered to provide 
a reasonably valid method for reducing the number of mood ratings 
(from 16 to 3 dimensions) for most of the participants in the 
present study. 
(e) Application and processing 
The VAMS was completed twice daily by subjects for the 
duration of the experiment. The scales were administered 
according to the instructions formulated by Norris 
consistent with subsequent applications of the scale. 
(1971) and 
Scales were measured and scored to the nearest 5mm. Norris 
( 1971) and Bond & Lader (1974) both claim to have measured the 
scales to the nearest 1mm, however, data relating to the 
achievement of accuracy in this regard is not documented. In the 
present investigation, measurement to the nearest 1mm proved 
unrealistic, i.e. tests of accuracy following repeated scoring of 
the same ratings only proved to be acceptable at a measurements 
to the nearest 5mms for the present author. In addition the 
rating marks made by some subjects frequently extended over 1-
2mm. Measurement to the nearest 5mm allowed an increase in the 
speed and reliability of the scoring process relative to 1mm 
trials. 
factorial 
The reduction of scales to Bond & Lader's 
dimensions, is described in section 
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(1965) gave the following reasons for developing the 
"We were interested in having a scale for assessing depression in 
patients whose primary diagnoses were that of a depressive 
disorder, which would fulfil the following: it should be all 
inclusive with respect to symptoms of the illness, it should be 
short and simple, it should quantitate rather than qualitate, and 
it should be self administered and indicate the patients own 
response at the time the scale is taken." 
The selection of SDS items was dependent on extensive factor 
analysis of concepts from several clinical sets of depressive 
symptoms. 
1963). 
(Grinker et al., 1961; Overall, 1962; Friedman et al., 
The final item wording was based on representative 
patient statements relevant to each symptom. As is evident from 
Appendix A, the scale comprises 20 symptoms rated on a four point 
scale of severity. The rating categories represent an update in 
wm-ding (Zung, 1974) from the original 1965 form to include 
·a little of the time' was updated to 'none extreme choices i.e. 
or a little of the time' and 'most of the time' to 'most or all 
of the time·. 
noted i.e. no. 
There are also two changes to item wording to be 
4: 'I have trouble sleeping' to 'I have trouble 
sleeping through the night' and no. 6: · I sti 11 enjoy sex· to · I 
enjoy looking at, talking to and being with attractive women (or 
men) ·• 
Cb) Validity 
The data base from which selection of SDS items was made was 
comprehensive in its incorporation of clinical concepts 
(factorially ordered prior to selection). The representativeness 
of Zung's (1965) final selection, with respect to clinically 
relevant concepts of depression, is less certain. 
maintains that that symptoms exclusive to one 
Zung (1974) 
theoretical 






scale's relevance across different concepts of depression. 
Evidence of concurrent validity has been demonstrated by 
significant correlations between specific depression scales e.g. 
Beck Inventory: 0.76 and Hamilton Scale: 0.56 (Zung, 1969). 
The pattern of normative data (Zung 1965) is supportive of 
the scale's discriminating power with respect to depressives, 
recovered depressives (observed to be free of their complaints 
and improved clinically), other psychiatric disorders (admitted 
as depressives and later discharged with other primary 
classifications) and normal individuals (professional staff & 
general medical and surgical patients). 
More recently, larger samples of normative statisf~}s have 
been prepared by Zung (1969,1971,1972). In all Zung's studies the 
means for the depressed samples were significantly (p <.01) 
higher than those of the normal groups, substantiating the power 
of the SDS for screening purposes and collaborating the utility 
of the scale in quantiatively discriminating between depressed 
and normal subjects. However, owing to the lack of demographic 
information in some of these samples Zung's data was not relied 
upon in the present study for judging the status of participants. 
Knight et al. (1983) have recently reported data for a 
comprehensive normal sample (N=1173) (Table 3-2). The sample 
appears significantly broader based in terms of occupational 
status than Zung's (1965,1968,1971 or 1972) control groups. 
Knight et al. 's (1983) sample yielded a higher mean score 
relative to Zung's (1965) normal group ( but comparable or lower 
relative to Zung's (1969,1971,1972) later reports) as well as 
distinct age category differences and a significant relationship 
for sex and total SDS scores. Females were shown to score 
significantly higher (F=84.73, p(.0001), the difference 
correlating negatively with age. 
Given the normal versus psychiatric bias of the present 
sample, most judgements regarding the depressive status of 
individuals were based on Knight et al. 's (1983) data. Reference 
was made to Zungs (1972) established categories, relating to 
magnitude of depression i.e. 
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mild-moderate 





70 and over 
approx tot. score 
40 47 
48 55 
56 and over 
Some reservations in using Knight et al. 's (1983) normative 
data relate to the assumption that such calculations were based 
on the 1965 form, i.e. there is no reference to Zung's later 
works. 
when 
It is also unclear from Zung's investigations 





Zung (1974) reports a split half reliabilty estimation based 
on correlations of odd and even items of oc = 0.73 (p<0.01). This 
is in keeping with Knight et al. ·s (1983) estimate of internal 
consistency Coc = 0.79). The meaningfulness of internal 
consistency in a scale measuring a clinically heterogeneous 
concept such as depression is uncertain. The use of a total 
(global) score, in the expectation that contributing items are 
internally consistent, may mask meaningful variability between 
item clusters composing the scale. Rickels et al. (1970) 
reported isolation of two major and three minor factors emerging 
from the factorial analysis of ratings by 700 neurotic, depressed 
patients. This result indicates the potential existence of 
separate item clusters which may be clinically meaningful in the 
sense of allowing a finer analysis of the symptom profile. Thus, 
the sensitivity of depression ratings in the present experiment 
may have been reduced due to dependence on total scores. 
(d) Justification for inclusion 
In order to justify investigation of 
action of tryptophan in the present study, 
the antidepressant 
it was necessary to 
include a means of screening and assessing participants for 
depressive symptomatology. 
Zung·s stated view of depression is as follows: ''Depression 
swings to a pathological state" (Zung,1974). Thus, depression is 
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conceived of as a state quantitatively removed from normal 
psychological functioning. For the purposes of screening 
individuals for the presence or absence of 'depressive· 
symptomatology, qualitative versus quantitative concepts of 
depression seem less important. If the scale is to be utilized 
as an indicator of changing state over time for non - depressed' 
individuals then the impact of the above alternatives on scale 
construction and utilization is more pertinent. The capacity of 
the SDS in this respect has not been demonstrated and cannot be 
assumed. Zung (1967 7 1968, 1971, 1972, 1973) has consistently 
reported significant mean differences in SDS scores between 
normals and depressives (i.e. quantitative). However a 
qualitative basis to this difference is indicated by the 
disparate factor structures emerging from analysis of the two 
samples (Zung, 1971; 1972). Consequently, the value of the SDS 
beyond a screening device for normal subjects in the present 
investigation is questionable in that SDS changes in normal 
subjects are likely to relate to a qualitatively distinct 
structure from that in depressives. Thus, changes in repeated 
administrations of the scale in normal subjects were treated 
cautiously and in conjunction with m• odscale ratings <where 
meaningful changes for normal subjects are more established). 
There is a lack of evidence indicating the sensitivity of 
this scale to drug effects, however it has been demonstrated to 
discriminate between and endorse the established antidepressant 
superiority of ECT over tricyclics (Cole, 1964; Klerman & Cole, 
1965; Zung, 1974). Also, Rickels et al. (1970), reported 
significant therapeutic benefits, for amitriptyline and 
trimipramine over placebo, in neurotic depressed outpatients. 
(e) Administration and processing 
As is evident from the scale format (Appendix A), responses 
are rated on a four point scale which quantifies experience of 
the symptom. Items 1,2;4,6,B,9,10,11,17,20 are worded 
symptomatically positive while the remainder are worded 
symptomatically negative in order to avoid response bias. Thus, 
scoring for positive items was 1,2,3,4, and for the negative 
items 4,3,2,1 for the categories: none or a little of the time, 
78 
some of the time, a good part of the time, 
time respectively. 
most or all of the 
The scales were administered according to the written 
instructions at the top of the farm (from Zung, 1965; 1974). The 
author was present during the initial completion of the scale by 
each participant. No subjects raised uncertainties with respect 
to item comprehension and after completion verbal checks ensured 
subjects had responded as they intended. As noted previously, 
scales were completed at the initiation of the program and weekly 
thereafter until termination of the trial. Processing of scales 
was limited to presentation and comparison of total scores. The 
total scores and the consequent depression status according to 
lung's (1974) outline and with respect to Knight et al. ·s ( 1983) 
normative data are presented within each subjects profile and 
analysis. 
Table (3-2) Normative data for the SDS from Kniqht et al. (1983) 
- all estimations based on total raw scores 
Age Male Female 
N mean SD N mean SD 
16-19 46 33.00 5.57 47 37.20 7. 12 
20-29 136 30.61 6.60 132 34.37 6.80 
30-39 111 30.67 6.28 109 35.28 8.23 
40-49 88 3C). 52 7.11 85 34.45 7.30 
50-59 81 33.40 7.06 85 36.85 6.98 
3.4.2.3 State-Trait Anxiety Inventory (STAI> 
(a) Description 
As is apparent from Appendix <A>, the STAI (developed by 
Spielberger et al., 1970) comprises two separate, 20 item, self 
administered forms corresponding to theoretically distinct 
concepts of anxiety. Self evaluation Questionnaire (1) purports 
ta quantify anxiety according to psychological State, while (2) 
is intended to measure Trait qualities. In the authors· words: 
"State an>:iety (A-State) is conceptualized as a transitory 
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emotional state or condition of the human organism that is 
characterized by subjective, consciously perceived feelings of 
tension and apprehension, and heightened autonomic nervous system 
activity. A-States may vary in intensity and fluctuate over time. 
Trait anxiety (A-Trait) refers to relatively stable individual 
differences between people in the tendency to respond to 
situations perceived as threatening with elevations in A-State 
intensity." Thus, the scales are distinguished by the time 
reference required for response, with the State form referring to 
"t-i ght now" ot- "at this moment", 
repsonse in "general". 
while the Trait form asks for 
Selection of scale items was based on the processing of three 
existing measures of Trait concepts of anxiety (Cattell & Sheier, 
1963; Taylor, 1953 and Welsh, 1956). Only items exceeding a 
correlation of .25 with any of the above scales were considered 
for inclusion. Original attempts at differentiating the State 
and Trait forms purely on the basis of the separate time 
references for response ( i . e. item contents and question 
formulation being equivalent) were unsucessful. The present 
scales demonstrate retention of only five content equivalent 
items (2 with identical wording). 
(b) Reliability 
Test - retest correlations, reported by Spielberger et al. 
(1970), are reasonably high for the Trait scale when taken (for a 
normal group) before and after relaxation instruction, a 
difficult IQ test and films of fatal or serious injury accidents. 
Trait correlations ranged from .73 (retest=104 days post test) to 
achieved r=.33 for both occasions. This is to be expected, given 
that State measures should exhibit sensitiv{ty and Trait measures 
stability with respect to stress specific changes in situation. 
Alpha coefficients were uniformily high, ranging from oc=.83 
to oc=.92 for State and oc=.86 to oc=.89 for Trait scales across 
all normative samples (freshmen, undergraduates and high-school 
students) (Spielberger et al., 1970). These findings are in 
keeping with Knight et a.l. ·s (1983) esti'mates of o:=.93 for State 
and oc=.87 for Trait scales based on a normal (N=l 173) sample. 
8{) 
Spielberger et al. (1970) have reported a reduction in the alpha 
coefficient for the State scale under conditions of increasing 
psychological stress, indicating a reduction in item homogeneity 
in such situations. Thus, depending on the measurement 
situation, attention to individual items may be more informative 
than sole reliance on total scores. For the purposes of the 
present investigation~ 
limited to total scores. 
Cc) Validity 
et al. 
processing and analysis of ratings was 
( 1970) have demonstrated reasonable 
concordance for the STAI A-Trait with (1) IPAT Anxiety Scale 
(Cattell 
<TAMS) 
~< Schei er, 1963) and (2) Taylor Manifest Anxiety Scale 
(Taylor, 1953). Correlations with IPAT are around • 76 
while those of the TAMS are slightly higher. The same authors 
have cited significant correlations of Tt-ai t scores with 
dimensions of commonly used personality tests - also purporting 
to assess enduring qualities of 
e>;ampl e, PRF (Jackson, 1967) 
psychological 
dimensions of 
prof i 1 e. For 
aggt-essi on, 
impulsivity and endurance and the EPPS (Edwards, 1954) dimension 
of abasement have produced significant correlations with Trait 
total scores. 
The validity of the State scale has been convincingly 
demonstrated by its authors. Significant differences were 
reported on total scores and 19 individual 
standard administration and a stress condition 
items between a 
(where subjects 
had to imagine their feelings prior to an important final exam). 
The limitation of normative samples in the manHual to 





and smaller groups of psychiatric and other medical 
was considered less pertinent to 







norms (see Zung discussion for description of 
The need for age and sex specific norms has been 
demonstrated and met by these authors. Some reference was made to 
Spiel bet-ger et al. ·s (1970) norms for depressive and anxious 
psychiatric patients and these are included in Table 3-3 along 
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X 
with Knight et al. s (1983) data. 
Reports of STAI application are detailed in the mannual and 
in further endorse its status with respect to construct and 
criterion validity. However, there is a lack of documentation 
relating to its application in psychotropic drug trials. 
Cd) Justification for inclusion 
The demonstrated sensitivity of the scales for measuring 
Trait and State anxiety in normal and patient populations were 
considered appropriate attributes for the present experimental 
requirements. Lack of information regarding measurement 
sensitivity to psychotropic drug effects is obviated by otherwise 
comprehensive demonstrations of 
various stress situations. 
discriminating power across 
Inclusion of the Trait scale at the start of the experiment 
was considered to provide a useful indicator of relatively stable 
psychological characteristicsj which were subsequently considered 
in relation to other more dynamic experimental variables. 
Indications of the concordance between the Trait scale and 
personality tests outlined above, as well as the demonstrated 
stability of Trait scores across altered states, is relevant to 
the present study in view of evidence for ''drug - personality" 
interactions (McNair et al., 1970). 
Finally, given the clinical blur surrounding partitioning of 
anxiety and depressive disorders CMcNair & Fisher, 1978) 1 it 
seemed appropriate to incorporate measures of both concepts in 
order that this communality could be explored. The meaning of 
significant correlations, 0.54 between SDS and State scales and 
0.70 between SDS and Trait scales in a normal sample (Knight et 
al, 1983) 
population, 
is uncertain but the possibility that "in the general 
low levels of anxiety and depression also tend to 
covary consistently" is suggested by l<ni ght et al. C 1983). 
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(e) Administration and processing 
Instructions for administration of the STAI were executed 
according to directions in the manual (Spielberger et al., 1970) 
with Trait completion preceeding that of State. The author was 
present during the completion of the Trait and initial State 
It was verbally established that all subjects were aware 
of the 'time reference' distinction between farms. Subjects 
raised no uncertainties regarding item semantics or response 
demands when questioned. 
Table (3-3) Means and SD's for A-State and A-Trait scales (from 
l<niqht et al., 1983) and for depressed and anxious 
psychiatric patients (from Spielberger et al., 1970) 
Male Female 
Aqe * n mean SD n mean SD 
A-State scale 
20-29 134 29.69 6.34 133 34.11 7.64 
30-39 110 29.92 7.41 110 34.47 10.18 
40-49 84 29.31 7.71 86 32 .. 47 7.57 
50-59 74 3<) .. 32 7.71 83 32.11 8.40 
depressive 28 54.43 13.02 
anxious 60 49.02 11.62 
A-Trait scale 
20-29 137 32.68 7.37 135 36.85 8.41 
30-39 112 32.96 8.18 111 38.39 10.18 
40-49 87 32.13 7.92 86 36.61 8.36 
50-59 80 34.40 8.57 88 36.70 8.86 
depressive 28 53.43 12.90 
anxious 60 48.08 10.65 
* only age categories relevant to the present investigation were included 
As is apparent from the scale farms (Appendix A), half the 
State items i.e. 1,2,5,B,10,11,15,16,19 and 20 were warded 
symptomatically negative and the remainder positive. In the case 
of the Trait scale only items 1,6,7,10,13,l6 and 19 are 
symptomatically negative with the remaining 13 positive. 
8 -::' ·-· 
Response categories: not at all', 'somewhat', 'moderately so' and 
'very much so were scored 1,2.3,4 respectively for positive 
items and 4,3,2,1 for negative items. No scales contained 
missing data for any subject. Analysis was confined to 
discussion of total scores within each subject and State-Trait 
correlations across subjects, as mentioned above. 
3.4.2.4 Hopkins Symptom Checklist <HSCL) 
(a) Description 
The HSCL is a self report symptom inventory comprising 58 
items (see Appendix A) rated on a four point scale of distress, 
which are, according to Derogatis et al. ( 1974) , "representative 
of the symptom configurations commonly observed amoung 
outpatients." Various altered forms of the scale developed both 
prior to and following the establishment of the HSCL are 
available. Development of all available forms can be traced to 
an extended format, the 'Discomfort Scale' established by Parloff 
et al. (1954) and designed for use as an improvement measure in 
studies of psychotherapy. The HSCL-58 is still considered 
preferable in terms of sensitivity and reliability over the 
shorter form by Derogatis et al. (1974). 
A series of factor analytic procedures have consistently 
isolated five principal dimensions (Table 3-6). This structure 
was demonstrated to exhibit a high level of invariance, for both 
psychiatrists and patients ratings, in a sample of 1066 anxious, 
neurotic outpatients (Derogatis et al., 1971). Independent 
investigations by Mattsson et al. (1969) and Williams et al. 
(1968) 7 employing self ratings from 404 and 1115 anxious, 
neurotic outpatients respectively, also yielded five principal 
factors. The first four factors in both studies were highly 
coincident in item composition. The fifth factor considered by 
Williams et al. (1968) as a more general depression dimension was 
similar in structure to a combination of Mattsson et al. 's (1968) 
'anxious depression' and 'somatic depression' factors. The 
results of these two investigations are supportive of Derogatis 
et al. 's (1971) more recent structure in terms of the commonality 
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of the items composing the essential five dimension division of 
the above studies. 
The orientation of this scale 'symptom 
manifestations' of anxiety and depression is justifiable with 
respect to its utilization in therapeutic drug trials. That is, 
Lipman et al. (1968) found the SCL Can extended form of the HSCL) 
to provide a more sensitive indicator of therapeutic change than 
non symptom' focused criteria of change - such as global 
improvement scales. The major focus of utilization has been in 
psychiatric outpatients presenting with anxiety and depressive 
conditions. Normative data is available for such groups as well 
as a 735 normal (non psychiatric) sample on the 5 principal 
factors (Table 3-4). 
(b) Reliability 
Reliability estimates for the HSCL-50 appear in Table 
Internal consistency estimates (oc coefficients) i.e. the average 
of item correlations within each dimension, are uniformily high. 
Test-retest coefficents were based on measurements taken a week 
apart for a sample of anxious, neurotic outpatients <N=425). 
Once again a high level of stability is demonstrated in this 
respect. Values for inter-rater reliability indicate there may 
be reasonable agreement between self concepts of the dimensions 
under study and clinical definitions/criteria of the same. 
(c) Factorial Invariance 
Derogatis et al. (1974) have also provided information 
relating to the factorial invariance of the HSCL-58 symptom 
dimensions. This property is concerned with the generalizability 
of dimensions to contexts <i.e. populations, ei~peri mental 
circumstances etc.) beyond that on which the structure was 
determined. Concern with this property is of particular 
relevance to the present inquiry, given that the final sample was 
composed mostly of individuals who could not be considered as 
"anxious neurotic outpatients". 
c. 
Consistency measurments in this respect (Derogatis et al. , 
fl. 
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1971, 1972) have been limited to variables such as social status, 
diagnostic classification (i.e. psychopathological) and to 
patients versus psychiatrists ratings. Given the small N (20) 
and the heterogeneity of the present sample it was not considered 
justifiable to conduct an independent determination of factor 
structure in this study. 
Despite concern over relevance of the factorial structure to 
the present sample, there is evidence indicating the sensitivity 
of the proposed dimensions in normal (non psychiatric) samples. 
The structure has been demonstrated to differentiate clinically 
based judgements of normal versus neurotic patients (Rickels et 
al. 1 1972). 
Table 3-4 Mean factor scores and SDs for the HSCL symptom 





somatization ..• 1.91 
obsessive 
compulsive ••••• 1.95 
interpersonal 
sensitivity ...• 2.00 
depression .•.•• 2.04 






































Concern with the criterion validity of this scale has 
centered around its major applications ta date i.e. detection of 
the effects of psychotropic drugs. Clinically relevant findings 
have been obtained by the HSCL for therapeutic effects of 
anxiolytic drugs (Rickels et al., 1971; Uhlenhuth et al., 1966, 
Hesbacher et al., 1970), withdrawl from major tranquilizers (Covi 
et al., 1973) and antidepressant effects of tricyclics (Raskin et 
al, 1970). The HSCL has also been demonstrated to differentiate 
significantly between imipramine, diazepam (tranquilizer) and 
placebo in depressed outpatients (Covi et al., 1973). 
With respect to construct validity, Derogatis et al. (1970) 
reported high agreement between clinical (psychiatrists) and 
empirical (structure determined by factor analysis) definitions 
of the five HSCL dimensions. 
Cd) Justification for inclusion 
One of the principal reasons for including the HSCL in the 
present study related to the significant representation of 
somatic symptomatology relative t • the Zung and state anxiety 
scales. As well as the factorial dimension of somatization there 
is a reasonable representation of somatic items in the depression 
and anxiety dimensions. Kiev (1974) claims the reported/ 
documented incidence of depression (in the U.S.) is likely to be 
much higher due to "nonrecognition ••• " often resulting " ••• from 
somatic symptoms which mask the depressed mood or serve to 
e~-: p 1 a in it 11 • 
Other researchers view such 





categories of relevant symptoms can be identified: 
(1) Sleep disturbances e.g. insomnia, early morning waking, 
frequent waking and various alterations in the qualitati~e and 
quantitative dynamics of the REM and short wave cycles have been 
extensively documented by Feighner (1974). Snyder (1969) reports 
general consistency between the degree of sleep disturbance and 
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the apparent degree of depression. 
(2) Gastrointestinal disturbance. Chaplan (1974) cites the gut as 
being the mast commonly attributed "target organ" for somatic 
expression of depressive disorders. Consideration has been given 
to associated symptoms or functional disturbances e.g. abdominal 
pain, nausea, vomiting and diarrhoea. 
(3) General fatigue or reports of 
languor, tiredness have been 
depressive disorders Karna & Hoffman 
loss of energy, listlessnss, 
frequently associated with 
( 1974) . 
(4) Pain: notable relationships have emerged between specific 
pain experiences e.g. headaches, backaches, abdominal pain and 
apparent depression (Sternbach, 1974; Cassidy et al., 1957). 
The etiological significance of such symptoms in depression 
is uncertain, however their implication by association with such 
disorders indicates that monitoring of somatic symptoms may aid 
in the identification of depressive states. 
Another reason for including the scale relates to its 
demonstrated sensitivity in psychotropic drug trials - including 
antidepressants, and separate demonstrations of its sensitivity 
to detect emotional change in normal (non-psychiatric) 
individuals. The factor structure demonstrated by Derogatis et 
al (1971) and utilized in the present study distinguishes 
dimensions of depression and anxiety which provide useful 
adjuncts to measurement of the same states by the Zung and State 
scales. The reduction of HSCL data ta factor scores is described 
in section 3.5. 
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•.• reflect distress arising from 
perceptions of bodily dysfunction. 
Complaints focused on cardiovascular 
gastrointestinal, respiratory and 
other systems with marked autonomic 
medication are included. Headaches, 
pain and discomfort localized in the 
gross musculature and other somatic 
equivalents of anxiety ••• 
.•• symptoms that are closely identi-
fied with the clinical syndrome of 
this name. ••. focuses on thoughts, 
impulses and actions •.• experienced 
as unremitting and irresistable by 
the individual, 
wanted nature. 
but are of .•• an un-
Behaviours indica-
tive of a more general 
difficulty also ••• 
cognitive 
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••. focus on feelings of personal in-
adequacy and inferiority, particul-
arly in comparison to other persons 
Self deprecation, feelings of un-
easiness and marked discomfort are 
characteristic •.. as are acute self-
consciousness and negative expectan-
cies regarding interpersonal commun-
ications. 
depression 5,15,19 7 20,22, ••• reflect a broad range of the con-
26,29,30,31, 
32,54 
comitants of a clinical depressive 
syndrome. Symptoms of disphoric 
mood and affect are represented as 
signs of withdraw! of life interest, 
lack of motivation and loss of vital 
energy. Feelings of hopelessness and 
futility as well as other cognitve & 
somatic correlates ••. 
anxiety 2 1 17,23,33,39, ••. associated clinically with high 
50,57 
(from Derogatis et al., 1974) 
manifest anxiety. General indicat-
ors such as restlessness, nervous-
ness and tension are represented as 
are additional somatic signs e.g. 
"trembling''. Items touching on free-
floating anxiety and panic attacks 
are also included. 
3.4.2.5 Side effect checklist 
The checklist of negative side effects (Appendix A) appeared 
on the back of the evening VAMS. Subjects were asked to check 
and mark the appropriate category only if they had experienced 
any of the symptoms during that day. There was also a category 
for unspecified symptoms. The motivation for including this list 
stemmed from reports of negative effects associated with 
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tryptophan administration in past studies, the most commonly 
listed side effects of tricyclic antidepressants (Feighner, 1974) 
and finally the most common negative, somatic symptoms associated 
depressive disorders (Kiev, 1974). Repetition of 
conditions/symptoms already included in the formal scales was 
avoided. For example, 'drowsiness· is one of the most commonly 
reported negative effects associated with tryptophan 
administration, however, this dimension was represented in the 
VAMS. 
No defense is presented in respect of 
validity or reliability of the scale and 
the statistical 
consequently the 
information obtained from this source was not subjected to any 
extensive evaluative or statistical processing. Justification 
for its inclusion was based on the need to monitor negative 
effects relevant to tryptophan administration which were not 
available in a concise established scale suitable for daily 
administration. The incidence of effects reported in this 
context was noted in relation to changes emerging within and 
across phases from the other data sources. This information is 
reported in assocation with each subject's analysis (Chapter IV). 
3.4.2.6 Additional daily questions 
As is evident from the morning and evening VAMS scales, 
several additional questions were inserted at the top of these 
response sheets by the author. The insertion of date and 
identification information was principally to facilitate orderly 
processing of scales. Responses to time of completion allowed 
checks of consisitency in this regard for all participants. The 
question an menstruation allowed investigation of this event in 
relation to changes emerging from the other scales and was 
particularly noted for females indicating experience of 
premenstrual tension. Responses to the question on drug 
consumption were also related to changes emerging from the 
alternative data sources. Subjects were instructed that this 
question included alcohol consumption. Finally, inclusion of the 
question relating to unusual or traumatic changes was considered 
necessary in the case of such events relating to sudden changes 
in VAMS ratings. 
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3.5 ANALYSIS 
3.5.1 Time series data 
Time series data may simply be defined as a data series with 
time as an independent variable. Such an approach to data 
collection, as employed in the present investigation~ has obvious 
advantages over ostensibly time independent approaches in 
psychological inquiry. That is, organismic processes relevant to 
the discipline (behavioural, emotional, biochemical) represent 
dynamic patterns. However, the approach does not represent the 
rule as Gt-egson ( 1983) notes, "The most common methods of 
frozen representing quantitative results in psychology are 
outside time; thus they deliberately average out much of the 
sequential structure that holds any sparse clues to the nature of 
processes within the organism." Thus, ignorance of time as a 
variable may suggest ignorance of the process being studied 
a dynamic process comes to be viewed statically. 
The evaluation of time series data does, however, present 
difficulties unique to this mode of investigation. A historical 
and current debate reigns over the merits of two major 
approaches to evaluation, namely: visual or statistical analysis. 
Kazdin (1982) maintains, in the context of the social sciences, 
"In single case research, 
to evaluate the data, 
statistical tests are occasionally used 
although this practice remains the 
exception rather than the rule." Visual evaluation involves the 
visual inspection of graphed data and subsequent formulation of a 
judgement regarding the consistency of data points over time. 
Kazdin (1982) states "When the data meet the criteria for visual 
inspection there is little need to corroborate the results 
with statistical tests." H• ~'Jever, the l i teratLwe turns out to be 
conspicuously lacking in the explication of guidelines for visual 
evaluation. The gap is frequently filled by statements to the 
effect that, because evaluation is restricted to time series 
exhibiting 'dramatic' intervention effects there is no need to 
investigate the principles or rules underlying such judgements. 
However, there are reasons, to be outlined below, that even when 
faced with dramatic effects, visual judgements may be biased. 
Strict adherance to exclusive acknowledgement of 'dramatic' 
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effects seems short-sighted - particularly in the context of 
exploratory investigations. That is, attention paid to less 
dramatic (but statistically significant) effects may lead to 
methodological refinements which later estabish their relevance. 
It is the present author's opinion that the methods 
incorporated by visual evaluation provide valuable and necessary 
aids in the design and analysis of time series processes. One 
major advantage would seem that it allows the investigator close 
contact with the unprocessed data set in a rapidly interpretable 
form. Data presented in this manner provides a valuable initial 
indication of 
variability 
the outcome, including all aspects of 
which may otherwise have been lost 
statistical techniques such as averaging. 
through 
Parsonson & Baer (1978) state "Persons confronted with 
graphed operant data usually have access to the primary data 
They can perform their own data analysis and reach their own 
conclusions, because the details necessary to do so often have 
not been obscured, coalesced or dissolved via mediation by a 
computer or statistical tables". However, while the lack of 
methodological documentation inhibits replication of statistical 
analysis, 
methods. 
it should not deter investigators from employing such 
In fact~ for the purposes of replication, visual 
analysis must also present the procedures followed for making 
judgements based on visually presented data - it is not enough to 
simply present the graphed results. 
3.5.1.1 Autocorrelation 
The statistical analysis of time series data in single case 
research has historically involved adoption of 
originally designed for between group evaluation e.g. 
techniques 











component of data points - turns out to be frequently violated by 
time se7{~ data sets. Jones et al. (1977) demonstrated the 
violation of this assumption in 83% (total=24) of time series 
data sets i.e. significant correlations between the error 
component of ( . d sucessive ata paints were demonstrated. This 
;,, 
ubiquitous phenomenon is termed ·serial dependency· or 
'autocorrelation'. Demonstr-ation of the phenomenon simply 
indicates that the data does not exhibit a random process over 
time, which explains its frequent occurance in time series data, 
i.e. as Jones et al. ( 1977) state# "The reason that one should 
expect serial dependency is that people and their environments do 
not behave or function randomly over time". Because the 
phenomenon is limited to the error component of data points the 
distortions arising from the application of such tests to 
serially dependent data will exclude deterministic parameters 
such as the mean. Rather, the correlation of error components 
threatens estimations of significance, leading to a conservative 
bias in the presence of negative autocorrelation and a liberal 
bias (the more common occurence) in the presence of positive 
autocorrelation (Hartmann et al. , 1980; Padia, 1973; 
Schef-fe, 1959). Thus, the application of traditional inter-group 
tests of significance can not be justified without demonstrating 
the absence of a significant level of serial dependency. The 
presence of serial dependency has also been demonstrated to 
corrupt the reliability and accuracy of visually based judgements 
(Jones et al.~ 1977) , although it is unclear whether the bias 
parallels that for statisical evaluation. 
3.5.1.2 Time series analysis 
The threat of serial dependency on the evaluation of time 
series data has contributed to the development of analytical 
methods to test for and remove the potential bias it confers. 
The statistical methodology developed for this purpose is simply 
referred to as Time Series Analysis. Where the focus of 
evaluation is to determine the influence of intervention effects, 
as in the present study, the approcach is termed interrupted time 
series analysis CITSA) (Gattman & Glass, 
1980). 
1978; Hartmann et al., 
While accomodating any effects associated with serial 
dependency, ITSA determines whether there is a significantly 
reliable change in level and trend from one phase to the next. 
In short, the goals of ITSA are to model the structure of the 
stochastic component of the time series data. Once a fitting 
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iTI• del is determined the systematic part of the error can be 
subtracted from each observation leaving the residuals free of 
serial dependency. 
data points assured, 
With the assumption of independence between 
conventional t tests can then be applied to 
assess the characteristics of changes over time and with respect 
to intervention effects. One restriction on the employment of 
ITSA concerns the recommended number of data points per phase. 
l<azdin ( 1982) notes estimates range from 20 to 100. The 
prominent founders and practitioners of ITSA e.g. Box g( Jenkins 
( 1970) recommend 100, Gattman & Glass (1978) at least 50 and 
Padia (1973) at least 50. 
Evidence from the above authors suggests the differencing 
errors resulting from data sets of less than 50 points may 
critically effect the ITSA outcome. That is 1 "Under-differencing 
leaves serial dependency in the series and over-differencing 
introduces unwanted serial dependency'' (Hartmann et al., 1980). 
According to Jones et al. ( 1977) , the final effect of too small 
an N 11-Ji 11 
significance. 
be to conservatively bias tests of statistical 
This results from the misidentification of the 
degrees of differencing required to bring the series to 
stationarity. 
It is the present authors opinion that time series analysis 
), 
offers a valuable supplement'to visual analysis, provided the 
required assumptions such as a sufficient number of data points 
are met. As well as detecting and dealing with the hazard of 
serial dependency, the methodology allows separate analysis of 
changes relating to level and trend. In the case of the present 
investigation, it was considered the shortage of data points per 
phase would provide a major threat to the validity of ITSA 
procedL!res. For this reason the procedL1re was declined in favoL1r 
of visual and statistical procedures ~escribed below. 
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3.5.2 Analytical procedures 
3.5.2.1 Visual Analoque Moodscales 
(a) Processing 
The information obtained from the 16 scales was condensed to 
three dimensions following application of the relevant processes 
from Bond & Lader·s (1974) factor analysis. 
for this purpose appears in Appendix B. 
The program written 
The procedure was as 
follows: scales 1j2,3,5,7,11,13 and 15 were reversed in order 
that the scores towards the 100 scale pole were consistently 
representative of positive attributes and those towards the 0 
pole representative of the negative attribute. The ne:{ t steps 
achieved by the factor extraction program (Appendix B) were to 
multiply each dimension score by its associated factor loading 
(Table 3-1), then sum the composite scores within each factor and 
divide the total by the summed loadings. The program itemizes 
the different processes followed in the case of 
e.g. in the case of a missing dimension score, 
missing data, 
the factor score 
was calculated on the remaining dimensions relevant to that 
factor. 
(b) Visual analysis 
Once in the condensed form, the first step towards analysis 
involved graphic representation of the three factors across all 
phases for each subject. As mentioned previously, the criteria 
for formulating what proponents claim to be valid, visually based 
judgements from graphed presentations of time sereis data have 
rarely been explicated. As Parsonson & Baer (1978) simply note, 
"deter mi nation of change is dependent on the change being of 
sufficient magnitude to be apparent to the eye". On the basis of 
comments in the literature (e.g. Baer, 1977; Jones et al., 1977; 
Parsonson & Baer, 1978; Kazdin, 1982) the consensus appears to be 
that one should only pay attention to dramatic changes. For the 
purposes of the present investigation attention was focused on 
dramatic alterations in those characteristics considered most 
pertinent by Kazdin (1982) to adequate visual inspection. These 
characteristics are typically statistically based concepts e.g. 
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level, trend and latency of change. The changes in mean, 
procedure followed in the present study was to state the mast 
obvious visual indicators for each subject, to establish the 
potential bias from autocorrelation and finally to determine the 
agreement with statistical outcome. Graphed data was also 
considered in conjunction with the additional 
side effect reports and weekly scale scores. 
(c) Statistical analysis 
Autocorrelation tests 
daily questions, 
Autocorrelation coefficients were computed within baseline, 
trypt • phan and placebo phases~ for most subjects, on the three 
mood factors (both morning and evening series). Coefficients were 
also computed on the combined series (consecutively combined 
morning and evening data) for subject 01. Combined series 
calculations for remaining sObjects were omitted, as there was no 
gt-aphi cal representation of this data and it was assumed that 
sufficient information could be obtained from the separate 
morning and evening series. There is some contention in the 
time series literature over the merits of estimating 
autocorrelations separately (within) as opposed to across pre and 
post intervention phases. Glass et al. (1975) <=¼nd l<azdin 0982) 
advocate the farmer procedure on the assumption that 
interventions may affect the relation of data points to each 
other. 
In order that autocorrelation reflects the stochastic 
component of the error process, data points of the time series 
must be separated by equal intervals (Hartmann et al., 1980; 
note Jones et al. , 1977), i.e. as Hartmann et al (1980) 
" .•. irregular or variable intervals are likely to disguise or 






Data in the present study was considered to meet this 
in that scale completion time rarely varied outside 
from day to day. Autocorrelations are generally 
lags of N/4, where N is the number of data points of 
to be tested (Box ~( Jenkins, 1970, Gettman 8( Glass, 
1978; Hartmann et al. , 1980). t•Ji th larger lags computations 
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become increasingly unstable due to the dependence on fewer 
observa.ti ons. 
The results of autocorrelation estimates for N/4 lags are 
presented for the relevant phases within each individual 
following the graphed results. Significant presence of this 
feature was acknowledged as a caution against placing too greater 
weight on graphical analysis and led to omission of statistical 
evaluation in some cases. The formula and and subsequent program 
written to test for the presence of autocorrelation appears in 
Appendi ;-~ B. 
{d) T Tests 
T test calculations were performed in order to compare 
adjacent phase means. In general, calculations were limited to 
comparisons between baseline, placebo and tryptophan phases. 
Significant results were only taken seriously where the relevant 
phases were free of significant levels of autocorr-elation. 
Results from such calculations are presented within each subject 
(Chapter IV). In many cases t test calculations were based on 
different N's between phases. In cases where there was a 
significant difference between the sample variances a more 
conservative estimation of the t statistic and associated degrees 
of freedom was employed as advised by Nie et al. 
(d) C statistic 
Finally; the C statistic, promoted as a quantitative method 
for the detection of trends in time series data (Tryon, 1982) , 
was applied to this purpose. Justification for application of 
this statistic rests on the premise that its operation is 
independent of the stationarity (i.e. heterogeneity/ stability 
of the mean, variance and autocorrelation) of the series. Tryon 
( 1982) maintains the procedure can be sucessfully applied to 
series with as few as eight points per phase - this was indicated 
by Young's (1941) paper outlining the original formulation of the 
statistic. He demonstrated the unreliability of the 
approximation to the type II curve with samples of n<B, while for 
n<B-50 the approximation curve was acceptable with little 
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increase in p2 values for n=B through to 50. 
The formula for the C statistic is as follows: 
N-1 
~ (Xi - Xi+1) 
i=l 
C = 1 
N 





1 - Sum((N-1)c• nsecutive diffs associated with the series)) 
C = 




Therefore, C evaluates how large squared deviations from the 
mean are (i.e. reflects trends) relative to the sum of the 
squared consecutive differences (i.e. independent of trends). 
The Z statistic (achieved via division of C by its standard error 
{Sc)) is then checked for the determination of significance. 
That is., Z = C 
Sc 
""Jhere Sc = 
N-2 
<N-U <N+U 
The standard error is entirely a function of sample size, thus, 
as with other statistical procedures, a significant Z can always 
be found for any value of C given a sufficiently large N. 
Although presented as a "simplified time series analysis" by 
Tryon (1982), the methodology does not claim to parallel the 
conventional complex methods of Box & Jenkins (1976). The two 
approaches are similar to the extent that they represent 
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statistical methods for analysing temporally ordered data series 
to determine if interventions have produced reliable changes in 
the scoring pattern. However, the C statistic attempts to 
accomplish less than conventional time series analysis, a major 
limitation being its inability to separate the changes in level 
from changes in slope. Thus, ~s Tryon (1985) has more recently 
stated the C statistic is ''an omnibus test regarding whether or 
not any nan r-andom trends exist". 
In the present study, the C statistic is seen to serve as a 
mar-e objective adjunct to visual analysis. In this manner, the 
confluence of the two approaches may increase confidence in the 
process of data interpretation. The major justification far its 
application over Box & Jenkins (1976) methods is the requirement 
for as few as eight data points per phase (Young, 
clearly less powerful than Bm{ ~~ Jenkins 
1941). 
( 1976) Although 
approach., the methodology appears to present a relatively simple 
and parsimonious procedure for detecting the presence of 
in time series data. 
Application of the C statistic 
L, 
trends 
Initially the statstic is applied to the baseline series. 
J~ 
It is preferable that the baseline data is free of significant 
trends as this allows for a more powerful subsequent application 
of the I ..l,., • .J.. -St.i:\LlS1...lC. Secondly, the statistic is applied to the 
appended baseline and first treatment phase: significance here 
indicating that the treatment period departs from baseline. 
If significant trends exist in the baseline data, two less 
powerful subsequent applications are available, both involving 
the establishment of a comparison series composed of difference 
scores between the baseline and treatment phases. The more 
powerful alternative involves fitting of a regression line to the 
baseline data. The comparison series is then obtained by 
subtracting trend line values associated with the first baseline 
point from the first treatment point, 
second until exhaustion, 
then the second from the 
i.e. comparison series= baseline(x) - treatment(x) (;,-:=1,n) 
where n is the length of baseline or treatment phase. 
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The second~ simpler and less powerful approach involves a 
comparison series obtained by subtracting consecutive baseline 
points directly from treatment points. The comparison series 
produced by either of these methods is then tested by the C 
statistic, with significance indicating that the treatment phase 
departs from the baseline trend. 
In the present investigation, morning and evening series 
were tested separately (except in the case of subject 01, 
the combined series was also tested). In most cases, 
where 
the C 
statistic was applied to the baseline-1 phases within subjects 
(n=l-4 days). Secondly (in the absence of baseline trends) the 
tryptophan phase (where n>B days) was appended to the baseline-1 
and the C statistic applied again to test departure from 
basel i ne-1. The shortness of the washout and baseline-2 phases 




the main object of inquiry concerned whether tryptophan 
demonstrated a significant departure from baseline. 
analysis and t tests (where appropriate) facilitated 
comparison of placebo with baseline-1 and trytophan phases. 
In cases where the baseline-1 series contained significant 
trends, 
powerful 
the comparison series was constructed via the less 
method • f subtracting consecutive baseline points from 
consecutive tryptophan points. The preferred procedure of 
fitting a regression line to the initial series was abandoned due 
to violation of the assumptions for this procedure. That is, 
n2gression analysis t-equires that "the sample is drawn at random" 
and "that each array of Y for a given combination of X's follows 
the n• t-mal di stri buti on" (Kim ~< Kohout, 1975). Such conditions 
were not characteristic of the present data series. 
3.5.2.2 Weekly scales 
Total weekly scores for the SDS, State Anxiety and HSCL 
scales are presented within each subject's analysis (Chapter IV). 
Results in this context were considered in relation to noticeable 
changes within or between phases for each subject and in relation 
to VAMS ratings. Data from the weekly administration of the HSCL 
was processed according to the factorial structure established by 
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Derogatis et al. (1974) (Table 3-6). Factor loadings for the 
individual items were obtained from Derogatis et al. (1971). 
Items were multiplied by their loadings. Then, the composite 
scores relevant to each dimension were added and divided by the 
associated sum of the factor loadings. The factor scores from 
this process are presented for each subject in the result 
section. The program written to achieve calculation of factor 
scores appears in Appendix B. Zung, Trait and State anxiety 
scores aided in determination of subjects' anxiety and depressive 
status. 
3.5.2.3 Clinical versus experimental/statistical significance 
There is a need to address the issue of whether 
statistically significant results have psychological meaning in 
the present study. It is probable that statistically based 
inferences will result in Type I errors if clinical criteria of 
change are invoked. That is, the direction of separation most 
frequently cited is for a statistically significiant finding 
having trivial clinical relevance. This dichotomy may widen in 
cases of large N (N=data points in the present study), due to the 
dependence of statistical significance on sample size. Thus, if 
N is sufficiently large, entirely trivial effects will be found 
to be statistically significant. 
The departure of statistical evaluation from clinical 
relevance has been employed as an argument against engaging 
statistical methodology in clinical trials (Baer, 1977). 
However, statistical analysis may be of value in detecting trends 
that would otherwise be passed over on the basis of stricter 
clinical criteria of change. Thus, statistically based 
judgements should not necessarily be dimissed as irrelevant if 
they fail to match the more conservative clinical 
success or failure. 
criteria far 
In the present study, employment of statistical methodology 
was seen as a means of introducing some degree of objectivity to 
the evaluation process. In addition, small statistical effects 
may indicate the chance of greater effects under replication or 
design reconstruction in future research. Statistical evaluation 
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employing statistical analysis reported low improvement rates 
relative ta nan statistical investigations. Thus, while the 
discrepency is usually in the direction of mare conservative 
clinical than statistical interpretation of change, there is a 
danger that in the absence of statistical validation the 
experimenter may tend towards positively biased clinical 
conclusions. It is of course possible that a real clinically 
meaningful improvement may remain statistically undetected. These 
factors are further considered in relation to the present results 
(Chapter IV & V). 
It is the authors opinion that in drug evaluation studies 
such as the present one statistical criteria of change should be 
considered in conjunction with clinical criteria. However, in 
the present investigation, where professional and experienced 
clinical opinion was not available, evaluation depended on the 
variety of analytical procedures outlined above. In the final 
analysis, opinion was volunteered by the author regarding the 
psychological significance of experimental results. 
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CHAPTER IV 
RESULTS AND EXPERIMENTAL DISCUSSION 
4.1 INTRODUCTION 
The first section of this chapter (4.2) presents evaluation 
and conclusions relating to results within subjects. Section 4.3 
presents a description of the sample and evaluation of results 
across subjects. Finally, in section 4.4 factors relevant to the 
validity and generality of results are discussed. 
4.2 WITHIN SUBJECT PROFILES AND ANALYSIS 
This section contains consecutive presentations of subject 
descriptions, experimental procedures and results from visual and 
statistical analysis for each participant. Each presentation is 
followed by brief evaluations and conclusions focused on 
relationships between tryptophan administration and psychological 
state. Result presentation exhibits considerable variability 
between subjects owing to the diversity in psychological status 
and differences in experimental variables such as dose level and 
phase length. However, there are some consistent aspects of 
presentation across subjects. 
Each analysis begins with a brief subject description, 
including assigned psychological status. Psychological status was 
formulated with reference ta normative data provided by Knight et 
al. (1983) on the SDS and STAI scales and Zung's (1972) 
depression categories based on SDS scores. Specific features 
such as premenstrual tension and vegetarianism were only included 
"L 1 I subjects responded positively. Following a description of 
experimental variables, results are presented far weekly scales, 
daily mood ratings, total sleep time, side effect quality and 
severity and any extra information relating ta effects such as 
premenstrual tension or reports of unusual happenings. 
Assessment of depression and anxiety status depended on 
intial 
I\ 
ratings, except when subsequent ratings exhibited 
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in which case this information contributed to 
assessments. For all subjects, visual and statistical analysis 
of daily mood ratings focused on comparison between baseline 1 ~ 
were tryptophan 
available. 
and placebo phases where .r r . . i.. SU-tTlC1en1.. data 
Breaks in the graphed mood factors indicate missing 
data. In some cases absence of or insufficient ratings during 
the placebo phase limited comparison to baseline and tryptophan 
periods. Autocorrelation estimates were limited to the phases 
amrnenable to visual and statistical analysis. C statistic 
applications were confined to baseline and tryptophan phases for 
most subjects due to the inappropriateness of 
adjacent phases e.g. tryptophan versus placebo. 
comparing non 
Statistical 
comparison of side effects and hours af sleep between baseline 1~ 
tryptophan and placebo phases was presented where data were 
available. Reports of unusual happpenings and drug consumption 
were considered in relation to altered mood ratings. 
In cases where female subjects responded positively to 
suffering 
changes 
from premenstral tension, consideration was given to 
(\ 
in mood ratings, side effect reports and weekly scales 
during the premenstrual phase. The phase of the menstrual cycle 
associated with premenstrual tension varies considerably arno1(ng 
both researchers in this field and those claiming to experience 
the synd1~ome. That is, some authorities consider the relevant 
phase to be confined to one to seven days prior to menstruation 
(Wilson & Rennie, 1976) while others consider up to 14 days prior 
to the onset of bleeding is mare usual (Brush, 1979). A period of 
14 days prior to menstrual onset is taken as the premenstrual 
phase in the present study. The purpose of this consideration 
was to determine whether psychological changes relating to the 
e:-;peri mental conditions might have been confounded by factors 
coincident with the premenstrual phase. 
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4.2.1 Subject 01 
Cl) Demoqraphic variables 
age(yrs): 39 se>i : female heiqht(cms}:173 
weioht(kgs):50.80 
(below desirable weight range 
regular consumption of: vit. A,B,C and E drug consumption: 
vegetarian: yes 
tryptophan experience: consumed prior to this project in the 
context of a dietary supplement 
motivation for participation: - general interest 
(2) Psycholoqical variables 
(a) Depression status 
Low initial and subsequent SDS scores (with respect to 
Knight et al. ·s (1983) norms), together with a 'general interest· 
motivation for participation was seen as confirmatory of a 
depressed' status. 
(b) Anxiety status 
'non 
With respect to Knight et al. 's (1983) norms, this subject 
exhibited a low score indicating freedom from significant levels 
of anxiety symptoms. 
(3) Experimental variables 
(a) Dose level(gms/day): 6 
(b) Phase description 
baseline 1 tryptophan :washoutl placebo baseline 2 
14days 28days 7days ?days 
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(c) Extra details 
Scale completion time was regular with missing data limited 
to the first baseline HSCL rating. Participation continued 
f uninterupted for the 84 day program 
JI\ 
(trytophan/placebo) being forgotten. 
(4) Results and analysis 
(a) Weekly scores 
with no tablets 
Table 4-1-1 Total scores for Zung, State anxiety and HSCL scales 
baseline 1 tryptophan wash placebo bs2 
day 01 07 14 21 28 35 42 49 56 63 70 77 84 
scale 
zung 24 24 26 24 26 22 31 33 30 25 28 31 28 
state r;c:- ....,,.., 22 24 26 26 ... ...,. 43 40 ~..., 26 31 -,.-;r ..:..,J ........ _..::.._) L,~ k•.:> 
HSCL 74 67 66 68 63 68 79 72 62 67 75 91 
Table 4-1-2 HSCL factor scores 
baseline 1 tryptophan wash placebo bs2 
day 01 07 14 21 28 -,-c;-._jJ 42 49 56 63 70 77 84 
factor 
1 L18 1.18 1.08 1.08 1. 19 1.08 1. 08 1.26 1. 16 1.08 1.08 1.45 1.98 
2 2.07 2.07 1.67 1.64 1.64 1.54 1.89 1.77 2.03 1. 41 1.73 1.89 1.89 
< ~· 1. 12 1. 12 1.00 1. 00 1.00 1. 00 1.00 1.34 1.00 1.00 1. 00 1.00 1. 18 
4 1. 18 1. 18 1. 09 1. 00 1. 09 1. 08 1. 09 1. 27 1. 16 1.00 1. 09 1. 16 1.44 
5 1.00 1. 00 1.00 1.00 1.00 1. 00 1. 00 1.75 1. 15 1.00 1. 00 1. 13 1.47 
Comment on wee kl ·:r scale scores 
This subject was characterized by consistently low scores on 
the above scales. There was a noticeable increase in the State 
scores for the two weeks following the cessation of tryptophan 
and a similar increase of less magnitude in the HSCL scores. 
However, this change could not be meaningfully related to other 
variables. The baseline 2 (bs2) peak for the final HSCL (total) 
rating could be related to reported flu experience at this time. 
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Reference to the factor score distribution for the HSCL also 
demonstrates considerable consisjkency throughout the entire 
series, except for the rise in baseline 2 ratings, which was 
predominantly attributable to factor 1 i.e. somatization - a 
dimension in keeping with the flu characteristics reported. HSCL 
factor scores were close to the means reported for a normal 
sample (Table 3-4). 
(b) Mood factors 
Visual analvsis of qraohed data 
There was a lack of variation across all phases for both 
morning and evening series in this case. Similarly, there was an 
absence of noticeable change in level or slope between phases~ 
The only marked changes in the morning series <Figure 4-1-1) 
concerned the concurrent troughs for all 3 mood factors in the 
washout and baseline 2 phases and the slightly separated but more 
exaggerated troughs in factors 2 and 3 of the baseline 1 phase. 
The washout dips on day 5 of this phase, coincided with reports 
of no sleep on the previous night. On days four and five of the 
baseline 2 phase, the subject reported experiencing flu symptoms 
including headaches and vomitting. For the baseline 1 phase 
th~re were no comments coincident with days 10 or 13 which showed 
dips on the calmness and alertness factors respectively. For the 
evening series (Figure 4-1-2) the troughs, apparent in the 
baseline 2 phase on days four and five, coincided with the 
reported flu symptoms. There were no reported comments to 
coincide with the dip in the calmness fact • t- on placebo phases. 
A domestic dispute was noted on day 2 of the baseline 1 
recordings which may relate to the dip in the contentedness 
factor. 
There was considered to be an absence of dramatic and 
consistent effects, within this subject, to meet the criteria for 
visually analysis of change (Kazdin, 1982; Parsonson & Baer, 
1978). The presence of the one to two day dips in mood ratings 
could not be meaningfully related to intervention 
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FACTOR SCORES FOR THREE MOOD DIMENSIONS - EVENING DATA 
SUBJECT: 01 
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Autocorrelation Crk) estimates 
Estimations were calculated within phases for morning, 
evening and combined series for this subject. 
Table 4-1-3 rk (k==1 7n/4) values for separate morn. ~< eve. series 
factor baseline 1 (n==14) tt-:tE•tophan (n==28) wa.sh (n==7) 
r1 ,.-2 r-3 r1 r2 r3 r4 r1 
alertness 
morning .58** .28 .24 .01 -.01 -.24 -.18 -.13 
evening -.18 -.01 -.01 -. 12 .34* .. 12 .19 -.03 
cont ••• ss 
morning -.17 - ...,..,.. -. (i2 • 01 .14 • 10 12 -.17 • ..£......:.. . 
evening -.32 .02 -.16 .07 -.27 . 01 • 04 .27 
calmness 
morning -. 15 .21 -a,(12 -.17 -.09 -. 13 -.02 . ~ -a 1..::, 
eveninq .16 -.37 -.38 .28* .29* .08 .17 •-u::-• .LJ 
Table 4-1-3 continued: 
factor placebo(n==28) bs2 (n==7) 
r2 r3 r4 rl 
alertness 
morning .34* .41** .38* .16 . 34 
evening .17 
...,..,.. .. ~...:• .38* .24 .18 
cont ••• ss 
morning -.10 
...,..,.. 
- II.£..~ -.03 .18 .19 
evening .24 • (13 .28* -.05 .15 
calmness 
morning .08 .28* .21 .40 .34 
evening -.04 -.08 -.04 -.04 . 28 
* exceeds the critical value for the ,05 1 eve l of significance 
** exceeds the critical value for the ,01 level of significance 
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Table 4-1-4 rkCk=less of N/4or4) values for combined morn. & eve. 
series 
factor baseline1(n=28) tryptophan(n=56) wash(n=14) 
rl r-2 r3 t-4 r1 r2 r3 r4 rl r2 
alert •• -.16 . 32*-- (}3 .19 .10 .01 -.04 • 24 .19 .06 
cont •. • (,)1 -.27 -.09 -.01 .04 • 11 -. 12 -.09 .36* .04 
calm .• -.14 -.01 -.15 .21 -.02 .15 -.14 .17 .43*-.02 
Table 4-1-4 continued: 
factor placebo(n=56) base2(n=14) 
rl r-2 r3 r4 rl r2 r3 
alert •. .,23* .. 25* .18 • 31 .52**-26 -.13 
cont •• .10 so 21 -.08 • 06 .47* .18 -.40 
calm .. -.07 -.02 .01 -.04 .41* .34 -.09 
* exceeds the critical value for the .05 level of significnce 
** exceeds the critical value for the .01 level of significance 
t test results 
Table 4-1-5 t test values for mean differences between 





alertness basel - tryp basel - plac tryp - plac: 
morning -1.43 ns -2.57* + 
evening -0.90 ns -0.67 ns 
combined -0.12 ns -3.19 ** + 
contentedness 
morning -0.74 ns -0.29 ns 
evening -0. 19 ns -0.21 ns 
combined -0.64 ns 0.14 ns 
calmness 
morning -1.38 ns -1.38 ns 
evening -0.51 ns 1.28 ns 
combined -1.44 ns -0.31 ns 
* exceeds critical value for the .05 level of significance 
** exceeds critical value for the ,01 level of significance 
+ sig, t values affected by sig, levels of autocorrelation 








1. 81 ns 
1. 72 ns 
Comment on t test results 
Significantly lower means for tryptophan versus placebo were 
demonstrated on alertness. The finding was maintained across 
comparisons of morning, evening and combined phases. However, as 
indicated from Table 4-1-5, significant levels of positive 
autocorrelation were indicated for placebo phases in all of these 
series and for the tryptophan phase in the evening series. Thus, 
significance levels for these t tests are likely to have been 
overestimated. The significance levels for alertness between 
baseline 1 and placebo phases (morning+ combined series) are 
also threatened by the presence of significant positive 
autocorrelation. The level of contentedness was significantly 
higher for tryptophan than placebo in the morning and combined 
series and these estimates were f1~ee from autocorrelation bias. 
However, the magnitude of difference in means was small in both 
cases, i.e. for the morning series the tryptophan mean was 87.93 
and placebo was 86.79 and for the combined series the respective 
means were 88.61 and 87.39. 
C statistic results 













cont ••. ss -1.201 ns 
calmness .764 ns 
combined 
alertness 
cont ..• ss 
-.561 ns 
.032 ns 
base1+tt-yp placebo bs2 plac+bs2 













1.857 ns 2.207 ns 5.002 ** 
1.133 ns 1.935 ns 5.321 ** 
calmness -.702 ns -.596 ns 1.048 ns 1.892 ns .464 ns 
** exceeds the critical value for the ,01 level of significance 
~ due to a sig, trend in the base1 phase, this calculation was based on a 
comparison series (see Chapter III for explanation) 
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Comment on C statistic results 
As is evident from Table 4-1-6, the presence of a 
significant trend was established for the alertness dimension 
within the baseline 1 phase of the morning series. This 
necessitated calculation Z for the baseline!+ tryptophan phases 
to be based on a less powerful procedure, which only used the 
first half of the tryptophan phase. On this basis a significant 
departure in trend for tryptophan alertness relative to baseline 
was demonstrated. Significant changes in trend were also 
indicated for baseline 2 phases relative to placebo, on 
alertness and contentedness, for the combined series. 
(c) Hours of sleep 
Table 4-1-7 Autocorrelation estimates: rk (k=n/4) values 
baseline1(n=14) tryptophan(n=28) 
t- 1 t-2 t-3 rl r-2 t-3 r4 
-.07 • 09 -.34 -.07 -.002 -,~ •.£..I -.24 
None of the above estimates proved significant 
t test value results for hours of sleep 
basel - tryp 
-0.002 ns 
tryp - plac 
1.28 ns 
C-statistic results (Z .values) 
- . 
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basel - plac 









Comment on hours of sleep 
r4 
. 09 
No significant changes emerged for hours of sleep in terms 
of the mean difference (t) between baseline 1 and tryptophan 
phases, baseline 1 and placebo phases or tryptophan versus 
placebo periods. In addition no significant trends were observed 
in any of the above phases. 
1i4 
(d) Side effects 
The baseline 1 phase was free of any reported side effects. 
Similarly, the first two weeks of the tryptophan phase showed an 
absence of reported effects until day 14 when the subject 
described symptoms such as flushing and pulsating - in keeping 
with the niacin reaction (Chapter II). The remainder of the 
tryptophan phase in addition to the placebo and baseline 2 phases 
were free of reported side effects while the symptoms noted on 
day four of the baseline 2 phase coincided with the reported flu 
experience at this time. 
(5) Summary and Conclusions 
Vi SW:il evaluations, indicating an absence of significant 
effects within and across mood factors, were corroborated by 
statistical findings except for two points of departure. 
Significantly higher mean values for tryptophan over placebo 
phases (for both morning and combined series) for the 
contentedness dimension were indicated statistically but were not 
supported visually and were not indicated relative to baseline. 
Also, the magnitude of difference between the respective means 
w2-.s smal 1 • Similarly, a significant departure in trend for 
alertness scores in the morning tryptophan versus baseline 1 
phase was statistically but not visually apparent. Due to the 
baseline 1 trend, the calculation was based on a less powerful 
application of the C statistic, which used only the first half of 
the tryptophan phase. As is evident from Table 4-1-5, there was 
a non significant mean difference between these two phases. 
Measures on the weekly scores remained quite consistent 
throughout the trial with elevation in the final 
probably associated with the reported flu experience. 
HSCL rating 
Similarly, 
there was no evidence for changes with respect to total hours of 
sleep between baseline 1, tryptophan and placebo phases. 
One noticeable change which could be attributed to 
tryptophan administration concerns symptoms reported on day 14 
of the tryptophan phase which parallel closely effects frequently 
reported in association with the niacin reaction (Chapter I I) • 
This subject was the only one to report such a dramatic effect. 
It could be speculated that a dose of 6gms for 28 days in a 
subject below the desirable weight for height range could have 
been responsible for such a reaction. However, no other 
significant increases in the incidence of reported side effects 
or subjective complaints support this possibility. Thus, 
consumption of 6gms/day of tryptophan for 28 days was not 
associated with consistent or dramatic changes on any of the 
psychological measures relative to placebo or baseline periods. 
4.2.2 Subject 02 
(1) Demographic variables: 
aqe(yrs): 37 sex: male heioht(cms):168 
weight(kqs):64.00 
(within desirable weight range) 
L 
druq consumption: high nicotine+ caffene intake 
~ 
1-tryptophan experience: - not consumed prior to this trial 
motivation for participation: - depression 
(2) Psychological variables 
(a) Depression status 
This subject could not be classed as depressed on the basis 
of the initial SDS score, if Zung's depressive categorization is 
although subsequent SDS scores throughout the study considered, 
reached 
X subsequent 
the mild - moderate category Clung, 1972). Initial and 
Knight et 
scores e>:cWeeded 1 SD above the mean with respect to 
al. 's (1983) norms. Given a depression motivation for 
participation and the fact that consumption of prescribed doses 
of antidepressants and hypnotics (i.e. 50 mg clomipramine + 2mg 
lorazepam/day) continued throughout the trial, this subject was 
classified as depressed. 
116 
(b) Anxiety status 
With respect to Knight et al. ·s (1983) norms, this SL(bject 
exhibited an initial Trait anxiety score exceeding 1 SD above the 
mean for the appropriate age and sex category, while initial and 
several subsequent State scores exceeded 2 SD's above the mean. 
Thus, this individual was considered to be experiencing moderate 
levels of anxiety. 
(3) Experimental variables 
(a) Dose level (gms/day): 6 
(b) Phase description 
baseline 1 placebo : t-.iashout: tryptophan lbaseline 2: 
14days 28days 7days 11days 3days 
(c) Extra details 
This subject was the only one to complete the placebo phase 
prior to tryptophan. Scale completion time was consistent from 
day to da.y (i.e. v-Ji thin 2 hours). Evening scales were completed 
on returning home from work. Only two moodscale ratings were 
missed. This subject expressed the desire to withdraw from the 
program after the 11th day of the tryptophan phase due to the 
lack of any beneficial effects. Following this decision, 3 days 
of the baseline 2 phase were completed before trial termination. 
(4) Results and analysis 
(a) Weekly scores 
Table 4-2-1 Total scores for Zuno. State anxiety and HSCL scales 
baseline 1 placebo wash tryptophan 
da.}:'.'. 01 07 14 21 28 35 42 49 56 63 
zung 38 34 37 -=!"'? ._ . .,:_ 40 30 31 31 40 42 
state 47 36 i=-:r '-1·--- 42 46 34 41 35 43 39 
HSCL 71 73 88 90 93 83 84 87 94 100 
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Table 4-2-2 HSCL factor scores 
baseline 1 placebo 11-Jash tryptophan 
day 01 07 14 21 28 7C::--~•.J 42 49 77 84 
factor 
1 1. 40 1.22 1.66 1.39 1.31 1. 41 1. 22 1. 30 1. 39 1.55 
~. 
..::. i C::- n J.. • ._,Lf- 1.27 1.75 2. 17 2 .. 43 2c02 2.04 2.41 2.45 2.28 
3 1. 00 1. 16 1.34 1. 50 1. 60 1. 34 1.34 1.34 1.52 1.34 
4 L 1 (i 1.10 1.56 1. 09 1.29 1.29 1.28 1.38 1.29 1.76 
c::- 1. 15 1.42 1.44 1.86 1.46 1.42 1.58 1.61 1.59 1.62 .J 
Comment on weekly scale scores 
This subject maintained relatively high SDS and State 
anxiety scores throughout all trial phases. There was an 
increase in HSCL total scores as the trial proceeded with the two 
highest ratings during the tryptophan phase. As evident from 
Table 4-2-2, the greatest increases seemed related to the HSCL 
factors 2, 4 and c:- • .J i.e. obsessive compulsive, depression and 
anxiety respectively. In relation to Derogatis et al. 's (1974) 
normative data for these factors (Table 3-4) , the present 
subject's score on 'obsessive-compulsive' lies closest to the 
anxious neurotic group with the last three scores tended closer 
to the depressed neurotic's mean. The 'depression' and 'anxiety' 
dimensions tend to drift from scores in keeping with the normals 
means to values closer to the anxious neurotic means. 
(b) Mood factors 
Visual analysis of qraphed data 
No dramatic trends or changes in level were apparent either 
within or across phases following visual inspection of morning 
and evening series (Figures 4-2-1 & 4-2-2). A slight increasing 
trend within the morning baseline 1 phase for the alertness and 
contentedness dimensions was detected. Flu symptoms were reported 
during the first four days of baseline 1 which may account for 
depressed scores at this time. A high level of day to day 
variability was exhibited across all phases in both series. 
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FACTOR SCORES FOR THREE MOOD DIMENSIONS - MORNING DATA 
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relative to the morning series were apparent. 
Autocorrelation estimates 
Table 4-2-3 rk (k=l.n/4) values for separate morn. & eve. series 
factor baseline 1 (n=14) placebo(n=28) 
r1 r2 r3 t- 1 r2 t-3 t-4 
alertness 
morning .26 .34* .07 ~37* .36* .30 . 12 
evening .06 -.41 -. 3(1 . 17 -.26 -.05 - . 19 
cont . . . ss 
morning .45* .35* J ,_, .24 16 .21 • 01 . l..<:. . 
eveninq . 13 .05 -.46 .05 .02 -.07 .07 
calmness 
morning -.25 .01 7"":"' - 19 - 16 -.03 11 - .. _ .. _ .. . = . 
evening . 14 -.30 -.33 . 13 . 14 - . 14 -.29 
* exceeds the critical value for the ,05 level of significance 
** exceeds the critical value for the ,01 level of significance 
t test i--esul ts 
tryp(n=11) 
t- 1 r2 
-.04 -.30 
- . 19 - . 16 
.05 .32 
.02 -.24 
- 15 -.34 . 
. 17 -.30 
Table 4-2-4 t test values for mean differences between 
baseline 1. trvptoohan and placebo phases 
ba.sel - pl a.c basel - tryp 
alertness 
morning "-' "'"'i --:r -..::... /._, *+ -0.11 ns 
evening -2.27 * 1. 23 ns 
contentedness 
m• r-ning "'-4.06 **+ -2.49 *+ 
evenino -4.28 ** -0. 14 ns 
calmness 
mrn-ni ng 0.60 ns -0.39 ns 
evening 0.45 ns -0.91 ns 
* exceeds critical value for the , 05 level of significance 
** exceeds critical value for the I O 1 level of significc:1nce 
+ sig, t values affected by sig. levels of autocorrelation 

















Comment on t test results 
As is evident from Table 4-2-4, significant findings, free 
from autocorrelation bias, were limited to the evening series. 
For the alertness and contentedness dimensions, the placebo phase 
exhibited a significantly greater mean than the baseline and 
tryptophan phases. In neither case, was there a significant 
difference between baseline and tryptaphan phases. The 
remaining significant t test outcomes (morning series) are likely 
to have been overestimated due significant levels of 
autocorrelation within the phases concerned. 
positive 
C statistic results 
Table 4-2-5 Z values for morning and evening series 
set-i es basel bsl+plcb plcb+wash (plcb+wash)+tryp 
mot-ni ng 
alertness 1.35 ns -:r ,,,..... ~-=·- L.4 ** 2a08 * "'-0.02 ns 
cont •.. ss 2. 11 * "' 0.01 ns 1.37 ns 1. 25 ns 
calmness -0.92 ns -1.05 ns -0.77 ns -0.85 ns 
evening 
alertness 0.80 ns 1. 95 * 1. 11 ns 2.00 * 
cont ... ss 0.94 ns ..... ...,.,.., .L.. • I -4. ** 0.67 ns 
..... ~~ 
L • . _::,.;:., ** 
calmness 0.65 ns 0.85 ns 0.76 ns 1.23 ns 
* exceeds the critical val Lie for the .05 level of significance 
** exceeds the critical value for the • 01 level of significance 
~ due to a sig, trend in the base1 phase, this calculation was based on a 
comparison series (see Chapter III for explanation) 
Comment on C statistic results 
As evident from the Table 4-2-5, presence of significant 
trends in the morning series for · baseline contentedness' and 
·(placebo+ washout) alertness· meant that respective comparison 
with the morning series 'placebo contentedness· and 'trypt • phan 
statistic alertness' 
appl i ca.ti on 
were based on the less powerful 
(see Chapter III for explanation). 
C 
A significant 
departure was indicated in the morning for the placebo phase 
relative to baseline on the dimension of alertness. Secondly, in 
the evening~ significant departures for placebo over baseline 
and trytophan over (placebo+washout) were indicated for alertness 
and contentedness dimensions. 
(c) Hours of sleep 








-.15 -.12 -.03 -.05 -.31 . 11 
None of the above estimates prooved to be significant 
t test results for hours of sleep 
basel - plac 
3.13 ** 
Comment on hours of sleep 
base1 - tryp 
4.89 ** 
plac - tt-yp 
"'0.65 ns 
As is evident from the above t-test results~ the mean hours 
of sleep during both placebo and tryptophan phases tended to be 
significantly lower (p<.01) than the tryptophan phase while no 
significant difference was apparent between the placebo and 
tryptophan periods. Results were free from autocorrelation bias. 
(e) Side effects 
Table 4-2-7 Autocorrelation estimates: rk (k=n/4) values 
baselineii:n=14) placebo(n=27) 
rl r2 r1 r2 r3 
. 10 . 29* - • 01 
r4 
.14 
tryptopr1an (n=l 1) 
.30 -.16 
* exceeds the critical value for ,05 level of significance 
t test results for severity of side effects 
base1 - plac 
-3.32 ** 
basel - tryp 
-6.84 ** 
plac - tt-yp 
-4.59 ** 
Comment on side effects 
A systematic increase in the severity of symptoms was 
observed throughout the trial with the mast severe levels 
reported during the tryptophan phase. Mean severity values were 
significantly higher during placebo and tryptophan phases 
relative to baseline 1 and the tryptaphan phase proved to be 
significantly greater than the placebo phase. In both cases the 
t value was particularly high, which may have counteracted the 
autocorrelation bia.s associated with the placebo phase. The only 
effect to appear with notable increase during the tryptophan 
phase, was described by the subject as 'hot flushes'. This 
effect was only reported on one occasion during the series pri ot-
to tryptophan ingestion but appeared frequently during the 
tryptophan and three days of the baseline 2 period. It could be 
speculated that this effect resembled symptoms associated with 
the 'niacin reaction' (described in Chapter II). 
(5) Summary and Conclusions 
Analysis for this subject focused on detection of 
antidepressant effects given the motivation for participation as 
'depression' and the tendency for elevation in some Zung scores 
throughout the trial. No noticeable effects could be detected on 
the basis of visual analysis of daily mood ratings. The visual 
indication of slight trends in the morning baseline phase for 
alertness and contendedness was only supported by a significant C 
statistic result in the latter case. 
Significant t test outcomes (free from autocorrelation) 
were limited to higher placebo means {relative to baseline and 
tryptophan phases) for alertness and contentedness dimensions on 
the evening series but were not supported by visual analysis. 
These findings were not considered particularly meaningful or 
relevant to the determination of tryptophan's antidepressant or 
general mood - altering effects, particularly since there were no 
baseline - tryptophan differences. 
In the case of C statistic applications, attention was 
directed to the detection of changes in' trend between (1)baseline 
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and placebo phases and (2) (placebo+washout) and tryptophan 
phases. In the first case, significant changes were detected in 
the morning for alertness and in the evening for alertness and 
contentedness. In the second case significant departures were 
noted on alertness and contentedness in the evening. 
analysis was not supportive of these findings. 
Visual 
The findings of slight visual and statistical (t test) 
increases in placebo relative to baseline phases on alertness and 
contentedness and apparent declines during tryptophan intake 
t-el ati ve to 
meaningful. 
Cplacebo+washout) phases were not psychologically 
The decline in alertness for the tryptophan relative 
to placebo phase is in keeping with tryptophan·s reputation for 
increasing drowsiness. The significant reduction in hours of 
sleep for tryptophan relative to baseline was not maintained 
relative to placebo. 
The most striking result for this subject concerned the 
increased +- . nega_1ve side effects during the 
tryptophan relative to baseline and placebo phases. This increase 
tended to be supported by increasing HSCL scores which also 
peaked during the tryptophan phase. The absence of clear 
antidepressant effects in this subject may be attributable to 
the brevity of the tryptophan phase. In addition, it is 
conceivable that the 6gms/day dosage in this subject was too high 
in combination with his standard antidepressant medication. 
4.2.3 Subject 03 
(1) Demographic variables 
aoe(y1~s): 33 se;-; : f ema.l e 




(within desirable weight range) 
1-tryctophan experience: - not consumed prior to this project 
motivation for participation: - depression 
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(2) Psychological variables 
(a) Depression status 
On the basis of the initial SDS total score this subject was 
classed as moderately depressed (Zung, 1972). According to 
Knight et al. ·s (1983) norms this score exceeded one standard 
deviation above the mean for the appropriate age and sex 
category. Relatively high subsequent SDS scores were maintained 
throughout the trial. 
Cb) Anxiety status 
With respect to Knight et al. ·s (1983) norms, this subject 
exhibited a Trait score (56) well in excess of one standard 
deviation above the mean for her age category. The initial State 
score was within one SD from the mean. However, three subsequent 
scores reached 60 in contrast to the mean for this age group of 
34.47 <Knight et al., 1983). Consequently this subject was 
considered to be experiencing reasonably high levels of anxiety. 
(3) Experimental variables 
(a) Dose level (gms/day): 3 
Cb) Phase description 
baseline 1 tryptophan lwashout: placebo lbaseline 2: 
14days 28days 7days 14days 7days 
Cc) Extra details 
Scale completion time was regular (within two hours from day 
to day>. No missing data was accrued for the moodscales. Weekly 
ratings for the Zung, State anxiety and HSCL scales were missed 
on the last week of baseline 1 and at the end of baseline 2. 
Otherwise participation continued, uninterupted for the 70 day 
trial with placebo ingestion forgotten on one night. 
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(4) Results and analysis 
(a) Weekly scores 
Table 4-3-1 Total scores for Zung, State anxiety and HSCL scales 
baseline 1 tryptophan wash placebo bs2 
day 01 07 14 21 28 ~C' ._,,_J 42 49 56 63 70 
scale 
ZLtng 49 52 52 45 48 c-,..., ..Jk 44 43 52 
state 4, ·-· c;:--,-~.....:.• 60 60 36 60 45 46 c::--:r ,_J._:, 
HSCL 102 123 123 118 107 113 101 96 118 
Table 4-3-2 HSCL factor scores 
baseline 1 tryptophan wash placebo 
day 01 07 14 21 28 -,,-,::- 42 49 56 63 ._:, ,.J 
factor 
1 1. 27 1.48 1.54 1.48 1.44 1.31 1.87 1.34 1.99 
2 1.95 2.58 2.31 2.60 1.94 2 .. 14 1.31 1.85 ,. ,,.,..,, L..-L~ 
' -· 1.73 2.98 2.98 2.44 2.50 2.89 1.93 1.50 2. £)5 
4 1. 60 2.62 2.70 ...... 17 2.: 16 2.60 ..... 19 2.04 2.44 .a::.si. ..::. .. 
5 2. 18 1.77 1.62 2s: (12 1.77 1. 74 1. 72 1.87 1.73 
Comment on weekly scale scores 
As evident from Table 4-3-1, relatively high Zung and State 
total scores were maintained throughout the trial with no decline 
during the tryptophan phase. 
maintained throughout the series. 
High total HSCL scores were 
There was a slight decline in 
HSCL total scores during the tryptophan, washout and first week 
of the placebo phase. HSCL factor scores were closer to means for 
depressed and anxious groups rather than normals (Table 3-4). 
(b) Mood factors 
Visual analysis of graphed data 
No dramatic or meaningful changes with respect to Kazdin's 
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FACTOR SCORES FOR THREE MOOD DIMENSIONS - EVENING DATA 
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either vJi thin or across ph-e.ses for the morning (Figure 4--3-1) or 
evening (Figure 4-3-2) series. There was some indication of 
greater day to day variability for the evening series relative to 
mm-ni ng ratings. 
Autocorrelation estimates 
Table 4-3-3 rk (k=1.n/4) values for separate morn. & eve. series 
factor baseline 1 (n=14) tt-yptophan (n=28) 
rl r-2 r3 rl r2 r3 
alertness 
morning .45* -.24 -.36 . 18 -.20 -,.32* 
eveninq • 31 .29 -.04 -.36* -.02 . 10 
cont . . . ss 
mm-ning .27 -.21 -.28 . 14 .01 • 06 
evening - . 15 . 34 . 10 . 16 -.21 -.86 
calmness 
morning - . 12 -.30 -.02 -.09 - . 12 - . 19 
eveninq .04 .. ()2 .. 22 .04 - . 12 - . 15 
Table 4-3-3 continued: 
factor placebo(n=14) 
rl r-2 r3 
aler--tness 
mm-ning -.42 .05 -~25 
evening -.39 -. (15 ... ~. A ..::....::. 
cont. . uSS 
morning - . 18 .37 - . 14 
evening "Z,..., • ·-~oil- -.20 -.47 
calmness 
morning -.45 . 18 -.27 
evening -.24 -.24 - . 11 
* exceeds the critical value for the ,05 level of significance 
** exceeds the critical value for the ,01 level of significance 
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- . 16 
- . 10 




t test results 
Table 4-3-4 t test values for mean differences between 
baseline 1. trvptophan and placebo phases 




























* exceeds critical value for the ,05 level of significance 
+ sig, t values affected by sig, levels of autocorrelation 
indicates the first mean of the pair is the lowest 
-2.54 





phase variances unequal,t-test approximation L1sed (see Chapter III) 







Significant findings were limited to the alertness and 
calmness dimensions for this subject. The mean for the placebo 
phase on the alertness dimension was found to be higher than 
baseline in the evening series. For the calmness dimension, the 
placebo mean was significantly higher than baseline in the 
evening and higher than tryptophan in the morning and evening 
series. In the cases of the tryptophan - placebo differences • n 
alertness the presence of significant negative autocorrelation 
during the tryptophan phase may have led to a conservative 
estimate <Hartmann et al., 1980) oft test significance, thus, 
the elevation of the placebo mean relative to tryptophan in both 
series should probably be considered as a valid result. The 
presence of positive autocorrelation during the morning baseline 
phase for alertness is more likely to have led to a liberal bias 
oft test significance between baseline and placebo phases in the 
morning and consequently must be treated cautiously. 
131 
C statistic results 
Table 4-3-5 Z values for mornino, evening and combined series 
series base1 bs1+tryp 
mm-ning 
alertness 1. 99 * 
rw -0.36 ns 
cont ••• ss 1. 69 * "' -0.06 ns 
calmness 0.10 ns -0.32 ns 
evening 
al et-tness 1.94 * ~ 1.99 * 
cant .•• ss -0.46 ns 0.23 ns 
calmness 0.81 ns 0.39 ns 
* exceeds the critical value for the ,05 level of significance 
~ due to a sig, trend in the base1 phase, this calculation was based on a 
comparison series (see section Chapter III for explanation) 
Comment on C statistic results 
As is evident from the Table 4-3-5 1 significant trends were 
detected in the baseline phases for alertness (mm-ning and 
evening) and contentedness (mon1i ng only). Subsequently~ a 
significant departure in the tryptophan relative to baseline 
phase was limited to the evening ratings on alertness. This 
calculation here was based on the less powerful application of 
the C statistic which effectively involved comparison of the 
baseline with only the first half of the tryptophan phase. 
Cc) Hours of sleep 
Table 4-3-6 Autocorrelation estimates: rk (k=n/4) values 
baseline1(n=1 
ri r2 r3 
.37* 
tt-yptophan(n=28) 
-.34* .04 -.21 
placebo(n=14) 
t- 1 t-2 
-.15 -.19 
* exceeds the critical value for the ,05 level of significance 
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t test value results for hours of sleep 
basel - tryp base1 - plac tryp - plac 
-0.25 ns "'-'-2.19 *+ "'-2. 12 *+ 
* exceeds the critical value for the ,05 level of significance 
~ t-test approximation used due to unequal phase variances 
+ sig, t values affected by sig, levels of autocorrelation 
Comment on hours of sleep 
As indicated from the t test results, mean hours of sleep 
tended to be significantly lower during the baseline and 
tryptophan phases relative to the placebo period. The pt-esence 
of significant negative autocorrelation during the baseline and 
tryptophan phases is more likely to have caL\sed an 
underestimation of significance, therefore, the significance of 
the above t tests can be interpreted relatively confidently. 
(d) Side effects 
Table 4-3-7 Autocorrelation estimates: rk (k=n/4) values 
baselinel (n=14) tryptophan(n=28) placebo(n=14) 
r1 ---"" I .L ... -""':!" ! ._. r-1 r2 r3 r4 rl ,-2 
.16 -.06 -.14 -.08 -.01 .01 -.26 .24 -.15 
None of the above estimates proved significant 
t test value results for severity of side effects 
basel - tryp 
-2.07 * 
base1 - plac 
-2.33 * 
tryp - plac 
-0. 12 ns 
* exceeds the critical value for the ,05 level of significance 
Comment on side effects 
A significant increase in side effects was noted for the 
tryptaphan and placebo periods relative to baseline, while the 
tryptophan phase demonstrated no significant elevation with 
respect to placebo. Symptom severity was characterized by a 
sudden rise during the tryptophan phase (mean=4.0) relative to 
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baseline 1 (mean=2.79) which continued through the placebo period 
(mean=4.1) and only began to decline during the second baseline 
period (mean=3.6). Headaches were reported only once during 
baseline 1 and placebo periods but on 14 occasions during the 
tryptophan condition. The difference is still impressive despite 
the tryptophan phase being twice the length of the other two. 
Reports of abdominal cramps were limited to the first week of 
tryptophan ingestion. 
(e) Premenstrual tension 
Menstrual bleeding was first noted during days 1 and 2 of 
baseline 1, thus, the associated premenstrual period could not be 
considered. The only other period of menstrual bleeding 
commenced on the 4th washout day and continued for six days. In 
this case no obvious changes were detected with respect to 
graphed mood data, side effect severity or quality for the 
prementrual period. The increased level of symptoms reported for 
the tryptophan phase tended to be particularly concentrated in 
the first 2 weeks (prior to the premenstrual phase). 
(5) Summary and Conclusions 
As indicated previously the present subject was considered 
to be suffering from mild to moderate levels of depression and 
demonstrated high initial Trait and subsequent State anxiety 
levels relative to other participants. There was no indication 
of significant alleviation of such symptoms during the tryptophan 
phase. Visual and statistical analysis of mood scale data was 
not supportive of antidepressant, antianxiety or general mood 
elevating properties for tryptophan in this subject. The 
significantly lower means for alertness during tryptophan 
relative to placebo periods could not be supported by visual 
analysis and the reduction in alertness for the tryptophan 
was not significant relative to baseline. The detection 
phase 
of a 
significant departure for the evening tryptophan phase relative 
to baseline on the alertness dimension should be interpreted 
cautiously. Firstly, the less powerful C statistic application, 
employed here, 
was considered~ 
meant only the first half of the tryptophan phase 
and secondly, the change was not supported by 
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visual analysis. The high daily variablity in mood ratings for 
this subject, as indicated from appraisal of Figures 4-3-1 and 4-
3-2 acted to reduce the confidence placed in the above 
statistically significant outcomes. 
The finding of significantly lower mean hours of sleep 
during the tryptophan phase relative to placebo was not 
considered particularly meaningful given that the baseline was 
also significantly reduced relative to placebo and that there was 
no difference between tryptophan and baseline periods. The 
severity of reported side effects for this subject demonstrated a 
marked elevation during the tryptophan relative to baseline 
phase. This elevation was also maintained througout the washout 
and placebo phases. Symptoms strongly associated with tryptophan 
ingestion were headaches and abdominal cramps. 
Thus, tryptophan administration could not be associated with 
therapeutic benefit or general mood altering effects in this 
subject. The most dramatic effect tended to relate to the 
increased incidence of headaches and abdominal cramps during the 
tryptophan phase relative to other trial periods. The lack of 
therapeutic benefit may have been attributable to the the lower 
than recommended antidepressant dose (Chouinard et al., 
this subject. 
1978) in 
4.2.4 Subject 04 
(1) Demoqraphic variables 




<within desirable weight range) 
motivation for participation: - general interest 
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(2) Psycholoqical variables 
(a) Depression status 
The initial SDS score for this subject was close to the mean 
for the appropriate age and sex category with respect to Knight 
et al. 's <1983) norms. Subsequent scores were either close to 
or below this mean. Consequently, on the basis of SDS ratings 
and a 'general interest' motivation for participation, 
subject was classed as 'non depressed'. 
(b) Anxiety status 
this 
With respect to Knight et al. ·s (1983) norms, the Trait 
anxiety score was close to the mean for this subject. Similarly, 
the initial and most subsequent State anxiety scores were below 
the appropriate mean. Consequently, this subject was considered 
relatively free from symptoms of anxiety. 
(3) Experimental variables 
(a) Dose level (qms/day): 6 
(b) Phase description 
baseline 1 tryptophan 
14days 14days 
(d) Extra details 
Scale completion time was regular with missing data confined 
to two consecutive days during the evening tryptophan phase. 
Participation was concluded earlier than expected for this 
subject due to his leaving Christchurch suddenly. 
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(4) Results and analysis 
Ca) Weekly scores 
Table 4-4-1 
Total scores for Zunq. State 
anxiety and HSCL scales 
baseline 1 tryptophan 






baseline 1 tryptophan 
01 07 14 21 28 
scale factm-
zung ..,. ..... "':!'..., 27 26 25 . .:, . ..::., -•.a:.. 1 1.84 1.08 1.35 1. 17 1.08 
'"j 
~ L74 2.07 1.59 L86 1.82 
state 28 25 3() ' ~· 1.12 1.54 1. 00 1.69 1.28 
4 1. 51 L44 1.35 1.47 1.00 
HSCL 86 84 77 83 72 5 1. 00 1. 00 1. 00 1. 16 1. 16 
Comment on weekly scale scores 
No dramatic differences were apparent between baseline and 
tryptophan phases for any of the weekly scales or HSCL factor 
HSCL factor scores were close to the normal means (Table 
3-4) according to Derogatis et al. (1974). 
(b) Moodscale ratings 
Visual analysis of qraphed data 
Graphs for both morning and evening series appear in Figure 
4-4 for this subject. The most notable feature of the graphed 
mood scale data was the appearance of a consistently increasing 
trend during the baseline phase (particularly during the evening) 
for the alertness dimension. Subsequently, in both series there 
was a marked decline for the first few days of the tryptophan 
phase on the alertness dimension. There was also evidence of a 
decline in contentedness for the first few days of the tryptophan 
phase (relative to baseline) in both series, and some indication 
of the same pattern with respect to the calmness dimension for 
the evening series. The increasing trends in the baseline series 
for alertness probably tend to exaggerate the appearance of 
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detract from the importance of this observation. 
Autocorrelation estimates 
Table 4-4-3 rk Ck=l~n/4) values for separate morn. & eve. series 
factor baseline 1 (n=14) tryptophan(n=14) 
rl t-2 r3 r1 r2 
alertness 
morning .60** .41* .37* .26 .26 - . 15 
eveninq . 71** .59* .36* .64** . 18 - . 17 
cont .. . ss 
morning .13 -.31 -.30 -.28 .28 -.24 
evening -.21 .22 -.34* • 06 • 02 -.40 
calmness 
morning -.32 - . 10 -.01 -. 2C) . 17 - . 11 
eveninq .14 .OB -.21 .27 -.45 -.34 
* exceeds the critical value for the ,05 level of significance 
** exceeds the critical value for the ,01 level of significance 
t test results 
Table 4-4-4 t test values for mean differences between 






ba.se1 - tryp 
contentedness 





* exceeds critical value for the ,05 level of significance 
+ sig, t values affected by sig, levels of autocorrelation 
indicates the first mean of the pair is the lowest 
Comment on t test results 
As is evident from Table 4-4-4 7 significant differences 
between baseline and tryptophan periods were limited to the 
evening series for the calmness dimension. 
free from autocorrelation bias. 
139 
This calculation was 
C statistic results 
Table 4-4-5 Z values for morninq, eveninq and combined series 
series basel bs1+trvp 
mm-ning 
alertness 3.16 ** "' 0.56 ns 
cont •.• ss 1. 02 ns -0.61 ns 
calmness -1. 18 ns -0.40 ns 
evening 
alertness ~ c:--.,::, •JI ** "' 1.84 ns 
cont •.• ss -0.31 ns 0.08 ns 
calmness 0.57 ns 1.85 ns 
** exceeds the critical value for the ,01 level of significance 
"'due to a sig. trend in the base1 phase, this calculation was based on a 
comparison series (see Chapter III for explanation) 
Comment on C statistic results 
Tryptophan phases did not exhibit any significant departures 
in trend from baseline on any dimension (Table 4-4-5). 
(c) Hours of sleep 
Table 4-4-6 Autocorrelation estimates: rk (k=n/4) values 
ba.sel ine (n=14) tryptophan (n=14) 
rl r2 r3 t- 1 r2 r3 
-.21 .03 - . 19 -.30 -.20 - . 10 
None of the above estimates proved significant 
t test value results for hours of sleep 
basel - tryp 
-1. 19 ns 
Comment on hours of sleep 
There was no significant difference between mean hours of 
sleep for the baseline and tryptophan periods. 
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(d) Side effects 
Side effects noted by this subject included two experiences 
of nausea during the baseline phase. During the tryptophan 
phase~ increased appetite was reported on 5 occasions, nausea on 
4 occasions, blurred vision twice and dry mouth twice. Thus, 
there is evidence in this subject of an increase in side effect 
severity associated with the tryptophan phase. 
(5) Summary and Conclusions 
Given that the present subject was not considered to be 
depressed or anxious attention was focused on general mood 
altering effects. Although visual analysis indicated some 
decline on the mood dimensions in the first few days of 
tryptophan ingestion, the increasing trend during the baseline 
phase probably exaggerated the effects. No changes with respect 
to side effects or unusual happenings coincided with this early 
part of the tryptophan phase. The brevity of the series and the 
absence of placebo phases for comparison limits confidence in the 
evaluation of tryptophan effects for this subject. On the basis 
of the available evidence it was concluded that tryptophan 
administration was not associated with any consistent mood 
altering effects. The most notable effects associated with 
tryptophan intake related to the increase in reported side 
effects, particularly 'increased appetite·. 
4.2.5 Subject 05 
(1) Demoqraphic variables 
aqe(yrs): sex: female height(cms):168 
weightCkos):57.20 
(within desirable weight range) 
motivation for participation: - general interest 
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(2) Psycholooical variables 
(a) Depression status 
The present subject was classified as 'non depressed' on the 
basis of low SDS scores throughout the trial i.e. all were below 
the mean with respect to Knight et al. 's (1983) norms, (see Table 
4-5-1), in keeping with the motivation for participation. 
Cb) Anxiety status 
The Trait anxiety score for this subject (39) was close to 
the approriate mean for a normal population while the initial 
(25) was relatively low (Knight et al. , 1983). State score 
Consequently, this subject was considered to be relatively free 
from anxiety symptoms. 
(3) Experimental variables 
(a) Dose level <oms/dav): 3 
Cb) Phase description 
baseline 1 tryptophan l ~•Jashout: placebo lbaseline ,...., I ..::. J 
14days 14d~.ys 7days 14days 7days 
(c) Extra details 
As is evident from the graphed mood data (Figures 4-5-1 and 
4-5-2), scale completion was missed by this subject on several 
occasions throughout both series. Otherwise completion time was 
regular and tablet consumption was not forgotten on any occasion. 
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(4) Results and analysis 
(a) Weekly scores 
Table 4-5-1 Total scores for Zunq, State anxiety and HSCL scales 
baseline 1 tt-yptophan wash placebo bs2 
dav 01 07 14 21 28 42 49 56 
scale 
zung 27 ..... cc L~ ry"":!' ~·-' 24 r'J~ .;,:_._. 29 24 
state 25 37 33 37 40 39 34 
HSCL 76 74 73 68 64 63 71 
Table 4-5-2 HSCL factor scores 
baseline 1 tryptophan vJash placebo bs2 
day 01 07 14 21 28 -,-cc ._:,.,_J 42 49 56 
factat-
1 1. 12 1.30 L 16 1.00 1. 00 1. 00 1. 09 
...... 1. 77 1.35 1.35 1.23 1.24 1.23 1.47 ..::. 
7 ._, 1.29 1.29 1.29 1. 29 1. 16 1. 12 1.46 
4 1. 16 1. 36 1. 19 1.26 1. 08 1. 08 1. 18 
5 1. 00 1. 15 1. 15 1. 15 • •c:- 1. 00 1.00 J. ... J..J 
Comment on weekly scale scores 
Low scores were maintained throughout the trial on all the 
weekly scales and HSCL factor scores were close to the normal 
sample <Table 3-4) according to Derogatis et al., (1974). 
(b) Mood factors 
Visual analysis of graphed data 
As is evident from graphed data for both morning and 
evening series (Figures 4-5-1 and 4-5-2), a relatively high 
level of missing data was accrued by this subject. During the 
evening series there was a slight but consistent drop in 
contentedness level for the tryptophan and washout periods 
relative to the baseline phase. Otherwise, there was considered 
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Figure 4-5-1 
FACTOR SCORES FOR THREE MOOD DIMENSIONS - MORNING DATA 
SUBJECT: 05 
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Fi gLu~e 4-5-2 
FACTOR SCORES FOR THREE MOOD DIMENSIONS - EVENING DATA 
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to be a lack of sufficiently dramatic or meaningful changes 
between or within phases for either series. 
Autocorrelation estimates 
Table 4-5-3 rk (k=1 2n/4) values for separate morn. & eve. series 
factor baseline 1 tt-vptophan pla.cebo 
rl r2 r3 rl r-2 r3 rl r2 t-3 
alet-tness 
morning • 02 -.34 • 05 -.42 • i)2 - 15 -.42 ,..,-=!' . "'k•-' 
evenino -. (i2 -.08 • 05 -.37 - . 18 . 09 i:26 - . 15 
cont • . . ss 
morning .22 . 06 -.09 - . 16 . 10 . 04 • 07 -. :::::o 
evening -.33 -.36 .24 ',C:- ., (i 1 -.05 17 -.40 • ..:..u . 
calmness 
morning -.36 - . 15 .36* -.36 .09 -.28 -.21 .36 
evenin• .33 -.01 • 03 - . 18 -.45 . 10 -.50* - . 13 
* exceeds the critical value for the ,05 level of significance 
t test results 
Table 4-5-4 t test values for mean differences between 
baseline 1~ tryptophan and placebo phases 
ba.sel - trvp basel - plac tt-yp - elac 
alertness 
morning 0.80 ns ~ 0.21 ns -0.95 ns 
evening "' 0.49 ns "' 0.28 ns 3.75 ** 
contentedness 
morning 1.90 ns ~ 1. 78 ns -0.40 ns 
eveninq 4.31 ** 4.98 ** 0.85 ns 
calmness 
morning "' 1-39 ns "' 2.30 * 1.61 ns 
eveninq 2.49 * 2.29 *+ -0. 13 ns 
* exceeds critical value for the .05 level of significance 
** exceeds critical value for the , 01 level of significance 
+ sig, t values affected by sig, levels of autocorrelation 
indicates the first mean of the pair is the lowest 
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Comment on t test results 
For the alertness dimension, the mean for the tryptophan 
phase was found to be significantly higher than placebo, however 
there was no significant elevation with respect to the baseline 
phase. For the contentedness dimension tryptophan and placebo 
means were significantly lower than baseline during the evening 
but were not different from each other. Finally, for the 
calmness dimension, the mean for tryptophan in the morning series 
was signficantly below the mean for the baseline period. The 
placebo mean was also found to be significantly below baseline in 
morning and evening series. The significance level associated 
with the evening difference may have been underestimated due to 
the presence of significant levels of negative autocorrelation in 
the placebo phase for this series. 
C statistic results 
Table 4-5-5 Z values for morninq. evenin• and combined series 
series basel bsl+tryp 
mor~ning 
alertness 0.20 ns -0.06 ns 
cont .. .ss ~0 .. 36 ns ()~ 40 ns 
calmness -0.93 ns -0.90 ns 
evening 
alertness 0.73 ns 0.24 ns 
cont ••• ss -1.04 ns 2.00 * 
calmness -0.90 ns o. 13 ns 
* exceeds the critical value for the .05 level of significance 
~ due to a sig, trend in the base1 phase, this calculation was based on a 
comparison series (see section Chapter III for explanation) 
Comment on C statistic results 
The only signifcant result, indicated from Table 4-5-5, was 
for a departure of the tryptophan phase relative to baseline for 
the contentedness dimension during the evening series. 
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(c) Hours of sleep 
Table 4-5-6 Autocorrelation estimates: rk (k=n/4) values 
baselinel tryptophan 
rl r2 r3 rl r2 
-.01 -.06 .25 -.20 
None of the above estimates proved significant 
t test value results for hours of sleep 
basel - tryp 
"' 1. 39 ns 
Comment on hours of sleep 
basel - tryp 
"'-0.59 ns 
placebo 
rl r2 r3 
.22 -.21 .01 
tryp - plac 
"'-1. 56 ns 
As evident from the above t test results, 
significant difference in the mean hours of 
baseline 1, tryptophan or placebo phases. 
there was no 
sleep between 
(e) Side effects 
No side effects were checked by this subject throughout the 
trial period. 
(5) Summary and Conclusions 
Due to the absence of depressive or anxious symptoms in this 
subject evaluation was focused on general mood alteration. As 
indicated from visual analysis, 
the high level of missing data. 
evaluation was hindered due to 
However the indication of a 
reduction in level for contentedness during the trypt • phan phase 
(relative to baseline) in the evening series was supported by 
statisitical outcomes. That 1 s, t test results indicated a 
significantly lower mean for the tryptophan phase relative to 
baseline and C statistc results indicated a significant 
departure in trend between the two phases. However, t test 
comparisons also indicated a significant drop for the placebo 
relative to baseline phase on this dimension in the evening. 
Fi na.11 y, although consistency between visual and statistical 
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analysis was demonstrated in this case, the change was visually 
slight and consequently not considered to be of particular 
psychological relevance. No other changes such as increased side 
effects of changes in total sleep time were associated with the 
tryptophan phase for this subject. 
The suggestion of increased alertness for the tryptophan 
phase relative to placebo in the morning was not considered 
particularly meaningful. There was no indication of increased 
tryptophan alertness relative to baseline for this series. The 
significant mean reduction in calmness for placebo and tryptophan 
relative to baseline during the morning was not considered 
particularly important in light of the high variability apparent 
in the baseline phase. Similarly, the statistically significant 
evening calmness reduction for placebo relative to baseline could 
not be supported by visual analysis. Thus" tryptophan 







4.2.6 Subject 06 
(1) demoqraphic variables 
aqe(yrs): 24 se>: ~ male 
changes in psychological state, 
time. and total sleep 
hei • ht(cms):183 
weight(kqs):71.00 
1-tryptophan experience: 
(within desirable weight range) 
- not consumed prior to this project 
motivation for participation: general interest 
(2) Psycholo• ical variables 
(a) Depression status 
The initial SDS total score for this subject was close to 
the normal mean with respect to Knight et al. ·s (1983) norms (see 
table 1). 
period 
A single subsequent score, during the remaining trial 
e>~ceeded one standard deviation above this mean. 
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Consequently, this subject was assigned a 'non depressed' status 
which was in keeping with the general interest motivation for 
pa~-ti ci pati on. 
(b) Anxiety status 
The Trait anxiety score for this subject was close to the 
appropriate normal mean (Knight et al. , 1983). Initial and 
subsequent State scores were generally close to or below the 
appropriate mean. Thus, the present subject was considered to be 
relatively free from anxiety symptoms. 
(3) Experimental variables 
(a) Dose level (gms/day): 3 
(b) Phase description 
baseline 1 trvptoohan :washout: placebo :baseline 2: 
14days 14days ?days 14days 7days 
(c) Extra details 
Scale completion time was regular for this subject. 
Although some daily scales were missed, the tryptophan and 
placebo periods were essentially complete. 
forgotten during tryptophan and placebo phases. 
4.2.6.4 Results and analysis 
(a) Weekly scores 
No tablets were 
Table 4-6-1 Total scores for Zung, State anxiety and HSCL scales 
baseline 1 tryptophan wash placebo bs2 
da:t 01 07 14 21 28 7C:-..:.,..J 42 L1r9 56 
scale 
zung 30 39 34 ~,., 27 -:,-c:- 35 ..,..,..., ..,...., ·-'"'- ..:.•..J ••• ).£... . ..:,,L,. 
state 27 26 32 32 29 27 28 29 24 
HSCL 66 68 64 70 69 68 68 63 66 
15(1 
Table 4-6-2 HSCL factor scores 
baseline 1 tryptophan wash placebo bs2 
day 01 07 14 21 28 ..,..= ...:,,_J 42 49 56 
factor 
1 1.18 1. 08 1.08 1.33 1.15 1. 18 1. 17 1. 00 1. 00 
2 1. 00 1.23 1.23 1. 12 1. 12 1.34 .,_ -Jr') l. • ..:... ... 1.00 1.35 
3 1. 00 1. 10 1. 00 1. 00 1. 00 1. 00 1.00 1. 00 1. 00 
4 1. 35 1.37 1.08 1.27 1.25 1. 17 1.26 1.27 1. 10 
5 1. 00 1. 00 1.00 1.42 1.15 L 16 1. 16 1. 00 1. 16 
Comment on i,.Jeekl v scale scores 
Total scores for all weekly scales remained consistently low 
throughout the trial period, reinforcing the non depressed and 
non anxious status of this subject. There was some indication 
from the HSCL factor scores (Table 4-6-2), of 2. rise in the 
somatization and anxiety dimensions during the first week of 
tryptophan ingestion. HSCL factor scores were close to normal 
sample means (Table 3-4) according to Derrogatis et al. (1974). 
(b) Mood factors 
Visual analysis of qraphed data 
No obvious patterns emerged from visual analysis of the 
graphed moodscale data (Figures 4-6-1 and 4-6-2) for this 
subject, either between or within phases. No clear differences 
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FACTOR SCORES FOR THREE MOOD DIMENSIONS - EVENING DATA 
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Autocorrelation estimates 
Table 4-6-3 rk (k=1.n/4) values for separate morn. & eve. series 
factor baseline 1 trvptophan placebo 
rl r2 r' ·-· t- 1 r2 r3 t- 1 r2 r3 
alertness 
morning - . 16 - . 11 - . 12 -.06 . 27 - . 18 .25 -.06 -.32 
evening -. (13 r:i~ • .i:_._. -.25 .38* ..... c:-• .,;:..._1 .08 -.30 -.03 -.00 
cont . . • ss 
morning -.08 -.08 -.08 . 04 -.03 -.24 .44 .06 -.08 
eveninq -.04 -.31 . 10 - . 12 -.26 .05 .05 -.33 - . 19 
calmness 
morning -.42 . 14 - . 14 .06 -.52* -.20 . 27 -.09 - . 10 
evening -.05 - . 10 .09 -.20 - . 18 - . 16 -.27 - . 22 .40 
* exceeds the critical value for the .05 level of significance 
t test results 
Table 4-6-4 t test values for mean differences between 
baseline 1 1 tryptophan and placebo phases 
base1 - tryp base1 - plac tryp - plac 
alet-tness 
morning "' 0.83 ns -0.68 ns -2~ (>4 ns 
evening 0.85 ns o. 15 ns -0.81 ns 
contentedness 
morning -1. 68 ns -4.49 ** -2ir (15 * 
eveninq 0.62 ns -1.43 ns -1.97 ns 
calmness 
m0t-ning 0.61 ns 0.21 ns -0~35 ns 
evening -0.70 ns -2.68 * -1.98 ns 
* exceeds the critical value for the • 05 level of significance 
*~ .,,,. exceeds the critical value for the • 01 1 eve l of significance 
indicates the first mean of the pair is the lowest 
Comment on t test results 
Significant mean phase differences were limited to 
contentedness and calmness dimensions. As indicated in Table 4-
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6-4, the mean for the tryptophan morning phase on contentedness 
was significantly lower than the placebo period. Howevet-, the 
baseline phase was also significantly lower than placebo in this 
series. The other finding was for a significantly higher mean 
on calmness during the tryptophan relative to baseline period in 
the evening. 
C statistic results 
Table 4-6-5 Z values for mornina, eveninq and combined series 
set-i es base1 bsi+tryp 
morning 
alertness -0.49 ns -0.34 ns 
cont .•. ss 0.01 ns 1. 18 ns 
calmness -1.37 ns -0.34 ns 
evening 
alertness 0.87 ns 1.78 * 
cont .•. ss -0.02 r1s -0.38 ns 
calmness 0.80 ns 0.29 ns 
* exceeds the critical value for the ,05 level of significance 
Comment on C statistic results 
There was a significant departure in trend for the evening 
b-yptophan 
2.lertness. 
phase t-el ati ve to baseline on 
Cc) Hours of sleep 
the -' . . w1mens1.on 
Table 4-6-6 Autocorrelation estimates: rk (k=n/4) values 
baselinel tryptophan placebo 
t- 1 r2 t-3 rl r--":l . """' r3 t- 1 r2 
19 - •o -.30 .07 c-,v - 13 .20 .01 -. . l , -= JOT. . . 
* exceeds the critical value for the ,05 level of significance 
t test value results for hours of sleep 









Comment on hours of sleep 
No significant differences between baseline, 
placebo phases were noted for mean hours of sleep. 
(d) Side effects 
Side effect reports for this subject were low. 
tt-yptophan or 
No effects 
were noted during the placebo phase. The mean severity of 
reported effects showed little change between baseline (1.4) and 
tryptophan (1.0) phases. 
most symptoms showed 
Similarly, the qualitative structure of 
little variation between phases. Two 
symptoms unique to the tryptophan phase were reported on several 
occasions during the first week, 
difficulty falling asleep. 
(5) Summary and Conclusions 
i.e. stomach cramps and 
Results from visual and statistical analysis confirmed a 
lack of general mood altering effects associated with tryptophan 
' . . ~ L. aomi ni straLl on in this subject. The statistically significant 
reduction in the mean for the contentedness dimension relative to 
placebo, in the morningJ was not supported by a reduction 
relative to baseline. The indication of a departure in • ..! t:renu on 
evening alertness for tryptophan relative to placebo was not 
considered sufficiently dramatic or meaningful fallowing visual 
analysis of these periods. The most notable feature for this 
subject ~"'llhi ch appeared specifically associated with the 
tryptophan period was the appearance of stomach cramps and 
sleeping difficulty ir1 the f i ~-st week of tryptophan 
admi ni s-trati on. 
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4.2.7 Subject 07 
(1) Demographic variables 
aqe(yrs): 60 sex: female heiqht(cms):164 
weight(kgs):69.85 
(above desirable weight range) 
- not consumed prior to this project 1-tryptophan experience: 
motivation for participation: - general interest 
(2) Psycholoqical variables 
(a) Depression status 
Initial and subsequent SDS scores for the present subject 
were close to the mean of the appropriate age and sex category 
according to Knight et al. 's {1983) norms. On the basis of these 
ratings and a 'general interest· motivation for participation, 
the present subject was classified as 'non depressed". 
Cb) Anxiety status 
With respect to Knight et al. ·s (1983) norms this subject 
exhibited initial Trait (32) and State (28) anxiety scores in 
keeping with the means for her age category. On this basis the 
present subject was considered relatively free from significant 
levels of anxiety. 
{3) Experimental variables 
(a) Dose level (gms/day): 3 
(b) Phase description 
baseline 1 tryptophan 
14days 7days 
157 
(c) Extra details 
The brevity of the trial period in this case was due to the 
need for this subject to withdraw from the experiment following a 
sudden requirement to move from her home. Scale completion time 
was regular, i.e. within a two hour day to day variation, with 
no missing data accrued. 
during the 7 day phase. 
No tryptophan tablets were forgotten 
(4) Results and analysis 
(a) Weekly scores 
Table 4-7-1 
Total scores for Zung 1 State 
anxiety and HSCL scales 
baseline 1 
day 01 07 14 
scale 
zung 34 35 32 
state 28 42 36 
HSCL 75 84 82 
Comment on weekly scale scores 
Table 4-7-2 
HSCL factor scores 
baseline 1 
day 01 07 14 
factor 
1 1.00 1.28 1. 18 
2 1.51 1.60 1.47 
3 1. 16 1. 34 1.34 
4 1.44 1.45 1.45 
5 1.43 2.02 2.02 
As is evident from Tables 4-7-1 and 4-7-2, weekly scale 
ratings for the initial baseline phase remained relatively low on 
all scales, except for the elevation in the State score on day 
seven. This rating coincided with the day the subject was 
informed of the requirement to vacate her home. HSCL factor 
scores were close to means for the normal sample (Table 3-4). A 
rise in the HSCL factor 5 was apparent on day seven and 14 
relative to the initial value. Factor 5 represents the dimension 
labelled 'anxiety· for this scale. This finding tends to be in 
agreement with the increased State an>;iety scores on days seven 
and 14 relative to the initial rating. 
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(b) Mood factors 
Visual analysis of graphed data 
The brevity of both series for this subject (Figure 4-7) 
imposed extreme limitations on establishing any confident 
interpretations of the graphed data. No meaningful changes were 
apparent between the two phases for this subject. Comparison of 
the morning and evening series indicated close similarity in the 
day to day fluctuations for the contentedness and calmness 
dimensions. However, the evening series was noticably depressed 
on the alertness dimension relative to the morning series. 
Autocorrelation estimates 
Table 4-7-3 rk (k=l,n/4) values for separate morn. & eve. series 
factor baseline 1 (n=13) tryptophan (n=7) 
rl r2 r3 rl 
alertness 
morning .01 .17 -. 12 -.30 
evening .25 -.11 -. 12 -.52* 
cont ... ss 
morning .05 .17 -.34 .09 
evening .13 .03 -.05 -.33 
calmness 
morning -,..r, • ,._;.L -.18 .00 7-:r -. _ .. .._Ji 
evening .36* -.05 -.29 .12 
* exceeds the critical value for the ,05 level of significance 
(c) Hours of sleep 
The information relating to hours of sleep was insufficient 
to allow for valid statistical analysis between phases i.e. only 
four ratings were obtained for the tryptophan phase. The means 
for the baseline 1 and tryptophan phases were 5.1 and 6.25 




























FACTOR SCORES FOR THREE MOOD DIMENSIONS - MORNING DATA 
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FACTOR SCORES FOR THREE MOOD DIMENSIONS - EVENING DATA 
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(d) Side effects 
The incidence of reported side effects was low 
subject and limited to one symptom in both phases. 
headaches were recorded twice in both baseline 1 and 
phases. 




The value of including the data for this subject is 
obviously limited. However, it was not considered justifiable to 
ignore subjects on the basis of shorter than desirable data 
series. Although the present subject only completed one week an 
tryptophan it may have been sufficient to establish the presence 
of undesirable side effects. That is, other subjects with side 
effect elevation during the tryptophan phase generally exhibited 
such increases by the first week of tryptophan ingestion. In 
this regard, the present subject did not demonstrate any marked 
elevation in side effects during the tryptophan relative to 
baseline phase. Visual analysis failed to indicate any relevant 
changes in the mood dimensions between baseline and tryptophan 
periods. It is possible that the presence of autocorrelation in 
parts of the mood series may have misled visual evaluation in 
this case. Jones et al. (1977) have indicated that 
autocorrelation may corrupt the process of visual analysis. 
However, the brevity of the tryptophan phase in this case would 
have required particularly dramatic and consistent effects before 
much confidence could be attached to between or within phase 
changes. 
4.2.B Subject 08 
(1) Demog~aphic variables 
aqe(yrs): 19 sex: female 





(within desirable weight range) 
tryptophan experience: not consumed prior to this project 
motivation for participation: general interest 
(2) Psychological variables 
(a) Depression status 
Initial and subsequent SDS total scores for this subject were 
below the appropriate mean according to Knight et al. ·s (1983) 




Cb) Anxiety status 
present 
'general interest' motivation 
subject was classed as 
for 
non 
With respect to Knight et al. ·s (1983) norms this subject 
exhibited a low Trait anxiety score and all State scores were 
below the corresponding mean, indicating freedom from significant 
levels of anxiolytic symptoms. 
(1) Experimental variables 
(a) Dose level(qms/day): 3 
(b) Phase description 
baseline 1 trypt • phan washout 
14days 14days 7 days 
(c) Extra details 
Scale completion time was regular with missing data limited 
to one evening baseline rating. No tablets were forgotten during 
the tryptophan phase. 
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(4) Results and analysis 
(a) Weekly scores 
Table 4-8-1 Table 4-8-2 
Total scores for- Zung 2 State HSCL factor scores 
an>:iety and HSCL scales 
baseline 1 tryptophan 
baseline 1 tryptophan day 01 07 14 21 28 
da}:'. 01 07 14 21 28 factor 
1 1.07 1. 15 1.00 L18 1. 34 
scale 2 1.00 1.12 1.00 1. 12 1.00 
zung 32 34 31 28 26 ...,,. ._;, 1.52 1.46 1.30 1. 73 1. 16 
state 33 33 ~r-, ~•k 35 29 4 1. 10 1.62 1. 09 1.36 1.08 
HSCL 67 79 64 76 67 5 1.15 1. 15 1.15 1.15 1. 16 
Comment on weekly scale scores 
Low total scores on the weekly scales were maintained 
throughout the trial period and no dramatic changes were noted 
between the two phases completed. Similarly, no consistent 
differences between phases were noted on the basis of HSCL factor 
scores. HSCL factor scor-es were close to the means for a normal 
sample (Table 3-4). 
(b) Mood factm-s 
Visual analysis of graphed data 
Graphed mood data for both mor-ning and evening series 
(Fi gw-e 4-8) exhibited high day to day variability across all 
phases. There was some indication of a reduction in alertness 
for the tryptophan relative to baseline phase in the evening 
series as well as a slight increase in calmness. However, the 





























FACTOR SCORES FOR THREE MOOD DIMENSIONS - MORNING DATA 
SUBJECT: OB 
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Table 4-8-3 rk Ck=l,n/4) values for separate morn. & eve. series 
factor baseline 1(n=14) tryptophan<n=14) 
r1 r2 t-3 r1 r2 r3 
alertness 
m• t-ning -.08 -.01 -. 17 -.10 -.08 • 06 
evening .06 -.05 -.25 .17 -. 15 -.17 
cont ••. ss 
morning .06 .42* -.19 -.34 -.05 -.11 
evening . 11 -.14 .03 -.08 -.56* -.00 
calmness 
morning -.38 .13 -.09 -.25 -.07 -.46 
evening -.06 -.12 -.26 -.01 -.14 -. 19 
* exceeds the critical value for the • 05 level of significance 
t test results 
Table 4-8-4 t test values for mean differences between 










basel - tryp 
"'-0.62 ns 
~ 1.86 ns 
"'-1.80 ns 
1. 38 ns 
-1. 32 ns 
-2.34 * 
value for the ,05 1 evel of * exceeds critical significance 
indicates the first mean of the pair is the lowest 
~ phase variances unequal 1 t-test approximation used(see Chapter III) 
Comment on t test results 
There was a significantly greater mean for tryptophan 
relative to baseline in the evening for the calmness dimension. 
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C statistic results 
Table 4-8-5 Z values for morninq. eveninq and combined series 
series basel bs1+tr}'.'.e 
morning 
alertness 0.05 ns 0.02 ns 
cont ••• ss 0.65 ns 0.65 ns 
calmness -1. 47 ns -1.14 ns 
evening 
alertness 0.25 ns 0.27 ns 
cont •.• ss 0.54 ns 0.76 ns 
calmness -0.14 ns 0.69 ns 
Comment on C statistic results 
As indicated from Table 4-8-5, no significant changes in 
trend between baseline and tryptophan periods were detected 
following application of the C statistic. 
(c) Hours of sleep 
Table 4-8-6 Autocorrelation estimates: rk (k=n/4) values 
baseline (n=14) tryptophan (n=14) 
r1 r2 r3 r1 r2 r3 
-.02 -.04 -.44 .08 -.31 .29 
None of the above estimates proved significant 
t test value results for hours of sleep 
basel - tryp 
0.55 ns 
Comment on hours of sleep 
There was no significant change noted between trptophan and 
baseline periods in mean hours of sleep. 
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Cd) Side effects 
The severity of side effects reported by this subject was 
low across all phases. There was little change in means between 
baseline (0.5) and tryptophan (0.64) periods. The only symptoms 
unique to the tryptophan phase included: dry mouth, increased 
appetite and dizziness. However 7 such effects were only noted on 
one occasion. 
(e) Premenstrual tension 
The present subject responded positively to suffering from 
premenstrual tension. The only onset of menstrual bleeding was 
noted on the 6th day of the tryptophan phase. There was a slight 
suggestion of increased variability in mood ratings for the 
premenstrual phase relative to the latter parts of the series on 
some dimensions. However, the visual impression was slight and 
was not considered to threaten the validity of the phase changes 
discerned. 
(5) Summary and Conclusions 
The absence of a placebo phase for the present subject 
imposed limitations on the evaluation. However, there were no 
dramatic or consistent changes noted with respect to mood ratings 
between baseline and tryptophan phases. The visual indication of 
an increase in calmness for the evening tryptophan phase relative 
to baseline was supported by the statistical finding of an 
increased mean in this direction. The visual impression of a 
slight reduction in alertness for the evening tryptophan phase 
relative to baseline was not, however 1 supported statistically 
and the change was not considered of sufficient magnitude to be 
of psychological relevance. Thus, there was a lack of general 
mood alteration associated with tryptophan intake of 3gms/day in 
this subject. In addition, no significant or meaningful changes 
with respect to mean hours of sleep or side effect severity were 
detected. 
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4.2.9 Subject 09 
(1) Demographic variables 
age(yrs): 19 sex: male height(cms):183 
weight(kgs):70.00 
tryptophan experience: 
(within desirable weight range) 
- not consumed prior to this project 
motivation for participation: - depression 
(2) Psychological variables 
(a) Depression status 
Initial and subsequent SDS scores (with one exception) for 
this subject were within one standard deviation above the 
appropriate mean with respect to Knight et al. 's (1983) norms. 
However, this subject clearly indicated 'depression' as his 
motivation for participation. The one elevated total score of 40 
just reaches inclusion in Zung's (1972) category for "mild to 
moderate" depression. On the basis of the motivation for 
participation and the fact that this subject had been taking 
conventional antidepressants prior to the present experiment led 
to consideration of antidepressant effects for this subject. 
Cb) Anxiety status 
The initial Trait anxiety score for this subject of 52 was 
in excess of 2 standard deviations above the mean according to 
Knight et al. ·s (1983) norms. Baseline State scores exceeded one 
standard deviation from the appropriate mean. As is evident from 
Table 4-9-1, later State scores were extremely elevated e.g. in 
excess of 5 standard deviations above the normative mean (Knight 
et al., 1983). Consequently, the present subject was considered 
to be experiencing considerable levels of anxiety relative to the 
normal population and attempts were made to evaluate the anti-
anxiety potential of tryptophan administration in this subject. 
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(3) Experimental variables 
(a) Dose level (gms/day): 6 
Cb) Phase description 
baseline 1 tryptophan 
28days 
:washout: placebo :baseline 2: 
14days 7days 14days 7days 
(c) Extra details 
Scale completion time was regular. Moodscale scale 
completion was missed occasionally and was not considered to 
significantly limit data interpretation. No tablets were 
forgotton by this subject during tryptophan or placebo phases. 
(4) Results and analysis 
(a) Weekly scores 
Table 4-9-1 Total scores for Zunq, State anxiety and HSCL scales 
baseline 1 tryptophan wash placebo bs2 




._,:i,.: 36 ~~ _,._, 38 34 40 39 41 35 
state 40 45 30 57 34 39 61 71 53 33 
HSCL 92 105 103 98 103 105 124 124 128 96 
Table 4-9-2 HSCL factor scores 
baseline 1 tryptophan wash placebo bs2 
day 01 07 14 21 28 35 42 49 56 63 70 
factor 
1 1.08 1.19 1. 19 1. 17 1.23 1.43 1.64 1.66 1.73 1.55 
2 1.88 2. 10 2.36 1.75 2.22 2.12 2.51 ~ C"'r-, .L.. W...:.. 2.47 1.88 
3 1. 85 1. 85 2.01 2.03 2.27 2.11 2.58 2.47 2.29 1.73 
4 2.09 2.28 2.09 2. 18 1.82 1.79 2.27 2.35 2.46 1.72 
5 1.43 1.73 1.43 1.28 1.47 1.47 2.02 2. 18 2. 18 1.31 
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Comment on weekly scale scores 
SDS total scores were maintained at a constant average level 
(according to Knight et al. ·s (1983) norms) throughout the trial. 
Some increase in State and HSCL total scores was evident through 
the washout and placebo phases. Examination of the HSCL factor 
scores indicated most of the elevation in total scores was 
attributable to increases on the anxiety dimensions followed by 
depression. Most HSCL factor scores were close the the means for 
a depressed sample (Table 3-4). 
Cb) Mood factors 
Visual analysis of graphed data 
As is evident from Figures 4-9-1 and 4-9-2, both morning and 
evening series for this subject exhibited high levels of day to 
day variability. No consistent trends or other alteration» 
between phases were apparent. On day 16 of the tryptophan phase 
(morning series), the subject reported an inability to sleep due 
to environmental noise on the previous night. The mood dimension 
scores for this day exhibited a decline. However, the drop was 
not outstanding relative to adjacent days for each dimension. 
Autocorrelation estimates 
Table 4-9-3 rk (k=l,n/4) values for separate morn. & eve. series 
factor baseline 1(n=14) tryptophan(n=27) 
rl r2 r3 rl r2 ,..., -· r4 
alertness 
morning .26 -.22 -.56* -.02 -.34 -.28 .35* 
evening .22 .30 -.27 .19 .12 -.17 -. 17 
cont ••. ss 
morning .30 -.22 -.48* .07 -.12 -.16 • 04 
evening .07 .001 -.12 .08 -.22 .17 .10 
calmness 
morning .40 .14 .22 .08 -.09 -.11 .15 
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r1 r2 r3 
-.21 .06 -.11 
.57** .20 -.14 
-.42 .13 -.07 
.46* .17 -.34 
-.12 .05 -.04 
• 42* • 14 -. 36 
* exceeds the critical value for the ,05 level of significance 
** exceeds the critical value for the ,01 level of significance 
t test results 
Table 4-9-4 t test values for mean differences between 
baseline 1. tryptophan and placebo phases 
basel - tryp basel - plac tryp - plac 
alertness 
morning 0.13 ns "'-1. 58 ns "'-2.49 *+ 
evening 1.84 ns -0.73 ns -2.00 ns 
contentedness 
morning -0.90 ns -0.24 ns 0.71 ns 
evening -2.36 * 1.49 ns 2.27 *+ 
calmness 
morning "'-1. 15 ns -1. 00 ns "'-0. 14 ns 
evening -0.08 ns 0.29 ns 0.23 ns 
* exceeds critical value for the • 05 level of significance 
+ sig, t values affected by si g I levels of autocorrelation 
indicates the first mean of the pair is the lowest 
Comment on t statistic results 
Significant differences were limited to lower means for 
morning alertness during baseline and tryptophan phases relative 
to placebo. There was also an increase in the contentedness mean 
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for tryptophan relative to baseline and placebo in the evening. 
Positive autocorrelation in the morning tryptophan phase for 
alertness may have led to an over-estimation of the significance 
of the placebo - tryptophan difference for this dimension. 
C statistic results 
Table 4-9-5 Z values for morning, evening and combined series 
set-ies base1 bsl+tryp 
morning 
alertness 1. 11 ns 0.71 ns 
cont ••• ss 1.48 ns 1. 32 ns 
calmness 1.83 * "' 2.15 * 
evening 
alertness 1.06 ns 0.71 ns 
cont ••• ss 0.67 ns 1.34 ns 
calmness 1.83 * "' 1.46 ns 
* exceeds the critical value for the .05 level of significance 
"'due to a sig, trend in the base1 phase, this calculation was based on a 
comparison series (see Chapter III for explanation) 
Comment on C statistic results 
The only significant result was for a departure in trend for 
tryptophan versus baseline on the morning calmness series. 
Cc) Hours of sleep 
Table 4-9-6 Autocorrelation estimates: rk <k=n/4) values 
baselinel(n=14) tryptophan(n=21) placebo(n=14) 
rl r-2 r3 rl r2 r3 r-4 r1 r2 r3 
.17 -.28 -.10 .00 -~19 -~11 a24 -.49* .09 -.02 
* exceeds the critical value for the ,05 level of significance 
t test results for hours of sleep 
basel - tryp 
0.71 ns 
basl - tryp 
0.26 ns 
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tryp - plac 
-0.51 ns 
Comment on hours of sleep 
No significant changes emerged for mean hours of sleep 
between baseline, tryptophan or placebo phases. 
(d) Side effects 
A low level of reported side effects was maintained by this 
subject throughout baseline and tryptophan phases; the mean 
severity of effects being 0.43 and 0.17 respectively. Thus, 
there was a slight decline during the tryptophan phase (relative 
to baseline) despite this subjects consumption of the maximum 
6gms/day dose for 28 days. Some rise in severity was noted for 
the placebo phase i.e. mean= 1.3 with 7 reports of dry mouth 
being the most prominent feature. No other qualitative 
differences between phases could be discerned for this subject 
and no other symptom was reported more than twice in one phase. 
(5) Summary and Conclusions 
Due to a motivation of depression for participation and the 
high anxiety scores for this subject, attention was given to 
therapeutic effects. Appraisal of weekly total scores on anxiety 
and depression indicated no evidence of consistent change with 
respect to tryptophan intake. Rather, there was a marked 
increase in reports of anxiety symptoms during the washout and 
placebo phases relative to the rest of the series as indicated by 
State scores and the anxiety dimension of the HSCL. This 
increase could not be meaningfully related to experimental 
conditions ~nd did not show any coincidence with reports of 
unusual happenings. 
As is evident from Figures 4-9-1 and 4-9-2, both morning and 
evening series were characterized by high day to day variability 
and no evidence of between or within phase changes for any 
dimension were apparent. The significantly lower mean for the 
tryptophan phase relative to placebo on morning alertness may 
have been overestimated due to the presence of positive 
autocorrelation in the tryptophan period. Also, there was no 
significant reduction in alertness for the morning tryptophan 
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phase relative to baseline. The statistically significant mean 
increase in contentedness during the evening tryptophan phase, 
relative to baseline and placebo, was not supported by visual 
analysis. The statistically significant departure in trend for 
tryptophan relative to baseline on the evening calmness dimension 
was based on the less powerful C statistic application which used 
only the first half of the tryptophan phase. Visual analysis did 
not support this finding as being of psychological significance. 
Thus, results for the present subject were not supportive of 
a therapeutic action for tryptophan. No general mood altering 
effects could be associated with tryptophan intake, nor was there 
any indication of an increase of side effects or change in total 
sleep time associated with this phase. 
4.2.10 Subject 10 
(1) Demographic variables 
age(yrs): 42 sex: male height(cms):152 
weight(kgs):60.00 
(above desirable weight range) 
tryptophan experience: not consumed prior to this project 
motivation for participation: - general interest 
(2) Psychological variables 
(a) Depression status 
The initial SOS score for this subject was within one 





scores slightly exceeded the one 
However, such elevated scores 
standard 
were not 
sufficient to achieve a depression classification based on Zung's 
(1972) criteria. On this basis and the motivation for 
participation of general interest, the present subject was 
considered 'non depressed". 
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(b) Anxiety status 
This subject commented on experiencing occasional high 
levels of anxiety and fustration. With respect to Knight et 
al. 's (1983) norms the Trait anxiety score (40) almost exceeded 
one standard deviation above the normal mean for the appropriate 
age category (Knight et al., 1983). Thus, the present subject was 
considered to exhibit slightly above normal levels of anxiety. 
(3) Experimental variables 
(a) Dose level (gms/day): 2 
(b) Phase description 
baseline 1 trvptophan washout 
14days 14days 7 days 
(c) Extra details 
Scale completion time was regular with no missing data 
accrued. No tryptophan or placebo tablets were forgotten. 
(4) Results and analysis 
(a) Weekly scores 
Table 4-10-1 Total scores for Zuno, State anxiety and HSCL scales 
baseline 1 tryptophan wash 
day 01 07 14 21 28 ..,..c:-• .;.,.J 
scale 
zung 37 39 38 33 26 
state 39 37 36 40 37 
HSCL 100 97 97 93 89 
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Table 4-10-2 HSCL factor scores 
baseline 1 tryptophan wash 
day 01 07 14 21 28 35 
factor 
1 1. 31 1.23 1.36 1.29 1.08 
2 2.26 2.11 2.34 2.07 1.84 
3 2.30 2. 14 1.98 1.98 1.98 
4 1. 54 1.54 1.61 1.61 1. 16 
5 1.44 1.44 1.44 1.59 1.44 
Comment on weekly scale scores 
No particular changes were noted during the first week of 
tryptophan consumption relative to the baseline phase. 
Similarly, there were no clear alterations apparent from the HSCL 
factor scores. Scores for HSCL factors 2 and 3 were close to 
means for a depressed sample, while factors 1, 
closer to the normal group (Table 3-4)~ 
Cb) Mood factors 
Visual analysis of graphed data 
4 and 5 were 
Both morning and evening series are presented in Figure 4-10 
for this subject. There was a lack of consistent change with 
respect to level or trend between or within phases for either 
series. However, the marked decline in ratings on day 11 of 
baseline 1 coincided with veiwing of a film on nuclear war the 
previous evening, which aroused anger and fustration. No other 
reports of unusual happenings or side effects were noted which 
could be related to subsequent dips in ratings for the morning 
series. The marked dip on day seven of the evening series 
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Table 4-10-3 rk (k=1,n/4) values for separate morn. & eve. series 
factor baseline 1(n=14) tryptophan(n=14) 
r1 r2 r3 rl r2 r3 
alertness 
morning -w03 -.06 -.04 -.13 -.05 . 02 
evening .23 .15 -.14 .59** .17 -.16 
cont ••. ss 
morning -. 15 . 19 -.03 -.20 .09 .24 
evening -.10 -.11 -.22 .64** .34 .004 
calmness 
morning -.15 .19 -.03 -.06 -.12 -.08 
evening -.08 -. 12 -. 10 -.23 .01 -. 14 
** exceeds the critical value for the ,01 level of significance 
t test results 
Table 4-10-4 t test values for mean differences between 
baseline 1, trypt • phan and placebo phases 
base1 - trvp 
alertness 
morning -0.43 ns 
evening -0.55 ns 
contentedness 
morning "'-1.23 ns 
evening "' -1.26 ns 
calmness 
morning -0.38 ns 
evening "' -0.78 ns 
Comment on t test results 
As evident from Table 4-10-4, no significant mean 
differences were detected between baseline and tryptophan phases. 
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C statistic results 
Table 4-10-5 Z values for morning, evening and combined series 
series base1 bsl+tryp 
morning 
alertness 1-52 ns -0.46 ns 
cont ••• ss -0.47 ns -0.50 ns 
calmness -0.47 ns -0.04 ns 
evening 
alertness 1.55 ns 2.77 ** 
cont •.• ss -0.34 ns 0.30 ns 
calmness -0.27 ns -0.41 ns 
** exceeds the critical value for the .01 level of significance 
Comment on C statistic results 
The only significant finding, as indicated in Table 4-10-5, 
was for a departure in trend for the evening tryptophan phase 
relative to baseline on alertness. 
(c) Hours of sleep 
The present subject failed to consistently respond to the 
hours of sleep question, consequently only two tryptophan 
were obtained which made comparison of 
inappropriate. 
Cd) Side effects 
phases 
There was a consistent lack of side effects reported by this 
subject throughout the trial. Only one headache and one 
increased appetite were noticed during baseline 1. 
(5) Summary and Conclusions 
The validity of results for this subject was limited by the 
absence of a placebo phase. However, there was no indication of 
I 
consistent changes on either weekly scales or daily mood 
dimensions between baseline and tryptophan phases. As indicated 
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earlier, this subject exhibited slightly elevated levels of 
anxiety (relative to Knight et al. 's {1983) norms). There were, 
however, no indications of changes in this state in association 
with tryptophan ingestion. The one statistically significant 
finding for this subject was for a significant departure in trend 
for the evening tryptophan phase relative to baseline on the 
alertness dimension. A clear dip over 3-4 days is apparent in 
this series (Figure 4-10). No increase in reported side effects 
was apparent for the tryptophan period. Thus, there was a lack of 
mood, side consistent change (relative to baseline) in general 
effects or anxiety levels associated with the low 
tryptophan dose in this subject. 
(2gms/day) 
4.2.11 Subject 11 
(1) Demographic variables 
aqe(vrs): 33 sen: female 
PMT?: ves --- . 
height(cms):158 
weight(kgs>:48.00 
(within desirable weight range) 
1-tryptophan experience: - not consumed prior to this project 
motivation for participation: depression 
(2) Psychological variables 
(a) Depression status 
For this subject, the initial and most subsequent SDS total 
scores exceeded one standard deviation above the mean relative to 
Knight et al. ·s {1983) norms. In addition, all scores fell 
within Zung's (1972) 'mild-moderate' depression category. Thus, 
on the basis of relatively elevated SOS scores and the motivation 
for participation, the present subject was classed as depressed. 
(b) Anxiety Status 
The Trait anxiety score for this subject enceeded one 
standard deviation above the mean with respect to Knight et 
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al. ·s (1983) norms. The initial State score for this subject was 
extremely elevated with respect to the above norms i.e. 3 
standard deviations above the appropriate mean, while subsequent 
scores varied between 1-2 standard deviations above the 
respective mean. Consequently, the present subject was 
considered to exhibit relatively high, fluctuating levels of 
State anxiety, in keeping with predictions based on the high 
Tt-ai t scm-e. 
(3) Experimental variables 
(a) Dose level (gms/day): 3 
(b) Phase description 
baseline 1 trvptophan :washout: placebo :baseline 2: 
14days 14days 7days 14days 7days 
(c) Extra details 
Scale completion time was regular with only one morning mood 
scale rating missed towards the end of the tryptophan period. 
No tablets (trytophan/placebo) were forgotten. 
4.2.11.4 Results and analysis 
{a) Weekly scores 
Table (4-11-1} Total scores for Zung, State anxiety and HSCL scales 
baseline 1 tryptophan wash placebo bs2 
da}'.'. 01 07 14 21 28 35 42 49 56 
scale 
zung 48 48 45 47 47 4..,.. _, 47 43 
state 67 54 49 57 52 48 48 49 
HSCL 100 111 92 113 99 89 93 92 
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Table 4-11-2 HSCL factor scores 
baseline 1 tryptophan wash placebo bs2 
dav 01 07 14 21 28 35 42 49 56 
factor 
1 1.59 1.65 1.39 2.26 1.77 1.62 1.49 1.38 
2 1.93 2.06 1.69 1.69 1.69 1.67 1.94 1.84 
3 1.62 1.90 1.34 1.46 1.34 L 16 1.34 1.32 
4 1.81 1.90 1.53 1.61 1.80 1.52 1. 53 1.72 
5 1. 31 1.62 1. 72 1.71 1.42 1.00 1.15 1.31 
Comment on weekl:t scale scores 
A slight reduction in State anxiety and HSCL total scores 
was apparent over the whole trial. However, there was no 
evidence of between phase changes for these scores or for Zung 
total scores. The slight reduction in HSCL scores noticeable 
during the second half of the trial appeared most attributable to 
factor anxiety. This is in keeping with the reduction in 
State scores over the same period. HSCL factor scores were 
elevated relative to the normal sample and in some cases were 
more in keeping with means for an anxious sample (Table 3-4). 
(b) Mood factm-s 
Visual analysis of graphed data 
Relatively high day to day variability marked both series 
(Figures 4-11-1 and 4-11-2) for this subject, with no systematic 
variation between or within phases, except for a slight overall 
reduction in the evening alertness level relative to basline and 
placebo periods. Little difference was apparent in the level or 
variability between morning and evening series. The reporting of 
Lmusual or traumatic events such as being woken at night 
coincided quite consistently with depressed mood ratings, e.g. 
the 1st, 10th and 14th baseline days days all coincided with the 
only reports of unusual events during this phase. Similar 
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FACTOR SCORES FOR THREE MOOD DIMENSIONS - EVENING DATA 
SUBJECT: 11 
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Autocorrelation estimates 
Table 4-11-3 rk (k=l,n/4) values for separate morn. & eve. series 
factor baseline 1(n=14) tryptophan(n=28) 
rl r2 r-3 r1 t-2 r-3 
alertness 
morning -.05 -.22 -.28 .07 .12 .12 
evening -.34 -.05 -.09 .14 -.14 - .. 24 
cont ... ss 
morning -.22 -.18 • 06 .58** a31 -.01 
evening -.23 -.27 .01 • 49·1Hf· .24 • 07 
calmness 
morning -.06 -.36 -.05 .18 -.OB • 01 
eveninci -.30 -.05 .06 .49** .23 . 07 
Table 4-11-3 continued: 
factor placebo(n=14) 
rl r-2 r-3 
alertness 
morning -.02 -.52* -.08 
evening -.28 -.14 -.-. ~~ 
cont ••• ss 
morning -.05 -.31 .20 
evenina .46* r"\C' .. ,L...,_J .08 
calmness 
morning -.10 -.25 -.21 
evening -.10 -.26 . 17 
* exceeds the critical value for the ,05 level of significance 
** exceeds the critical value for the ,01 level of significance 
t test results 
Comment on t test results 
As demonstrated in Table 4-11-4, the only significant 
findings were for a lower mean during the evening tryptophan 
phase relative to placebo and baseline periods. These findings 
were not affected by the presence of significant autocorrelation. 
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Table 4-11-4 t test values for mean differences between 





















~ 1.90 ns 
"'-0.62 ns 
""-0.74 ns 
* exceeds critical value for the .05 level of significance 
** exceeds critical value for the ,01 level of significance 
indicates the first mean of the pair is the lowest 
C statistic results 






~-1. 14 ns 
Table 4-11-5 Z values for morninq 1 eveninq and combined series 
series basel bsl+trvp 
morning 
alertness 0.08 ns 0.29 ns 
cont ..• ss -0.36 ns 0.80 ns 
calmness 0.64 ns 0.43 ns 
evening 
alertness -1.16 ns 0.79 ns 
cont •.• ss -0.63 ns 1. 19 ns 
calmness -0.50 ns 1.22 ns 
Comment on C statistic results 
As is apparent from Table 4-11-5, no significant departures 
in trend were evident for tryptophan periods relative to 
baseline. 
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{c) Hours of sleep 
Table 4-11-6 Autocorrelation estimates: rk (k=n/4) values 
baselinel(n=14) 
rl r2 r3 
-.06 .25 -.20 
tryptophan(n=13) 
rl r2 r3 
.49* -.11 -.30 
placebo(n=14) 
rl r2 r3 
.10 -.36 -.11 
* exceeds the critical value for the .05 level of significance 
t test value results for hours of sleep 
basel - tryp 
"'-0.23 ns 
Comment on hours of sleep 
basel - plac 
"'-0.69 ns 
tryp - plac 
"'-1.23 ns 
No significant changes emerged for hours of sleep in terms 
of the mean difference between baseline, tryptophan and placebo 
phases. 
{d) Side effects 
Table 4-11-7 Autocorrelation estimates: rk (k=n/4) values 
baseline1<n=14) 
rl r2 r3 
.50** .12 -.05 
trvptophan<n=14) 
rl r2 r3 
.22 -.24 -.30 
placebo<n=13) 
r1 r2 r3 
• 26 -. 16 • 12 
** exceeds the critical value for the .01 level of significance 
t test results for side effect severity 
basel - tryp 
"'-3.57 ** 
base1 - plac 
-2. 51 *· 
tryp - plac 
2.20 * 
Comment an side effects 




periods exhibited significant elevations in side effect 
relative to baseline. The most severe levels were 
during the tryptophan phase which exhibited a 
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significantly higher level than the placebo period. The rise in 
tryptophan phase levels was associated with qualitative changes 
relative to baseline and placebo. That is, frequent reports of 
constipation (9 times) and increased appetite (7 times) were 
unique to this period. 




first onset of menstruation for this subject was noted 
8 of the tryptophan phase and lasted for three days. 
is difficult to determine how much of the increased 
incidence in side effect levels {associated with the tryptophan 
phase) should be attributed to possible premenstrual symptoms. 
However, the high level of negative symptoms experienced at this 
time continued into the post menstrual phase, while tryptophan 
was still being consumed. This subject began menstruating again 
on the last day of baseline 2: the mean severity of side effects 
for the associated premenstrual phase was 1.5 which was identical 
to the first premenstrual phase. Since the two phases were 
comparable, it might be assumed that premenstrual symptoms could 
not account for the overall elevation in side effect severity 
associated with the tryptophan phase. 
(5) Summary and Conclusions 
As indicated previously this subject was classed as 
depressed relative to other participants. More significant than 
the depressive symptomatology exhibited by this subject, however, 
were the high levels of anxiety as measured by the State scales. 
There was a slight decline on State anxiety scores and the HSCL 
anxiety factor for the second half of the trial period. However, 
no change in relation to the tryptophan phase versus other 
pet-i ods was 
significant 
apparent. Statistical analysis indicated 
reduction in the level of evening alertness for 
a 
the 
tryptophan versus placebo and baseline periods which was also 
detected by visual analysis. 
The most noticeable effect during the tryptophan phase, was 
for a signficant increase in the level of side effects. As 
discussed previously part of the tryptophan period coincided with 
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a premenstrual phase for this subject. However, comparison of 
both premenstrual phases indicated that the rise in symptom 
severity could not be confidently accounted for by the 
premenstrual phase alone. In addition, tryptophan intake and 
high levels of side effects continued for some days after the 
premenstrual phase. Although the placebo phase demonstrated an 
elevation in side effects relative to baseline, the tryptophan 
phase was still associated with the highest significant level. 
Thus, intake of 3gms/day of trypt• phan for this subject 
was associated with a reduction in alertness and an increase in 
side effects - particularly constipation and increased appetite. 
There was no evidence of therapeutic effects associated with 
tryptophan intake with respect to reduction in depressive or 
anxious symptomatology as measured by the weekly and daily 
scales. 
4.2.12 Subject 12 
(1) Demoqraphic variables 
age(yrs): 31 sex: female heiqht(cms):166 
weight(kgs):54.00 
(within desirable weight range) 
chemical contraceptives?: yes 
PMT?: yes 
1-tryptophan experience: - not consumed prior to this project 
motivation for participation: depression 
(2) Psychological variables 
(a) Depression status 
The initial and several subsequent SDS total scores for this 
subject exceeded one standard deviation above the mean according 
to Knight et al. 's (1983) norms. On the basis of Zung's (1972) 
criteria the first SDS score for this subject could be considered 
to lie within the 'moderate to severe' depression category. Most 
subsequent elevated scores? however, only reached the 'mild 
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moderate' division. The present subject was consequently 
classed as depressed. 
Cb) Anxiety Status 
The present subject exhibited a Trait anxiety score (70) 
greater than three standard deviations above the appropriate age 
and sex mean according to Knight et al. 's ( 1983) norms. The 
initial and most subsequent State scores exceeded two standard 
deviations above the respective mean. Consequently the present 
subject was considered to exhibit high levels of State anxiety 
throughout the trial in keeping with the initial Trait total. 
(3) Experimental variables 
(a) Dose level Cgms/day): 3 
Cbr Phase description 
baseline 1 trvptophan :washout: placebo lbaseline 2: 
14days 28days 7days 14days 7days 
(c) Extra details 
Scale completion time was regular with little missing data 
accrued. No tablets (trytophan/placebo) were forgotten. 
(4) Results and analysis 
(a) Weekly scores 
Table 4-12-1 Total scores for Zunq, State anxiety and HSCL scales 
baseline 1 tryptophan wash placebo bs2 
day 01 07 14 21 28 35 42 49 56 63 70 
scale 
zung 47 49 42 44 38 42 48 45 38 37 
state 58 68 51 51 48 52 71 56 51 45 
HSCL 140 131 117 107 103 111 130 117 107 95 
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Table 4-12-2 HSCL factor scores 
baseline 1 tryptophan wash placebo bs2 
dat 01 07 14 21 28 35 42 49 56 6< ..... 70 
factor 
1 1.65 1.34 1. 77 1.60 1. 77 1.41 1.40 1.24 1.44 1. 15 
2 3.27 3.15 2.79 2.67 2.63 2.90 2.78 2.90 2.67 2. 18 
3 2.75 3.03 2.46 2.14 2.37 1.88 2.64 2.33 2.13 2.04 
4 2.64 2.40 1. 76 1.70 1.78 1.95 2.52 2.06 1.52 1.79 
5 2.37 2.50 1.93 1.62 1.47 1. 90 2.52 2.19 1. 91 1. 47 
Comment on weekly scale scores 
There was a slight decline in Zung scores during the 
tryptophan phase relative to baseline and washout. A more 
noticeable decline was apparent in State and HSCL total scores 
during the tryptophan relative to baseline phase, followed by a 
rise in both scores during the washout period. However, the 
decline for the tryptophan period on all scales was no greater 
than that for the placebo phase. Most of the decline associated 
with the HSCL scores was attributable to factors 4 and that 
is: depression and anxiety respectively, which is in keeping with 
the SDS and State trends. HSCL factor scores were most in 
keeping with means for a depressed sample (Table 3-4). 
(b) Mood factors 
Visual analysis of graphed data 
Examination of the morning (Figure 4-12-1) and evening 
(Figure 4-12-2) series indicated high day to day variability for 
alertness with no obvious changes within or between phases. 
There was evidence that the evening and to a lesser extent the 
morning contentedness dimension stabilized at a higher level 
(during the tryptophan phase) than that for the baseline period. 
However, there was no elevation with respect to the placebo 
phase. Consistency in the level and variability of ratings was 
apparent between morning and evening series. The large dip on 
calmness in both series (day 11 of baseline) coincided with a 























FACTOR SCORES FOR THREE MOOD DIMENSIONS - MORNING DATA 
SUBJECT: 12 
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Fi gw-e 4-12-2 
FACTOR SCORES FOR THREE MOOD DIMENSIONS - EVENING DATA 
SUBJECT: 12 
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Autocorr-elation estimates 
Table 4-12-3 rk (k=1,n/4) values for separate morn. & eve. series 
factor baseline 1(n=14> 
r1 r2 r3 
alertness 
morning -.04 -.03 -.21 
evening -.16 -.06 .13 
cont •.• ss 
morning .22 .28 -.27 
evenina .12 .13 
_.,. --~-... 
calmness 
morning .14 .01 -.25 
evening -.28 -.05 .13 












r1 r2 r3 
-.40 -.29 .03 
- . 41 . 23 - • 13 
.01 .04 -.14 
-.54* .29 -.30 
-.11 -.03 -.25 
-.22 .35* .03 
* exceeds the critical value for 
t test results 
Comment on t test results 
the 
tryptophan<n=28> 
rl r2 r3 r4 
.19 .26 .15 .02 
.18 .13 .15 .10 
.10 - .. 22 .02 -. 12 
.12 -.14 -.OB -.13 
.18 .13 -. 13 .04 
.05 -.10 -.02 .22 
,05 level of significance 
The means of the tryptophan and placebo periods were 
significantly higher than baseline in both morning and evening 
series for contentedness (Table 4-12-4). Significant negative 
autocorrelation in the evening seris for contentedness may have 
led to an overestimation of significance for the baseline 
-tryptophan difference for this dimension. 
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Table 4-12-4 t test values for mean differences between 
baseline 1. trvptophan and placebo phases 
basel - tryp base1 - plac 
alertness 
morning 0.03 ns o. 11 ns 
evening -0.12 ns -0.24 ns 
contentedness 
morning ""'-2. 78 ** "'-2.69 * 
evening "'-2.80 * ~-2.72 *+ 
calmness 
mor-ning -0.01 ns "'-0.59 ns 
evening "'-1. 09 ns "'4-{). 53 ns 
* exceeds critical value for the , 05 level of significance 
** exceeds critical value for the IO 1 level of significance 
+ sig. t values affected by sig, levels of autocorrelation 
indicates the first mean of the pair is the lowest 















Table 4-12-5 Z values for mor-ning. evening and combined series 
series base1 bsi+trvp 
morning 
alertness 0.11 ns 0.80 ns 
cont ••. ss -0.88 ns 0.46 ns 
calmness 0.83 ns 1.36 ns 
evening 
aler-tness -0.60 ns 0.64 ns 
cont .•• ss 0.58 ns ,.,_ r'\~ * .L..k-..:• 
calmness -1.03 ns -0.49 ns 
** exceeds the critical value for the ,01 level of significance 
Comment on C statistic results 
As indicated in Table 4-12-5, the contentedness dimension 
exhibited a significant departure in tr-end fr-om the baseline 
phase in the evening series only. 
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(c) Hours of sleep 
Table 4-12-6 Autocorrelation estimates: rk (k=n/4) values 
baseline1(n=13) 
r1 r2 r3 
-.65** .16 .06 
trvptophan(n=23) 
rl r2 r3 r4 




** exceeds the critical value for the ,01 level of significance 
t test value results for hours of sleep 
base1 - tryp 
-0.75 ns 
Comment on hours of sleep 
base1 - plac 
0.18 ns 
tryp - plac 
0.92 ns 
No significant changes emerged for hours of sleep in terms 
of the mean difference between baseline, tryptophan or placebo 
phases. 
(d) Side effects 
Table 4-12-7 Autocorrelation estimates: rk Ck=n/4) values 
baselinel<n=14) tryptophan(n=27) placebo(n=143) 
r2 r3 r1 r3 r4 rl r2 r3 
-.01 -.01 -.02 .48 .22 .18 .19 -.32 a20 -a12 
None of the above estimates proved significant 
t test value results for side effect severity 
base - tryp 
-7.43 ** 
Comment on side effects 
base - plac 
,.,_,-3. 32 ** 
tryp - plac 
"'2.46 * 
As is evident from the t test results, both tryptophan and 
placebo periods were associated with higher levels of side 
effects than baseline, but the severity level for the tryptophan 
phase remained higher than that of placebo. The main qualitative 
198 
change in symptoms associated with the tryptophan phase was the 
unique and frequent reporting of constipation. Other symptoms 
demonstrating marked increases during the tryptophan phase were 
appetite and headaches. 
Ce) Premenstrual Tension 
The present subject was menstruating during the first five 
days of baseline 1, thus, the associated premenstrual phase could 
not be assessed. The second onset of menstruation was noted on 
day 15 of the trytophan phase and continued far four days. The 
third and final menstrual onset for the trial period was noted on 
day 7 of the placebo phase and lasted three days. The mean 
severity of side effects for the first premenstrual phase (during 
tryptophan administration) was 2 compared to 1.2 for the second 
premenstrual phase. Consequently, there is a need to interpret 
the rise in side effects associated with tryptophan cautiously 
given coincidence of the premenstrual period with the first half 
of this phase. 
(5) Summary and Conclusions 
As indicated previously, the present subject was considered 
to be experiencing moderate depression and much higher than 
normal levels of anxiety. There was some evidence of a reduction 
in anxiety symptoms as measured by the State anxiety scale and 
the anxiety dimension of the HSCL during the tryptophan period 
relative to the first baseline phase. However, the reduction of 
scores was of a similar magnitude to that expressed during the 
placebo period. The visual indication of an increase in 
contentedness particularly during the evening - was supported 
by statistical evidence of increased tryptophan versus baseline 
means. In addition, a significant departure in trend for the 
tryptophan relative to baseline phase was indicated following 
application of the C statistic for, the contentedness dimension 
in the evening series. However, as evident from both statistical 
and visual anaylses the increase was not maintained relative to 
the placebo phase. 
The statistically significant increase in the level of side 
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effects associated with the tryptophan phase relative to baseline 
and placebo needs to be interpreted cautiously due to the 
coincidence of a premenstrual phase with the first two weeks of 
tryptophan intake. Compared to the second premenstrual phase, 
the level of symptoms in the first case was higher, indicating 
that tryptophan intake could have been responsible for at least 
part of the rise. The fact that increased consitpation and an 
extreme elevation in the frequency of increased appetite (i.e. on 
19 out of 28 days) were unique to the tryptophan period does 
indicate such changes could be attributable to tryptophan intake. 
Thus, therapeutic effects above placebo were not supported 
following consumption of 3gms/day of tryptophan for 28 days by 
this subject. Large increases in reported side effects 
particularly constipation and increased appetite were uniquely 
associated with the tryptophan phase. 
4.2.13 Subject 13 
(1) Demographic variables 




(within desirable weight range) 
tryptophan experience: - not consumed prior to this project 
motivation for participation: - general interest 
(2) Psychological variables 
Ca) Depression status 
The initial SDS total score for the present subject was 
below the appropriate mean according to Knight et ala's (1983) 
norms and subsequent scores throughout the trial remained within 
standard deviation of this value. On this basis and one 
the general interest motivation for participation the 




(b) Anxiety status 
The Trait score (28) for this subject was low relative to 
l<night et al. 's (1983) norm, that is, under one standard 
deviation below the mean. The initial State score was also below 
the appropriate mean with subsequent scores remaining within one 
standard deviation from the mean. Consequently this subject was 
considered free from significant levels of anxiety. 
(3) Experimental variables 
(a) Dose level (gms/day): 3 










Scale completion time was regular with missing data confined 
to one morning and one evening rating at the end of the 
tryptophan and baseline 2 phases respectively. 
(trytophan/placebo) were forgotten. 
(4) Results and analysis 
(a) Weekly scores 
No tablets 
Table 4-13-1 Total scores for Zung 2 State Anxiety and HSCL scales 
baseline 1 tryptophan wash placebo 
dav 01 07 14 21 28 -:re-..:.,..i 42 49 
scale 
zung 28 30 31 30 40 40 32 26 
state 27 35 29 26 32 45 31 28 
HSCL 70 74 77 79 103 90 64 65 
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Table 4-13-2 HSCL factor scores 
baseline 1 tryptophan wash placebo 
day 01 07 14 21 28 35 42 49 
factor 
1 1.27 1.26 1.42 1.15 2.32 1.78 1.09 1.07 
.., 1.40 1.52 1.40 1.37 1.91 1.37 1.00 1 .00 ... 
3 1.34 1.47 1.29 1.62 1.13 1.34 1.18 1.00 
4 1.00 1.28 1.46 1.46 2.10 1.57 1. 10 1.10 
5 1.16 LOO 1.00 1.31 1.00 1.15 1.00 1.15 
Comment on weekly scale scores 
As is evident from Table 4-13-1, there was a slight 
elevation in all weekly scores during the second week of 
trytophan intake 
rest of the trial. 
and during the washout phase relative to the 
While this subject was not considered to be 
particularly anxious, the State total score and the HSCL anxiety 
factor demonstrated sensitivity for this individual. However, 
the elevation in Zung scores was not supported by elevation in 
the HSCL depression dimension. Thus, the elevation in Zung 
total scores may have been attributable to the increase in 
anxiety and somatic symptoms (supported by the HSCL dimensions 
exhibiting most increase at this time)rather than depressed mood. 
HSCL factor scores were most in keeping with means for a normal 
sample (Table 3-4). 
(b) Mood factors 
Visual analysis of graphed data 
The most consistent feature apparent from examination of 
Figures 4-13-1 and 4-13-2 concerned the declines on contendedness 
and alertness in both series during the last 4 days of tryptophan 
consumption. This decline coincided with reports of severe flu 
symptoms over the same period. No meaningful changes between or 



















FACTOR SCORES FOR THREE MOOD DIMENSIONS - MORNING DATA 
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Table 4-12-3 r-k <k=1~n/4) values for separate mot-n. 8< eve. series 
factor baseline 1(n=13) tryptophan(n=14) 
rl r2 r3 r1 r-2 r3 
alertness 
morning -.39 -. 16 .16 • 64** a39* . 003 
evening -.13 -.16 .06 .74** .43* .16 
cont .•• ss 
morning -.21 -. 18 -.16 .21 -.12 -.06 
evening -.10 -.24 .09 .30 .15 -.06 
calmness 
morning • 11 -.16 • 04 -.05 -.60 .04 
evening .28 -. 17 -.29 1'"' • .L. -. 16 -.02 
Table 4-12-3 continued: 
factor placebo(n=14) 
rl r2 r3 
alertness 
morning -.03 .17 -.06 
evening -~23 .01 .09 
cont ••. ss 
morning -a 13 -.33 "26 
eveninq .44* -.19 -.35 
calmness 
morning .26 -.40 -.46 
evening -.18 • 001 -.03 
* exceeds the critical value for the ,05 level of significance 
** exceeds the c: r i ti cal val u e for the , 01 l eve l of s i g n i f i c: an c: e 
t test results 
Comment on t test results 
As indicated in Table 4-13-4, the mean for morning 
contentedness in the tryptophan period was significantly below 
baseline and placebo phases. In addition., the level of morning 
alertness was found to be significantly lower during trytophan 
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phase relative to placebo. However, the reduction was not 
significant relative to baseline. 
Table 4-13-4 t test values for mean differences between 
baseline 1, trypt• phan and placebo phases 
alertness 






















ba.sel - plac 




"' 1.31 ns 
-0.48 ns 
* exceeds critical value for the ,05 level of significance 
+ sig, t values affected by sig, levels of autocorrelation 
indicates the first mean of the pair is the lowest 















Table 4-11-5 Z values for morninq, evening and combined series 
series basel bsl+tryp 
morning 
alertness -1.49 ns 3.31 ** 
cont ••• ss -0.60 ns 2.13 * 
calmness 0.95 ns 0.80 ns 
evening 
alertness -0.49 ns 3.32 ** 
cont .•. ss -0.35 ns 1.06 ns 
calmness 1. 18 ns 1. 12 ns 
* exceeds the critical value for the .05 level of significance 
** exceeds the critical value for the ,01 level of significance 
Comment on C statistic results 
As is evident from Table 4-11-5, for both morning and 
evening tryptophan phases, alertness and contentedness were found 
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to exhibit significant departures in trend relative to baseline. 
(c) Hours of sleep 
Table 4-13-6 Autocorrelation estimates: rk (k=n/4) values 
baseline1(n=13) tryptophan(n=11) 
rl r2 r-3 
.28 -.45 .22 
r1 r2 
-.21 -.21 
None of the above estimates proved significant 
t test value results for hours of sleep 
base1 - tryp 
0.67 ns 
Comment on hours of sleep 
basel - plac 
0.86 ns 
placebo(n=13) 
r-1 r2 r3 
-. 10 -. 11 • 05 
tryp - plac 
0. 12 ns 
As indicated from the t test results, no significant 
differences were apparent with respect to the mean hours of sleep 
between baseline tryptophan and placebo phases. 
(d) Side effects 
Table 4-13-7 Autocorrelation estimates: rk (k=n/4) values 
baseline1(n=14) tryptophan(n=14) placebo(n=14) 
r1 r2 r3 rl r2 r-3 r1 r2 r-3 
-. 20 -. 11 • 07 .77**-50**-23 -.10 -.11 -.12 
** exceeds the critical value for the ,01 level of significance 
t test value results for side effect severity 
basel - tryp 
"'-1.57 ns 
Comment on side effects 
basel - plac 
"' 1.41 ns 
As indicated from the above t tests, 
severity was higher during the tryptophan 
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tryp - plac 
2.44 * 
although side effect 
phase relative to 
placebo, the elevation was not significant with respect to 
baseline. An extreme elevation in the last four days of the 
tryptophan phase coincided with reports of flu over this period. 
Otherwise symptoms during the rest of the tryptophan period did 
not appear elevated, that is, the mean for the first 4 tryptophan 
days was 0.6 compared to 11.5 for the final 4 days. The presence 
of significant positive autocorrelation in the tryptophan phase 
may have resulted in an over-estimation of significance here. 
(e) Premenstrual tension 
The first menstrual onset for this subject was noted on day 6 
of baseline 1 and the second on day 6 of the washout phase. The 
overlap of the second premenstrual phase with the last week of 
tryptophan intake as well as a flu attack makes it difficult to 
attribute symptom elevation to any one factor. However, 
elevation in side effects was confined the days of flu. 
(5) Summary and Conclusions 
The main findings for this subject were limited· to slight 
elevation in weekly scale scores around the final week of 
tryptophan administration and during the washout phase. 
HSCL factor scores indicated most of the elevation was 
attributable to anxiety and somatic symptoms. This finding could 
be considered to coincide with the reduction in alertness and 
contentedness which was most apparent during the last four 
tryptophan days. 
the period. The 
This decline coincided severe flu symptoms over 
experience of flu might also account for the 
statistically significant reduction in the level of contentedness 
for the tryptophan phase relative to baseline and placebo and the 
significant departures in trend for tryptophan relative to 
baseline on both alertness and contentedness dimensions. The 
remaining statistically significant finding of reduced alertness 
in the morning (and increased side effects) for tryptophan 
relative to placebo was not maintained in relation to baseline. 
Thus, no significant changes in mood, total sleep time or side 
effects (relative to baseline and placebo periods) could be 
confidently associated with ingestion of 3gms/day of tryptophan 
for 14 days in this subjects. 
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4.2.14 Subject 14 
(1) Demographic variables 
age<yrs): 22 sex: male height(cms):185 
weight(kgs):76.00 
(within desirable weight range) 
- not consumed prior to this project 1-tryptophan experience: 
motivation for participation: general interest 
(2) Psychological variables 
{a) Depression status 
The initial SDS score for this subject was close to the 
appropriate mean with respect to Knight et al. 's (1983) norms. 
Subsequent scores were close to or below this value. On this 
basis as well as a general interest motivation for participation 
the present subject was not considered to be depressed. 
(b) Anxiety status 
The Trait anxiety score for this subject (33) was well 
within one standard deviation from the appropriate mean according 
to Knight et al. 's (1983) norms. While the first baseline State 
score slightly exceeded one standard deviation above the mean, 
subsequent values were under this limit. Consequently this 
subject was not considered to be particularly anxious. 
(3) Experimental variables 
(a} Dose level (gms/day): 4 
Cb) Phase description 
baseline 1 trvptophan :washoutl placebo lbaseline 2: 
14days 7days 7days 14days 7days 
Mood ratings were not obtained for this subject during the 
washout phase. Originally this subject had intended completing 
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two weeks of tryptaphan consumption. However, owing to a sudden 
requirement to leave Christchurch, data was not obtained for the 
second tryptophan week or the washout phase. 
(c) Extra details 
Scale completion time was regular and moodscale ratings were 
missed once. Weekly rating for mid baseline and the end of 
baseline 2 were missed. No tablets were forgotten. 
(4) Results and analysis 
(a) Weekly scores 
Table 4-14-1 Total scores for Zung 2 State anxiety and HSCL scales 
baseline 1 tryptophan wash placebo 
day 01 07 14 21 28 35 42 
scale 
zung 33 30 25 26 24 
state 40 34 -,.,:--.:,..i 34 25 
HSCL 68 71 74 75 65 
Table 4-14-2 HSCL factor scores 
baseline 1 tryptophan wash placebo 
day 01 07 14 21 28 35 42 
factor 
1 1. 18 1. 15 1.49 1. 17 1.20 
2 1. 10 1. 22 1.48 1.46 1. 00 
..,.. 1.16 1. 16 1. 12 1. 32 1. 16 ...:, 
4 1.29 1.28 1.18 1.40 1.09 
5 1.15 1. 15 1. 00 1. 15 1. 15 
Comment on weekly scale scores 
The consistency of low scores across all phases was 
confirmatory of the present subject's non depressed and non 
anxious status. HSCL factor scores were in keeping with means 
far a normal sample (see Table 3-4). 
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(b) Mood factor-s 
Visual analysis of graphed data 
No consistent or- meaningful changes could be detected from 
the graphed morning and evening data for this subject in Figure 
4-14. The brevity of the tryptophan period was a handicapp to 
valid analysis in this respect. The unusual events noted e.g. 
smoking of 6 marijuana joints on the second evening of baseline 1 
were not associated with any dr-amatic or meaningful changes in 
mood ratings. However, it should be noted that the first mood 
scale completion following this event was not until the next 
morning. Similarly, consumption of two (unspecified) 
antidepressants on the evening prior to day 6 of the placebo 
phase was not associated with any outstanding changes in mood 
ratings. 
Autocor-relation estimates 
Table 4-14-3 rk (k=1,n/4) values for- separate mor-n. & eve. series 
factor baseline 1(n=14} tryptophan(n=7) placebo(n=14) 
rl r2 r3 r1 rl r-2 r-3 
alertness 
morning .13 .36 .07 -.02 -.30 -.19 .18 
evening .45* .04 -1125 - .. 24 -.08 -.18 -.29 
cont .•. ss 
morning -.38 .12 -.28 • 01 -.10 -1122 -.05 
eveninq -.38 =12 -.28 .40* .49** • 37* .20 
calmness 
morning .12 --,, -. ~--... 1222 .18 .10 .12 .23 
evening -.09 .10 .19 -.35 .27 .24 -.09 
* exceeds the critical value for the ,05 1 evel of significance 




























FACTOR SCORES FOR THREE MOOD DIMENSIONS - MORNING DATA 
SUBJECT: 14 
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FACTOR SCORES FOR THREE MOOD DIMENSIONS - EVENING DATA 
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t test results 
Table 4-14-4 t test values for mean differences between 
baseline 1 2 tryptophan and placebo phases 
base1 - tryp trvp plac base1 -
alertness 
morning r"1 C'C" .£.. • ..J..J * "' 0.88 ns "'-0.65 
evening -0.28 ns -1.54 ns -1.12 
contentedness 
morning 1. 05 ns 0.70 ns -0.20 
eveninq "' 1.80 ns 2.89 **+ "'-0.08 
calmness 
morning -1.36 ns -0.21 ns 0.87 
eveninq ~ 1.30 ns 3.28 ** 0.80 
* exceeds critical value fer the .05 1 evel of significance 
** exceeds critical value fer the . 01 level cf significance 
+ sig. t values aff ec:ted by sig, levels cf autocorrelation 
indicates the first mean of the pair is the l cweist 








As evident from Table 4-12-4, the level of morning alertness 
was found to be significantly lower than baseline but not placebo 
for this subject. In addition, the level of evening 
contentedness and calmness was significantly lower for placebo 
relative to baseline. The significance of the placebo - baseline 
difference on contentedness may have been underestimated due to 
the presence of significant positive autocorrelation in both 
these phases. 
(c) Hours of Sleep 
Table 4-14-5 Autocorrelation estimates: rk Ck=n/4) values 
baseline1(n=13) 
r 1 r2 r3 




None of the above estimates proved significant 
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placebo<n=14) 
r 1 r2 r3 
-.16 -.11 -.03 
t test results for hours of sleep 
base1 - tryp 
-1.38 ns 
Comment on hours of sleep 
base1 - plac 
0.02 ns 
tryp - plac 
1.05 ns 
No significant differences in mean hours of sleep were 
apparent between baseline, tryptophan and placebo phases for this 
subject. 
(d) Side effects 
No side effects were checked by this subject throughout the 
total trial length. 
(5) Summary and Conclusions 
Both statistical and visual analysis, for this subject, were 
hindered by the brevity of the tryptophan phase. Consistently low 
scores on the weekly scales, were confirmatory of the lack of 
depressive and anxious symptomatology in the present subject. 
The statistically significant finding of reduced morning 
alertness for tryptophan relative to baseline in the morning 
series was not considered particularly relevant due to the 
shortness of this phase, the lack of difference relative to 
placebo and the absence of visual support. The significant 
reduction in calmness and contentedness for evening placebo 
relative to baseline phases was not supported by visual analysis. 
Thus, consumption of 4gm/day of tryptophan for 7 days by the 
present subject could only be associated with a slight 
statistically significant reduction in alertness. No elevation in 
side effect severity was attributable to this treatment. 
214 
4.2.15 Subject 15 
(1) Demographic variables 
age(yrs): 20 height<cms):175 
weightCkgs):83.00 
(above desirable weight range) 
tryptophan experience: - not consumed prior to this project 
sex: male 
motivation for participation: - general interest 
(2) Psychological variables 
(a) Depression status 
The initial SDS score for this subject was close to the 
appropriate mean for age and sex according to Knight et al. 's 
(1983) norms. Despite a general interest motivation for 
participation, most of the remaining scores were particularly 
elevated according to the above criteria. On the basis of Zung's 
(1972) depression categories, two scores were within the mild to 
moderate range and one fell within the moderate to severe class. 
While, 
this 
some consideration was given to therapeutic relationships 
subject was not considered in the depressive category. 
(b) Anxietv status 
The Trait score (42) for the present subject exceeded one 
standard deviation above the mean for Knight et al. ·s (1983) 
norms. Initial State scores were close to the mean, while, four 
subsequent scores exceeded one standard deviation above the mean 
and one of these scores was in excess of three standard 
deviations above the mean. Thus, the present subject experienced 
elevated levels of anxiety on occasions. 
(3) Experimental variables 
(a) Dose level(gms/day): 3 
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(b) Phase description 
baseline 1 tryptophan :washout: placebo 
14days 14days 7days 14days 
(c) Extra details 
Scale completion time was regular with some missing data 
accrued for the daily mood ratings. The final weekly scale 
ratings were missed. No tablets were forgotten. 
(4) Results and analysis 
(a) Weekly scores 
Table 4-15-1 Total scores for Zung, State anxiety and HSCL scales 
baseline 1 tryptophan wash placebo 
da:t 01 07 14 21 28 ..,..c:-..:.•W 42 
scale 
zung 33 35 40 38 37 43 50 
state 32 34 58 38 41 36 29 
HSCL 89 85 96 89 93 107 108 
Table 4-15-2 HSCL factor scores 
baseline 1 tryptophan wash placebo 
day 01 07 14 21 28 35 42 
factor 
1 1.48 1.26 1. 56 1.37 1.41 1.25 1. 07 
2 1.77 1.73 1. 85 1.57 1.57 2.24 2.49 
-:r ~· 1.46 1.26 1. 85 1.29 1.29 2.06 1.72 
4 1.44 1.53 1. 51 1.70 1. 56 2.20 2.11 
5 1.58 1.73 1.55 1.42 1.70 1.70 1.73 
Comment on weekly scale scores 
A rise in total scores for the Zung and HSCL scales was 
apparent during the washout and placebo phases. 




'depression· and 'obsessive-compulsive' factors. The elevated 
State score at the end of the baseline phase was associated with 
a notable rise on the HSCL factor of 'interpersonal sensitivity·. 
No changes in weekly ratings could be meaningfully related to 
tryptophan intake. HSCL factor scores 2 to 5 exhibited levels 
close to depressed and anxious groups at times <Table 3-4). 
(b) Mood factors 
Visual analysis of graphed data 
Morning and evening series <Figure 4-15) did not indicate 
any dramatic within or between phase changes. There was, however, 
a slight trend for reduced alertness in the morning and evening 
series during the tryptophan phase relative to baseline, with the 
indication being most consistent in the morning. The reductions 
were less pronounced relative to the erratic and broken placebo 
periods. Frequent consumption of alcohol by this subject did not 
bear any consistent relationship to mood ratings. Evening scales 
were generally completed prior to alcohol consumption at night, 
thus, only the morning after ratings could be considered. The 
peak during the evening placebo phase (day 42) for all dimensions 
coincided with an apparently enjoyable celebration. 
Autocorrelation estimates 
Table 4-15-3 rk (k=1 2n/4) values for separate morn. 8( eve. series 
factor baseline 1(n=14) tryptophan(n=13) placebo(n=14) 
r1 r2 r3 r1 r2 r-3 r1 r2 r3 
alertness 
morning -.10 -.15 .05 .19 -.02 .33 .17 -.54* -.51* 
evening -.22 .28 -.27 -.11 -.08 -.24 .06 -.35 -.53* 
cont .•• ss 
morning .25 .08 -.03 -.15 -.20 .02 -.07 -.43 -. 13 
evening .13 -.08 • 01 -.45 .19 .03 -.06 -.34 -.41 
calmness 
morning -.23 .16 -.02 -.32 .03 .15 -.37 • 03 .09 
evenin!;I ,.22 .05 .04 -.50* .44* -.05 .22 -.60* -.43 
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FACTOR SCORES FOR THREE MOOD DIMENSIONS - EVENING DATA 
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J:>a!Eeline 1 l-=tr-yp1:oph.an 
l l 1 
1--
/, Jt-B, 
l \ f ·~. 
..... _ 1, / 0\1 
(,.d 
'~I 
i' 1 I f' l 11 I 
d I .-Fl ,' 
Cl ~• 
alertness 
A I ', p 





__ , ~ I _.a·-1'1 
,r I I I n 
I I I 
11 I 11 .f 
,1 I 1 
























:tit ,:tit; ~11; 
. ~ •. \ l I 






..,! .. ,.~1 11 ,-,..., r 











, ;iir 1\ 1\/ 
I I I 11 I ,1 ~~ V ', 1i ~· ~·· 
calmness 
\ 
' ~I ~. II / ' / \ ... ,11-... _...m 
I I ~ 1 
1
1 I 11 • .ii 










l ... ,, ~ I " ~ I r·•\ m .... 



















.__ __ _,__!l, _ ____. __ ._____JL _________ J. __ , ____ J 
7 14 21 28 35 42 49 
time (days> 
t test results 
Table 4-15-4 t test values for mean differences between 





















evening -1.96 ns -2.59 *+ 
* exceeds critical value for the ,05 level of significance 
** exceeds critical value for the ,01 level of significance 
+ sig. t values affected by sig. levels of autocorrelation 
indicates the first mean of the pair is the lowest 








As is evident from Table 4-15-4, the level of alertness was 
found to be significantly reduced relative to baseline in morning 
and evening series. For the evening series, tryptophan alertness 
was also found to be significantly lower than placebo, although 
the significance in this case may have been overestimated due to 
the presence of negative autocorrelation in the placebo phase. 
The other significant finding was for increased calmness for 
placebo relative to baseline in the evening. 
C statistic results 
Comment on C statistic results 
As indicated in Table 4-15-5, the trend in mood ratings for 
morning alertness during the tryptophan phase was shown to depart 
significantly from baseline. 
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Table 4-15-5 Z values for morning, evening and combined series 
series base1 bsl+tryp 
morning 
alertness -0.21 ns 2.66 ** 
cont ••. ss 1.14 ns 1.03 ns 
calmness -0.83 ns -1.43 ns 
evening 
alertness -0.08 ns 1.03 ns 
cont ••• ss 0.65 ns -0.42 ns 
calmness 0.99 ns 0.28 ns 
** exceeds the critical value for the ,01 level of significance 
<~> Hours of sleep 
Table 4-15-6 Autocorrelation estimates: rk <k=n/4) values 
basel ine1 (n=11> tryptophan<n=13> 
rl r2 rt r2 r3 
.12 -.22 -.42 .20 -.22 
None of the above estimates proved significant 
t test results for hours of sleep 
basel - tryp 
-2.22 * 
Comment on hours of sleep 







tryp - plac 
1.80 ns 
The mean hours of sleep were significantly higher for the 
tryptophan phase relative to baseline but not placebo. 
Cd) Side effects 
Table 4-15-7 Autocorrelation estimates: rk (k=n/4) values 
baseline1(n=13) tryptophan(n=12) placebo<n=12) 
rl r2 r3 rl r2 r3 rl r2 r3 
• 47 • 01 -. 25 -. 18 • 06 • 01 .04 -.13 .33 
None of the above estimates proved significant 
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t test results for hours of side effect severity 
base1 - tryp 
-0.57 ns 
Comment on side effects 
basel - plac 
1.06 ns 
tryp - plac 
1. 66 ns 
As is evident from the above t test results, no significant 
changes in symptom severity were apparent between baseline, 
tryptophan and placebo phases for this subject. Examintation of 
the types of symptoms reported throughout the trial indicated no 
obvious between phase differences. 
(5) Summary and Conclusions 
The main feature which could be quite confidently associated 
with tryptophan intake in this subject was the reduction in the 
level of alertness for tryptophan relative to baseline in both 
series. This finding was corroborated by both visual and 
statistical analysis. A reduction in slope for tryptophan 
relative to baseline in the morning, was supported by the C 
statistic application in this case. A significant t test, 
indicating the level of tryptophan alertness to be below placebo 
in the evening, was not supported visually. The second main 
finding of increased sleep time during the tryptophan phase 
relative to baseline could be considered in keeping with the 
reduction in alertness. Although the above changes associated 
with tryptophan intake were not maintained relative to placebo, 
they were still considered to be potentially meaningful. Factors 
such as increased drowsiness emerge as one of the most common 
effects associated with tryptophan intake in past investigations 
of normal subjects. 
Thus, there were no indications of any therapeutic benefits 
in the present subject or changes relating to elevation of side 
effects following consumption of 3gms/day of tryptophan. 
Although there was consistent demonstration of reduced alertness 
for tryptophan relative to baseline periods, the reduction was 
only slight. 
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4.2.16 Subject 16 
(1) Demooraphic variables 
age(yrs): 39 sex: male 
drug consumption: antidepressant 
height(cms):179 
weight(kgs):70.00 
(within desirable weight range) 
(mianserin: 60mg/day) was 
consumed prior to the tryptophan phase 
for comparison. 
tryptophan experience: - not consumed prior to this project 
motivation for participation: - depression 
(2) Psycholoqical variables 
Ca) Depression status 
The inital and most subsequent SDS scores for this subject 
were in excess of 3 standard deviations above the mean according 
to Knight et al. ·s (1983) norms. According to Zung's (1972) 
depression categories five out cf six SDS scores for this subject 
were within the moderate to severe class with the sixth score 
just reaching the severe class. Thus, in combination with the 
motivation for participation, this subject was classed as 
depressed. In addition, it should be noted that the present 
subject was consuming therapeutic doses of mianserin on entry to 
the study and had been referred to the project from Student 
Health at Canterbury University. 
(b) Anxiety status 
The Trait score (62) for the present subject exceeded three 
standard deviations above the mean according to Knight et 
al. ·s (1983) norms. The initial and all subsequent State scores 
exceeded 4 standard deviations above the mean. Thus, the present 
subject was considered to be experiencing extremely high levels 
of anxiety relative to a normal population (Knight et al., 1983). 
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(3) Experimental variables 
(a) Dose level(gms/day): 3 
(b) Phase description 
mianserin washout tryptophan 
10days 14 days 26days 
(c} Extra details 
Since the present subject was consuming mianserin at the 
time of inquirng about the project it was decided to collect mood 
data under this condition for comparison with tryptophan. The 
subject had been taking mianserin (60mg/day) for 4 weeks prior to 
the commencement of data collection. Scale completion time was 
regular. While several mood ratings were missed during the 
mianserin period the data for the tryptophan phase are relatively 
complete. 
(4) Results and analysis: 
(a) Weekly scores 
Table 4-16-1 
Total scores for Zung, 
State anxiety and HSCL 
scales 
mianserin tryptophan 
day 01 07 14 21 28 35 
scale 
zung 53 50 50 47 51 56 
state 66 62 62 59 67 65 
HSCL 114 144 127 133 130 138 
Table 4-16-2 
HSCL factor scores 
mianserin 
day 01 07 14 21 
factor 
1 1. 75 2.26 1.98 2.04 
2 2.49 2.60 2.33 2.34 
..,.. . ..) 2.03 2.75 2.14 2.59 
4 2.39 2.71 2.64 2.36 









Comment on weekly scale scores 
Total Zung, State anxiety and HSCL scores maintained an 
elevated level for the present subject across both mianserin and 
tryptophan phases. A two week washout period intervened between 
mianserin and tryptophan phases. However, data could not be 
obtained for this period. HSCL factor scores were in keeping 
with means for a depressed group (Table 3-4>. 
(b) Mood factors 
Visual analysis of graphed data 
The high incidence of missing data during the mianserin 
phase made comparison of drug conditions inappropriate. Although 
not evident from the graphs in Figure 4-16, a two week washout 
period intervened between mianserin and tryptophan periods. No 
trends were apparent to the present author for any dimension in 
either series. Morning and evening series showed similarity in 
the magnitude and direction of ratings. 
Autocorrelation estimates 
Calculations were omitted for the mianserin period due to 
the brevity and brokeness of this phase. 
Table 4-16-3 rk <k=l~n/4) values for separate morn. & eve. series 
factor tryptophan(n=26) 
rl r2 r3 r4 
alertness 
morning .29* .27 -.14 -.02 
evening .34* -.08 -.04 -.10 
cont ••• ss 
morning -.16 .28* -.27 .03 
evening .26 -.03 -.35 -.27 
calmness 
morning -.11 .35* -.14 .18 
evening .22 . 07 .07 .07 
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t test results 
Owing to the brevity an frequency of missing data during the 
mianserin phase t-test comparisons could not be justified. 
C statistic results 
C statistic analysis was limited t • the tryptophan period 
due to the brevity of the mianserin phase. 
Table 4-16-4 Z values for morning and evenino series 
series tryptophan 
morning 
alertness 1. 70 * 
cont ••. ss -0.79 ns 
calmness -0.41 ns 
evening 
alertness 1. 87 * 
cont .•• ss 1.71 * 
calmness 1. 31 ns 
* exceeds the critical value for the ,05 level of significance 
Comment on C statistic results 
Statistically significant trends were detected for alertnes~ 
in the morning and evening and for contentedness in the evening 
during the trypt • phan phase. 
(c) Hours of sleep 
C-statistic result (Z value) 
tryptophan 
0.40 ns 
Comment on hours of sleep 
No significant trend, following C statistic application, 
was apparent for hours of sleep during the tryptophan phase. 
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(d) Side effects 
C-statistic result <Z value) 
tryptophan 
0.09 ns 
Comment on side effects 
No significant trends with respect to side effect severity 
were apparent within the tryptophan phase as indicated by the C 
statistic. 
(5) Summary and Conclusions 
The moderately high levels of depression and quite extreme 
elevation of anxiety symptoms were maintained across both phases. 
Thus, there was no indication of therapeutic effects associated 
with tryptophan intake on the basis of these scales. 
The brevity of the mianserin phase and the 
missing data during this period hindered 
statistical comparison the_ two conditions. 








was therapeutically superior to mianserin. While there was 
detection of statistically significant trends within the 
tryptophan phase for morning alertness and evening alertness and 
contentedness they were only slight and could not be confirmed as 
being particularly meaningful through visual inspection. 
It is difficult to make a valid judgement 
tryptophan's antidepressant and anxiolytic potential 




the severity of symptoms in this case, it was not considered 
justifiable to subject this individual to non therapeutic 
conditions. There was no obvious increase in side effects 
throughout the tryptophan period. Thus, after a fair trial 
period of 26 days, tryptophan was unsucessful in reducing anxiety 
and depression scores to acceptable levels from the subject's 
view point or relative to Knight et al. ·s (1983) anxiety and 
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depression scale norms. 
Finally, it should be noted that this subject claimed to 
have obtained no therapeutic benefit from mianserin following, at 
least, a five week trial. There are claims that mianserin 
possesses antidepressant as well as antianxiety activity 
(Duquesne & Reeves, 1982). In addition, the subject claimed to 
have obtained little benefit from tricyclic compounds such as 
imipramine in the past. Thus, it could be speculated that the 
present subject was characterized by resistence to some forms of 
antidepressant medication. 
4.2.17 Subject 17 
(1) Demographic variables 
age(yrs): 24 sex: male height(cms):160 
weight(kgs):60.00 
(within desirable weight range) 
- not consumed prior to this project tryptophan experience: 
motivation for participation: - depression 
(2) Psycholoqical variables 
(a) Depression status 
initial and subsequent SDS scores The 
subject were all within one standard deviation 
for the present 
from the mean 
according to Knight et al. 's (1983) norms. On this basis the 
present subject could not be considered depressed. However, 
subject had been prescribed antidepressants in the recent 
this 
past. 
In addition a motivation of depression for participation led to 
investigation of tryptophan's therapeutic potential in this case. 
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(b) Anxiety status 
The Trait score (36) for this subject and the State anxiety 
scores throughout the trial were all within one standard 
deviation of the mean according to Knight et al. 's (1983) norms. 
On this basis the present subject was considered to be relatively 
free from anxiety symptoms. 
(3) Experimental variables 
(a) Dose level(gms/day): 4 
Cb) Phase description 
baseline 1 tryptophan :washout: placebo :baseline 2: 
14days 21days 7days 14days 7days 
(c) Extra details 
A washout period of 7 days intervened between the second 
tryptophan period and the placebo phase, although data were not 
obtained fcir this time. Scale completion time was regular with a 
relatively low level of missing data. Weekly scale ratings were 
missed at the end of the second tryptophan and second baseline 
weeks. No tablets were forgotten. 
(4) Results and analysis 
(a) Weekly scores 
Table 4-17-1 Total scores for Zung, State anxiety and HSCL scales 
baseline 1 tryptophan wash tryp2 placebo 
day 01 07 14 21 28 35 42 49 56 63 
scale 
zung -- 35 37 31 30 30 ..,..C' 33 36 .:..-..::., ..:,,_J 
state 31 36 31 32 26 ..,....,.. _,..:, 34 32 39 
HSCL 68 71 72 64 62 66 67 66 67 
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Table 14-17-2 HSCL factor scores 
baseline 1 tryptophan wash tryp2 placebo 
day 01 07 14 21 28 35 42 49 56 63 
factor 
1 1.15 1.08 1.30 1.30 1. 16 1. 16 1.00 1.00 1.08 
2 1.00 1. 00 1. 12 1. 00 1.00 1.00 1. 10 1.00 1. 12 
..,. 
....:> 1.00 1.50 1.34 1.16 1.33 la 33 1.51 1.00 1. 00 
4 1.44 1.37 1.46 1. 09 1.09 1.18 1.26 1.56 1. 71 
5 1.00 1.00 1. 13 1.00 1.00 1. 00 1.00 1. 16 1.00 
Comment on weekly scale scores 
Low total scores on the Zung, State and HSCL scales were 
maintained across the total trial. Although a slight decline in 
scores was noted at week two of tryptophan ingestion, it was not 
considered sufficient to be of psychological significance. HSCL 
factor scores were in keeping with means from a normal group 
{Table 3-4) throughout the trial. 
Cb) Mood factors 
Visual analysis of graphed data 
The main between phase comparisons for this subject 
concerned baseline 1, the first tryptophan period and the placebo 
phase. No noticeable changes between or within such phases were 
apparent for the morning or evening series (Figures 4-17-1 and 4-
17-2). The second tryptophan period did not exhibit any 

















FACTOR SCORES FOR THREE MOOD DIMENSIONS - MORNING DATA 
SUBJECT: 17 
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FACTOR SCORES FDR THREE MOOD DIMENSIONS - EVENING DATA 
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7 14 21 28 35 42 49 56 63 
time (days> 
Autocorrelation estimates 
Table 4-17-3 rk (k=l.n/4) values for separate morn. & eve. series 
factor baseline 1Cn=14) tryptophan(n=21) 
rl r2 r3 rl r2 r3 r4 
alertness 
morning -.58* .39* -.06 • 07 .05 • 01 -.37 
eveninCJ -.01 -.OB -.05 . 11 -.48* -.09 .02 
cont ... ss 
morning -.43 .13 -.OB -.11 -.29 .10 -.19 
evening -.21 • 55·!H -.14 -. 11 .17 .16 -.16 
calmness 
mot-ning • 14 • 02 . 16 • 09 7C: • __ -.,_J -.07 .20 
evening -.15 .08 -.05 -.02 -.02 -.02 -.22 
Table 4-17-3 continued: 
factor placebo(n=14) 
r1 r2 r3 
alertness 
morning .13 -.06 
evening .42* -. (12 -.25 
cont ••• ss 
morning • 11 -5139 
evening .41 -. 15 -.14 
calmness 
morning -.43 -.24 
evening . 21 -.24 -.45 
* exceeds the critical value for the .05 level of significance 
** exceeds the critical value for the ,01 level of significance 
t test resL1l ts 
Comment on t test results 
The mean for morning alertness was significantly lower 
during baseline than tryptophan. The tryptophan phase exhibited 
significantly higher levels than either baseline or placebo for 
morning contentedness and the evening tryptophan period was 
higher relative to placebo for this dimension (Table 4-17-4). 
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Table 4-17-4 t test values for mean differences between 
baseline 1 7 tryptophan and placebo phases 
basel - tryp basel - plac tryp 
alertness 
morning -2.26 *+ -0.59 ns 1.81 
evening -0.28 ns -0.08 ns 0.17 
contentedness 
morning -3.01 ** 0.02 ns 2.85 














"' 1. 17 ns 
* exceeds critical value for the .05 level of significance 
** exceeds critical value for the , 01 level of significance 
+ sig. t values affected by sig, levels of autocorrelation 
indicates the first mean of the pair is the lowest 
C statistic results 























** exceeds the critical value for the ,01 level of significance 
"'due to a sig. trend in the basel phase, this calculation was based on a 
comparison series (see Chapter Ill for explanation) 
Comment on C statistic results 
As indicated in Table 4-17-4, there was a signifcant 
departure for the first tryptophan period relative to baseline. 
However, due to the presence of a significant trend in the 
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baseline 1 phase, the baseline - tryptophan comparison only 
involved the 12 tryptophan days. As indicated in figure 4-17-1, 
the first part of the tryptophan phase for alertness was 
associated with an increasing trend which was not characteristic 
for the entire phase. 
(c) Hours of sleep 
Table 4-17-6 Autocorrelation estimates: rk <k=n/4) values 
baseline1(n=10) tryptophan(n=18) 
rl r2 r1 r2 r3 r4 
-.26 -.12 .05 .18 .43** .11 
t test value results for hours of sleep 
basel - tryp 
-0.64 ns 
Comment on hours of sleep 





tryp - plac 
2.24 *+ 
As indicated from the above t test results, the mean hours 
of sleep was significantly greater for this subject during the 
tryptophan phase relative to placebo, however, the difference was 
not significant relative to baseline. The presence of signifcant 
positive levels of autocorrelation in the tryptophan period may 
have led to an underestimation of significance for the tryptophan 
- placebo difference. 
(d) Side effects 
A very low incidence of side effects was noted for this 
subject throughout the trial period. Only two headaches were 
reported during the baseline and first tryptophan periods. Thus, 
there was no indication of increasing side effect severity 
assocaited with either tryptophan phase. 






the present subject's stated motivation for 
of depression, SDS scores were not supportive of 
either at entry to the trial or at later stages of 
The main statistical finding of increased morning 
for the trypt • phan period relative to baseline and 
placebo phases was mildly corroborated following visual analysis. 
However only a few scores could be considered particularly 
elevated in this phase. 
The other statistical finding of a significant increase in 
the alertness level for the tryptophan phase relative to baseline 
was in part supported by the significant C statistic outcome 
indicating that the tryptophan ratings departed in trend from 
baseline. However, as mentioned previously, the C statistic 
application only involved the first 12 points of the tryptophan 
phase. As is evident from visual appraisal, the increasing trend 
for this section could not reasonably be generalized to the 
remainder of the phase and the change in level for the 
tryptophan phase was not maintained relative to the placebo. 
An increase in total sleep time during the tryptophan phase was 
significant relative to placebo but not to baseline. Finally 
there was no evidence for increased severity and qualitative 
changes with respect to side effects associated with either 
tryptophan period for the present subject. 
At completion of the trial the present subject claimed to 
have felt much better during the first and second periods of 
tryptophan intake but not during the placebo phase. While an 
increase in contentedness was indicated statistically (and to a 
slight extent visually), it may be that the scales employed in 
the present study were irrelevant or insenstive to the kind of 
depression the present subject claimed to experience and obtain 
relief froma 
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4.2.18 Subject 18 
(1) Demographic variables 
age(yrs): 22 height(cms):162 
weight(kgs):59.00 
(within desirable weight range) 
tryptophan experience: - not consumed prior to this project 
sex: female 
motivation for participation: - depression 
(2) Psychological variables 
(a) Depression status 
The initial SOS score as well as most subsequent totals 
exceeded 2 standard deviations above the mean according to Knight 
et al. 's (1983) norms. Five of the seven ratings obtained 
throughout the trial for this subject were within the range 
appropriate to Zung's (1972) category of moderate to severe 
depression. This information together with a motivation of 
depression for participation led to placement of this subject 
within the depressed category. 
Cb) Anxiety status 
The Trait anxiety score for the present subject (62) was 
approximately 3 standard deviations above the mean according to 
Knight et al. 's (1983) norms. The initial State score, however, 
was below the mean and most subsequent ratings were within one 
standard deviation above this mean. Although the Trait score may 
indicate a tendency towards experiencing high State anxiety in 
certain circumstances, this potential was not realized during the 
present study. This subject only exhibited significant elevation 
in anxiety on one occasion during the experiment. 
(3) Experimental variables 
(a) Dose level(gms/day): 3 
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Cb) Phase description 
baseline 1 tr-yptophan :washout: placebo baseline 2 
14days 14days 7days 7days 7days 
(c) Extra details 
Scale completion time was regular and weekly scales were 
missed at the end of the second baseline week, while only two 
morning mood r-atings were missed. No tablets were forgotten. 
(4) Results and analysis 
(a) Weekly scores 
Table 4-18-1 Total scores for Zung, State an>:iety and HSCL scales 
baseline 1 tryptophan wash placebo 
day 01 07 14 21 28 35 42 
scale 
zung 50 51 49 49 39 48 39 
state 29 35 36 41 36 54 41 
HSCL 124 107 114 113 101 115 91 
Table 4-18-2 HSCL factor scores 
baseline 1 tryptophan wash placebo 
day 01 07 14 21 28 35 42 
factor 
1 2. 15 1.98 1.73 1.72 1. 76 1.97 1.70 
2 2.36 1. 65 1.67 2.13 1.91 1.99 1.69 
..,.. 
~ 2.09 1.91 2.37 1.62 1.85 1.85 1.61 
4 1.76 1.93 2.47 2.88 1.95 2.47 1.77 
5 2.61 1.59 1.77 1.62 1. 75 2.04 1.31 
Comment on weekly scale scores 
As is apparent from Table 4-18-1, Zung total scores were 
maintained at a high level throughout the trial period. The 
limitation of single scores for the placebo phase hindered 
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comparison of this period with tryptophan and baseline phases. 
There was a slight reduction in Zung scores for the tryptophan 
phase relative to baseline. However, the reduction was also 
apparent during the placebo phase. The week of the highest State 
anxiety rating i.e. at the end of the washout phase coincided 
with reported nervousness relating to exams the following week. 
No clear patterns of changing factor scores for the HSCL scale 
could be determined between phases. 
(b) Mood factors 
Visual analysis of graphed data 
Both morning and evening graphed data for this subject 
appear in Figure 4-18. High day to day variability was apparent 
for both series, across all phases. No consistent trends or 
changes in level between or within phases could be detected by 
the author. Reporting of unusual events such as nervousness 
relating to impending exams were not marked by any obvious 
changes in graphed mood ratings. 
Autocorrelation estimates 











r1 r2 r3 
tryptophan(n=14) 
rl r2 
.24 -.03 -.06 -.003 -.14 .32 
.24 -.03 -.06 .07 -.01 -.02 
-.15 -.24 .06 -.38 -.17 .21 
.23 -.19 -.07 .07 -.01 -.02 
.14 -.19 -.15 -.32 -.10 -.06 
evening .08 .26 -.27 -.17 .18 -.26 




















FACTOR SCORES FOR THREE MOOD DIMENSIONS - MORNING DATA 
SUBJECT: 18 
______ basri.ne ... 1 ·rr 1-tr_yrophan washout Flacebo base 2 
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FACTOR SCORES FOR THREE MOOD DIMENSIONS - EVENING DATA 
SUBJECT: 18 
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t test results 
Table 4-18-4 t test values for mean differences between 
baseline 1 7 tryptophan and placebo phases 
basel - tryp basel - plac tryp 
alertness 
morning -1.33 ns -1.49 ns -0.60 
evening 0.93 ns 0.31 ns -0.45 
contentedness 
morning 0.62 ns 1.10 ns 0.59 
evening -0.06 ns 0.97 ns 0.91 
calmness 
morning 1.45 ns 1.60 ns 0.52 
evening o. 15 ns 0.02 ns -0.12 
None of the above calculations proved to be significant 








Table 4-18-5 Z values for morning. evening and combined series 
series basel bsl+tryp 
morning 
alertness 1. 10 ns 1.29 ns 
cont •.• ss -0.58 ns -1.14 ns 
calmness 0.90 ns 0.50 ns 
evening 
alertness 1. 00 ns 0.65 ns 
cont ... ss 0.97 ns 0.80 ns 
calmness 0.78 ns -0.50 ns 
None of the above calculations proved to be significant 
(c) Hours of sleep 
Table 4-18-6 Autocorrelation estimates: rk (k=n/4) values 
baseline1(n=13) 
r! r2 r-3 
-.48 .45* -.29 
tryptophan(n=12) 
r1 r2 r3 




* exceeds the critical value for the ,05 level of significance 
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t test results for hours of sleep 
basel - tryp 
"" 1. 08 ns 
Comment on hours of sleep 
basel - plac 
0.68 ns 
tryp - plac 
-0.32 ns 
No significant changes emerged for hours of sleep in terms 
of the mean difference between baseline, 
phases. 
tryptophan and placebo 
(d) Side effects 
Table 4-18-7 Autocorrelation estimates: rk Ck=n/4) values 
baselinel(n=14) tryptophan(n=14) placebo(n=7) 
rl r2 rl r2 r3 rl 
.49 .29 .21 -.18 -.11 -.12 • 27 
* exceeds the critical value for the ,05 level of significance 
t test results for side effect severity 
basel - tryp 
"' 2.58 * 
Comment on side effects 
basel - plac 
""-0.61 ns 
tryp - plac 
"'-1.39 ns 
level 
As is evident from the above results, a significantly higher 
of side effects was apparent during the baseline period 
relative to the tryptophan phase. 
4.2.18.5 Summary and Conclusions 
As is evident from the consistently high SDS scores, a state 
of depression was maintained throughout the trial period with no 
evidence of reduced scores associated with tryptophan intake. 
There was no evidence from visual or statistical analysis of mood 
scale data to support therapeutic effects associated with 
tryptophan ingestion. Tryptophan intake was not associated with 
changes in total sleep time or increased side effect severity. 
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4.2.19 Subject 19 
(1) Demographic variables 
height(cms):152 
weight(kgs):52.00 
(within desirable weight range) 
tryptophan experience: - not consumed prior to this project 
aqe(yrs): 43 sex: female 
motivation for participation: - general interest 
(2) Psychological variables 
(a) Depression status 
The initial and subsequent SDS scores for the present 
subject were all below the mean according to Knight et al. 's 
(1983) norms. On this basis and a general interest motivation 
for participation, this subject was not classed as depressed. 
(b) Anxiety status 
The Trait anxiety score (37) for the present subject was 
close to the mean according to Knight et al. 's (1983) norms and 
all State scores were below the respective mean. Consequently, 
this subject was considered to be free from significant levels of 
anxiety symptoms. 
(3) Experimental variables 
(a) Dose level(gms/day): 3 
(b) Phase description 
baseline 1 tryptophan :washoutl placebo 
14days 14days 7days 7days 
(c) Extra details 
Scale completion time was regular with missing data limited 
to three mood scale ratings. 
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(4) Results and analysis 
(a) Weekly scores 
Table 4-19-1 Total scores for Zung 7 State anxiety and HSCL scales 
baseline 1 tryptophan wash placebo 
dat 01 07 14 21 28 35 42 
scale 
zung 26 25 27 27 28 27 28 
state 25 ~-~.::,. 25 29 26 29 29 
HSCL 76 64 70 74 68 65 63 
Table 4-19-2 HSCL factor scores 
baseline 1 tryptophan wash placebo 
day 01 07 14 21 28 -c-.::.,,._J 42 
factor 
1 1.08 1.00 1.00 1.07 1.07 1.00 1.07 
2 1.34 1.34 1.36 1.34 1.34 1.34 1.24 
< ~· 1.72 1.13 1.46 1.47 1.29 1.25 L12 
4 1.26 1.09 1.37 1.45 1.09 1.09 1.09 
5 1.15 1. 00 1. 15 1. 15 1.15 1.15 1.00 
Comment on weekly scale scores 
E;-:ami nation of the weekly scale scores (Tables 4-19-1 and 
4-19-2) indicates the stabilty of low ratings across the entire 
trial with no noticeable changes between phases. HSCL factor 
scores were close to the means for a normal sample (Table 3-4). 
Cb) Mood factors 
Visual analysis of araphed data 
Graphs of morning and evening series for this subject appear 
in Figure 4-19. There was a slight increase in the level of 
evening alertness during the tryptophan phase relative to 
baseline. There was an extreme decline on morning alertness and 
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coincided with a dramatic elevation in reported side effects. 
The dips on all dimensions for the first baseline rating of the 
evening series did not relate to reports of unusual events or 
negative side 
(pat-ti cul arl y 
effects. The 
contentedness} 
evening dips on all dimensions 
on day 5 of the tryptophan phase 
coincided with reports of tiredness and headaches. 
Autocorrelation estimates 
Table 4-19-3 rk Ck=l,n/4) values for separate morn. & eve. series 
factor baseline 1(n=14) tryptophan(n=14) placebo(n=6) 
r1 r2 r-3 r1 r2 r3 r1 
alertness 
morning .30 • 11 -.10 -.07 -.07 -.03 -.53 
evening -.04 -.02 -.05 . 04 • 02 .17 -.08 
cont .•. ss 
morning -.25 .31 -.28 -.01 • 08 ()? . .... -.50 
evening -.09 .06 -.01 -.05 -. 10 .05 -.19 
calmness 
morning .10 ,..,..,.. -• _c.._ ... • 17 -.27 . 05 .27 -.52 
evening -.15 -.18 .07 ., ... • k~ -.27 -.19 -.41 
None of the above cal cul ati ons proved significant 
Table 4-19-4 t test values for mean differences between 
baseline 1 7 tryptophan and placebo phases 
base1 - tryp base1 - plac tryp 
alertness 
morning ~ 1.22 ns "' 1.81 ns 0.23 
evening -2.37 * -0.13 ns 1.48 
contentedness 
morning "' 0.36 ns "'-0. 71 ns "'-1. 06 
evenin51 -0.72 ns -0.39 ns 0.21 
calmness 
morning 0.75 ns 0.40 ns -0.26 
evening "' 0.25 ns -0.13 ns -0.43 
* exceeds critical value for the I 05 level of significance 
indicates the first mean of the pair is the lowest 









Comment on t test results 
As is evident from Table 4-19-4, the only statistically 
significant finding was for increased evening alertness during 
the tryptophan phase relative to baseline. However, this 
elevation was not maintained relative to the placebo condition. 
C statistic results 
Table 4-19-5 Z values for morning, evening and combined series 
series base1 bs1+tryp 
morning 
alertness 1. 38 ns 0.04 ns 
cont •.. ss -0.92 ns -0.88 ns 
calmness 0.71 ns -0.11 ns 
evening 
alertness 1.38 ns 2.42 ** 
cont •.• ss -0.25 ns -0.18 ns 
calmness -0.52 ns -0.20 
** exceeds the critical value for the .01 level of significance 
Comment on C statistic results 
As indicated in Table 4-19-5, a significant departure in 
trend was indicated for the evening tryptophan phase on alertness 
relative to baseline. 
(c) Hours of sleep 
Table 4-19-6 Autocorrelation estimates: rk (k=n/4) values 
baseline1Cn=14) tryptophan(n=14) placebo(n=6) 
r1 r2 r-3 r1 r2 r3 r1 
-.06 -.02 .03 -.30 .28 -.29 -.23 
None of the above estimates proved significant 
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t test results for hours of sleep 
base1 - tryp 
~-o.15 ns 
Comment on hours of sleep 
base1 - plac 
"'-0.40 ns 
tryp - plac 
"'-1. 17 ns 
No significant changes emerged for hours of sleep in terms 
of the mean difference between baseline, tryptophan and placebo 
phases. 
(d) Side effects 
Table 4-19-7 Autocorrelation estimates: rk Ck=n/4) values 
baseline1Cn=14) trvptophan(n=14) 
rl r2 r3 rl r2 r3 
-.01 -.01 -.02 • 14 -. 12 • 24 
None of the above estimates proved significant 
t test value results for side effect severity 
basel - tryp 
-2.07 * 
Comment on side effects 










indicated from the above t test results, side effect 
was higher during both tryptophan and placebo periods 
to baseline. The placebo period only consisted of six 
days. On this basis, comparison of the first six days of the 
tryptophan period with the placebo phase would have indicated a 
significantly higher level of symptoms for the tryptophan 




associated with the tryptophan phase was essentially 
to the first five days with greatest severity noted on 
day. The most obvious symptom volunteered by the 
present subject concerned 10 reports of tiredness during the 
tryptophan phase. Only two other reports of tiredness were noted 
outside the tryptophan phase, i.e. within the placebo period. 
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all 
(5) Summary and Conclusions 
As 
the 
is apparent from the foregoing analysis, low scores on 
weekly scales were maintained throughout the trial 
period, confirming 
this subject. The 
the non-depressed and non-anxious status of 
visual indication of increased alertness 
during the tryptophan phase relative to baseline in the evening 
was confirmed by statistical anaylsis on the basis of both t test 
and C statistic calculations. However, neither visual nor 
statistical analysis confirmed the tryptophan elevation to be 
significant relative to placebo ingestion. 
The main finding for the present subject was the coincidence 
between the dramatic declines on the moodscales during the 
tryptophan period 
for the evening 
(i.e. on day 1 of the morning phase and day 5 
phase particularly for the alertness and 
contentedness dimensions) and reports of negative effects such as 
headaches and tiredness. Such findings were confined to the 
first five days of tryptophan intake. The level of side effects 
was found to be higher during both the tryptophan and placebo 
phases relative to baseline. However, the most severe levels 
were clea~ly confined to the first week of tryptophan intake. 
Thus tryptophan ingestion in the present subject, at 3gms/day for 
14 days, could be most confidently associated with an increase in 
side effect severity for the first five days relative to baseline 
or placebo phases. There was a lack of evidence for consistent 
mood altering effects in relation to tryptophan intake, with 
declines on contentedness and alertness being confined to one or 
two days at the beginning of this phase. 
4.2.20 Subject 20 
(1) Demographic variables 
age(yrs): 19 sex: male height(cms):173 
weight(kgs):76.50 
(within desirable weight range) 
- not consumed prior to this project trypt• phan experience: 
motivation for participation: - general interest 
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{2) Psychological variables 
(a) Depression status 
The initial and subsequent SDS total scores for the 
subject were all below the appropriate mean according to 
et al. 's (1983) norms. On this basis and that of a 
interest motivation for participation, this subject 
classed as depressed. 





The Trait score (28) and all State anxiety scores were below 
the appropriate means according to Knight et al. ·s (1983) norms. 
Thus, the present subject was considered to be free from elevated 
levels of anxiety. 
(3) Experimental variables 
Ca) Dose level (gms/day): 3 
Cb) Phase description 
baseline i tryptophan :washout: placebo 
14days 14days ?days 7days 
(c) Extra details 
Scale completion time was regular with a relatively high 
level of missing data for daily mood ratings. The weekly ratings 
for the end of the second baseline week and the end of the first 
tryptophan week were also missed. No tablets were forgotten. 
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(4) Results and analysis 
(a) Weekly scores 
Table 4-20-1 Total scores for Zuna, State anxiety and HSCL scales 
baseline 1 
day 01 07 14 
scale 
zung "7"7 _ ... _ ... -~ ..::,.<.. 
state 25 26 
HSCL 66 62 
Table 4-20-2 HSCL factor 
baseline 1 
day 01 07 14 
factor 
1 L46 1.12 
2 1. 00 1.12 
"?" . ..) 1. 00 1. 00 
4 1. 10 1.00 
5 1.00 1.00 










1. 40 1.29 
1. 00 1.00 






























No obvious between phase differences were apparent for total 
scores on the weekly scales. Low scores were maintained 
throughout the trial period. There was a slight elevation for 
factor 3 (interpersonal sensitivity) on the HSCL scale during the 
tryptophan phase which could not be meaningfully related to 
trypt • phan intake. HSCL factor scores were close to the means 
for a normal sample (Table 3-4). 
(b) Mood factors 
Visual analysis of graphed data 
No consistent trends or changes could be detected on morning 
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FACTOR SCORES FOR THREE MOOD DIMENSIONS - EVENING DATA 
SUBJECT: 20 
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relationships between unusual events and changes in mood ratings 
were apparent. Occasional reports of alcohol consumption did not 
show any relationship to visually significant changes in the mood 
dimensions. However, alcohol consumption generally occurred 
after completion of the evening scales so that the closest 
ratings to this event were those for the morning after. 
Autocorrelation estimates 












r1 r2 r3 
-.42 -.08 .29 
-.76** • 41* -.09 
-.44 .20 --,c:-• .,:_,.J 
-.01 .14 • 11 
-.32 .18 • 07 
-. 14 -.23 .02 
tryptophan(n=13) 
rl r2 r3 
• 07 -.19 -. 14 
-.12 -.07 .19 
- r-:1~ • .a:...~ -.08 -.19 
-.10 -.27 .27 
-.24 -.21 .06 





* exceeds the critical value for the ,05 level of significance 
** exceeds the critical value for the ,01 level of significance 
t test results 
Comment on t test results 
As is indicated in Table 4-20-4, the alertness and 
contentedness dimensions were found to be significantly elevated 
in the evening during tryptophan and placebo phases relative to 
baseline. Morning contentedness during the tryptophan phase was 
significantly elevated relative to baseline. Finally, the level 
of calmness in the evening on the tryptophan phase was found to 
be significantly below placebo, but not baseline. Comparisons of 
placebo periods with baseline and tryptophan had to be omitted 
for all dimensions in the morning series owing to the high level 
of missing data during this period. In the case of the evening 
baseline-tryptophan difference, significance levels may have been 
biased due to the presence of autocorrelation in the baseline 
phase. Similarly the placebo-baseline difference for evening 
contentedness and the placebo-tryptopha~ difference for evening 
calmness could not be interpreted confidently due to the presence 
of signifcant negative autocorrelation. 
Table 4-20-4 t test values for mean differences between 
baseline 1~ tryptophan and placebo phases 
basel - tryp basel - plac 
alertness 
morning -1. 17 ns 
evening -2.43 *+ -2.30 * 
contentedness 
morning -2.94 ** 
eveninQ -3.50 ** -2.15 *+ 
calmness 
morning 0.41 ns 
evening ~ 1.24 ns -0.99 ns 
* exceeds critical value for the ,05 level of significance 
** exceeds critical value for the I 01 level of significance 
+ sig, t values affected by sig, levels of autocorrelation 
indicates the first mean of the pair is the lowest 









Table 4-20-5 Z values for morning, evening and combined series 
series basel bsl+tryp 
morning 
alertness -1.62 ns -0.57 ns 
cont •.. ss -1.21 ns 0.33 ns 
calmness -0.53 ns -0.81 ns 
evening 
alertness -2.80 ** "'-2.07 * 
cont ••• ss 0.03 ns 1.52 ns 
calmness -0.43 ns -0.56 ns 
** exceeds the critical value for the , 01 
"' due to a sig. trend in the base1 phase, 
comparison series ( see Chapter I I I for 
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level of significance 
this calculation was based on a 
explanation) 
Comment on C statistic results 
As indicated in Table 4-20-5, the tryptophan period 
demonstrated a significant departure in trend from baseline in 
the evening series only. 
(c) Hours of sleep 
Table 4-20-6 Autocorrelation estimates: rk (k=n/4) values 






rl r2 r3 
-.18 -.50* .39* 
* exceeds the critical value for the .05 level of significance 
** exceeds the critical value for the ,01 level of significance 
t test results for hours of sleep 
basel - tryp 
-0.73 ns 
Comment on hours of sleep 
As evident from the t test result, no significant difference 
could be established between the baseline and trypt• phan periods 
for hours of sleep. 
(d) Side effects 
No side effects were reported by the present subject 
throughout the trial period. 
(5) Summary and Conclusions 
As indicated in the foregoing description this subject was 
not considered to be depressed or particularly anxious on the 
basis of depression and anxiety scores relative to Knight et 
al. 's (1983) norms. 
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The relatively high level of missing data in conjunction 
with the brief placebo period limited the validity of visual and 
statistical analysis for this subject. Given these limitations, 
statistically significant findings for changes in level between 
phases were limted to a placebo elevation on alertness relative 
to baseline in the evening and a tryptophan elevation on 
contentedness relative to baseline, in the morning and evening. 
However, confident visual support could not be given to such 
statistical outcomes. The significant C statistic result, 
demonstrating a departure in trend for the tryptophan phase 
relative to baseline in the evening, was also unsupported by 
visual analysis. 
No significant difference was detected between baseline and 
tryptophan periods for hours of sleep and there were no reports 
of negative side effects for the total trial period. Thus, no 
changes for general mood, side effect experience or total sleep 
time could confidently be associated with ingestion of 3gms/day 
of tryptophan over a 14 day period in the present subject. 
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4.3 SAMPLE PROFILE AND EVALUATION 
4.3.1 Sample descritpion 
(a) Se •: 
males (N=10) females CN=10) 
(b) Age (years) 










(c) weight-height relationships 
Although no attempt was made to relate dose level with 
weight to height ratio or to body weight in the present study it 
seems probable that significant relationships may emerge between 
dose to weight ratios, tryptophan response and/or side effects. 
There is also evidence to support differences in brain serotonin 
metabolism in relation to weight level (Kaye et 





levels were recognized by the 'Royal College of Physicians of 
London' in 1983. 
weight-height category 
below recommended range 
within recommended range 




(d) Marital status Ce) Living situation 
category N category N 
single 11 alone 2 
defacto 2 sharing (excl. spouse) 10 
married 5 with spouse 6 
divorced 1 with parents 2 
separated with children 4 
widowed 1 other 
(f) Highest education level (g) Occupations 
category N category N 
primary student 13 
4th form paid empl. 9 
school cert. unempl (reg.) 4 
U.E. 5 homemaker 4 
tech. qualif. 1 retired 1 
univ. degree 14 
other 
(h) Medical or psychological conditions 
As noted previously, subjects were excluded if they 
experienced any of the medical/psychological conditions described 
on the demographic questionnaire. 
Ci) Drug consumption 
At entry to the program two subjects were regularly 
consuming prescribed doses of antidepressants and one of these 
subjects was concurrently consuming tranquilizers. Subject 02 
continued with his prescribed therapeutic medication of 50mg 
clomipramine/day and 2mg lorazepam/day throughout the trial. 
Subject 16: was taking 60mg mianserin/day and ceased intake two 
weeks prior ta the commencement of tryptophan ingestion. Finally 
there were six regular consumers i.e. daily of different vitamin 
supplements. Four subjects admitted occasional consumption of 
analgesics, five to occasional consumption of marijuana and one 
to occasional consumption of diet medication. 
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(j) Information relevant to female participants 




and three were regulary taking chemical contraceptives. 
the ten females reported suffering from premenstrual 




the 20 participants had previously consumed 
Subject 01 had taken it occasionally as a diet 
Subject 16 had taken it on a short term basis and 
low dose (3gms/day) for stress relief . 
subjects recall any noticeable effects. 
(1) Vegetat-ian 
In neither case could 
Seven of the 20 participants said they were vegetarian. 
(m) Motivation for participation 
The motivations for participation, as stated by subjects on 










The two most depressed subjects also gave anxiety or stress as 
a reason for participation. This was corroborated by both 
subjects exhibiting high Trait anxiety scores. 
Cn) Zung depression scale scores 
mean= 36.30 min= 24.00 max= 53.00 
259 
Depression status (based on Zung's (1972) categories) 
normal (not depressed) 
N 
13 
mild-moderate depression 5 
moderate to severe 2 
The above categorization was based on ratings at the point of 
entry to the program. The five individuals classed as depressed 
on Zung's C 1972) scheme also gave their motivation for 
participation as depression. In addition, three individuals 
classified as non-depressed under this scheme also gave their 
reason for participating as depression. One of these three was 
currently taking prescribed antidepressants on entry to the study 
and the other two had been taking antidepressant medication in 
the recent past. On this basis 8 out of the 20 participants were 
classified as depressed. 
(o) STAI scores 
Trait 
mean= 42.10 min= 26 max= 70 
With reference to the appropriate norms for age and sex 
(Knight et al., 
follows: 
category 
< 1 SD above the 
1-2 SDs above the 
2-3 SDs above the 
> ...,,. ._, SDs above the 





mean ...,,. ..:, 
If subjects' scores are considered with respect to 
Spielberger's (1970) norms based on depressed and anxious male 
psychiatric patients (see Table 3-3), then certain individuals 
scores could be considered more in keeping with this 
classification. That is, the eight subjects with scores exceeded 
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one SD above Knight et al. ·s (1983) means exhibit scores close 
to Spielberger's (1970) norms. 
A fairly systematic relationship between (1) depression as 
the motivation for participation, (2)elevated SDS scores, and 
{3)elevated Trait anxiety scores is apparent for the present 
sample. The relationship of the last two variables is 
substatiated by the more general finding of a high correlation 
C. 90) between SDS and Trait anxiety scores for the whole sample 
on entry to the program. Knight et al. (1983) have also reported 
a relatively high correlation of .70 for the above scales in 
their (n=1173) normal sample. 
State 
mean= 36.90 min= 25 max= 67 
Once again,, with reference to Knight et al. 's (1983) norms 
the sample can be classified as follows: 
categor}'.'. N 
·' 1 SD above the mean 13 ,,
1-2 SDs above the mean 4 
2-3 SDs above the mean 1 
3-4 SDs above the mean 1 
> 4 SDs above the mean 1 
Six of the eight subjects with Trait scores exceeding one SD 
above the mean also exhibited State scores in this range. 
However, the overall relationship between State and Trait scores 
does not appear as consistent as that for Trait and Zung scores. 
That is, a correlation of only .69 was achieved between Trait and 
State scores for the sample as a whole. This is again in keeping 
with findings by Knight et al. 
correlation between these scales. 
4.3.2 Overview of the sample 
(1983) who reported a .65 
The sample could be considered to consist of predominantly 
young, single university students equally represented by both 
seHes. Most subjects conformed to desirable weight to height 
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ratios and were apparently free from chronic medical or 
psychological conditions. 
stated vegetarians. 
Seven out of twenty participants were 
Two distinct psychological groups were considered in the 
evaluation. 
subjects. 
The first group consisted of 'non-depressed' 
Eleven of this group gave a motivation for 
participation of 'general interest' and exhibited no notable 
elevations on SOS or STAI scores (in relation to Knight et al. 's 
(1983) norms> at entry to the program. The remaining subject in 
this group reported experience of slight levels of anxiety prior 
to entry to the program, and this was supported by moderately 
elevated STAI scores. 
The second group included five subjects classified as 
depressed on the basis of Zung's (1972) classification who also 
gave 'depression' as their motivation for participation and 
exhibited elevated Trait anxiety scores. The remaining three 
subjects in this group expressed the same motivation for 
participation and were either consuming antidepressants at entry 
to the trial or had been in the recent past. 
4.3.3 Evaluation of tryptophan administration for the sample 
This section provides a broad overview of the experimental 
outcome for the sample as a whole. 
4.3.3.1 General mood altering effects 
If attention 
statis/iical and fL 
tryptophan relative 
is limited to findings supported by both 
visual analysis and to differences for 
to both placebo and baseline phases, then for 
18 of the 20 participants no significant relationships could be 
established between tryptophan ingestion and mood alteration. 
Results for the remaining two subjects were only indicative of 
slight associations. In the first case (subject 11), the finding 
was a reduced evening alertness level associated with tryptophan 
intake and in the second case (subject 17) an increase in morning 
contentedness associated with tryptophan intake. 
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If consideration is extended to cases where the placebo 
phase was absent or inadequate (too brief or missing large 
amounts of data) then a few further associations are apparent for 
tryptophan administration relative to baseline. For subjects 10 
and 15 a significant reduction in morning alertness was apparent 
for the tryptophan phase and this effect was maintained into the 
evening for subject 15. Once again the reduction was slight in 
both cases but in keeping with past reports of tryptophan's 
psychological effects. Both subjects 10 and 15 were classified 
as non-depressed. For subject B, visual and statistical analysis 
supported a significant but slight increase in evening calmness 
relative to baseline. 
Finally, when consideration was extended to effects 
associated with tryptophan intake, which were significant 
relative to baseline but not to placebo, the number of 
significant associations between tryptophan intake and mood 
alteration increased. For subject 12, a slight increase in 
morning and evening contentedness was apparent for tryptophan 
relative to baseline, while an evening reduction in tryptophan 
contentedness relative to baseline was apparent for subject 05. 
In addition, a reduction in morning alertness was associated with 
tryptophan intake in subject 14 and an increase in evening 
alertness in subject 19a 
As is apparent from the above discussion, the number of 
significant relationships between tryptophan intake and mood 
alteration increases as the criteria for change are reduced from 
significant trypt • phan-placeba differences to significant 
tryptophan-baseline differences. The most general finding was for 
reduced alertness for one or bath series in 4 subjects. These 
subjects could not be distinguished from the rest of the sample 
with respect to any relevant psychological or experimental 
variables. The only other finding ta extend beyond one subject 
was for an increase in contentedness associated with tryptophan 
intake. This slight elevation was indicated for two individuals 
both of whom were classified as depressed. 
The psychological significance of the above findings is 
uncertain in view of the slight differences involved. In no case 
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did subjects indicate noticeable awareness of the states by 
additional daily comments or following retrospective assessment 
at the trial termination. The main finding across subjects of 
reduced alertness, while limited to 4 subjects and of slight 
magnitude in all cases, could be considered in keeping with 
evidence from past studies of increased drowsiness in relation to 
tryptophan intake (Yuwiler et al., 1981; Carroll et al, 1970; 
Smith & Prockop, 1962; Charney et al., 1982; Shopsin, 1978). 
4.3.3.2 Therapeutic effects 
Consideration of antidepressant effects was limited to eight 
subjects i.e. subjects 02,03,09,11,12 who were classified as 
experiencing/exhibiting mild to moderate levels of depression, 
subjects 16 and 18 classified as suffering moderate to severe 
depression and subject 17 whose depressed status could not be 
confirmed with respect to SDS scores. In addition, attention was 
given to evidence for anxiolytic effects in six of the above 
subjects and two additional participants demonstrating elevated 
anxiety levels. That is, subject 10 was considered to be 
experiencing slight anxiety and volunteered this as a tendency on 
entering the trial. Subjects 02 and 15 were classified as 
exhibiting moderate levels of anxiety and subjects 03,09,11,12 
and 16 as demonstrating high levels of anxiety relative to Knight 
et al. 's (1983) norms. 
Slight reductions were apparent for the tryptophan period 
relative ta baseline on Zung and State scores as well as the 
depression and anxiety dimensions of the HSCL for subject 12. 
Similarly for subject 18, there was a noticable decline on the 
Zung score after the second week of tryptophan ingestion. 
However, in neither case were the changes significant relative to 
placebo periods. Reductions in weekly scale scores were not 
apparent for other subjects. 
For 6 of the 10 subjects considered in this section, i.e. 
02,03,10 7 11,15 and 18 there was insufficient statistical or 
visual evidence to support elevation on any of the mood 
dimensions. In addition, for subject 16 there was no evidence to 
support changes during the tryptophan period relative to 
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mianserin. For subject 09, a statistically significant elevation 
in the level of contentedness was apparent in the evening 
relative to baseline and placebo. However, the importance of this 
finding could not be confirmed by visual analysis. Statistical 
and visual analysis confirmed a slight increase for subject 12 in 
morning and evening contentedness relative to baseline but not 
placebo. For subject 17 a slight elevation in morning 
contentedness was indicated following visual and statistical 
analysis and this effect was significant relative to both 
baseline and placebo phases. 
Thus, slight reductions in weekly depression and anxiety 
dimensions were indicated for subject 12 and slight increases in 
contentedness for subjects 12 and 17. However, in neither case 
were such changes interpreted as representing significant 
therapeutic effects. For subject 12, SDS scores showed only 
slight reductions and did not drop below Zung's (1972) 'mild to 
moderate' depression category except on one occasion during the 
tryptophan phase. Similarly, State anxiety scores still remained 
significantly elevated relative to Knight et al. ·s (1983) norms. 
Even if such changes could be considered to represent true 
ther'll\~tic effects, then they were not in excess of placebo 
change and were only slight relative t • baseline levels. Subject 
12 was also unaware of any improvement in affective state 
associated with tryptophan intake following questioning at the 
end of the trial. While subject 17 gave a motivation for 
participation of depression and claimed to have much improved 
while taking tryptophan, total SDS scores gave no confirmation of 
this status or of a reduction in association with tryptophan 
intake. While it is possible that the increase in morning 
contentedness was reflective of a psychologically significant 
response to tryptophan ingestion, the elevation was not 
maintained into the evening. 
4.3.3.3 Effects on total sleep time 
There was no significant difference in mean hours of sleep 
between tryptophan and baseline or placebo periods for 18 
subjects. In the remaining two cases change for the tryptophan 
phase was significant relative to baseline but not placebo 
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periods. For subject 2, the mean hours of sleep during the 
tryptophan phase was significantly below baseline, while for 
subject 15 the mean was significantly above baseline. In both 
cases the obtained differences were statistically small. For two 
subjects (10 and 16) comparisons with the tryptophan phase were 
not possible due to missing ratings or phases. For subject 16, 
application of the C statistic to the tryptophan phase indicated 
no trends in total sleep time over the 21 day period. 
There is some uncertainty as to the consistency within and 
across subjects for total sleep estimation. That is, it is not 
clear whether estimates were tied to the time of retiring or the 
conjectured time of sleep onset. Whatever the case, there was no 
emergence of general effects across subjects for total hours of 
sleep in relation to tryptophan intake. 
4.3.3.4 Side effects 
As is evident from the conclusions for individual subjects, 
associations between negative side effects and tryptophan intake 
were frequent and often represented the most dramatic and 
consistent of all relationships. 
No quantitative or qualitative effects were apparent for 11 
out of 20 subjects. For three subjects CO2, 11 and 12) clear 
increases in side effect severity during the tryptophan phases 
were evident relative to baseline and placebo periods. In 
addition, significant marked elevations in severity were apparent 
for subjects 03 and 19, relative to baseline only. For subject 
19 the placebo phase only consisted of 6 days. If this phase had 
been compared with the first six days of the tryptophan period, 
then severity for the tryptophan phase would have been 
significantly elevated relative to placebo. That is, most of the 
increase in side effects during the tryptophan phase (for subject 
19) was confined to the first 5 days. 




the placebo phase also showed significant 
to baseline. Dramatic elevations in side 
placebo administration have been reported 
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previously (Green, 1964). Four of the above 
exhibiting tryptophan elevations in side effect 
five subjects, 
severity, were 
classified as depressed. As in the case of significant mood 
changes associated with placebo intake, elevation in side effects 
may have been contributed to by phase order. That is, experience 
of side effects during tryptophan intake may have carried over in 
the form of expectancies to the placebo phase. In this case, one 
would expect qualitative similarities between tryptophan and 
placebo periods. In fact Green (1964) noted that placebo side 
effects in experiments where placebo served as the control for 
the active drug were almost invariably similar to those 
experienced with the active drug itself. While this was true to 
some extent in the present study there were also large increases 





tryptophan and placebo 
the selective focus on 
considered relevant to tryptophan intake. 
symptoms seems 
a few symptoms 
Nine subjects exhibited noticeable elevations in symptoms 
that were unique to the tryptophan phase, the most common symptom 
being 'increased appetite· for four subjects. Other reports were 
of increased constipation in two subjects, and abdominal cramps 
during the first week for another two individuals. Subject one 
experienced virtually no symptoms until day 14 of the tryptophan 
phase, when she reported dramatic effects in keeping with the 
'niacin reaction' (described in Chapter II). The niacin reaction 
may also be relevant to subject 02 where reports of hot flushes 
were frequent during the tryptophan phase but not during other 
periods. Finally, further dramatic increases for single subjects 
during the tryptophan phase were associated with symptoms such as 
headaches, extreme tiredness and dry mouth. 
Four of the five subjects experiencing notable increases in 
symptom severity were classified as depressed. Experience of 
side effects could not be consistently related to dose level. 
While four of the subjects experiencing significant side effect 
increases were on the maximun dose of 6gms/day, a further three 
subjects on this do~e and two on the next highest level of 
4gms/day experienced no noticeable increases. 
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4.4 EXPERIMENTAL DISCUSSION 
This section is concerned with a discussion of factors 
relevant to the present experiment which may act to limit the 
validity and generality of the foregoing results. 
4.4.1 Psychological status of the participants 
On the basis that 12 of the 20 participants were not 
depressed it could be speculated that most subjects were primed 
more towards the expectation of negative side effects rather than 
positive therapeutic benefits. Some empirical support for such a 
speculation comes from a study by Green (1964) where the 
incidence of reported side effects was significantly greater 
following placebo for well subjects than for psychiatric 
(including depressed) patients. 
The classification of depressed subjects in the present 
study remains somewhat dubious. That is, at most, the criteria 
for a classification of 'depression' depended on a motivation of 
such for participation, demonstration of SDS total scores within 
Zung's (1972) 'moderate - severe' category and finally, 
information relating to recent consumption of prescribed 
antidepressant or hypnotic medication. Similarly, judgements 
that subjects exhibited relatively high levels of anxiety were 
simply based on Trait and State scores considered to be 
exceptionally elevated relative to Knight et al. ·s (1983) norms 
and information relating to recent consumption of anxiolytic 
medication. Such criteria clearly fall short of those required 
for a formal diagnosis of depression or anxiety based on systems 
such as the DSM III and are essentially limited ta estimates of 
the severity of depression with no qualitative evaluation. Thus, 
results may not be generalizable to depressed and anxious 
individuals classified by alternative criteria. 
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4.4.2 Other subject variables 
(a)~ 
As indicated in the sample description, the majority of 
participants were young, i.e. within the 19-24 age group. While 
there were no clear relationships between age and outcome in the 
present study, there is evidence of plasma tryptophan 
concentration being age related CBanki & Molnar, 1981 (a) & Cb)). 
If it is assumed that this parameter bears relvance to central 
utilization of tryptophan loads then the present results should 
not be freely generalized to older age groups. 
Cb) Contraception and premenstrual tension 
Two of the three subects consuming chemical contraceptives 
were classified as depressed. Neither of these subjects 
exhibited significant antidepressant responses. It has been 
claimed that depressive syndromes induced by oral contraceptives 
relate to a disruption of tryptophan metabolism which reduces 
brain serotonin concentration (Malek-Ahmadi & Behrmann, 1976; 
Leeton, 1974). It was not clear whether these subjects' 
depressions related to contraceptive intake. However, it could 
be speculated that the lack of therapeutic response in these 
cases related to contraceptive induced disorders of tryptophan 
metabolism. 
No clear relationships were apparent between sex and 
psychological status of subjects or general mood altering 
effects. Three of the female subjects expressing significant 
elevations in side effects during tryptophan ingestion also 
admitted to suffering from premenstrual tension. In each case 
there was some overlap between the tryptophan period and a two 
week premenstrual phase. Where it was possible to compare the 
premenstrual phase coinciding with tryptophan intake with another 
phase, it was evident that the premenstrual period could not 
account for the total rise in tryptophan related side effects. 
Still, it is possible that premenstrual symptoms confounded the 
tryptophan side effect elevation far these subjects. 
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Cc) Weight to height relationships 
Subject 01 
and subjects 07, 
was considered to be below the desirable range 
In 10 and 15 above this range (Bray, 1978). 
the case of subject 01, the dramatic experience of a potential 
'niacin reaction' during tryptophan intake may have been 
attributable to a low height to weight level in combination with 
a high 6gms/day dose. In the subjects above the desirable weight 
to height range it could be argued that the lack of general mood 
altering effects was attributable to inadequate dosage relative 
to body weight i.e. 2gms/day for one and 3gms/day for the other 
two. Certainly, these three subjects did not exhibit any 
noticable elevation in side effects in relation to tryptophan 
intake. 
(d) Vegetarianism 
The seven vegetarians could not be distinguished from the 
rest of the sample with respect to mood change, therapeutic 
efficacy or side effect expression. However, on the basis of 
tryptophan - diet relationships considered in Chapter III, dose 
level requirements may be expected to differ between omnivores 
and vegetarians. 
4.4.3 Experimental variables 
Experimental conditions exhibiting most variation between 
subjects were dose level and the phase length for tryptophan 
administration. 
(a) Dose level 
Dose level varied between 2 and 6gms/day across subjects. 
This variable could not be related to differences in general mood 
change, therapeutic effects or side effects. 
.While specific dose recommendations have been made 
optimal therapeutic levels (Chouinard et al., 1978), 








recommended 6gms/day {n=3) may have related to a dosage 
inappropriate to body weight. In the remaining five 'depressed' 
subjects receiving 3gms/day, such a dose would be regarded as 
inadequate, by Chouinard et al. 's (1978) standards, to effect a 
significant antidepressant response. However, significant 
antidepressant effects have been documented for doses of 3gms/day 
(Kline & Shah, 1974). While Walinder et al. (1976) demonstrated 
150mg/day clomipramine + 3gms/day tryptophan to be significantly 
more effective than clomipramine alone, it is possible in the 
case of subject 02 that the concomitant intake of 50mg/day of 
clomipramine made consumption of 6gms/day tryptophan 
therapeutically excessive. 
Since it was not possible in the present study to investigate 
tryptophan dose variation within subjects, it must be considered 
that inappropriate levels in some individuals may have 
contributed to a lack of mood altering or therapeutic effects or 
to an elevation of side effects. If optimal therapeutic doses 
are in fact confirmed to be in the order of 6gms/day, the 
declination by the majority of subjects in the present study to 
consume this quantity (i.e. 12x0.5 mg tablets) may indicate a 
practical drawback to the therapeutic or general research value 
of tryptophan. 
Cb) Tryptophan phase lenqth 
Five of the eight depressed subjects were considered to have 
completed trial lengths of sufficient duration for the detection 
Although of antidepressant effects (i.e: greater than 21 days). 
significant antidepressant effects have been detected as soon as 
seven days following therapeutic administration of tryptophan 
(Moller et al., 1980), it must be considered that tryptophan 
periods of 11 and 14 days for the remaining three 
have been inadequate. 
antidepressant drugs 
Therapeutic effects for 
(tricyclics and MADI's) are 




The required trial period for a valid analysis of general 
mood altering effects in non depressed subjects is uncertain. 
Although some significant psychological effects have been 
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detected as soon as 2 hours after a single tryptophan load in 
normal subjects (Yuwiler et al., 1981; Greenwood et al., 1974; 
1975; Smith & Prockop, 1962; Charney et al., 1982) such reactions 
have typically been in the class of negative side effects, e.g. 
drowsiness, lethargy and nausea. Only one non depressed subject 
completed a tryptophan phase of greater than 14 days, thus it 
must be considered that phase lengths for the remaining 11 
participants may have been inadequate for the detection of 
general mood altering effects. 
(c) Tryptophan administration procedures 
The consumption of tryptophan as a single dose after 
completion of the evening mood scale (by all subjects), meant 
that the psychological ratings closest to tryptophan consumption 
'/ occurred aprjoximately 8 hours after ingestion. As stated in 
Chapter II, studies investigating the effects of acute tryptophan 
administration on plasma levels and psychological state indicated 
that free plasma concentrations were returning to baseline levels 
after about 6 hours. The same pattern was still apparent after 
7-9 days administration (Yuwiler et al., 1981). While 
significant mood altering effects have been demonstrated 
following single daily dose schedules (Jensen et al., 1975; 
Lindberg et al., 1979) the majority of studies indicating 
positive mood altering effects, e.g. antidepressant properties 
have involved administration of two or three divided daily doses 
(Chouinard et al, 1979; Herrington et al., 1976; Rao & 
Broadhurst, 1976; Thomson et al., 1982). 
Although, from a physiological veiw point it may have been 
more desirable to have employed an administration regime of two 
or three divided daily doses, there remain various practical and 
psychological reasons, discussed in Chapter III, for adhering to 
the single nightly schedule following evening mood ratings. 
Thus, it is possible that if psychological ratings had occurred 
closer in time to tryptophan ingestion or if tryptophan intake 
had been divided throughout the day, that the pattern of results 
would have been signifcantly altered. 
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(d) Sensitivity and 
1l 
/. t appror,-1a eness 
/'' 
of psychological scales 
The requirement for self rating scales which could both be 
applied to a heterogeneous psychological sample and bear 
relevance to the psychology of tryptophan administration may have 
compromized sensitivity of measurements for some subjects. As 
already mentioned, in the case of subject 17, the Zung total and 
the VAMS factor scores may have been insensitive or inappropriate 
to the kind of depression this subject claimed to have 
experienced and obtained relief from, following tryptophan 
consumption. Although there were no other dramatic discrepancies 
between empirical findings and subjective comments, it is still 
possible that certain scales may have been inadequate in the 
detection of effects relevant to the experimental 
some participants. 
inquiry for 
While single VAMS dimensions have demonstrated significant 
sensitivity to tryptophan effects in normal subjects (Greenwood 
et al. , 1974; 1975), it is possible that the condensation of 
dimensions to the three factor structures determined by Bond & 
Lader 0974) were inappropriate to detection of tryptophan 
effects in certain participants. As discussed in Chapter III, 
the alternative of determining factor structures relevant to 
depressed and non depressed groups in the present sample was not 
justifiable. 
·contendedness· 
Thus, Bond & Lader's (1974) factors of ·alertness' 
and 'calmness· may have have been inappropriate 
to detection of tryptophan effects in the present sample. Also, 
while the above dimensions showed sensitivity in several subjects 
to effects expected to alter mood, e.g. flu and tiredness they 
may have been inadequate to detect more subtle psychological 
changes associated with tryptophan intake. 
Given that past demonstrations of the VAMS sensitivity were 
limited to normal subjects, these scales may have been less 
t-elevant 
E•:amination 
to depressed individuals in the 





individuals did not, however, indicate limitation of ratings to 
the extreme ends of scales in any case. That is, as with the non 
depressed subjects, ratings for depressed individuals covered a 
reasonable range of the dimension and rarely hit the end points. 
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Although, SDS total scores have gained a reputation as 
reliable quantifiers of depressive states, this does not 
preclude the possibility that the index may have been inadequate 
to detect and monitor of the type of depression changes subject 
17 claimed to experience. Also, the use of total scores for the 
Zung and STAI scales may have reduced the sensitivity of these 
scales in the present sample relative to item/factor scores. 
Reliance on self rating procedures, in the present study, 
mode of may have contributed to distortions peculiar to this 
evaluation. For example, Hersen & Barlow (1976) cite evidence 
from the behavioural literature to suggest that self evaluation 
may be a reactive process, that is, by virtue of only monitoring 
and recording certain behaviours, the rates of such behaviours 
will change despite the absence of therapeutic intervention. In 
fact, some authors e.g. Johnson & White (1971), have proposed 
employing self monitoring as a deliberate manipulation for 
behaviour change. The specific effect of this kind of process on 
experimental outcome is uncertain. However, it is possible that 
·other· rater' procedures might have altered the experimental 
outcome. 
Another confounding factor which may be exaggerated under 
self assessment conditions relates to the phenomena of 'demand 
characteristics·. That is, the tendency for response to be in 
favour of the experimental hypotheses when the subject is aware 
of their existence. Although subjects were not informed of the 
specific focus of the psychological states under study, 
familiarity with the scales may have oriented subjects 
towards relevant dimensions. While placebo periods 
attention 
might be 
expected to control for such influences it is also possible that 
subject awareness of the objects of inquiry may have 




Another uncertainty with respect to self assessment 
procedures concerns the consistency of subjects in their ability 
to evaluate and rate psychological states as these processes 
change across time. Here the question arises as to whether the 
subject can perform the process of self assessment in as reliable 
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and meaningful a way while experiencing disturbed states, as at 
times of adaptive/normal functioning. As discussed in Chapter 
II, concern is frequently voiced over the reliability and 
validity of self assessment procedures in severely depressed 
individuals. However, on the basis of depression measures in the 
present study, most depressed subjects were only considered to 
exhibit moderate levels of depresssion. 
(e) Other experimental variables 
The potential bias resulting from the tryptophan - placebo 
phase order for 19 out of 20 subjects must be considered as a 
limitation to the generality of findings, given demonstrations 
that variables such as phase order may significantly and 
predictably alter experimental outcome (Wittenborn, 1978; Koch et 
al, 1983). 
The absence of adequate placebo and baseline phases for 
comparison was a clear limitation to valid interpretation of 
outcome in certain individuals. However, most importance was 
attached to outcomes which could be supported by both statistical 
and visual analysis and were significant in relation to both 
baseline and placebo conditions. 
Given the relative absence of therapeutic or general mood 
altering effects within subjects, factors such as spontaneous 
remission coinciding with changing conditions need not be 
considered in the present experiment. Other potential threats to 
longitudinal designs, such as waning enthusiasm and changing 
commitment to experimental tasks over time were not indicated in 
the present study. That is, no obvious effects such as lack of 
scale completion or failure to consume tablets were noted to 
increase with time. However, less easily detectable effects such 
as attention to accurate scale completion may have changed over 
the trial perioda 
It is conceivable that a seven day washout phase between 
tryptophan and placebo periods was pharmacologically inadequate 
for some individuals. Consequently, it is possible that carry 
over effects with a physiological basis in addition to those in 
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the form of expectancies (discussed in section 5.1) from 
tryptophan to placebo phases may have led to a conservative bias 
in the interpretation of phase differences. 
As indicated in Chapter III, it was hoped that informing 
subjects that they could receive placebo or tryptophan an any 
night of both phases would reduce expectancies relating ta phases 
differences. Exposure to both conditions within subjects is more 
likely ta reinforce perceptions of differences between conditions 
than in group designs where each individual is typically exposed 
to only one treatment. However, no subject indicated awareness of 
receiving only one substance per phase at trial completion. 
The interactive importance of the above variables as 
potential contributors to the the generality and validity of 
experimental outcome may well be greater than that indicated by 
each factor alone. However, given the known diversity between 
subjects in terms of psychological and experimental variables it 
was not considered justifiable to perform any multivariate 
statistical procedures an data across subjects. 
such a procedure would have been contrary to the 












from the present investigation indicated a lack of 
consistent relationships between tryptophan 
and psychological state within or across normal 
and depressed individuals. 
The most consistent changes on VAMS dimensions, associated 
with tryptophan ingestion, were for reduced alertness in four 
subjects and increased contentedness in another two depressed 
individuals. However, only in two of the above cases were 
findings maintained relative to both baseline and placebo phases. 
Two of the findings were not significant relative to placebo, and 
the remaining two had missing or inadequate placebo phases for 
the purposes of valid comparison. Changes in all cases were 
statistically and visually slight and did not warrant comment by 
subjects at any point throughout the.trial. 
There was a lack of empirical evidence to indicate 
significant therapeutic effects (i.e. antidepressant • r 
antianxiety> on the basis of Zung, State Anxiety, HSCL scores and 
the daily mood factors for most of the 10 subjects (8 depressed, 
2 anxious) considered. Small reductions on weekly measures of 
depression and anxiety and increases in daily contentedness for 
one depressed subject (12) were significant only relative to 
baseline periods. Thus, if such trends were indicative of 
therapeutic change they were not maintained relative to placebo. 
The most dramatic feature within and the most consistent 
pattern across subjects during tryptophan intake was limited to 
an increase in the severity and quality • f side effects for nine 
subjects. There was reasonable variability in the type of symptom 
elevations between subjects, although increased appetite was 
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frequently and exclusively reported during the tryptophan period 
by four individuals. Tryptophan intake was not associated with 
any dramatic change in total hours of sleep for any subjects. 
While this parameter has shown significant effects in the past 
(Hartmann, 1976), it appears sleep latency is probably a more 
pertinent sleep index in relation to tryptophan intake. This 
point is further elaborated in the final part of this chapter. 
It is possible that the requirement for statistical and 
visual criteria of change to be met before results were 
considered seriously, may have led to a conservative bias in the 
evaluation of outcome. However, the threat from type II errors 
is unlikely to be great, given the slight magnitude of effects 
demonstrated in all cases. 
The generality and validity of the above outcome pattern 
was limited by the various design and methodological features 
discussed in Chapter IV. While comparison of experimental 
conditions within subjects was considered more valid than 
comparisons between subjects, the assumption that subjects were 
acting as their own controls in the former case may be in error. 
That is, as Grice (1966) aptly states,: 11 a subject who has 
served as his own control may not be the same subject that he 
would have been if he had not". 
A common pattern of results to emerge within individuals was 
for placebo changes which were qualitatively and quantitatively 
similar to those demonstrated in the preceeding tryptophan phase. 
This outcome pattern was noted for both mood factor changes and 
side effect experience. Koch et al. 's (1983) demonstration that 
drug-placebo differences may be significantly affected by phase 
order suggests limitations on the validity of the present 
experiment due to the placebo - tryptophan order for 19/20 
subjects. It is possible that psychological experience during 
the tryptophan period, combined with expectation of receiving 
tryptophan in both tablet phases, may have carried over in the 
form of expectancies to the placebo period - thus exaggerating 
phase similarities. Similarly the washout period may have been 
insufficient to avoid a pharmacological carry over of tryptophan 
effects to the placebo phase. While the effects of phase order 
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demand further investigation, the ignorance of tryptophan 
placebo differences did not lead to any dramatic increase in the 
number or magnitude of significant .relationships between 
tryptophan and baseline phases in the present experiment. 
While significant levels of autocorrelation occurred 
frequently in the present data, reliance on the validity of 
statistical and visual analysis was generally limited to series 
free of this effect. The cautions employed in this respect 
undoubtedly contributed to a conservative interpretation of 
results. 
A range of possibilities for the lack of therapeutic effects 
in the present investigation was put forward in the previous 
chapter. Such factors as the type or severity of depression, 
inappropriate dose levels, inadequate trial lengths, phase order, 
diet, insensitivity of scales or bias attributable to self rating 
procedures may all have contributed to the lack of response. A 
further potential contribution to the lack of therapeutic effect 
concerns the biochemical status of individuals classified as 
depressed. As mentioned in Chapter II, indices such as free 
plasma tryptophan concentration and the trp/5aa ratio are 
emerging as more powerful predictors than most psychological 
variables of therapeutic response to tryptophan administration 
(Moller et al., 1980). Knowledge of such parameters in the 
present investigation could have reduced the uncertainty 
associated with the cause of outcome in depressed subjects. 
Despite the above limitations on the validity and generality 
of results, it seems fair to conclude that tryptophan is unlikely 
to possess dramatic and consistent mood altering effects across 
normal or depressed individuals. As discussed in the next 
sections, 
potential 
adequate investigation of tryptophan's 
is considered to demand inclusion of 
psychological 
physiological 
parameters (e.g. trp/5aa ratio) as independent variables. 
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5.2 THERAPEUTIC AND GENERAL MOOD ALTERING EFFECTS 
The high level of conflict associated with purely 
psychological studies (discussed in the first part of Chapter II) 
was considered to reduce the importance of this information in 
the evaluation of relationships between tryptophan ingestion and 
psychological state. It was proposed that one source of 
controversy may be attributable to design and methodological 
differences between studies. 
respect are also considered 
psychological investigations. 
Various inadequacies in 
to reduce the validity of 
this 
many 
Thus, the outcome from purely psychological studies was 
considered limited to indications of tryptophan's potential 
antidepressant value. While significant antidepressant effects 
have been repeatedly indicated, the level of efficacy relative 
to placebo, standard tricyclics or ECT remains controversial. In 
the context of potentiating effects, evidence is more 
consistently positive, indicating that tryptophan may possess 
significant therapeutic value in combination with the MAOI's. 
This indication also has reasonable theoretical support based on 
the presumed pharmacological actions of tryptophan and MAOI's 
described in Chapter II. Tryptophan's potentiating influence in 
conjunction with the tricyclics and ECT appears less promising on 
the basis of available evidence reviewed. 
The limitation of significant psychological 
normal subjects, to principally negative states e.g. 
effects, in 
drowsiness 
and nausea (Charney et al., 1982; Greenwood et al., 1974; 1975; 
Smith & Prockop, 1962; Yuwiler et al., 1981), may be a 
consequence of focus of these inquiries on short term effects 
following acute tryptophan administration. 
Methodological differences such as the psychological status 
of participants, dose level and duration of administration, 
between psychological studies were considered to inhibit valid 
comparison. The deviation of many studies from optimal dose 
levels and administration times (Chouinard et al., 1978) or the 
failure to investigate these parameters as independent variables 
was considered to restrict the validity of outcome far many 
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psychological trials. 
Thus, purely psychological studies are not considered to 














classifications (Murphy et al., 1974; Farkas et al. , 1976) 
indicates that tryptophan is unlikely to have a dramatic and 
uniform action across all psychological categories of depression. 
Given the emergence of relationships between psychological 
state and biochemical indices of tryptophan metabolism, described 
in Chapter II, it became apparent that individual differences in 
such parameters may have contributed to the conflict and 
invalidity of outcome both between and within psychological 
studies. 
Psychophysiological and psychopharmacological investigations 
of tryptophan were also considered to suffer methodological 
'/ inadequacies similar to purely ~e( psychological studies. Such 
factors have been raised and discussed in the last section of 
Chapter II. As with psychological investigations, the main 
criticism concerned the focus on between group differences, thus 
overlooking identification and analysis of individual responders. 
Despite such limitations, reasonable evidence has emerged to 
support the value of free plasma tryptophan concentration and the 
trp/5aa ratio as meaningful correlates of antidepressant response 
in some cases, as well as providing a biochemical basis for 
discriminating between normal and depressed individiuals. 












information may lead ta a significant reduction in 
the uncertainty surrounding tryptophan's therapeutic value. 
Moller et al. (1980) demonstrated 80% remission after 14 days of 
tryptophan therapy in depressed patients selected for low 
tryp/5aa ratios. If the entire sample (which was heterogeneous 
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with respect to this parameter) had been considered then 
remission would only have been of the order of 28%. In the same 
study, a significantly high proportion of the bipolar depressives 
exhibited tryp/5aa ratios below the 15th percentile while no such 
pattern was apparent within unipolar depressives. Thus, the 
significantly superior therapeutic response demonstrated for 
bipolars versus unipolars (Murphy et al, 1974; Farkas et al., 
1976; Moller et al., 1980) may relate ta a higher representation 
of individuals with lower than normal tryp/5aa ratios. 
Moller et al. 's (1980) investigation indicates the 
necessity of considering peripheral physiological indicators of 
tryptophan metabolism in order to accomplish a valid evaluation 
of its therapeutic potential. The possibility for a significant 
response in depressives with low free plasma concentrations, 
indicated in Chapter II, has not been so consistently endorsed. 
It seems probable that the tryp/5aa ratio may override the 
significance of free plasma tryptophan levels. That is, while 
free plasma concentrations appear to provide an index of brain 
tryptophan availability, it seems the amount of tryptophan that 
actually enters the brain will be finally dependent on the amount 
that can be carried. The trp/5aa ratio would seem to represent a 
closer indicator of this latter requirement. 
Thus, it seems likely that investigation of the biochemical 
mechanisms proposed to intervene between tryptophan 
administration and altered psychological state (Figure 2-2), will 
significantly contribute to a valid evaluation of tryptophan's 
therapeutic potential. 
5.3 TRYPTOPHAN'S POTENTIAL FDR INVESTIGATION OF SEROTONERGIC 
FUNCTION 
Another potential area for tryptophan's utility concerns 
its value in determination of serotonin function. Understanding 
of tryptophan's psychopharmacological activity may also lead to a 
more informed evaluation of its mood altering potential and to 
possible refinements of its application in this context. 
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As indicated in Chapter II, past attempts at elucidating 
serotonin's psychobiochemical functions have involved 
investigation of the psychology and pharmacology of drugs assumed 
to alter serotonergic activity. On theoretical grounds, it is 
reasonable to assume that tryptophan may have some advantages 
over drugs such as LSD or reserpine which appear to 
si gni f i cantl y alter other neurotransmitter substances ,9~f-- as 
well as serotonin. Serotonin synthesis arising from tryptophan 
application should be selectively located within 5HT neurons due 
to the restriction of tryptophan hydroxylase to 
neurons within the raph,te system (Aghajanian ~< Wang, 
serotonergic 
1978). The 
use of tryptophan in this respect in humans is limited by 
uncertainty over whether application will result in sufficient 
elevation of brain tryptophan concentration. In addition, 
reliance on CSF 5HT-metabolite concentration as an indication of 
functional brain serotonin turnover may be in error as suggested 
by Grahame-Smith (1973) in Chapter II. 
While it has been frequently assumed that the synthesis of 
brain serotonin is the most psychologically relevant effect of 
tryptophan administration, there is a need to further establish 
the psychoi • gical significance of other effects such as increased 
brain tryptamine, melatonin and nicotinic acid. 
5.4 RECOMMENDATIONS FOR FUTURE RESEARCH 
Conclusions relating to the present experiment and past 
investigations have been formulated with stated reservations 
regarding the adequacy of methods and relevance of the subjects 
studied. For this reason it is considered necessary to propose 
alternative research strategies which may avoid the criticism 




conflict emd~ating from purely psychological ,,., 
that tryptophan administration is unlikely to 




psychological groups or general antidepressant activity across 
psychologically and biochemically heterogenous groups of 
depressives. Progression from a review of purely psychological 
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studies to evaluation of trials including biochemical indices 
(e.g. free plasma tryptophan concentration and trp/5aa ratio) as 
a means of differentiating response indicated a positive but 
selective relevance for therapeutic tryptophan administration. 
Given that most therapeutic investigations, thus far, have failed 
to include biochemical information, the majority of past research 
is considered inadequate as a background for determination of 
tryptophan's antidepressant value. In addition, much past 
research was considered to be dependent on inappropriate design 
and methodological criteria. Consequently, it is considered that 
future research should be focused at methodological refinements 
for investigating the selective relevance of tryptophan's mood 
altering effects. 
One of the most basic methodological requirements for valid 
evaluation of tryptophan's mood altering potential is seen as the 
need for within subject experimental and analysis procedures. 
There is a requirement for more specific psychological and 
biochemical identification of subjects in relation to outcome. 
Already, there is some evidence to support response difference 
between groups classified according to the polarity of depression 
(Farkas et al., 1976; Murphy et al., 1974; Moller et al., 1980). 
While significant relationships between severity of depression 
and therapeutic outcome have not yet been demonstrated, it was 
suggested in discussion of psychological studies that this 
variable may effect reaction to non specific e.g. environmental 
factors (Carroll, 1970), frequency of spontaneous remission or 
magnitude of the placebo effect (d'Elia et al., 1978). Thus, 
there is a need for further investigation of these relationships. 
Moller et al. 's (1980) investigation has revealed more 
consistent promise for tryptophan's therapeutic efficacy in 
biochemically selected depressives. This finding concords with a 
proposed view of depression as "a biochemically heterogeneous 
group of disorders each requiring different treatment procedures 
to achieve maximal therapeutic effects" (Cotman & McGaugh, 1980). 
While there is evidence to suggest a significantly reduced 
turnover of CNS serotonin in some depressions (Coppen, et al. 
1972; 
1981; 
Asberg & Traskman, 1981; Bridges et al., 1976; Garelis, 
van Praag & Korf, 1970; Coppen, 1969; Aghajanian & Wang, 
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1978), CSF metabolites of serotonin do not offer a practical 
biochemical index for monitoring or screening in antidepressant 
trials. However, the peripheral plasma indicators - particulalry 
the trp/5aa ratio - have been demonstrated to correlate 
positively with CSF 5HIAA (Perez-Cruet et al .• , 1974) and appear 
to be predictive of therapeutic outcome (Moller et al., 1980). 
Such indices, in contrast to CSF, metabolites represent acessible 
and routine parameters for sampling and analysis. Relationships 
between such biochemical indicators and psychological state need 
to considered with respect to extraneous variables such as diet 
composition, spacing of meals, time of day, season, age, weight 
to height relationships and sex which have all been shown to 
demonstrate significant associations with plasma tryptophan 
levels. Thus, further investigation is required to establish the 
value of the plasma tryptophan parameters as predictors of 
therapeutic outcome. 
As is evident from the discussion of design for the present 
experiment, within subject approaches to pharmacological 
investigation tend to be more extravagent with time and clearly 
place greater demands on individual subjects. The need for all 
subjects ~o pass through all conditions also demands employing 
precautions such as washout periods between active drug and 
placebo phases and gaining awareness of the potential bias from 
factors such as phase order (Koch et al., 1983). 
Although across subject recommendations regarding optimal 
f' ther.f~jf'tAc dose levels for tryptophan have been forwarded 
(Chouinard et al., 1978), reports of therapeutic efficacy have 
been claimed for doses well outside the recommended 6gms/day 
(Coppen et al., 1972). In addition, there seem to be logical 
reasons, e.g. differences in body weight and evidence indicating 
at least 15 fold differences in tricyclic dose requirements 
(Duquesne & Reeves, 
nutrient requirements 
1982) or thousand fold differences in 
(Hoffer, 1974), to expect significant 
individual 
Finally, 
variation in therapeutic tryptophan requirements. 
Scoggins et al. 's (1976) estimations that 83i. of 
interindividual variability in the plasma level of tricyclics 
could be attributed to individual metabolic differences, suggests 
the need for further investigations of dose level as an 
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independent variable within subjects. Further empirical 
investigation is also required to establish theoretical proposals 
that the psychopharmacological action of tryptophan will be 
enhanced by concomitant administration of tryptophan pyrrolase 
inhibitors and pyridoxine supplements. 
Several theoretical and practical factors collaborate to 
suggest that administration in the form of a single nightly dose 
may be optimal. Given evidence for positive correlations between 
free plasma tryptophan levels and brain serotonin turnover 
CCurzon, 1981; Knott & Curzon, 1972; Young et al., 1976), 
Tagliamonte et al. 's (1974) report of free plasma tryptophan 
levels being 45% higher at midnight than at than at midday, 
suggest that the central process of tryptophan conversion to 
serotonin may be most active at night. Evidence from rat studies 
has also shown brain serotonin levels to peak at times of rest 
and to drop to their lowest during waking states (Luce, 1973). 
Other sources of evidence have indicated that the major catabolic 
pathway for tryptophan (kynurenine-anthranilate pathway) is least 
active at night (Curzon, 1969). Consequently, if the mechanism of 
action proposed (Figure 2-2) in this thesis is relevant it would 
seem that the psychological response to tryptophan administration 
should be improved with nightly administration due to increased 
activity of the serotonin pathway and reduced activity of the 
kynurenine pathway. Finally, the long biological half life of 15 
hours reported for tryptophan (Ritschel, 1970) suggests that 
elevated plasma levels may be adequately maintained by a single 
nightly dose. 
Other practical advantages of a single nightly dose include 
increased convenience for subjects having to remember only one 
ingestion time and the possibility of turning a frequently 
reported side effect of drowsiness shortly after ingestion 
(Yuwiler et al., 1981; Greenwood et al., 1974; 1975; Charney et 
al., 1982), to advantage (i.e. aiding sleep onset). Further 
investigation of the comparative efficacy of single versus two or 
three daily dose regimes within individuals is required. 
The above recommendations for future reasearch into 
tryptophan·s therapeutic potential are based on assumptions that 
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some depressive disorders may be associated with diminished 
serotonin turnover which may consequently be remedied through 
tryptophan loading. The relevance of such a procedure is 
logically limited to depressed individuals in the above category 
who do not exhibit abnormalities with respect to plasma-brain 
transport of tryptophan or other factors such as the enzymes 
required for serotonin synthesis. Similarly, such procedures 
would not be of relevance in depressions associated with abnormal 
elevations of tryptophan pyrrolase activitya Disorders in these 
latter respects are unlikely to be ammended through tryptophan 
loading and may account for therapeutic resistence in some 
subjects. 
Tryptophan's level of efficacy and associated side effects 
relative to placebo and the tricyclics, needs to be clarified in 
order to assess its value in relation to standard medications. 
In this context there is a necessity to compare tryptophan with 
both placebo and active antidepressants within the same 
individuals. Clearly findings that tryptophan is not superior to 
placebo should not be taken as evidence for dismissal of 
tryptophan's antidepressant value. That is, several authors have 
failed, aiso, to demonstrate superiority of the tricyclics over 
placebo (Klerman & Cole, 1965; Raskin et al., 1970; Raskin, 1974; 
Morris & Beck, 1974). 
As previously discussed, there is consistent evidence to 
support a more specific therapeutic role for tryptophan as a 
potentiating agent with MAOI's. Theoretical assumptions with 
respect to the action mechanisms of both substances support the 
expectation of synergistic psychopharmacological effects in this 
context. Further investigation is needed to determine the 
clinical significance of the improvement and to establish optimal 
dose levels for both compounds within individuals. 
As was mentioned in Chapter II, several investigations have 
been undertaken to determine relationships between tryptophan 
administration and various sleep parameters. It was not the 
intention of the present thesis to review this area of 
application in detail. However, there are indications that future 
research in this area may establish another locus of therapeutic 
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potential for tryptophan administration. That is, a review of B 
studies in this area by Cooper (1979), supported overall findings 
of significantly reduced sleep latency and increase in total 
sleep time as well as trends towards improved subjective quality 
of sleep. 
Although self rating methods of psychological assessment 
were promoted in the present investigation, there are certain 
contexts e.g. in cases of severe depression, where expectation of 
subjects to conduct reliabale self assessment may be 
inapproriate. In this respect, it is considered desirable that 
other rater scales should be included in addlion to self rating f c: 
procedures. Other recommendations for scales suitable in the 
detection of tryptophan effects have been discussed in detail in 
Chapter III. 
The value of future research on tryptophan intake in normal 
subjects is less certain than that of therapeutically oriented 
evaluations. As noted in Chapter II, most investigations with 
normal subjects involved short term monitoring of mood and side 
effects following single doses of tryptophan. There is a need for 
further investigation of chronic tryptophan administration in 
normal subjects before the psychoactive properties of tryptophan 
in this group can be established. It is not considered that 
normal subjects should be employed as models for investigation of 
antidepressant effects. However, normal subjects may have 
relevance in studies of depression if the point of inquiry is to 
specifically investigate hypotheses that depression is simply an 
extension of normal downward mood swings. 
Another reason for continued investigation of tryptophan's 
effects in populations free of psychiatric disturbance is the 
provision of scientific information which may aid the decisions 
of potential consumers. This area of investigation is of 
particular relevance within New Zealand where tryptophan 
availability is unrestricted. While it is seen as desirable for 
individuals to formulate their own judgements with respect to 
tryptophan's efficacy it is also considered expedient to increase 
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APPENDIX A 
PSYCHOLOGICAL SCALES USED IN THE PRESENT THESIS 
I. Demographic questionnaire 
II. Morning Moodscale 
III. Evening Moodscale 
IV. Side effect checklist 
V. Zung Depression Scale 
VI. Trait Anxiety Scale 
VII. State Anxiety Scale 
VIII. Hopkins Symptom Check List <HSCL) 
Call scales are reduced to 3/4 of the original size) 
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r. Demographic questionnaire 
PLEASE RESPOND TO ALL QUESTIONS - ALL INFORMATION WILL REMAIN STRICTLY CONFIDENTIAL, 
NAME:--------------.....,..,~--,--~------------ ID: ___ _ 
(surna• el lfirstna• el 
PHONE1 HOME: ----POSTAL ADDRESS1 _______________________ _ 
( 1l AGE: ____ _ !2lSEX: _____ _ 
(5lMARITAL STATUS: 








(tick all applicable) 
alone 




other(specifyl1 ____ _ 
(7JEDUCATION LEVEL: 







other(specify> ____ _ 
18! OCCUPATIOth 











alcoholic proble• s 
otherlspecifyl _____ _ 
WORK: ----
(31HEI6HT1 14lWEI6HTr ------ ------
(10lDRUG CONSUMPTION1 - in the last • onth 
ltick all applicable) 








specify: _______ _ 
other 
specify: _______ _ 
!11)Do you consider you are likely to be/come a 
regular/occasional consu1er of any of the above 
in the next 6 111onths? Yes_ No __ 
(12lPSYCHOTHERAPY: - in last •onth -




other(specifyl ____ _ 
!13)Do you consider it likely that you 
will partake of any of the above 
in the next 6 months? Yes __ No:____ 
!14)IF FEMALE ARE/DD VDU: 
pregnant 
take chemical contraceptives 
suffer pre• ens~rual tension 
!15)L-TRYTOPHAN CONSUMPTION 
Y11s No 
Have you consuaed L-Tryptophan Yes 
tablets, - before 
- in the last •onth 
If Yes in last. month please 
specify hoM much 
In· either cast did you notice 
any change in the Hay you felt -
No 
please specify: ____________ _ 
(16lARE YOU VEGETARIAN? Yes __ No_ 
(17lW~re there any questions you did not answer for personal reasons: Yes __ No 
- please specify numbers: 
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II. Morning Moodscale 
Morning Moad scale all information will remain strictly confidential 
Day+ date: Time: 
How many hours of sleep did you have last night? 
If female - are you menstruating? Yes: 
ID: ------
Na: 
Has anything unusual/traumatic happened since you completed the last scale 
to make you feel very different from normal? Yes: Nos 
please specify: _________________________________ _ 
Have you consumed any drugs since completing the last scale? Yes: No: 
please specify types & dose: _________________________ _ 
(!)Please rate your subjective state in terms of the dimensions given below. 
C2)Regard the adjectives as representing the extreme condition. For 
example, one is seldom absolutely "Honest" or Dishonest", normally 
honesty would be rated in the mid range of the line. 
(3)Deal with one dimension at a time, expressing haw you feel at the moment. 


















III. Evening M•• dscale 
Evening Mood scale all information will remain strictly confidential 
Day+ date: __________ Time: ID1 _____ _ 
If female - are you menstruating? Yes: Noa 
Has anything unusual/traumatic happened since you completed the last scale to 
make you feel very different from normal? Yes: No: 
please specify: _________________________________ _ 
(!)Please rate your subjective state in terms of the dimensions given below. 
(2)Regard the adjectives as representing the extreme condition. For 
example, one is seldom absolutely "Honest" or. Dishonest",.normally 
honesty would be rated in the mid range of the line. 
(3)Deal with one dimension at a time, expressing how you feel at th~ moment. 








































IV. Side effect checklist 
TICK THE FOLLOWING ONLY IF THEY AFFECT/ED YOU TODAY: 
1. Headache •••••••••••••••••••• 
2. Nausea/vomitting •••••••••••• 
3. Blurred vision ••••••••••••••• 
4. Constipation ••••••••••••••••• 
5. Diarrhoea •••••••••••••••••••• 
6. Dry mouth •••••••••••••••••••• 
7. Urinary retention •••••••••••• 
B. Increased appetite ••••••••••• 
9. Decreased appetite •••••••••• ~ 
10.Dizziness •••••••••••••••••••• 
11.Sweating ••••••••••••••••••••• 
a little quite a bit extreme 
please specify any other symptoms: ________________ _ 
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V. Zung Depression Scale 
ZUNG 
ID: ----- DATE: ------
Listed below are 20 statements. Please read each one carefully and 
decide how much of the statement describes how you have been feeling 
during the past week. .Decide whether the statement applies to you 
for none 9r a little of the time, same of the time, a good part of 
the time, or most or all.of the time. Tick the appropriate column 
for each statement. 
None or a Ii ttle 
of the ti1e 
1. I. feel d_ownhearted and blue •••••• 
2. Morning is when I feel the best •• 
3. I have crying spells or feel like 
it. - .................•..•........ 
4. I have trouble sleeping through 
the night •••••••••••••••••• ~···•• 
5. I eat as much as I used to ••••••• 
6. I enjoy looking at, talking to and 
being with attractive women (or 
men> .............................. . 
7. L notice that I am losing weight 
B. I have trouble with constipation 
9. My heart beats faster than usual 
10. I get tired far no reason •••••••• 
11. My mind is as clear as it used to 
be • .............................. !f !II 
· 12. I find it easy ta do the things I 
used to •••••••••••••••••••••••••• 
13. I am restless and can't keep still ___ _ 
14. I feel hopeful about the future •• 
15. I am more irritable than usual ••• 
16. I find it easy to make decisions 
17. I feel that I am useful and needed ___ _ 
18. My life is pretty full ••••••••••• 
19. I feel that others would be better 
off if I were dead ••••••••••••••• 
20. I still enjoy the things I used to __ _ 
PTO ••••• 
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Soae of the A good part of Host or al I of 
ti1e the tile the ti•e 
VI. Trait Anxiety Scale 
SELF-EVALUATION QUESTIONNAIRE (2) 
ID: DATE: ------- --------
Directions: A number of statements which people have used to describe them-
selves are given below. Read each statement and then tick the appropriate 
space to the right of the statement to indicate how you generally feel. ' 
There are no right or wrong answers. Do not spend too much time an any 
one statement but give the answer which seems to describe how you generally 
feel. 
21. I feel pleasant ••••••••••••••••••••• 
22. I tire quickly •••••••••••••••••••••• 
23. I feel like crying •••••••.•••••••••• 
24. I wish I could be as happy as others 
seem to be •.••.•...•.••.•••.•..•.•.• 
25. I am losing out on things because I 
can·t make up my mind soon enough ••• 
26. I feel rested ...................... . 
27. I am "calm, cool and collected" ••••• 
28. I feel that difficulties are piling 
up so that I cannot overcome them ••• 
29. I worry too much over something that 
really doesn't matter ••••••••••••••• 
30. I am happy •••••••••••••••••••••••••• 
31. I am inclined to take things hard ••• 
32. I lack self-confidence •••••••••••••• 
33. I feel secure ••••••••••••••••••••••• 
34. I try to avoid facing a crisis or 
difficulty •••••••••••••••••••••••••• 
35. I feel blue •.••••.••.••.••••.•••••.• 
36. I am content •••••••••••....••••.••.• 
37. Some unimportant thought runs through 
my mind and bothers me •••••••••••••• 
38. I take disappointments so keenly that 
I can't put them out of my mind ••••• 
39. I am a steady person ••••••••• , .••••••• 
Not at all 
40. I get in a state of tension or turmoil 
as I think over my recent concerns 
and interests .....••..•..••..••••• A. 
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Soaewhat Moderate I y so Very auch so 
VII. State Anxiety Scale 
SELF-EVALUATION QUESTIONNAIRE (1) 
ID: ------- DATE: ______ _ 
Directions: A number of statements which people have used to describe them-
selves are given below. Read each statement and then tick the appropriate 
space to the right of the statement to indicate how you feel right now, ' 
that is at this moment. There are no right or wrong answers. Do not 
spend too much time on any one statement but give the answer which seems 
to describe your present feelings best. 
Not at all S01ewhat Hoder ate I y so Very 1uch so 
1. I feel calm ••••••••••••••••••••• ~ ••• 
2. I feel secure . .................•...• 
3. I am tense •••••••••••••••••••••••••• 
4. I am regretful •••••••••••••••••••••• 
5. I feel at ease • ••••••••••••••••••••• 
6. I feel upset • .•.••••••••..•••••••••.• 
7. I am presently worrying over 
possible misfortunes ••••..••.•..•••• 
E;l. I feel rested ••••••••••• ~ ••••••••••• ---~ ---
9. I feel anxious . ...•...•......•...... 
10. I feel comfortable ••••• ===9••·•·•••· 
11. I feel self-confident ••••••••••• ; ••• - ---
12. I feel nervous .•.•.••••.• ~•···•·•••· 
13. I am Jittery •••••••••••••••••••••••• 
14. I feel "high strung"•••··•••··•·~·•· 
15. I am relaxed•••·•·••••··~··••··••••• 
16. I feel can tent . ...... ., .....• -.. _ ..... . . . 
17. I am worried •••••••••••••••••••••••• 
18. I feel overexcited and "rattled" ••.•• 
19. I feel joyful .•....•.• · ....•.•.••....• 
20. I feel pleasant .. .................• 9'. • ----· 
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VIII. Hopkins Symptom Check List (HSCL) 
SYMPTOM CHECKLIST 
Below is a list of problems and complaints that people sometimes have. 
Please read each one carefully. After you have done so, please tick only 
one of the four spaces to the right that best describes HOW HUCH THAT 
PROBLEM HAS BOTHERED OR DISTRESSED YOU DURING THE PAST WEEK, INCLUDING 
TODAY. Make only one tick for each problem and do net skip any items. 
**ID: DATE: ______ WEIGHT: ______ _ 
Not at all 
1. Headaches • •••.••••.•.••.•.••••.••••••••••••• 
A I ittl e Ouite a bit Extre•el,Y 
2. Nervousness or shaking inside ••••••••••••••• 
3. Being unable to get rid of bad thoughts/ideas __ _ 
4. Faintness of dizziness •••••••••••••••••••••• 
5. Lass of seKual interest er pleasure ••••••••• 
6. Feeling critical of others •••••••••••••••••• 
7. · -Bad dreams • •••••••••••••••••••••••••••••••.•• 
8. Difficulty in speaking when you are excited 
9. Trouble remembering things •••••••••••••••••• 
10. Worried about sloppiness or carelessness •••• 
11. Feeling e~sily annoyed or irritated ••••••••• 
12. Pains in the heart or chest ••••••••••••••••• 
13. Itching ••••• ~••·••~··•·••·•···••···•·••·~··· 
14. Feeling low i_n energy er slowed down ••••••••. , __ _ 
15. Thoughts of ending your life •••••••••••••••• 
16. Sweating"' ••••.••••.•.••••.•.••••••.••••••.•• 
1 7. Tremb 1 i ng • •••••••••••••••••••••••••••••••••• 
18. Feeling confused •••••••••••••••••••••••••••• 
19. Po(?r appetite .............•.......•..•... · .... · __ _ 
20. Crying easily ..... ., ....... .,_'" .......•..••...•••.•. , __ _ 
21. Feeling shy ar uneasy with the opposite sex 
22. A feeling of being trapped or caught •••••••• 
23. Suddenly scared for na reason ••••••••••••••• 
24. Temper outbursts you could not control •••••• 
25. Constipation ...•............................ 
26. Blaming yourself for things ••••••••••••••••• 
27. Pains in the lower part of your aack •••••••• 
28. Feeling blocked or stymied in getting things 
done • •••••••••.•••••••••••••••••• • •• • • • •• • • • 
PTO ••••• 
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Not at all A Ii ttle Quite a bit Extrml y 
29. Feeling lonely •••• ~····•··••·~·············· 
30. Feeling blue •••••••••••••••••••••••••••••••• 
31. Worrying or stewing about things •••••••••••• 
32. Feeling no interest in things ••••••••••••••• 
33. Feeling fearful ••••••••••••••••••••••••••••• 
34. Your feelings being easily hurt ••••••••••••• 
35. Having to ask others what you should do ••••• 
36. Feeling others do not understand you or are 
unsympathetic •••••••••••••.••••••••••••••••• 
37. Feeling that people are unfriendly or 
dislike you •••••••••••••••.••••••••••••••••• 
38. Having to do things very slowly in order to 
be sure you were doing them right ••••••••••• 
39. Heart pounding or racing •••••••••••••••••••• 
40. Nausea or upset stomach ••••••••••••••••••••• 
41. Feeling inferior to others •••••••••••••••••• 
42. Soreness of your muscles •••••••••••••••••••• 
43. Loose bowel movements •••••••••••••••.••••••• 
44. Difficulty in falling asleep/staying asleep 
45. Having to check and double check what you do 
46. Difficulty making decisions ••••••••••••••••• 
47. Wanting to be alone ••••••••.••••••••••••••••• • 
48. Trouble getting your breath ••••••••••••••••• 
49. Hot or cold spells •••••••••••••••••••••••••• 
50. Having to avoid certain things, places or 
activities because they frighten you •••••••• 
51. Your mind going blank ••••••••••••••••••••••• 
52. Numbness or tingling in parts of your body •• 
53. A lump in your throat ••••••••••••••••••••••• 
54. Feeling hopeless about the future ••••••••••• 
55. Trouble concentrating ••••••••••••••••••••••• 
56. Weakness in parts of your bo~y •••••••••••••• 
57. Feeling tense or keyed up .•••••••••••••••••• 
58. Heavy feeling in your arms or legs •••••••••• 
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APPENDIX B 
COMPUTER PROGRAM LISTINGS USED FOR ANALYSIS IN THE PRESENT THESIS 
I. Factor extraction program for VAMS 
II. Autocorrelation program 
III. C statistic program 
IV. Factor extraction program for HSCL 
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I. Factor extraction proqram for VAMS 
The following program outputs factor scores for three mood 
dimensions: alertness, contentedness and calmness, using factor 
loadings from Bond & Lader (1974). Input is in the form of mood 
scores for the 16 scales (see VAMS: Appendix A). The program 
also outputs factor score means for experimental phases relevant 
to each subject. 
~ I ,J,K,L,i.'4,N,ID,I61EE:(81,16) ,~(84,3) 
~ :rr.mD(l.6) ,IlW(l6} 
:INlE'.ER IBLl., IIL,IvL,IEL,IBL2, mD ,rw:D,IErD,T 
BFAI., I..00 (16) ,CM?.:rn.( 84,16} ,BASIDI','JWIOI',W3HIDI' ,R32IDI' 
~ ~,J:fiEM:J2,JHM-B, '.IREM'U, 'JREt.N2, 'JRR.N3,\'6H-Nl. 
R&zt, WH--N2,W:H.'®3,:i.:rD,Nl,R..GN2,H:ON3,B3J.Nl,BS2N2,R:32-N3 
REN. BLL, 'IL,WL,:EL,:er.2,ND\Dl,.Ar.mD'.2,N.O'ID3,MMl?Sl,P011?S2,PCM!?S3 
Wffi:JE (1, ffi) 
(I) KBYm' (SX, 'SIB.ECJS IO: I ,/ ,5X, "IDI' ID EXP IJ\'tS: I ,/ ,SX, 'N) ~ 
6 ll\lS: ',/,SX, 'ID 'lRYI? IAJS: ',/,SX:, 'NJ WR rn:iS: ',/,SX, 'NJ B:lB 
6 J:A'iS: I ,/ ,SX, 'NJ PASE2 r:ros: I ) 
Im) (1, :D) ID,N;BI,l, 'JL,W:..,PL,BL2 
.:0 R:Rvm'(2(I2,/) ,S(E2.0,/)) 
WHrIB(l,61.) 
61. lUMU' ( 5X' I MINING (1) /BJEN]N:; (2) : I ) 
:iE!-\0(1,51) ·r 
51 liffivm'(Il) 
.IBLl = JllIX (BLl) 




CTEN((NIT = 6,F.IIE = •~• ,SIFfil.B = 'a:D') 
ID l I=l,N 
1 l:HID{6,10) ~(I,J) ,J=l,16) 
10 RHvm' (16 (13)) 
a.cm ((NIT = 6) 
C8N ((NIT = 6 ,F.II.E = 'I.CN)' ,sn:m.B = 'a:D') 
REW{6,Al) {lliM(K) ,K=l,16) 
al RlMil' (16 (I4)) 
a.asE:((NIT = 6) 
OH.N ((NIT = 6 ,F.IT.E = 'JRW' ,SIJ'fil.B = 'a:D' ) 
RE1ID(6,Z3) {Iffiil~) ,M=l,16) 
Z3 RlM':«'(16 (12)) 
aaE((NIT = 6) 
OH.N ((NIT = 6 ,F.IIE = ·~· ,Sil'filE = 't-EW') 
ID 3 D=l,N 
ro 7 I=l,16 
7 IQ:\D(I)=EfJ:lll'(JI..CN:>(I))/lOJO.O 
ID 4 M=l,16 
:IF ( (.ESIEE(L,M)) .EQ.99) IrnDf,1)=0.00 
IF ( (RURE(L;.\1)) .EQ.-1) RnFE(L;4) = 100 
1F (JR&Q.'4) .EQ.l) R9'.Im(L,.'4)=.1.DO--RnEE(L,M) 
IF ( (R3(XRE(L,M)) .EQ. 00) .£€<.Xl£(L,M.) =ill. 
4 (Mffi:R {L,M)=l:SIEE(L,M) ~f-1) 
N.a\Dl ::::(Q\I) (1) -!Dlill(ll) -H:.(llJ)( 6)-!Dlill ( 4)-tta\D (5) +r.00 (9) + 
6£0ID(3)-l-illill(l5) -ffi:lill(12) 
IF(ll.ffiDl .EQ. 0.00) ill 'ID 110 
POP31-0m:R (L,1) -tavm:R (L,ll)-KMJ?S:R(L,6)-KMS:R{L,4) 
6+Q"IS:R(L, 5)-KMB.:R(L, 9)-KMl:frn (L, 3)-tO-m:R(L, 15)-t<:MIB:R (L,12) 























ID 6 I=l,IBLl 
6 ~(I,J) 
m:.D=lBLl+m.. 
ID 8 I=lBLl+ l,mD 
8 ~(I,J) 
lWD=D.IDHK, 
ID 9 I=mn+-1,IWD 
9 ~El\Cm(I,J) 
1B]):: lWl)f-m:. 
ID ]3 I=:rw:Df-1,Ilffi 
13 ~ffi(I,J) 
ID 15 I=lRDl-1,N 
l5 ~BCL'CR(I,J) 
lE' (J.EQ.l) CD 'IO 100 
lF (J.EQ.2) <D 'ID 200 

















lE' (T.EQ.l) (D 'ID 401 
IF(T.EQ.2) <D 'IO 400 
400 W:U'JE (6,500) 
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!iXl RlMil'(SK,'E.VENlN'.3mti\') 
(D '.ID 000 
401 WRI'JE( 6, 501) 
9)1 R1Mil'(9{, ·~mm.') 
aJ0 WRl'IE ( 6 ,33) ID 
33 R:Rvffl'V, 'sc.BEr ID: ',12) 
mrIE(6,35)N 
35 RR\ffl' V / /, ''lUIN. ID. IWiS: ' ,I2) 
WRI'JE( 6, 83)BLl, 'lL,W:.,PL,BL2 
83 RlMCU'V ,SK, ':eAS&Jt£l = ',ES.2,/ ,SK, 'TRYl?la?fm = ',ES.2,/ ,SK, 
6'W?SEIDI' = ',ES.2,/,SK, 'Pl"Mm) = ',FS.2,/,SK, ·~ = ',ES.2) 
ID 14 J=l,3 
WRI.'lE( 6, 3)) J 
3l RlMil'V/ ,ID{, 'Efl,CL(R' ,m 
WRBE(6,40) (OCTCR(I,J) ,I=l,26) 
m'IB(6,40) (EAC!m(I,J) ,I='Il,52) 
WRI'IE(6,40) (EtCKR(I,J) ,I=53, 78) 
mr:IE(6,40) (FACKR(I,J) ,I='i9 ,84) 
ll) Rlfflr(26(I3)) 
14 CINr.INJE 
m'1E ( 6, 00) l,IJEvNl, 'IREM{l,W3fMU,l:U:}Nl,B3J,,NL 
WRI'JE( 6, 81) 2,~2,'.ImwN2,vaM-s2,:B:ON2,ffi21'12 
m'IE ( 6, 82) 3,.BS!!Mi3, '1REM.£,W3H-N3,~,B32N3 
ro R:Dffl'V I I, 'E?\Cl.m ',n,~,' ~ =' ,Eo.3,' ~ =' ,Eo.3, 
61 W,~ =' ,lffi.3,/ ,JJX, I = 1 ,lffi.3, I =' ,Jffi.3) 
81 RIMil'V I 'FOCKR I ,n,~, I ~ =' ,E6.3, I ~ =' ,E6.3, 
61 W3~ =' ,lffi.3,/ ,JJX, I =' ,lffi.3, I =' ,E6.3) 
82 RR-m'V, 'FOCKR ',n,~,' ~ =' ,E6.3,' ~ =' ,Eo.3, 
6' W,~ = I ,lffi.3,/ ,JJX, I = I ,lffi.3, I = I ,Jffi.3) 
aaE ((N1T = 6) 
]ID 
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II. Autocorrelation program 
The following fortran program listing includes the 
computational proceedures designed according to the formula: 
N-k N 




Where: N is the total nu~ber of observations in the series, z. is 
the value of the obserJation at time period i, Z is the mea~ of 
the series and k is the number of lags. 
The program outputs the raw data and associated rk scores 
(k=lag1 7 lag4) for input ~eries up to 100 paints: 
PROGRAM AUTCOR 
INTEGER SERIS(lOO),N,I,J,L,M,P,S,Q 
REAL ZMEAN,T,RN,ZN,ZD,Rl,R2,R3 7 R4 
WRITE(l,11) 
11 FORMAT(5X,'ENTER LENGTH OF SERIES: ') 
READ<1,1O)N 
10 FORMAT(I3) 
T = 0.0 
ZN= 0.0 
ZD = 0.0 
CALL OPEN (6, 'SERIS DAT',O) 
DO 1 I=l ,N 
1 READ(6,20)SERIS(I) 
20 FORMAT (I2) 
ENDFILE 6 




DO 3 L=1,N 
3 ZD~ZD+(CSERIS(L)-ZMEAN)**2) 
DO 4 M=1,4 
S=N-M 
DO 5 P=l,S 









CALL OPEN (6, 'RANSWER DAT',O) 
WR I TE (1 , 21 ) 
WRITE(6,21) 
21 FORMATC//,5X,'data seris: ') 
WR I TE ( 1 , 31 ) (SERI S C I ) , I= 1 , N) 
WRITE (6, 31) <SERIS ( I) , I=l, N) 
31 FORMATC/,5(20I3 7 /)) 
WRITEC1,41> 
WRITEC6,41) 




51 FORMATC/,5X, 'rl = 'F12.10,l,5X,'r2 = 'F12.10,l,5X, 'r3 = 
6F12.10,l,5X, 'r4 = 'F12.10) 
ENDFILE 6 
END 
III. C statistic program 
The following program outputs the data series understudy, 
the associated C (C statistic), SC (standard error of C) and Z (Z 
statistic, ie: ratio of C to SC). 
PROGRAM CSTAT 
C 
C outputs values for: C statistic CC) 
C standard error of C (Sc) 
C Z statistic ie: ratio of C to Sc (Z) 









60 FORMAT<BX, 'SUBJECT ND?: ') 
READ (1 ,9) ID 
9 FORMAT ( 12) 
WRITE(l,80) 
80 FORMAT(/l,8X, 'ENTER SERIES ND.: ',/,BX, 'morning(!): 
6 evening(2): combined(3): ') 
READ(1,13)SER 
13 FOF:MAT < 11) 
WRITE ( 1, 18) 
18 FORMAT(//,BX, 'ENTER PHASE: ',l,BX,'baseline(l): 
6tryptophan(2): washout(3): placebo(4): base2(5): '/,BX, 
6'mianserin(6): tryp2(7): baseline+tryptophan(S): ·,1,sx, 




16 FORMAT(//,BX,'ENTER MOOD FACTOR: ',J,BX, 'alertness(!): 
6 contentedness (2): calmness (3): ·) 
READ(1,17)FAC 
1 7 FORMAT ( 11) 
WR 1 TE ( 1 , 11 ) 
11 FORMAT(///, 5X,'NO OF DATA POINTS?: ') 
READ(1,10)N 
10 FORMAT (I3) 
CALL OPEN (6,'TSCORE DAT',O) 
C READ DATA 
DD 1 I = 1,N 
1 READ(6,20)TSCORE(I) 
20 FORMAT ( 13) 
ENDFILE 6 
C CALCULATE SUM OF (N) DATA POINTS (T) 
DD 2 J = 1,N 
2 T = T + TSCORECJ) 
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RN= FLOAT(N) 
C CALCULATE MEAN OF DATA POINTS 
MEAN= T/RN 
C CALCULATE 2xSUM OF CN) SQUARED DEVIATIONS FROM THEIR 
C MEAN <MS) 
DO 3 I<= 1,N 
3 MS= MS+ (TSCDRE(K)-MEAN)**2 
LN = N-1 
C CALCULATE CN-1) SQUARED CONSECUTIVE DIFFERENCES CDS) 
DO 4 L = 1,LN 
4 DS = DS + (TSCORECL)-CTSCORECL+1>>>**2 
C = 1 - (DS/(2*MS)> 
MSx2 = MS*2 
SC= SQRT((RN-2)/C(RN-l>*<RN+l))) 
Z = C/SC 
C OUTPUT - C, Sc and Z: 
CALL OPEN(6,'CANS DAT',O) 
WRITEC6,41)ID 
WRITE C 1, 41> ID 
41 FORMATC5X,'SUBJECT: ',I2) 
IF (SER .EQ. 1) GO TD 100 
IF <SER .EQ. 2) GO TD 200 
IF <SER .EQ. 3) GO TO 300 
100 WRITE<l,110) 
WRITEC6,110) 
110 FORMAT(/,5X, 'TIME SERIS: morning') 
GO TO BOO 
200 WRITE(i,210) 
WRITE<6,210) 
210 FDRMATC/,5X,'TIME SERIS: evening') 
GO TO BOO 
300 WRITE<l,310) 
WRITEC6,310) 
310 FORMAT(/,5X,'TIME SERIS: combined morn+ eve data') 
800 IF (PHS .EQ. 1) 60 TO 1000 
IF CPHS .EQ. 2) GO TO 2000 
IF <PHS .EQ. 3) GO TO 3000 
IF CPHS .EQ. 4) GO TO 4000 
IF (PHS .EQ. 5) GO TO 5000 
IF CPHS .EQ. 6) GO TO 6000 
IF (PHS .EQ. 7) GO TD 7000 
IF CPHS .EQ. 8) GO TD 8000 
IF (PHS .EQ. 9) GO TD 9000 
IF (PHS .EQ. 10)80 TO 10000 
1000 WRITE<1,1010) 
WRITE<6,1010) 
1010 FORMATC5X,'PHASE: baseline 1') 
GO TO 900 
2000 WRITE<l,2010) 
WRITE<6,2010) 
2010 FORMAT(5X,'PHASE: tryptophan') 
GO TO 900 
3000 WRITE(l,3010) 
WRITE(6,3010) 
3010 FORMAT<5X,'PHASE: washout') 
GO TO 900 
4000 WRITE(l,4010) 
WRITE(6,4010) 
4010 FDRMAT(5X,'PHASE: placebo') 




5010 FORMAT(5X,'PHASE: base 2') 
GO TO 900 
6000 WRITE(l,6010) 
WRITE(6,6010) 
6010 FORMAT(5X, 'PHASE: mianserin") 
GO TO 900 
7000 WRITE<l,7010) 
WRITE<6,7010) 
7010 FORMAT(5X,"PHASE: tryp2") 
GO TO 900 
8000 WRITE(l,8010) 
WRITE(6,8010) 
8010 FORMAT<5X,'PHASE: baseline 1 + tryptophan ') 
GO TO 900 
9000 WRITE<l,9010) 
WRITE(6,9010) 
9010 FORMAT(5X, 'PHASE: tryptophan + placebo ') 
GO TO 900 
10000 WRITE(l,10010) 
WRITE<6.,10010) 
10010 FORMAT(5X, 'PHASE: placebo+ base2 ') 
900 IF CFAC .EQ. 1) GO TD 1111 
IF (FAC .EQ. 2) GO TO 2222 
IF (FAC .EQ. 3) GO TD 3333 
1111 WRITE(l,1110) 
WRITE(6,1110) 
1110 FORMAT(5X,'MDOD FACTOR: alertness') 
GO TO 600 
2222 WRITE<l,2220) 
WRITE<6,2220) 
2220 FORMAT(5X,'MOOD FACTOR: contentedness') 
GO TO 600 
3333 WRITE(l,3330) 
WRITE(6,3330) 
3330 FORMAT(5X,'MODD FACTOR: calmness') 
600 WRITE(6 7 31) (TSCDRE(l),I=l,N) 




21 FORMAT(///,5X,'C = "FB.3, 5X,'DS=',F9.3,3X,'MSx2='F12.3, 
6//,4X, 'SC= 'FB.3,//,5X,'Z = 'FB.3) 
ENDFILE 6 
END 
IV. Factor extraction program for HSCL 
The following program outputs factor scores an a series of 
ratings for the fallowing HSCL dimensions: 
1. somatizatian 
2. obsessive-compulsive 
3. interpersonal sensitivity 
4. depression 
5. an>~iety (P.T.O) 
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PROGRAM HSCLFAC 









11 FORMAT(5X,'SUBJECTS ID?: ') 
READ(1,10)ID 
10 FORMAT (12) 
WRITE ( 1, 21) 
21 FORMAT(5X,'NO. OF SCALES?: ') 
READ<l, 10)N 
CALL OPEN(6,'SCORE DAT',0) 









CALL OPEN(6,'FSCORE DAT',O) 
DO 2 I=l ,N 





















31 FORMAT (5X, 'SUBJECT NO: ', I2) 
DD 4 J=l,5 
WRITE(6,41)J 
41 FORMAT(/,5X, 'FACTOR',I1) 








I. SOURCE OF INGESTABLE MATERIALS 
Tryptaphan used in the present study was obtained from 
Healtheries of New Zealand Ltd. The quantities required for the 
present investigation were supplied in the form of 500mg tablets. 
Healtheries also supplied placebo in the same sized tablet form. 
There was a slight colour coat difference between the respective 
substances. 
II. SPECIFICATIONS OF TRVPTOPHAN USED IN THE PRESENT STUDY 
The certificate of 











PH (7. solution) 
specific rotation CocJ 0 20 
appearance after resolution 
chloride (Cl) 
sulfate (8• 4 ) 
ammonium (Nh4 ) 
heavy metal (as Pb) 
iron 
arsenic <ASr:,• -> .,__.,::, 
other amino acid 
loss an drying 
residue on ignition 
III. PLACEBO COMPOSITION 
99.47. 





less than 0.02% 
less than 0.02Y. 
less than 0.02;. 
less than lOppm 
less than 30ppm 





compound: di calcium 
crystalline cellulose. 
composed of the physiologically 
phosphate dihydrate with traces of 
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inert 
micro-
